<SEC-DOCUMENT>0001437749-21-006236.txt : 20210317
<SEC-HEADER>0001437749-21-006236.hdr.sgml : 20210317
<ACCEPTANCE-DATETIME>20210316215821
ACCESSION NUMBER:		0001437749-21-006236
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210317
DATE AS OF CHANGE:		20210316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		21748270

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dffn20201231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/8/2021 8:17:52 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>dffn20201231_10k.htm</title>



</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" docsect="2" id="175441" sectdesc="Cover Page">&nbsp;</div>

<div data-td-statement-type="cover" data-td-v2v-id="1615409448429">
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 9pt;"><b>UNITED STATES</b></p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 9pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>FORM</b>&nbsp;<b>10-K</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="3" style="vertical-align: top; width: 16%;">(Mark one)</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: right;">&#9746;</td>
			<td style="vertical-align: top; width: 10%;">
			<p style="font-family: Wingdings; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 6%; text-align: right;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>For the fiscal year ended December</b>&nbsp;<b>31, 2020</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 6%; text-align: right;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OR</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: right;">&#9744;</td>
			<td style="vertical-align: top; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the transition period from</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;</b>&nbsp;<b>to</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Commission file number: 000-24477</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dffn20201231_10kimg001.gif" src="dffn20201231_10kimg001.gif" style="width:275;height:85;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">(Exact Name of Registrant as specified in its Charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%; text-align: center;">(State or Other Jurisdiction of Incorporation or Organization)</td>
			<td style="vertical-align: bottom; width: 50%; text-align: center;">(I.R.S. Employer Identification No)</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%; text-align: center;"><b>1317 Carlton Avenue, Suite 200</b></td>
			<td style="vertical-align: bottom; width: 50%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%; text-align: center;"><b>Charlottesville, VA</b></td>
			<td style="vertical-align: bottom; width: 50%; text-align: center;"><b>22902</b></td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%; text-align: center;">(Address of Principal Executive Offices)</td>
			<td style="vertical-align: bottom; width: 50%; text-align: center;">(Zip Code)</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>(434) 220-0718</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">(Registrant's telephone number, including area code)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">Securities registered pursuant to Section&nbsp;12(b) of the Act:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 37%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Title of Each Class&nbsp;</u></b></p>
			</td>
			<td style="vertical-align: bottom; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Trading Symbol</u></b></p>
			</td>
			<td style="vertical-align: bottom; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Name of Each Exchange on Which Registered</u></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 37%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="vertical-align: bottom; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">DFFN</p>
			</td>
			<td style="vertical-align: bottom; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The Nasdaq Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">Securities registered pursuant to Section&nbsp;12(g) of the Act:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>None</b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&nbsp;&#9744; No&nbsp;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&nbsp;&#9744; No&nbsp;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes&nbsp;&#9746; No&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes&nbsp;&#9746; No&nbsp;&#9744;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 69%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer &#9744;</p>
			</td>
			<td style="vertical-align: bottom; width: 31%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#9744;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 69%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-accelerated filer &#9746;</p>
			</td>
			<td style="vertical-align: bottom; width: 31%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company &#9746;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 69%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company &#9744;</p>
			</td>
			<td style="vertical-align: bottom; width: 31%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicated by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&nbsp;&#9744; No&nbsp;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The aggregate market value of the registrant&#8217;s common stock beneficially owned by non-affiliates of the registrant, calculated based upon the closing sale price of the common stock as quoted by the Nasdaq Capital Market on June 30, 2020 (the last business day of the registrant&#8217;s second fiscal quarter), was approximately $62.4 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">As of March 12, 2021, 101,903,979 shares of common stock of the registrant were outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Portions of the registrant's definitive Proxy Statement on Schedule 14A for its 2021 Annual Meeting of Stockholders are incorporated by reference into the indicated parts of this Form 10-K, as specified in the responses to the item numbers involved. Such Proxy Statement will be filed within 120 days after December 31, 2020, the end of the fiscal year to which this Annual Report relates.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="3" id="175442" sectdesc="Table of Contents">&nbsp;</div>

<div data-td-statement-type="toc" data-td-v2v-id="1615409468611">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%;">PART I</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 1.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BUSINESS</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 1A.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">RISK FACTORS</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 1B.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">UNRESOLVED STAFF COMMENTS</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">36</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 2.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PROPERTIES</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">36</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 3.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LEGAL PROCEEDINGS</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">36</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 4.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MINE SAFETY DISCLOSURES</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">36</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%;">PART II</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">37</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 10%; padding-left: 9pt;">ITEM 5.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">37</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 6.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SELECTED FINANCIAL DATA</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">37</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 7.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">38</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 7A.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">45</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 8.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">46</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 9.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">62</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 9A.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CONTROLS AND PROCEDURES</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">62</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 9B.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">OTHER INFORMATION</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">62</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%;">PART III</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">63</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 10.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">63</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 11.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EXECUTIVE COMPENSATION</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">63</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 12.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">63</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 13.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">63</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 14.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PRINCIPAL ACCOUNTING FEES AND SERVICES</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">63</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%;">PART IV</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">64</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 15.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">64</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 84%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 10%; padding-left: 9pt;">ITEM 16.</td>
			<td style="vertical-align: bottom; width: 84%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FORM 10-K SUMMARY</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">67</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="12" id="175443" sectdesc="Other">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INTRODUCTORY NOTES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Company References and Other Defined Terms</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Unless the context otherwise requires, in this Annual Report, (i) references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221; refer to Diffusion Pharmaceuticals Inc. and its subsidiaries and (ii) references to &#8220;common stock&#8221; refer to the common stock, par value $0.001 per share, of the Company. We have also used several other defined terms in this Annual Report, which are explained or defined below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Term</b></p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Definition</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2015 Equity Plan</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2017 Tax Act</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tax Cuts and Jobs Act of 2017</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">401(k) Plan</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. 401(k) Defined Contribution Plan</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Affordable Care Act</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ANDA</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">abbreviated new drug application</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Annual Report</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">this Annual Report on Form 10-K</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">API</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">active pharmaceutical ingredient</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARDS</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">acute respiratory distress syndrome</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASC</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounting Standard Codification of the FASB</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">ASC 740-10</td>
			<td style="vertical-align: bottom; width: 85%;">ASC Subtopic 740-10, <i>Accounting for Uncertainty of Income Taxes</i></td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASC 815-40</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASC 815-40, <i>Derivatives and Hedging, Contracts in an Entity's Own Equity</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASUs</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounting Standards Updates of the FASB</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASU 2018-07</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASU 2018-07, <i>Compensation--Stock Compensation (Topic 718): Improvements to Non-employee Share Based Payment Accounting</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Black-Scholes Model</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Black-Scholes-Merton derivative investment instrument pricing model</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our board of directors</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Bylaws</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Company's bylaws, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">COVID-19</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Corona Virus Disease 2019, the novel coronavirus disease known as COVID-19, caused by SARS-CoV-2 infection</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">cGMP</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">current good manufacturing practices</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CMO</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">contract manufacturing organization</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CRO</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">contract research organization</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CTA</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">clinical trial application</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 2019 Offering</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our registered direct public offering and sale of 6,266,787 shares of common stock and concurrent private placement of warrants to purchase up to 6,266,787 shares of common stock completed in December 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion LLC</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals LLC, a Virginia limited liability company and our wholly owned subsidiary</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DLCO</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">diffusion capacity of lung for carbon monoxide</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dodd-Frank Act</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">E.U.</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">European Union</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ETASU</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">elements to assure safe use</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exchange Act</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Exchange Act of 1934, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FASB</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial Accounting Standards Board</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDA</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Food and Drug Administration</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDC Act</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Federal Food, Drug, and Cosmetic Act</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 2021 Offering</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our public offering and sale of 33,658,538 shares of common stock completed in February 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">G&amp;A</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">general and administrative</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GAAP</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. generally accepted accounting principles</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GBM</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">glioblastoma multiforme brain cancer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GCP</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">good clinical practice</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GLP</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">good laboratory practice</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HIPAA</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Health Insurance Portability and Accountability Act of 1996</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HITECH</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Health Information Technology for Economic and Clinical Health Act of 2009</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IMM</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">irreversible morbidity and mortality</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IND</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">investigational new drug application</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IPR&amp;D</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">in-process research and development</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IRB</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">institutional review board</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">January 2018 Offering</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our public offering and sale of 1,131,375 shares of common stock and warrants to purchase up to 1,131,375 shares of common stock completed in January 2018</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 2019 Offering</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our registered direct public offering and sale of 1,317,060 shares of common stock and concurrent private placement of warrants to purchase up to 1,317,060 shares of common stock completed in May 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 2020 Investor Warrant Exercise</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the exercise of the Prior Warrant in May 2020 pursuant to a warrant exercise agreement</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 2020 Offering</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our registered direct public offering and sale of 11,428,572 shares of common stock completed in May 2020</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Nasdaq</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Nasdaq Stock Market, LLC</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NDA</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">new drug application</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NIID</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">National Institute of Infectious Diseases in Bucharest, Romania</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NOL</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">net operating loss</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 2019 Offering</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our public offering and sale of 5,104,429 shares of common stock, pre-funded warrants to purchase up to 6,324,143 shares of common stock, and warrants to purchase up to 22,857,144 shares of common stock completed in November 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PaO2</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">partial pressure of blood oxygen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">Planned Phase 2 Hypoxia-related Indication Trial</td>
			<td style="vertical-align: bottom; width: 85%;">a Phase 2, controlled, clinical outcome study evaluating TSC in one or more appropriate hypoxiarelated indications that we intend to initiate assuming success in one or more of the TSC Oxygenation Trials</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prior Warrant</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a previously outstanding warrant to purchase up to 5,000,000 shares of common stock at an exercise price of $0.35 per share</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Proxy Statement</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our definitive proxy statement on Schedule 14A for our 2021 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after December 31, 2020, the end of the fiscal year to which this Annual Report relates</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">R&amp;D</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">research and development</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regulation S-K</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regulation S-K promulgated under the Securities Act</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">REMS</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">risk evaluation and mitigation strategy</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SARS-CoV-2</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">severe acute respiratory syndrome coronavirus 2, the virus responsible for COVID-19</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEC</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Securities and Exchange Commission</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Act</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Act of 1933, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SOX</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sarbanes-Oxley Act of 2002, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tax Code</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Internal Revenue Code of 1986, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TCOM</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">transcutaneous oxygen measurement</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 85%;">&nbsp;</td>
		</tr>

</table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">tPA</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">tissue plasminogen activator</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">trans sodium crocetinate</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC COVID Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Phase 1b clinical trial evaluating TSC in hospitalized COVID-19 patients, completed in February 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC DLCO Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our planned Phase 2a clinical trial evaluating the effects of TSC through the measure of DLCO through the lungs as a surrogate measure of oxygen transfer efficiency in patients with previously diagnosed interstitial lung disease who have a baseline DLCO test that is abnormal</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC GBM Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Phase 3 clinical trial evaluating TSC in a newly diagnosed inoperable GBM patient population initiated in December 2017</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC Induced Hypoxia Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our planned Phase 1b clinical trial evaluating the effects of TSC on VO2 and PaO2 in normal healthy volunteers exposed to conditions that induce hypoxia</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC Oxygenation Trials</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collectively, the TSC TCOM Trial, the TSC Induced Hypoxia Trial, and the TSC DLCO Trial</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC Stroke Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Phase 2 clinical trial evaluating TSC in the treatment of acute ischemic or hemorrhagic stroke, initiated in October 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC TCOM Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our planned Phase 1b clinical trial evaluating the effects of TSC on peripheral tissue oxygenation in healthy normal volunteers using a TCOM device, which we expect to commence before the end of March 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">United States</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">USPTO</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Patent and Trademark Office</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 15%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">VO2</p>
			</td>
			<td style="vertical-align: bottom; width: 85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">maximal oxygen consumption</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This Annual Report (including, for purposes of this Note Regarding Forward-Looking Statements, any information or documents incorporated herein by reference) includes express and implied forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, liquidity and prospects may differ materially from the forward-looking statements contained in this Annual Report. In addition, even if our results of operations, financial condition, liquidity, and prospects are consistent with the forward-looking statements contained in this Annual Report, they may not be predictive of actual results or reflect unanticipated developments in future periods.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Forward-looking statements appear in a number of places throughout this Annual Report. We may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements also include statements regarding our intentions, beliefs, projections, outlook, analyses, or expectations, including our intentions, beliefs, projections, outlook, analyses, or expectations concerning, among other things:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success and timing of our clinical and preclinical studies, including our ability to enroll subjects in our ongoing and planned clinical studies at anticipated rates;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to obtain and maintain regulatory approval of our product candidates and, if approved, our products, including the labeling under any approval we may obtain;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our plans and ability to develop and commercialize our product candidates and the outcomes of our research and development activities;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the accuracy of our estimates of the size and characteristics of the potential markets for our product candidates, the rate and degree of market acceptance of any of our product candidates that may be approved in the future, and our ability to serve those markets;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success of products that are or may become available which also target the potential markets for our product candidates;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to operate our business without infringing the intellectual property rights of others and the potential for others to infringe upon our intellectual property rights;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our failure to recruit or retain key scientific or management personnel or to retain our executive officers;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the performance of third parties, including contract research organizations, manufacturers, suppliers, and outside consultants, to whom we outsource certain operational, staff and other functions;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to obtain additional financing in the future and continue as a going concern;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our estimates regarding expenses, future revenues, capital requirements, and needs for additional financing;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory developments in the U.S., E.U., and other foreign jurisdictions;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">recently enacted and future legislation related to the healthcare system, including trends towards managed care and healthcare cost containment, the impact of any significant spending reductions or cost controls affecting publicly funded or subsidized healthcare programs, or any replacement, repeal, modification, or invalidation of some or all of the provisions of the Affordable Care Act;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any significant breakdown, infiltration, or interruption of our information technology systems and infrastructure;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to satisfy the continued listing requirements of the NASDAQ Capital Market or any other exchange on which our securities may trade in the future;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">uncertainties related to general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 2%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">other risks and uncertainties, including those discussed in <i>Part I - Item 1A. - Risk Factors</i> of this Annual Report and elsewhere in our other public filings.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result of these and other factors, known and unknown, actual results could differ materially from our intentions, beliefs, projections, outlook, analyses, or expectations expressed in any forward-looking statements in this Annual Report. Accordingly, we cannot assure you that the forward-looking statements contained in this Annual Report will prove to be accurate or that any such inaccuracy will not be material. You should also understand that it is not possible to predict or identify all such factors, and you should not consider any such list to be a complete set of all potential risk or uncertainties. In light of the foregoing and the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any forward-looking statement that we make in this Annual Report speaks only as of the date of such statement, and, except as required by applicable law or by the rules and regulations of the SEC, we undertake no obligation to update such statements to reflect events or circumstances after the date of this Annual Report or to reflect the occurrence of unanticipated events. Comparisons of current and any prior period results are not intended to express any ongoing or future trends or indications of future performance, unless explicitly expressed as such, and should only be viewed as historical data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Stock Splits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Unless the context otherwise requires, in this Annual Report, all share and per share amounts related to our common stock give effect to (i) our 1-for-15 reverse stock split effective December 13, 2018 and (ii) our 1-for-10 reverse stock split effective August 17, 2016.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Trademarks, Trade Names, and Service Marks</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This Annual Report contains certain trademarks, trade names, and service marks of ours, including &#8220;DIFFUSIO2N.&#8221; All other trade names, trademarks, and service marks appearing in this Annual Report are, to the knowledge of Diffusion, the property of their respective owners. To the extent any such terms appear without the trade name, trademark, or service mark notice, such presentation is for convenience only and should not be construed as being used in a descriptive or generic sense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART I</b></p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 1.</b></td>
			<td style="width: 88%;"><b>BUSINESS</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Diffusion Pharmaceuticals: Enhancing Oxygen, Fueling Life</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to the areas where it is needed most. Our lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition to TSC, our product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR pathway inhibitor, is in early-stage development. We previously completed two Phase 1 clinical trials evaluating DFN-529 in age-related macular degeneration. DFN-529 was also previously in preclinical development in oncology, specifically GBM.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Highlights from 2020 and Early 2021</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Board &amp; Management Additions and Changes </i></b>- During the second half of 2020, our leadership team changed significantly. We appointed our new chief executive officer, Robert J. Cobuzzi, Jr., Ph.D., and our new general counsel, William Elder, in September 2020, followed by our new chief medical officer, Christopher Galloway, M.D., in October 2020. We also welcomed a new director, Jane Hollingsworth, to our Board in August 2020. Dr. Cobuzzi joined the Board in January 2020.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Initiation and Completion of TSC COVID Trial</i></b>&nbsp;- In September 2020, we announced the dosing of the first two patients in our TSC COVID Trial evaluating TSC in hospitalized COVID-19 patients at the NIID in Bucharest, Romania. On February 9, 2021, we completed dosing of the twenty-fourth and final patient in the TSC COVID Trial. No dose-limiting toxicities or serious adverse events were observed among any patients in the study, including those who received the highest dose of 1.5 mg/kg every 6 hours. Evaluation of secondary endpoint data is ongoing and we anticipate this data will be available early in the second quarter of 2021.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>February 2021 Equity Offering &amp; Selected Unaudited Financial Information</i></b>&nbsp;- During the first quarter of 2021, we completed the February 2021 Offering resulting in aggregate gross&nbsp;proceeds to the Company of approximately $34.5 million, before deducting underwriting discounts and commissions and offering expenses payable by us. In addition, during the period from January 1, 2021 through March 15, 2021, certain holders of warrants to purchase common stock cash exercised those warrants resulting in aggregate gross proceeds to the Company of approximately $2.2&nbsp;million. As a result, combined with our cash and cash equivalents as of December 31, 2020 of $18.5 million, we expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditures (including our planned clinical trials) through 2023.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Strategic Priorities for 2021</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Since the founding of Diffusion LLC, we have been principally focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia. Prior to 2020, these efforts generated a substantial amount of data related to TSC, including data related to chemistry, manufacturing, and controls, preclinical safety and/or efficacy data in a wide array of experimental models, single dose safety, tolerability, and pharmacokinetic data, and clinical data and other information related to TSC's potential as a supplement to standard-of-care treatment in GBM, peripheral artery disease, and stroke.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In March 2020, the COVID-19 pandemic accelerated in the U.S. resulting in numerous delays and other challenges for biopharmaceutical companies conducting clinical studies in indications not related to COVID-19, including our TSC Stroke Trial. In early April 2020, we announced plans to initiate a clinical research program to evaluate TSC in patients with COVID-19 due to the anticipated persistence of the COVID-19 pandemic coupled with our belief in the potential of TSC to improve low tissue oxygen levels, a common symptom and complicating factor in the treatment of COVID-19. We believe this decision was both opportunistic and a natural extension of the previous development work conducted with TSC, and in September 2020 we commenced the TSC COVID Trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In November 2020, we announced that, following changes to our management team in the prior two months, we had initiated a thorough review of our then-existing development program for TSC and commenced plans to modify the program with the intent of accomplishing two principal strategic objectives:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;To optimize the clinical dose and dosing frequency for TSC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;To evaluate TSC in clinical models designed to establish proof of concept for improvement in oxygenation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The completion of the TSC COVID Trial in February 2021 provided the first multiple daily dose safety and tolerability data for TSC. We expect corresponding pharmacokinetic and other secondary endpoint data from this trial to be available early in the second quarter of 2021. Obtaining these data represents the first, major step in our ongoing efforts to implement our modified development strategy, intended to strategically&nbsp;gap-fill, supplement, and expand on our past development work in TSC, with the ultimate goal of maximizing the probability of regulatory approval and, if TSC is approved, commercial success.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the next twelve months, we intend to continue to execute our strategy and accomplish the following principal, strategic objectives, all of which we expect to be able to fund with cash-on-hand:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;"><b><i>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Complete the TSC Oxygenation Trials</i></b>&nbsp;&#8211;&nbsp;As described in more detail under the heading, &#8212;<i>&nbsp;Our Lead Product Candidate: Trans Sodium Crocetinate </i>&#8212;<i>&nbsp;Our Anticipated Next Steps in the TSC Development Program: The TSC Oxygenation Trials</i>,&nbsp;the next phase in our development plan is to evaluate TSC's effects in clinical models of oxygenation in an effort to establish a dose-response relationship. We expect to commence&nbsp;the TSC TCOM Trial before the end of&nbsp;March 2021 with data expected in the second quarter of 2021, and we intend to commence both the TSC DLCO Trial and TSC Induced Hypoxia Trial in the third quarter of 2021 with data expected from each study expected within two months of their respective completion.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;"><b><i>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Initiate Phase 2 Trial of TSC in Hypoxia-related Indication</i></b>&nbsp;&#8211;&nbsp;We believe positive data from one or more of the three TSC Oxygenation Trials would provide&nbsp;definitive evidence&nbsp;of TSC's enhancement of&nbsp;oxygenation, whether through increased uptake in the lungs, enhanced delivery, increased utilization at the tissue level, or some combination thereof.&nbsp;&nbsp;Positive data from any of these studies, if obtained, will guide the subsequent steps of our development strategy focused on demonstrating the clinical and therapeutic benefits of TSC in relevant patient populations on the hypoxia continuum. In particular, if successful in one or more of the three TSC Oxygenation Trials, we intend to initiate a Phase 2, controlled, clinical outcome study evaluating TSC in one or more&nbsp;appropriate hypoxia-related indications, which we refer to as our Planned Phase 2 Hypoxia-related Indication Trial, in the first quarter of 2022.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;"><b><i>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Continue to Improve Our Efficiency and Effectiveness</i></b> &#8211; This will include evaluating, refining, and improving our policies, procedures, and processes related to chemistry, manufacturing, and controls, quality assurance, information technology, intellectual property, human capital, and other areas, including as described in more detail under the headings, &#8212; <i>Products, Product Development, and Our Competition</i>&nbsp;and &#8212;<i> Our People and Human Capital Resources</i>.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&nbsp;</p>

<div style="text-align: center;"><img alt="rider.jpg" src="rider.jpg"></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Representation of data supporting the potential use of TSC for the treatment of certain medical conditions complicated by hypoxia. Incidence numbers represent annual incidence in U.S. as reported by U.S. Centers for Disease Control and Prevention and other publicly available sources. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Lead Product Candidate: Trans Sodium Crocetinate</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Hypoxia: A Key Driver of Unmet Medical Needs</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Oxygen is fuel for life. The constant uptake and delivery of oxygen within our body is necessary to sustain life whether at rest or under stress, in sickness and in health.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Normally, the body&#8217;s supply of oxygen sustains life by meeting the demand for oxygen at the cellular level. This availability of sufficient oxygen enables efficient and sustainable generation of energy to support the metabolic demands of the cells. Low oxygen content in the blood stream, also known as hypoxemia, often leads to hypoxia, a condition in which a region of the body's tissues is deprived of sufficient oxygen to produce the energy it needs to survive. This state can only be sustained for very brief periods of time, sometimes just minutes, before the body tissue experiences ischemia, damage, and, eventually, cellular death.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under normal conditions, when oxygen is inhaled through the lungs it diffuses from this area of high oxygen concentration in the air sacs of the lungs, or alveoli, into pulmonary circulation where the oxygen concentration is lower.&nbsp; This diffusion process is passive.&nbsp; Oxygen moves across cell layers and vessel walls into the blood stream in a manner that does not require energy and avoids over-oxygenating the body.&nbsp; Once oxygen reaches the blood stream, it is rapidly taken up onto our red blood cells while a very small amount dissolves in the plasma.&nbsp; The hemoglobin within the red blood cells act as mass transport carriers for oxygen.&nbsp; Red blood cells are pumped throughout our circulatory system by the heart, reaching every cell in our body.&nbsp; Upon reaching its cellular destination, the oxygen is released from the hemoglobin and again passively diffuses from the area of high concentration in the bloodstream to the lower concentration areas in the tissues.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our body's ability to deliver sufficient oxygen in this manner is determined by several factors, including the amount of oxygen in the air we breathe, our cardiac output (i.e., how well the heart circulates the oxygen), our hemoglobin content (i.e., how many transporters there are to carry the oxygen), and the level of oxygen saturation of hemoglobin, which can carry up to four oxygen molecules.&nbsp; A variety of medical interventions are available to augment or supplement these factors in the oxygen delivery process in order to increase mass oxygen delivery.&nbsp; For example, there are medications and mechanical pumps designed to improve cardiac output, blood transfusions to increase hemoglobin content in the blood, and other passive and mechanical methods to increase the systemic availability of oxygen. However, while these existing strategies can be very effective in certain circumstances, they do not specifically focus on enhancing the diffusion process by which oxygen moves from a high concentration area in the bloodstream to a lower concentration are in hypoxic tissue.&nbsp; Accordingly, we believe there remains a significant unmet need in the treatment of hypoxia.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">An additional, important factor in oxygen uptake and delivery is how efficiently the oxygen moves or diffuses across the many impediments that can slow the movement of oxygen through the body, such as the red blood cell walls, water molecules in plasma, cellular layers of the blood vessels, and other tissues. Currently, there is no well-known or widely-used medical method to augment or supplement this factor in the oxygen delivery process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>TSC: A Novel Mechanism of Action and Demonstrated Safety Profile</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We believe that TSC's novel mechanism of action would be the first therapy specifically designed to enhance the oxygen diffusion process, thereby supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>TSC's Novel Mechanism of Action</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Blood plasma is approximately 90.0% water and these water molecules are constantly moving, bound together in a loosely organized matrix by hydrogen bonds. Due to oxygen&#8217;s passive diffusion process through the plasma from areas of high oxygen concentration to areas of low oxygen concentration, a treatment that can reduce the factors that resist this movement should make oxygen more available to hypoxic tissues.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dffn20201231_10kimg003.gif" src="dffn20201231_10kimg003.gif" style="width:499;height:216;"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Representation of oxygen molecules moving from red blood cells, across the concentration gradient, to oxygen-consuming tissues.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">TSC was designed to enhance the level of organization among water molecules by increasing the amount of hydrogen bonding. This creates a less dense matrix of water molecules, reducing the resistance to oxygen diffusion across the concentration gradient. In animal models, this diffusion-enhancing mechanism of action has been observed to affect hypoxic tissue preferentially while avoiding excessive oxygen-related tissue toxicity, also known as hyperoxia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="dffn20201231_10kimg004.gif" src="dffn20201231_10kimg004.gif" style="width:689;height:165;"></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Representation of the indirect course of oxygen molecule movement through </b>&#8220;<b>unorganized</b>&#8221;<b> or randomly moving water molecules (left panel) versus the more direct path through </b>&#8220;<b>organized</b>&#8221;<b> molecules allowed by TSC (right panel).</b><b> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>TSC's Clinical Safety Profile</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">TSC has been observed to be safe and well-tolerated at most doses tested in over 180 subjects included to-date in clinical studies. A maximum tolerated dose was identified in the initial clinical study of TSC conducted in normal healthy volunteers, and subsequent clinical studies have been conducted with lower doses. These studies have included patients with variety of medical conditions often complicated by hypoxia, including our clinical studies conducted in patients afflicted with GBM, peripheral artery disease with intermittent claudication, stroke, and, most recently, COVID-19. In each of these conditions and many others, hypoxia is a significant contributor to morbidity and mortality, and a considerable treatment obstacle for medical providers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the TSC COVID Trial, which we completed in February 2021, we evaluated the safety and tolerability of TSC administered on a more frequent dosing regimen&nbsp;than had been previously tested in a clinical trial setting. No dose-limiting toxicities or serious adverse events were observed among any patients in the TSC COVID Trial, including those who received the highest tested dose of TSC, 1.5 mg/kg administered intravenously every six hours for a period of at least five and up to 15 days.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>TSC's Potential to Treat Hypoxia-Related Conditions</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Hypoxia is a critical, complicating factor in many intractable and difficult-to-treat conditions affecting people of all ages, including cancers, cardiovascular disease, stroke, respiratory disease including ARDS, skin and soft tissue diseases, and neurodegenerative diseases. &nbsp;We have previously evaluated TSC in a variety of preclinical and clinical studies.&nbsp; We believe that the data we have obtained through certain preclinical studies provide support for TSC&#8217;s ability to improve oxygenation, while data obtained through the clinical trials we have undertaken to date suggest TSC is safe and well-tolerated at the doses tested, including administration of TSC to more than 180 human subjects and patients with GBM, acute stroke, COVID-19, acute lung injury, and peripheral artery disease with intermittent claudication.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Clinical and Preclinical Development of TSC to Date</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Selected Preclinical Experiences</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">TSC has been evaluated in a variety of preclinical models intended to mimic relevant human conditions known to be complicated by hypoxia. In these studies, a number of positive effects have been observed in connection with TSC administration, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Reducing hypoxia in rat brain tumors without hyper-oxygenation of normal tissue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dffn20201231_10kimg006.gif" src="dffn20201231_10kimg006.gif" style="width:599;height:273;"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Positron emission tomography scans showing reduction in hypoxia in a rat C6 glioma brain tumor model 45 min after TSC administration.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Improving survival in a rat brain tumor model when added to radiotherapy, whether or not combined with chemotherapy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Improving tissue oxygenation without hyper-oxygenation of normal tissue and reducing infarct size in a rat ischemic stroke model.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Demonstrating a functional benefit in a rabbit ischemic stroke model, with or without tPA at one-hour post-clot infection and with tPA at three hours post-clot infection.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Improving arterial PaO2 levels in a rat model of ARDS.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Glioblastoma Multiforme</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe TSC may be able to benefit cancer patients by re-oxygenating hypoxic cancer tissue, making the cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. In particular, GBM is an especially deadly form of brain cancer that each year affects approximately 12,000 patients in the U.S. and approximately 35,000 patients worldwide, and for which TSC has received an Orphan Drug Designation from the FDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We previously completed a Phase 2 clinical trial that evaluated 59 patients with newly diagnosed GBM. This open-label, historically controlled trial demonstrated a favorable safety and tolerability profile for TSC when combined with standard of care treatment for GBM. Although not prospectively defined, a post hoc subgroup analysis of inoperable patients suggested a higher proportion of TSC-treated patients survived at two years compared to those in the historical control group.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based upon data from the inoperable patient subgroup in the Phase 2 trial and guidance from the FDA received at our End-of-Phase-2 meeting, we initiated the TSC GBM Trial in the newly diagnosed inoperable GBM patient population in December 2017. The TSC GBM Trial was designed to enroll 236 patients in total, with 118 in the treatment arm and 118 in the control arm. The trial began with an FDA-mandated, open-label, dose-escalation safety run-in for which enrollment was completed and has closed. A total of 19 patients were enrolled in an attempt to ensure that at least 8 patients completed the FDA-specified 42-month exposure period. At a meeting in the third quarter of 2019, the data safety monitoring board for the trial concluded that no adverse safety signal was present and unanimously recommended the trial continue as planned, with TSC to be used in combination with temozolomide, an anti-cancer chemotherapy drug, during the adjuvant treatment chemotherapy period. However, we determined we did not have adequate resources at the time to fully support the randomized portion of the TSC GBM Trial and commencement of enrollment in the randomization portion of the TSC GBM Trial was suspended. Further consideration of if, when, and how to continue the development of TSC as a treatment for GBM &#8212; including any restart of the TSC GBM Trial &#8212; will take place following completion of the TSC Oxygenation Trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Stroke</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe TSC has potential applications in both ischemic and hemorrhagic stroke through mitigation of stroke-induced hypoxia and related damage to brain tissue. A stroke occurs when blood flow to the brain is blocked, referred to as an ischemic stroke,&nbsp;or a blood vessel in the brain ruptures, referred to as a hemorrhagic stroke, causing damage to surrounding brain tissue. According to the U.S. Centers for Disease Control and Prevention, stroke is the fifth leading cause of death and a leading cause of adult disability in the U.S. The hypoxic conditions in the brain of stroke patients may be a significant factor contributing to morbidity and mortality and, based upon certain preclinical safety and efficacy data and additional clinical safety data, we believe TSC could enhance the diffusion of oxygen into brain tissue to reduce stroke-induced hypoxia and neuronal death.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In October 2019, we began enrolling patients in our TSC Stroke Trial, a randomized Phase 2 trial designed to evaluate TSC in the treatment of acute ischemic or hemorrhagic stroke. The TSC Stroke Trial was planned to enroll 160 total patients, evenly split between the TSC treatment arm and the control arm, with all patients to receive TSC or placebo treatment, as applicable, while in the ambulance to ensure treatment as soon as possible after the onset of clinical symptoms. However, due to a variety of factors, including challenges related to the trial's on-ambulance treatment design and overall healthcare system capacity related to the onset of the COVID-19 pandemic during the first half of 2020, we voluntarily terminated the TSC Stroke Study in the second half of 2020 in order to prioritize resources to shorter duration studies, including the TSC COVID Trial and the TSC Oxygenation Trials. Further consideration of if, when, and how to continue the development of TSC as a treatment for stroke will take place following completion of the TSC Oxygenation Trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>COVID-19</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We believe TSC&#8217;s oxygen-enhancing mechanism could potentially provide benefit to patients with low oxygen levels at risk of developing ARDS and multiple organ failure, such as patients with COVID-19.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On September 10, 2020, we announced the dosing of the first two patients in our TSC COVID Trial evaluating TSC in hospitalized COVID-19 patients at the NIID in Bucharest, Romania. The primary endpoint of the TSC COVID Trial was to evaluate the safety and tolerability of TSC administered every six hours for at least five and up to 15 days, a more frequent dosing regimen than had been used in our previous clinical studies. Secondary endpoints included pharmacokinetic measurement of TSC levels after dosing, relative improvements in blood oxygen levels, and certain other clinical parameters related to COVID-19.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 9, 2021, we completed dosing of the twenty-fourth and final patient in the TSC COVID Trial. No dose-limiting toxicities or serious adverse events were observed among any patients in the study, including those who received the highest dose of 1.5 mg/kg every 6 hours. Evaluation of secondary endpoint data is ongoing and we anticipate this data will be available early in the second quarter of 2021. Further consideration of if, when, and how to continue the development of TSC as a treatment for COVID-19 &#8212; including any commencement of enrollment in the previously announced Phase 2b portion of the TSC COVID Trial &#8212; will take place following completion of the TSC Oxygenation Trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Our Anticipated Next Steps in the TSC Development Program: The TSC Oxygenation Trials</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Following completion of the TSC COVID Trial in February 2021, the next step we have planned in the development of TSC is the design and execution of a trilogy of clinical studies using short-term, experimental models to evaluate the clinical effects of TSC on oxygenation. As of March 15, 2021, TSC has been administered to more than 180 subjects in our clinical trials. Data from these clinical trials have contributed significantly to our understanding of the safety, tolerability, and pharmacokinetics of TSC. In addition, post hoc analyses of two of our prior studies involving patients with peripheral artery disease with claudication and unresected GBM tumors have provided preliminary signals suggesting TSC's effect on oxygenation. However, neither of these studies was statistically powered to formally evaluate efficacy, and we therefore believe that further, robust clinical development of TSC requires a prospective exploration of the relationship between the level of exposure (dose) and response (change in oxygenation).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">To this end, we plan to execute three short-term clinical trials during 2021, each of which we expect to conduct in the U.S. and fund with cash-on-hand. We believe positive data from any one or more of the three TSC Oxygenation Trials would provide evidence of a definitive effect of TSC on oxygenation, whether through increased uptake in the lungs, enhanced delivery, increased utilization at the tissue level, or some combination thereof. Positive data from any of these studies, if obtained, will also guide the subsequent steps of our development strategy focused on demonstrating the clinical and therapeutic benefits of TSC in relevant patient populations across the hypoxia continuum.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>The TSC TCOM Trial: TSC's Effects on Peripheral Tissue Oxygenation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The first of the three Oxygenation Trials is the TSC TCOM Trial, which we expect to initiate before the end of March 2021. The TSC TCOM Trial is designed as a double-blind, randomized, placebo-controlled study in healthy volunteers breathing 100.0% oxygen. The study is designed to evaluate the effects of TSC on peripheral tissue oxygenation using a TCOM device. The TCOM device directly measures the release of oxygen from the blood vessels through the skin and is commonly used to predict the likelihood of wound healing, the potential for success with hyperbaric therapy, and to map the appropriate location for limb amputation. The TSC TCOM Trial will test single, ascending doses of TSC in an attempt to establish the exposure-response relationship between TSC and enhanced oxygen delivery and will be statistically powered to evaluate the difference in tissue oxygenation levels versus placebo. We anticipate this study will be completed in the second quarter of 2021, with topline results available within two months following study completion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>The TSC Induced Hypoxia Trial: TSC's Effects Under Induced Hypoxic Conditions</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The second TSC Oxygenation Trial is our planned TSC Induced Hypoxia Trial, which we expect to initiate in the third quarter of 2021. The TSC Induced Hypoxia Trial is expected to be a double-blind, randomized, placebo-controlled study which will evaluate the effects of TSC on maximal oxygen consumption, or VO2, and partial pressure of blood oxygen, or PaO2, in normal healthy volunteers exposed to simulated altitude conditions that induce hypoxia.&nbsp; Subjects in the TSC Induced Hypoxia Trial will be subjected to incremental levels of physical exertion while exposed to hypoxic and hypobaric conditions. The primary endpoints in the TSC Induced Hypoxia Trial will be change from baseline in VO2 and PaO2 after receiving a single intravenous dose of TSC. The study will be statistically powered to evaluate the difference in effect of escalating doses of TSC versus placebo in an attempt to establish a dose-response relationship on oxygen consumption and availability. We anticipate this study will be completed in the second half of 2021, with topline results available within two months of study completion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>The TSC DLCO Trial: TSC's Effects on Oxygen Transfer Efficiency</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The third TSC Oxygenation Trial is our planned TSC DLCO Trial, which we expect to initiate in the third quarter of 2021. The TSC DLCO Trial is expected to be a double-blind, randomized, placebo-controlled study which will evaluate the effects of TSC on the diffusion of carbon monoxide through the lungs, also known as DLCO, in patients with previously diagnosed interstitial lung disease who have a baseline DLCO test result that is abnormal. DLCO testing is commonly performed as part of standard pulmonary function testing and aids in the diagnosis or dyspnea, also known as shortness of breath, as well as to track improvement or progression over time on prescribed treatments. In the TSC DLCO Trial, DLCO will act as a surrogate measure of oxygen transfer efficiency, or uptake, from the alveoli of the lungs, through the plasma, and onto hemoglobin within red blood cells. The TSC DLCO Trial TSC will test single, ascending doses of TSC in an attempt to establish the exposure-response relationship between TSC and oxygen transfer efficiency. The study will be statistically powered to evaluate the difference in effect of TSC on improvement in DLCO versus placebo. We anticipate this study will be completed in the second half of 2021, with topline results available within two months of study completion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Anticipated Next Steps Following Completion of the TSC Oxygenation Trials</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Assuming success in one or more of the three TSC Oxygenation Trials, we expect to identify and announce the specific, hypoxia-related indications we will target in advancing TSC's development in the fourth quarter of 2021 and intend to initiate our Planned Phase 2 Hypoxia-related Indication Trial in the first quarter of 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dffn20201231_10kimg005.gif" src="dffn20201231_10kimg005.gif" style="width:498;height:351;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Certain medical conditions complicated by hypoxia.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Second Product Candidate: DFN-529</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our product candidate DFN-529 is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase 1 clinical trials for age-related macular degeneration and was previously in preclinical development in oncology, specifically for GBM. DFN-529 has shown activity in both in vitro and in vivo GBM animal models and has been demonstrated to be orally bioavailable and capable of crossing the blood brain barrier. We are currently in discussions with multiple third-party research scientists regarding the potential initiation of further studies to evaluate the effects of DFN-529 in preclinical cancer models. We believe these additional data may help guide us in choosing an appropriate clinical development pathway for DFN-529. We also continue to explore business options for DFN-529, including out-licensing opportunities and other strategic partnerships.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Products, Product Development, and Our Competition</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Research and Development</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In recent years, the majority of our research and development expenditures have been directed to the development of TSC. For example, during the year ended December 31, 2020, we incurred approximately $9.4 million in costs related to research and development of our products, an increase of approximately $2.8 million compared to the year ended December 31, 2019.&nbsp; The majority of these costs were related to the development of TSC and related personnel, including costs associated with the TSC COVID Trial, which commenced in September 2020 and was completed in February 2021, as well as the wind down of the TSC Stroke Trial, which commenced in October 2019 and was terminated in the second half of 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We expect this trend to continue for the foreseeable future, including planned expenditures related to the TSC Oxygenation Trials and other costs associated with the conduct of additional, supportive preclinical studies and general research and development activities related to TSC. We intend to focus the remainder of our foreseeable research and development expenditures will on the development of DFN-529, including additional preclinical studies evaluating DFN-529 in cancer models that we are in the early stages of planning.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As a development-stage company, we continuously evaluate opportunities to improve the value of our development pipeline, including potential acquisition and in-licensing opportunities.&nbsp; Our efforts include ongoing evaluation and modification of our development plans intended to maximize the probability of technical, developmental, and regulatory success while enhancing patient and stockholder value. These activities have, and we expect they will continue to be for the foreseeable future, focused on opportunities that are synergistic with our overall corporate strategy to develop novel treatments for the treatment of hypoxia and conditions complicated by hypoxia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Our Intellectual Property</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We believe that a strong intellectual property portfolio is critical to our success. We are committed to obtaining and maintaining appropriate patent and other protections for our products candidates and other technologies, preserving and protecting our trade secrets and other confidential and proprietary information, and fiercely defending our intellectual property portfolio against any potential infringement by third parties. We attempt to protect our intellectual property through among other things, the filing of applications for patent, trademark, and other appropriate intellectual property protections, the use of confidentiality agreements with consultants, contractors and other third parties, our employee policies regarding confidentiality, invention disclosure, and the assignment of inventions, as well as regular meetings of members of our internal development and legal teams, which contains key members of our management team. We are also committed to operating our business without infringing on the intellectual property of others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In general, patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in various countries where patent protection is obtained, with term adjustments or extensions possible in certain cases based on patent office delays or pursuant to certain administrative and legislative exceptions. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We continue to invest significant time, effort, and resources into the development and maintenance of our patent portfolio. As of December 31, 2020, we owned 16 issued U.S. patents and 36 issued non-U.S. patents, and had numerous patent applications pending worldwide including issued patents and applications in major markets such as the U.S., E.U., China, Japan, and India. The normal life (i.e. with no adjustments or extensions) of our key issued patents related to the composition of matter of TSC extends to 2026, with potential patent term extensions to 2031, and the normal life of our patents related to an oral formulation of TSC extends to 2031, with potential patent term extensions to 2036. Additional information regarding patent term extensions can be found under the heading, see &#8212;<i> Government Regulation </i>&#8212;<i> The Hatch-Waxman Amendments </i>&#8212;<i> Patent Term Restoration and Marketing Exclusivity</i>. In addition, TSC has been granted Orphan Drug designation by the FDA for the treatment of both GBM and metastatic brain cancer, which may provide us with certain rights of exclusivity under certain FDA regulations. Additional information regarding orphan and ultra-orphan can be found under the heading, see &#8212;<i> Government Regulation </i>&#8212;<i> Certain Other FDA Regulations </i>&#8212;<i> The Orphan Drug Act of 1983</i>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Materials and Manufacturing</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We do not currently own or operate any facilities suitable for manufacturing TSC or any of our other product candidates on a scale required to support either clinical development or commercialization. We currently use third-party CMOs to manufacture API, other starting materials, and finished drug product for our preclinical studies and clinical trials and we intend to continue doing so for the foreseeable future. We anticipate this strategy will be scalable in a manner sufficient to support the production capacity required to support continued clinical development and ultimate commercialization. However, we do not have any formal agreements at this time with any CMO to cover commercial production of TSC or any other product candidate.&nbsp; Although the use of third party CMOs to manufacture pharmaceutical products is common within the industry, this dependence on third-party CMOs exposes our business to certain risks, including those described in <i>Part I </i>&#8211;<i> Item 1A. Risk Factors </i>&#8211;<i> Risks Related to the Development, Regulatory Approval, and Commercialization of TSC and Our Other Product Candidates</i>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b><i>Our Competition</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Currently, medical options to improve oxygenation without risk of hyper-oxygenation are limited and we believe that TSC's diffusion enhancing mechanism of action make it a first-in-class, novel, small molecule. However, there are several companies currently developing or marketing products, therapeutics, or devices that may nevertheless be competitive with TSC, if approved, including NuvOx Pharma LLC, Hemoglobin Oxygen Therapeutics LLC, and Cardax, Inc. In addition, in the first quarter of 2021, we became aware of a third party affiliated with a former outside consultant of the Company which claims to be in early-stage development of a product candidate that purportedly may operate through a similar mechanism of action to TSC. It is unclear if this particular product candidate would, if developed and approved, actually be competitive with TSC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our industry is highly competitive and subject to rapid and significant change. Potential competitors in the United States are numerous and include major pharmaceutical and specialty pharmaceutical companies, smaller biopharmaceutical companies, research universities, and others. The biopharmaceutical and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing, and marketing of health care products competitive with those that we are developing. Many of our competitors have longer operating histories, greater name recognition, substantially greater financial resources, and larger research and development staffs than we do, as well as substantially greater experience than us in developing products, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. In addition, a significant amount of research is carried out at academic and government institutions. These institutions are aware of the commercial value of their findings and are aggressive in pursuing patent protection and negotiating licensing arrangements to collect royalties for use of technology that they have developed. One or more of these companies or other entities may have one or more products under development that would be competitive with TSC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Sales and Marketing</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We currently have no marketed products and, accordingly, currently have no sales or marketing personnel.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Government Regulation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pharmaceuticals like TSC, DFN-529, and other product candidates we may develop are highly regulated by governmental authorities in the U.S. and other countries at the federal, state, and local levels. These regulations are numerous and extensive in their scope, relating to, among other things, the research and development, manufacture, storage, quality control and testing, approval, labeling and packaging, promotion, marketing, and advertising, distribution, post-approval monitoring and reporting, export and import, and record keeping of pharmaceutical products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>The FDA Drug Approval Process</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Generally, before a new pharmaceutical product can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each applicable regulatory authority, submitted for review, and approved by the competent regulatory authority. In the United States, the competent regulatory authority is the FDA, which, pursuant to the FDC Act, is responsible for the review and approval of all data required to support a license to commercially market pharmaceuticals such as TSC and DFN-529.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The process of obtaining regulatory approvals and the subsequent compliance with FDA regulations requires the expenditure of substantial time and financial resources and failure to comply with the applicable requirements at any time during the product development process, approval process, or, if approved, following approval may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls, market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties, any of which could have a material adverse effect on our business, financial position, or results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Process Overview</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The FDA drug approval process generally involves the following steps:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;completion of extensive preclinical laboratory studies , including studies conducted in accordance with GLP requirements;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;submission to the FDA of an IND application, which must become effective before clinical trials involving human subjects or patients may begin;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP requirements, and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication, including approval by an IRB or independent ethics committee before each trial may be initiated;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;submission to the FDA of an NDA;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;a determination by the FDA within 60 days of its receipt of an NDA as to whether it will accept the filing for review;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;a potential FDA audit of the clinical trial sites that generated the data in support of the NDA;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;payment of user fees for FDA review of the NDA; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the biologic or drug in the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preclinical and clinical testing and approval process requires substantial time, effort, and financial resources and satisfaction of FDA pre-market approval requirements typically takes many years, though the actual time required may vary substantially based upon the type, complexity, and novelty of the applicable product or indication to be treated. We cannot be certain that any approvals for TSC, DFN-529, or any product candidates we attempt to develop in the future will be granted on a timely basis or at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Preclinical Studies</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Preclinical studies include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the drug. The results of preclinical testing are submitted to the FDA as part of an IND along with other information related to the drug, including information regarding its chemical make-up, manufacturing process, and quality controls, as well as a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Clinical Trials</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Following completion of preclinical studies and the submission on an IND to the FDA, a 30-day waiting period is required. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Clinical trials involve the administration of an investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. These trials must be conducted in compliance with federal regulations as well as GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors. Each trial is conducted under a protocol detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap, especially in certain indications such as cancer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;<u>Phase 1</u> - In Phase 1 trials, an investigational new drug is introduced into healthy human subjects and is evaluated to assess pharmacological actions, side effects associated with increasing doses and, in certain cases, early evidence on efficacy.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;<u>Phase 2</u> - In Phase 2 trials, the drug is introduced to a limited patient population in a particular indication to determine metabolism, pharmacokinetics, the effectiveness of the drug for the indication, dosage tolerance and optimum dosage, and to identify potential adverse effects and safety risks.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;<u>Phase 3</u> - In Phase 3 trials, if a drug has demonstrated evidence of effectiveness and an acceptable safety profile in prior Phase 2 trials, the drug is introduced to a larger patient population in the relevant indication to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug, and to provide adequate information for the labeling of the drug, if approved.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Not all drug development programs are required to follow the order and content of all three phases. For example, in August 2018, the FDA released a draft guidance entitled, &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development, i.e., the first-in-human clinical trial, to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts is included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce developmental costs and time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators 15 calendar days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Phase 1, Phase 2, Phase 3, and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>New Drug Application and FDA Review Process</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA containing data intended to provide substantial evidence that the drug is safe and effective in the relevant indication, and FDA approval of the NDA is required before commercial marketing of the product may begin in the United States. The NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacturing, and controls. The cost of preparing and submitting an NDA is substantial, and the submission of most NDAs is also subject to substantial initial and ongoing fees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The FDA has 60 days from its receipt of an NDA to determine whether the NDA will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review subject to certain performance goals agreed upon by the FDA. Priority review can be applied in certain instances, including with respect to drugs that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy exists. The review process, whether standard or priority, may be extended by the FDA for three additional months to consider certain late-submitted information or information intended to clarify information already provided in the submission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or facilities at which the drug is manufactured to confirm compliance with cGMP. The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee. This advisory committee is typically a panel that includes clinicians and other experts in the relevant indication or subject matter who review and evaluate the NDA and provide a recommendation to the FDA as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">After the FDA evaluates the NDA, the clinical sites, the manufacturing facilities, and, as needed, receives a recommendation from the advisory committee, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. The FDA has committed to reviewing such resubmissions in two to six months depending on the type of new information included.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>FDA Approval Letter</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">An FDA approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy including, in certain cases, REMS as described in more detail under the heading, &#8212;<i>Certain Other FDA Regulations </i>&#8211;<i> Risk Evaluation and Mitigation Strategies and Other Post-Approval Requirements</i>. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Further, changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses similar procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>The Hatch-Waxman Amendments</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Drug Price Competition and Patent Term Restoration Act, commonly referred to as the Hatch-Waxman Amendments, is a 1984 U.S. federal law which established the modern system of generic drug regulation in the U.S. The Hatch-Waxman Amendments were enacted to encourage the manufacture of generic drugs by outlining the process for generic pharmaceutical manufacturers to file an abbreviated new drug application and to provide certain related protections to drug development innovators, namely a new kind of market exclusivity period and the ability to potentially extend patent life by a portion of the time a drug is under regulatory review by the FDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Orange Book Listing and Abbreviated New Drug Applications</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#8217;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an ANDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">An ANDA applicant is required to make certain certifications to the FDA concerning any such patents listed in the Orange Book for the approved reference drug intended to confirm that the proposed generic equivalent will not infringe on any intellectual property related to the reference drug, commonly referred to as a Paragraph IV certification. The ANDA process gives the owner of the reference drug an opportunity to assert a patent infringement claim if it believes its intellectual property rights are being infringed upon following the submission of a Paragraph IV certification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">An ANDA will not be approved until all patents and non-patent exclusivity periods listed in the Orange Book for the reference drug have expired.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Patent Term Restoration and Marketing Exclusivity</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Certain of our current and future product candidates, including TSC, may be eligible for patent term restoration and marketing exclusivity under the Hatch-Waxman Amendment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally 50.0% of the amount of time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for such an extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Marketing exclusivity provisions under the FDC Act can also delay the submission or the approval of certain marketing applications. The FDC Act provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example investigations related to new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of use. The FDC Act also provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity, meaning the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. Three-year and five-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b><i>Certain Other FDA Regulations</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>The Orphan Drug Act of 1983</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.&nbsp;Our lead product candidate, TSC, has been granted Orphan Drug designations by the FDA with respect to the t</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. For example, we previously announced that TSC was granted orphan drug designation by the FDA for the treatment of GBM and metastatic brain cancer in July 2011 and in December 2012, respectively. However, orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process but may result in certain financial and marketing incentives if approved.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because health care professionals are free to prescribe products for off-label uses, the competitor&#8217;s product could be used for the orphan indication despite our orphan exclusivity. Orphan drug exclusivity could also block the approval of one of our products for seven years if a competitor obtains approval before we do for the same drug and same indication, as defined by the FDA, for which we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the E.U. has similar, but not identical, requirements and benefits.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Expedited Development and Review Programs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than IMM that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. If the FDA determines that the conditions of approval are not being met, the FDA can withdraw its accelerated approval for such drug.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Additionally, a drug may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Rare Pediatric Disease Priority Review Voucher Program</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For purposes of this program, a &#8220;rare pediatric disease&#8221; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (b) rare diseases or conditions within the meaning of the Orphan Drug Act. On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any Rare Pediatric Disease Priority Review Voucher.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Disclosure of Clinical Trial Information</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Sponsors of clinical trials of FDA-regulated products are required to register and disclose to the public certain clinical trial information, including information related to the product, patient population, phase of investigation, study sites, investigators, and other aspects of the trial design. Sponsors are also obligated to discuss the results of their clinical trials after completion. However, disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved as competitors may otherwise use this or other publicly-available information to gain knowledge regarding the progress of development programs and gain a competitive advantage.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Risk Evaluation and Mitigation Strategies and Other Post-Approval Requirements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a condition of NDA approval, the FDA may require a REMS to help ensure that the benefits of the drug&#8217;s continued approval outweigh the potential risks. In determining whether a REMS is necessary, the FDA must consider the size of the population likely to use the drug, the seriousness of the disease or condition to be treated, the expected benefit of the drug, the duration of treatment, the seriousness of known or potential adverse events, and whether the drug is a new molecular entity. If the FDA determines a REMS is necessary, the drug sponsor must agree to the REMS plan at the time of approval. REMS can include medication guides, communication plans for healthcare professionals, and ETASU, or elements to assure safe use. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring requirements, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of a drug product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Even if the FDA does not require a REMS, once an NDA is approved, a product will be subject to certain post-approval regulations. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet. Adverse event reporting and the submission of periodic reports are also required following FDA approval of an NDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><b><i>Drug Approval Process and Other Regulations Outside of the U.S.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to regulations in the U.S., we are and will be subject to the regulations of other countries in which we conduct any of our clinical trials or engage in commercial sales or other distribution of our products, if approved. Whether or not we obtain FDA approval for conduct of a clinical trial or distribution of a product, we must obtain approval from the competent regulatory authority of any country or economic area in which we would seek to commence a clinical trial or market products. For example, conduct of the TSC COVID Trial at the NIID in Bucharest, Romania, required certain approvals from regulatory authorities in Romania and the E.U. Certain countries outside of the United States have a process similar to the FDA&#8217;s IND process which requires the submission of a CTA prior to the commencement of human clinical trials. In the E.U., for example, a CTA must be submitted to each country&#8217;s national health authority and an independent ethics committee, which operates similar to an IRB under U.S. regulations. Once the CTA is approved in accordance with a country&#8217;s requirements, the clinical trial may proceed in the applicable country. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In particular, in the E.U. a company may submit marketing authorization applications (comparable to an NDA submission in the US to the FDA) under either a centralized or decentralized procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders, or diabetes and is optional for medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all E.U. member states. The decentralized procedure provides for mutual recognition of national approval decisions. Under this decentralized procedure, the holder of a national marketing authorization in any E.U. member state may submit an application to the remaining member states. Within ninety days of receiving the applications and assessments report, each member state must decide whether to recognize approval. If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. The E.U. also has procedures similar to those of the FDA pursuant to which a company may obtain marketing exclusivity for a product for up to 11 years and/or orphan drug designation and related exclusivity for up to ten years, as well as other expedited approval pathways available to certain drugs.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a product candidate must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the E.U. provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product candidates launched in the E.U. do not follow price structures of the U.S. and generally tend to be significantly lower.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b><i>Certain Other Legislation and Regulations</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Current Healthcare Laws and Regulations</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Healthcare providers, physicians, and third party payors, including governmental payors such as Medicare and Medicaid, will play a significant&nbsp;role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements with third party payors, healthcare providers, and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute any drugs for which we obtain marketing approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">These laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, and other federal, state, and local regulations and legislation impacting the pharmaceutical and biopharmaceutical industries, including but not limited to those described below.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Health Insurance Portability and Accountability Act</u>&nbsp;- HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, or falsifying, concealing, or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. HIPAA, as amended by HITECH and their respective implementing regulations, imposes, among other things, specified requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information, including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state Attorneys General new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;&nbsp;fees and costs associated with pursuing federal civil actions.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Affordable Care Act</u>&nbsp;- The Affordable Care Act was enacted in March 2010 and included measures intended to significantly change the way healthcare is financed in the U.S. by both governmental and private insurers which have and may continue to impact the pharmaceutical and biopharmaceutical industries, including expanded Medicare and Medicaid benefits, expansion of healthcare fraud and abuse laws, establishment of the Centers for Medicare &amp; Medicaid Services, annual reporting requirements for manufacturers and distributors. Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. In addition, subsequent legislation, including the Budget Control Act of 2011, American Taxpayer Relief Act of 2012, and Coronavirus Aid, Relief, and Economic Security Act of 2020, has limited and supplemented various provisions of the Affordable Care Act. While we cannot predict what effect further changes to the Affordable Care Act would have on our business, the Affordable Care Act is likely to continue to impact the regulatory regime to which we are subject for the foreseeable future, and we cannot predict the ultimate content, timing, or effect of any healthcare reform legislation or the impact of potential legislation on us.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>21st Century Cures Act</u>&nbsp;- The 21st Century Cures Act, which the U.S. House of Representatives passed in July 2015 and President Obama signed into law in December 2016, provides for a wide range of reforms that may impact our business, such as broadening the types of data required to support drug approval, extending protections from genetic competition, accelerating approval of breakthrough therapies, expanding the orphan drug product and compassionate use programs, and clarifying how manufacturers communicate about their products.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Anti-Kickback Laws</u>&nbsp;- The federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer, or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug or any other good or service, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties, and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>False Claims Laws</u>&nbsp;- The federal False Claims Act imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money to the federal government. The government may deem manufacturers to have &#8220;caused&#8221;&nbsp;the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Medicare Prescription Drug, Improvement, and Modernization Act</u>&nbsp;- The Medicare Prescription Drug, Improvement, and Modernization Act of 2003&nbsp;imposes requirements on the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans, but plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any reduction in payment that results from this or any similar legislation in the future may result in a similar reduction in payments from non-governmental payors.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>The Physician Payments Sunshine Act</u>&nbsp;- The Physician Payments Sunshine Act, enacted as part of the Affordable Care Act,, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, for certain payments and &#8220;transfers of value&#8221;&nbsp;provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>State, Local, and Non-U.S. Legislation and Regulations</u>&nbsp;- In addition, to the legislation summarized above, we may also be subject now or in the future to analogous state, local, and non-U.S. laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply regardless of payor. Such laws are enforced by various state agencies and through private actions. For example, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, and restrict marketing practices or require disclosure of marketing expenditures. Certain state and foreign laws also govern the privacy and security of health information in some circumstances and these data privacy and security laws may differ from both HIPAA and each other in significant ways, which would potentially increase our compliance burden.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight, and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Future Healthcare Laws and Regulations</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the United States and foreign jurisdictions, there have been a number of proposed changes regarding the healthcare system and its regulation that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that further implementation of current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any strategic collaborators, may receive for any approved products. Further, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;"><i>U.S. Environmental, Health, and Safety Laws</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are subject to numerous environmental, health, and safety laws and regulations. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Public Company Status</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a public company, we incur significant legal, accounting and other expenses to comply with the reporting requirements of the Exchange Act and applicable requirements of SOX and the Dodd-Frank Act, as well as rules and regulations subsequently implemented by the SEC and Nasdaq, including the establishment and maintenance of effective disclosure and financial controls, changes in corporate governance practices and required filing of annual, quarterly and current reports with respect to our business and operating results. These requirements increase our legal and financial compliance costs and make some activities more time-consuming and costly. In addition, our management and other personnel devote significant time and attention to these public company requirements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our People and Human Capital Resources</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b><i>Employees</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of December 31, 2020, we had 12 full-time employees and one part-time employee, up from 12 employees as of December 31, 2019, and as of March 15, 2021, we have added one additional full-time employee in 2021. We also regularly work with several independent consultants and other contract organizations to support our business and we regularly evaluate additional talent to help support our product manufacturing, development, financial, and other capabilities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Diversity and Inclusion</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We believe that an inclusive culture is required to understand and develop products that benefit all patients.&nbsp; By embracing differences, we aim to foster an environment of respect and trust in an effort to facilitate creativity, spark passion, and help us achieve better outcomes for all those who work at and with Diffusion. We are committed to creating and maintaining a workplace free from discrimination or harassment, including on the basis of any class protected by&nbsp;applicable&nbsp; law, and our recruitment, hiring, development, training, compensation, and advancement practices are based on qualifications, performance, skills, and experience without regard to gender, race, or ethnicity.&nbsp; Our management team and employees are expected to exhibit and promote honest, ethical, and respectful conduct in the workplace, including adhering to the standards for appropriate behavior set forth in our code of conduct.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Compensation and Benefits</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We operate in a highly competitive environment for human capital, particularly as we seek to attract and retain talent with relevant experience in the biotechnology and pharmaceutical sectors. Therefore, we strive to provide a total rewards package to our employees that is competitive with our peer companies, including competitive pay, a comprehensive healthcare benefits package (including an 80.0% employer contribution to family medical coverage), health savings accounts with a company contribution, 25 days of paid leave, the 401(k)&nbsp;plan, flexible work schedules, and other benefits.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We also offer every full-time employee the benefit of equity ownership in Diffusion through stock option grants. We believe these grants both help promote alignment between our employees and our stockholders and provide retention benefits, as the awards generally vest over a three-year period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We do not have any employees that are represented by a labor union or that have entered into a collective bargaining agreement with the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Safety, Wellness, and Our Response to COVID-19</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At Diffusion, we believe that health matters to everyone, and the safety health, and wellness of our employees is one of our top priorities. We are committed to developing and fostering a work environment that is safe, professional, and promotes teamwork, diversity, and trust in order to afford all of our employees the opportunity to contribute to the best of their abilities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During 2020, in response to the COVID-19 pandemic, we took certain measures and responded to changes in our operational needs, including actions designed to provide a safe work environment for our employees. These actions included investing in technology solutions to support increased work-from-home capabilities, shifting work schedules to reduce the number of people present in our offices, requiring mask wearing and social distancing, making hand sanitizer readily available, and other measures intended to comply with health and safety protocols as required by federal, state, and local governmental agencies, as well as guidance from the U.S. Centers for Disease Control and Prevention and similar public health authorities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Employee Development and Training</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe our people are among our most important assets. We focus on attracting, retaining, and cultivating talented individuals and believe in investing in our people to help them grow. Employees are encouraged to attend scientific, clinical, technological, and other relevant meetings and conferences and we strive to provide employees access to a broad set of internal resources intended to help them be successful, including a variety of training and educational materials. During 2021, we intend to implement a new, comprehensive employee evaluation program tied to the achievement of individual, team, and company goals to help further support, retain, and develop our people and further promote alignment of interests between our employees, future target customers, and our stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Directors and Executive Officers</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The information set forth in&nbsp;<i>Part III </i>&#8212;<i> Item 10 </i>&#8212;<i> Directors, Officers, and Corporate Governance</i>&nbsp;of this Annual Report is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Company</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Corporate Information and History</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We were originally incorporated under the laws of the State of Nevada on January 10, 1995 and reincorporated under the laws of the State of Delaware on June 18, 2015 under the name, &#8220;RestorGenex Corporation.&#8221; On January 8, 2016, we completed the merger of our wholly owned subsidiary with and into Diffusion LLC, which was treated as a "reverse acquisition" under GAAP pursuant to which Diffusion LLC's historical results of operations replaced the Company's for all periods prior to the merger. Immediately following the closing of the merger, we changed our name from "RestorGenex Corporation" to "Diffusion Pharmaceuticals Inc." Our principal corporate office is located at 1317 Carlton Avenue, Suite 200, Charlottesville, Virginia 22902, and our telephone number is (434) 220-0718.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our website, www.diffusionpharma.com, including the Investor Relations section, investors.diffusionpharma.com, and our social media channels &#8211; Facebook (www.facebook.com/diffusionpharmaceuticalsinc/), Twitter (www.twitter.com/diffusionpharma) and LinkedIn (https://www.linkedin.com/company/diffusion-pharmaceuticals/) -- contain a significant amount of information about the Company. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared. However, the information included on our website and available through our social media channels is not incorporated by reference into, and should not be considered part of, this Annual Report or any other filings we make with the SEC.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Available Information</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We make available on or through our website certain reports that we file with or furnish to the SEC in accordance with Exchange Act. These include our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K, as well as any amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC. The SEC also maintains a website, www.sec.gov, that contains reports, proxy and information statements, and other information regarding the Company and other issuers that file electronically with the SEC. We also make available, free of charge and through our website, the charters of the committees of the Board, our Corporate Governance Guidelines, and our Code of Business Conduct and Ethics.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt; font-family: Times New Roman; font-size: 10pt;"><b>ITEM 1A.</b></td>
			<td>
			<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;"><b>RISK FACTORS</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Investing in our common stock involves a high degree of risk. Set forth below are certain material risks and uncertainties known to us that could adversely effect our business, financial condition, or results of operations or could cause our actual results to differ materially from our expectations expressed elsewhere in this Annual Report. The occurrence of the events contemplated by one or more of the factors we describe below could cause the market price of our common stock to decline, resulting in the loss of all or part of any investment in our common stock. Furthermore, other risks that are currently unknown to us or that we currently believe to be immaterial may also, nevertheless, adversely effect our business, financial condition, or results of operations in a way that is material.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Before investing in our common stock, you should carefully consider these risks and uncertainties, together with all other information in this Annual Report, including our consolidated financial statements and related notes, the information included in <i>Part II </i>&#8212;<i> Item 7 </i>&#8212;<i> Management</i>&#8217;<i>s Discussion and Analysis of Financial Condition and Results of Operations </i>of this Annual Report, and the information incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Development, Regulatory Approval, and Commercialization of TSC and Our Other Product Candidates</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b><i>The success of Diffusion is dependent on the successful development, regulatory approval, and, ultimately, commercialization of TSC and our other product candidates. However, the drug development process is expensive, time-consuming, and uncertain. Our efforts to develop, obtain regulatory approval for, and commercialize TSC or any other product candidate could fail at any stage of the development process for a variety of reasons, including the possibility that TSC fails to adequately demonstrate efficacy or proof of concept in the TSC Oxygenation Trials. Furthermore, because the results of preclinical studies and early-stage clinical trials are not necessarily predictive of future results, even if we are able to advance TSC or another product candidate into additional clinical trials </i></b>&#8211;<b><i> for example, </i></b><b><i>our Planned Phase 2 Hypoxia-related Indication Trial</i></b><b><i> we intend to commence assuming success in the TSC Oxygenation Trials </i></b>&#8211;<b><i> we may not continue to experience favorable results.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The success of Diffusion, including our ability to finance our operations and generate revenue in the future, will depend primarily on the successful development, regulatory approval, and, ultimately, commercialization of our product candidates. Currently, the majority of our product development resources are dedicated to our lead product candidate, TSC. We are also in early-stage development of our second product candidate, DFN-529, and, in the future, we may also seek to develop or commercialize additional product candidates, including product candidates that we may in-license or acquire to supplement our internally developed portfolio.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The drug development process is very expensive, time-consuming, difficult to design and implement, and its outcome is inherently uncertain. Most product candidates that commence clinical trials are never approved by regulatory authorities for commercialization and success in early-stage clinical trials does not ensure that later clinical trials will demonstrate the efficacy and safety of an investigational drug in a manner adequate to support regulatory approval. Countless other companies, including many with greater resources and experience, have failed or suffered significant setbacks attempting to navigate the drug development process, including failed attempts to develop treatments for hypoxia and indications on the hypoxia-continuum that we may ultimately choose to target with TSC, and there can be no assurance that we will have success where others have failed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our product candidates, including TSC, remain in early stages of the development process and we expect that the additional clinical trials necessary to support an NDA will take several years to complete. We do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety or otherwise provide adequate information to result in regulatory approval to market any of our product candidates in any particular jurisdiction. Furthermore, the timeline for our clinical trials may be delayed in the future for a variety of reason, including delays related to regulatory and IRB review and approval, slower than anticipated rates of enrollment in or early withdrawals from the trial, third party performance issues beyond our control including any CRO engaged in the conduct of the trial, discovery of series or unexpected toxicities or side effects, or a lack of effectiveness.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Whether we are able to successfully develop TSC or any of our other product candidates will depend on a large number of factors, including the following:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to complete our planned and future clinical trials in a timely manner and, with respect to any future trials beyond the TSC Oxygenation Trials and our Planned Phase 2 Hypoxia-related Indication Trial we intend to commence assuming success in the TSC Oxygenation Trials, our ability to fund them;</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to demonstrate safety and efficacy to the satisfaction of the FDA and similar foreign regulatory authorities, and whether we are required by any such body to conduct additional clinical trials to support approval;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the receipt of necessary regulatory approvals, including acceptance of our proposed indications and primary endpoint assessments, marketing approvals, and labeling claims;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a continued acceptable safety profile during development and following approval, including the prevalence, duration and severity of potential side effects experienced; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to commercialize successfully, including scaling our manufacturing capabilities, the development of sales and marketing capabilities internally or through a third party, acceptance by physicians and patients of the benefits, safety and efficacy of our treatments.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any of these factors, many of which are beyond our control, could result in significant delays or an inability to develop, obtain regulatory approvals for, or commercialize our product candidates, and we may ultimately be able to receive regulatory approval or generate revenue from the sale of TSC or any other product candidate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A number of companies in the pharmaceutical and biopharmaceutical industry have suffered significant setbacks in later-stage Phase 3 clinical development even after promising results in earlier preclinical studies or clinical trials. If later-stage clinical trials do not produce favorable results for TSC or any other product candidate, or we are unable to complete the necessary clinical trials for any reason (including a lack of funding), our ability to achieve regulatory approval or successfully commercialize may be compromised. At any time, we may decide or be forced by circumstance to delay or discontinue the development or commercialization of TSC or any of our other product candidates, including as a result of unfavorable results in later-stage clinical trials, changes in our internal product, technology or indication focus, the appearance of new technologies that make our product candidate obsolete, competition from a competing product, or changes in (or failure to comply with) applicable regulatory requirements. If we decide or are forced to terminate the TSC development program or any future program in which we have invested significant resources, we will not receive any return on our investment despite the allocation of significant resources, we may not be able to execute on our business plan effectively, and our business, financial condition, or results of operations may be materially and adversely effected.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Even if we are able to successfully complete the clinical trials and over development activities necessary to submit an NDA to the FDA or an application for marketing approval to an equivalent non-U.S. regulatory authority, we may be unable to obtain regulatory approval for TSC, DFN-529, or any other product candidates we may attempt to develop in future, for the indications for which we initially seek approval or at all. The FDA and similar non-U.S. regulatory authorities have significant discretion in the approval process, including the ability to delay, limit, or deny approval of product candidates. The delay, limitation, or denial of regulatory approval for any of our product candidates, and TSC in particular, would limit or restrict altogether our ability to commercialize the product and generate revenue, which could materially and adversely impact our business, financial condition, or results of operations.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We currently have no products approved for sale, and we may never obtain regulatory approval to commercialize TSC, DFN-529, or any other product candidates we may attempt to develop in the future. The research, testing, manufacturing, safety surveillance, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, sale, marketing, distribution, import, export, and reporting of safety and other post-market information related to drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and abroad, which often differ from country to country. We will not be permitted to market TSC or any of our other current product candidates in the U.S. until we receive approval of an NDA or other applicable regulatory filing from the FDA, and we will not be permitted to market TSC or any of our other current product candidates in any non-U.S. countries until we receive the requisite approval from the applicable regulatory authorities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To gain approval to market a new drug, such as TSC, the FDA and similar non-U.S. regulatory authorities require the submission of an NDA (or similar application) that contains preclinical and clinical data adequately demonstrating the safety, purity, potency, efficacy, and compliant manufacturing of the product for the intended indication. The FDA and their non-U.S. counterparts have substantial discretion in the drug approval process, including the ability to delay, limit, or deny approval of applications for many reasons, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deemed issues with the design or execution of one or more clinical trials;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deemed deficiencies in the formulation, quality control, labeling, or specifications of the product candidate;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deemed issues in our manufacturing processes or in the controls or facilities of third-party manufacturers or testing labs with which we contract;</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that the data from preclinical studies and clinical trials included in the application is not sufficient to support approval, or do not meet a required level of statistical or clinical significance, including as a result of a differing interpretation of the data than that presented by the Company in our application;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that the perceived risks of approving the product candidate outweigh the clinical and other benefits of approval;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that additional preclinical studies or clinical trials are required, either prior to or as a contingency to approval, and, for certain target indications such as pediatric populations, in the targeted sub-population;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that a product candidate may only be approved on a contingent basis or for a more limited indication or patient population than we request;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that labeling we believe is necessary or desirable for successful commercialization cannot be approved; or</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">unanticipated future changes to the approval process and related regulations.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Historically, of the large number of drugs in development at any given time, only a small percentage successfully complete the regulatory approval processes and are ultimately commercialized. Our product candidates may not be approved for sale and marketing by the FDA or any other governmental authority, even if they meet specified endpoints in our clinical trials. The FDA or applicable foreign regulatory agencies may ask us to conduct additional costly and time-consuming clinical trials in order to obtain marketing approval or approval to enter into a further phase of clinical development, or may change the requirements for approval even after such agency has reviewed and commented on the design for the clinical trials.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any delay in obtaining, or inability to obtain, the regulatory approvals necessary to market and sell our product candidates would delay or prevent commercialization and would materially and adversely effect our business, financial condition, or result of operations. Furthermore, if we determine in the future that the development, approval, or commercial prospects of any product candidate are insufficient to justify our continued expenditure of the associated development and other costs, we may choose to delay, suspend, or abandon our development or commercialization efforts with respect thereto, which would reduce or eliminate our potential return on investment for those product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Our ability to develop our product candidates depends, and, if TSC or any of our other product candidates are approved, our ability to successfully commercialize our products will depend, in part on our ability to successfully obtain sufficient quantities of the necessary APIs, other component substances and materials, and finished drug product for our product candidates. We are currently entirely dependent on third parties for the manufacture and supply of our product candidates and their component parts, including, with respect to TSC, a sole supplier. We may be unable to continue to develop or commercialize our product candidates or face significant delays in that process if we are unable to successfully obtain these materials or manufacture drug product in sufficient quantities.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Maintaining an adequate supply of TSC and our other product candidates to meet our needs is critical to the success of our business. However, manufacturing and supply of APIs, other substances and materials and finished drug products is a complex and technically challenging process, and changes beyond our direct control can impact the quality, volume, price, and successful delivery of our product candidates or impede, delay, limit or prevent the successful development and commercialization of our product candidates. Mistakes and mishandling are not uncommon in the biopharmaceutical and pharmaceutical industry and can affect successful production and supply significantly.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of the date of this Annual Report, we have no internal manufacturing capabilities and therefore we do not have direct control over our ability to maintain drug supply sufficient to serve our needs for our ongoing and planned clinical trials or, if any of our product candidates are approved, commercialization. Although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on our third party CMOs and other contract suppliers and manufacturers for the manufacture of our drug product, including both APIs and finished products, as well as day-to-day compliance with cGMPs and certain other manufacturing-related regulatory requirements. Facilities used by our contract suppliers and manufacturers to produce the APIs and other substances and materials or finished products for commercial sale must pass inspection, provide regulators with certain technical information, and be approved by the FDA and other relevant regulatory authorities to confirm compliance with cGMP requirements and other regulatory requirements. If the safety of TSC or any of our other product candidates (or any component thereof) is found in the future to be compromised, we may not be able to successfully commercialize or obtain regulatory approval for the product candidate, and we may be held liable for injuries sustained as a result.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any disruption in our relationship with these third parties or their ability to manufacture the APIs and finished drug product we need for our clinical trials and other development activities could result in significant delays in our anticipated development timelines and/or significant additional supply costs. Such a disruption could be the result of any number of reasons, including contractual disputes with our partners, regulatory issues at our partner or at their facilities (whether or not related to Diffusion or our drug product), financial issues faced by our partners (including bankruptcy or insolvency), damages to our partners facility or equipment, communication breakdowns, or acts of God. For example, we are currently facing certain delays in the manufacturing process for planned, new batches of TSC drug product due to the fact that, in connection with the U.S. federal government&#8217;s Operation Warp Speed initiative in response to the COVID-19 pandemic, the facility at which our primary CMO partner conducts significant portions of the TSC manufacturing process has been mandated to devote the majority of the facility&#8217;s available resources to the manufacture of components of the COVID-19 vaccine. If our CMO is unable to manufacture sufficient quantities of drug supply to meet our needs in a timely fashion or in accordance with the specifications contracted for, we may be forced to delay our development plans for TSC, find alternative suppliers, or pursue other available remedies, which could result in additional costs and the diversion of management&#8217;s time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Amplifying this risk is the fact that we currently depend upon a sole source for manufacture of API for TSC and other aspects of our manufacturing process, limiting our available options to troubleshoot these issues. Although we are currently in the process of identifying and developing alternative manufacturing and supply alternatives, this process remains ongoing, will take time, and will involve significant costs. Furthermore, due to the significant regulatory oversight of the pharmaceutical manufacturing process, any changes in the identity of our third-party partners or in our manufacturing processes &#8211; even if in the best interests of the Company and successful &#8211; could result in regulatory and other delays, as well as significant additional costs. In addition, if our current supplier terminated our arrangement or failed to meet our supply needs for any reason prior to the time we are able to identify sufficient alternative manufacturing capacity, we may be forced to delay our development plans significantly.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our CMO and other manufacturing and supply partners are also engaged to supply and manufacture materials or products for other biopharmaceutical and pharmaceutical companies, exposing them to regulatory risks unrelated to the work they are doing for Diffusion but which may nevertheless impact their ability to meet their contractual requirements to us or otherwise impede their ability to supply us with sufficient quantities of drug product. Failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a contract supplier&#8217;s or manufacturer&#8217;s facility. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the supply or manufacture of our product candidates or if it withdraws its approval in the future, even if such lack of approval is unrelated to Diffusion or our product candidates, we may need to find alternative supply or manufacturing facilities.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, to date we have only manufactured TSC and our other product candidates in relatively small quantities for preclinical studies and clinical trials. As we prepare for additional, later-stage clinical trials and potential commercialization, we will need to take steps to substantially increase the scale at which we are able to product TSC, its API, and its other component parts. In order to meet these needs, our CMOs and suppliers will need to be able to produce our API, other components, and finished product in larger quantities, more cost effectively and, in certain cases, at higher yields than they currently achieve. These third-party contractors may not be able to successfully increase the manufacturing capacity for any of such drug substance and product candidates in a timely or cost-effective manner or at all. Even if such a scale up is possible, it may require additional processes, technologies, and validation studies, which are costly, may not be successful, and which the FDA and foreign regulatory authorities would need to review and approve prior to any commercial sale of TSC or any other product candidate. In addition, quality issues may arise during those scale-up activities because of the inherent properties of a product candidate itself or in combination with other components added during the process of manufacturing, packaging, shipping, or storage.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our reliance on contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may misappropriate our trade secrets or other proprietary information. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our products or product candidates or their components into the United States or other countries as a result of, among other things, regulatory agency approval requirements or import inspections, incomplete or inaccurate import documentation or defective packaging.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any of these factors could cause a delay or termination of preclinical studies, clinical trials, other development activities, regulatory submissions or approvals of our product candidates, or, if approved, commercial supply, and could result in significant, unanticipated costs or an ability to effectively develop our products candidates or commercialize our approved products on a timely basis, or at all, which could materially and adversely effect our business, financial condition, or&nbsp;results of operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We expect to rely on third-party CROs and other third parties to conduct and oversee our clinical trials and other aspects of our development process for TSC and our other product candidates. If these third parties do not meet our requirements or otherwise conduct the trials or perform the other services for which they are engaged, we may not be able to successfully develop, obtain regulatory approval for, or commercialize our product candidates when expected or at all. Furthermore, if we are not able to establish and maintain the necessary collaborative relationships with our CROs and other third party partners, we may have to alter our development and commercialization plans.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Conducting our clinical trials in a safe, compliant, and timely manner is critical to our success. We currently rely on third-party CROs to conduct and oversee our clinical trials and other aspects of our product development, as well as various medical institutions, clinical investigators, contract laboratories, consultants, and other third parties to design and conduct our trials, to analyze the results therefrom, and to ensure that the trials are conducted in accordance with our clinical protocols and all applicable regulatory requirements, including the FDA&#8217;s regulations and GCPs. These CROs and other third parties play a significant role in the conduct of these trials and the subsequent collection and analysis of data therefrom, as we control only certain aspects of their activities and rely heavily on them to execute our trials in a safe, compliant, and timely manner. Although we intend to internalize portions of some of these functions during 2021 and beyond as our organization grows, we expect to continue to rely on these third parties to a significant degree in the future.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If any of our CROs, clinical trial sites, or other third party partners terminates their involvement in one of our clinical trials (or with Diffusion entirely) for any reason, we may not be able to enter into alternative arrangements sufficient to meet our needs, on a timely basis, on commercially reasonable terms, or at all. In addition, if our relationship with clinical trial sites is terminated, we may incur significant additional costs or experience the loss of follow-up information on patients enrolled in our ongoing clinical trials, unless we are able to transfer the care of those patients to another qualified clinical trial site.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We, as well as the CROs and other third-party contractors acting on our behalf, are required to comply with GCP and GLP requirements in all of our clinical trials, which are enforced through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of these third parties fail to comply with applicable GCP, GLP, or other regulatory requirements, the clinical data generated in our clinical trials may be deemed unreliable and we may be required to perform additional clinical trials to supplement or replace such data before receiving approval of a product candidate from the FDA or a non-U.S. regulatory authority. Our clinical trials must also generally be conducted with product produced under cGMP regulations. Our and our partners&#8217; compliance with these various regulations may be reviewed by regulatory inspections at any time, processes over which we will have very little control or immediate visibility, and a failure to comply with these regulations and policies by us, our CROs, or any of our other third party partners may result in significant delays in our development programs. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, in order to fund or otherwise further development of our current or future product candidates, we may collaborate with other pharmaceutical and biotechnology companies on their development and potential commercialization of those product candidates. We would face significant competition in seeking appropriate partners and whether we reach a definitive agreement for a collaboration will depend on many factors, including, our assessment of the partner&#8217;s resources and experience, the terms and conditions of the proposed collaboration, the likelihood of approval by the FDA or other regulatory authorities; the potential market for the subject product candidate; uncertainty with respect to our ownership of our intellectual property; and industry and market conditions generally. These types of collaborations are complex and time-consuming to negotiate and document and could ultimately result in lower returns on investment for our stockholders than would have been achieved developing the product candidate without a partner. Further, if we were to breach our obligations under the agreements governing any such future collaboration, we may face substantial consequences, including potential termination of the collaboration, and our rights to our partners&#8217; product candidates, in which we have invested substantial time and money, would be lost.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any failure to successfully enter into and maintain the necessary relationships with CROs and our other current and future third party partners and collaborators could materially and adversely effect our business, financial condition, or results of operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>General Risks Related to the Development, Regulatory Approval, and Commercialization of TSC and Our Other Product Candidates</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our business, financial condition, or results of operations may also be materially adversely effected by a number of general risks related to the development and regulatory approval of our product candidates that are not specific to our Company, including:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Our TSC COVID Trial, which we completed in February 2021, was conducted at the NIID in Bucharest, Romania and we may in the future conduct additional clinical trials for TSC or our other product candidates outside the U.S. In connection with an application for marketing approval, the FDA may determine not to accept data from clinical trials conducted outside of the U.S. if they determine the data presented therefrom cannot be considered valid without further inspection of the clinical trial site, are not applicable to the U.S. population and U.S. medical practice, or as a result of certain other factors. There can be no assurance that the FDA will accept any data we obtain from the TSC COVID Trial or other trials we may conduct outside the U.S. in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;We face a number of risks related to the potential for one or more of our product candidates to cause undesirable side effects, have other unexpected properties, contain manufacturing defects, or be subject to misuse or abuse. The occurrence of one or more of these events with respect to a product candidate or product could delay or prevent its regulatory approval, limit its commercial potential, result in additional pre- or post-approval regulatory requirements, or subject us to product liability exposure to consumers, health care providers, or others. Product liability claims could be brought in the future even if a product is approved for commercial sale and manufactured in facilities licensed and regulated by the appropriate governmental authorities, and if product liability claims brought against us in the future were to be successful, we could incur substantial liability if our insurance coverage for those claims proved to be inadequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Our employees, independent contractors, principal investigators, consultants, vendors, CROs, and other third parties we work with in the course of our development activities may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, during the course of their employment or other engagement with us. Any such misconduct or improper activities, whether intentional or negligent, could result in regulatory sanctions or other penalties against the Company, exclusion from federal healthcare programs such as Medicare and Medicaid, the incurrence of substantial defense costs, and serious harm to our reputation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, although we currently have no marketed products, in the event TSC or any of our other product candidates are approved for marketing and commercial sale by the FDA or any other regulatory authority, our business, financial condition, or results of operations may be materially adversely effected by a number of general risks related to the commercialization of such products that are not specific to our Company, including:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Even if our product candidates obtain regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success. The degree and rate of physician and patient adoption will depend on a number of factors, including the clinical indications for which a product candidate is approved and its effectiveness compared to other therapies, cost and the availability of reimbursement and other coverage from third party payors, our ability to educate patients and healthcare providers regarding a new therapy, and the effectiveness of our sales and marketing efforts. Furthermore, we will face significant competition, often from products sold and marketed by companies with far greater resources than Diffusion, and our failure to effectively compete may prevent us from achieving significant market penetration.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;With respect to any such future products available only by prescription, if we are unable to achieve and maintain coverage and adequate levels of reimbursement from third party payors &#8211; including governmental health programs such as Medicare and Medicaid and private insurance companies &#8211; and access to such third party payors&#8217; drug formularies, the commercial success of those products may be severely hindered. If any such products do not demonstrate attractive efficacy profiles, they may not qualify for coverage and reimbursement and, even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate, may require co-payments that patients find unacceptably high, and may vary from payor to payor, and there is no assurance that coverage and reimbursement levels necessary to achieve commercial success will be obtained..</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Any such future products candidates that we commercialize will be subject to ongoing and continued regulatory review, including rules and regulations of the FDA and similar non-U.S. governmental authorities relating to advertising, marketing and labeling (including restrictions on the promotion of off-label use), potential REMS requirements, routine manufacturing and other review, and required compliance with GLP. If we or a regulatory agency discovers previously unknown problems with any such product, or any facility at or process by which it is manufactured, we may face restrictions on the sale or distribution of such product or on our Company as a whole, including regulatory actions requiring us to modify marketing or sales materials, suspend manufacturing or ongoing trials, initiate a recall or withdrawal the product from the market entirely, enter into a consent decree, or submit to other civil or criminal investigations and penalties. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to market our product candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;The biopharmaceutical and pharmaceutical industries are highly regulated and the potential for future legislative reform provides uncertainty and potential threats to our business and our potential future revenue and profitability of any such future products. In the U.S., there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system intended to contain or reduce the costs of medical products and medical services including those described in&nbsp;<i>Part I </i>&#8211;<i> Item 1. Business </i>&#8211;<i> Certain Other Legislation and Regulations </i>&#8211;<i> Current Healthcare Laws and Regulations</i> of this Annual Report. Additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, whether in the U.S. or other market territories we may pursue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b><i>Since the founding of Diffusion LLC in 2001, we have been principally focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia. Many of our issued patents were issued early in our Company</i></b>&#8217;<b><i>s history. While we are regularly engaged in further research and development activities with respect to TSC and our other product candidates that may result in novel developments and findings that ultimately lead to further intellectual property opportunities, if the terms of any of our key patents expire before or soon after our therapeutic candidates are approved, or if manufacturers of biosimilar drugs successfully challenge our patents, our business, financial condition, or results of operations may be materially adversely effected.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Patents have a limited duration. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date in the U.S. Various extensions may be available, including under the Hatch-Waxman Amendments as described elsewhere in this Annual Report, but the life of a patent, and the protection it affords, is limited. Even if patents covering TSC and our product candidates, including with respect to their manufacture or use, are obtained, once the patent life has expired, we may be open to additional competition from competitive medications, including biosimilar medications.&nbsp; In the case of Diffusion, the normal lives (in other words, prior to the application of any patent term restoration of marketing exclusivity periods that may be available) of our issued U.S. patents related to TSC begin to expire in 2023, which may be prior to the time that we are able to obtain regulatory approval for and, if approved, commercialize TSC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Even if patent term extension or other protections such as marketing exclusivity are available upon the regulatory approval (if any) of TSC or any of our other product candidates, the benefits provided by these regulatory and legislative mechanisms is limited and typically less robust than full patent protection. For example, the five-year extension of patent life potentially available under the Hatch-Waxman Amendments cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended. Receiving such an extension is also subject to compliance with applicable deadlines for application and certain other regulatory requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner than we expect. Also, the scope of our right to exclude during any patent term extension period may be limited or may not cover a competitor&#8217;s product or product use.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Given the amount of time required for the development, testing, and regulatory review of new drug candidates, patents protecting any drug candidate might expire before or shortly after such drug candidate is approved or commercialized. Similarly, our patents and patent applications may not provide us with sufficient time or rights to commercialize our product candidates or exclude others from commercializing products similar ours. If our patent protections for our product candidates have expired, this could include manufacturers of identical, biosimilar drugs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If we are unable to obtain new, patent claims with respect to our existing product candidates and other technologies, in particular those related to our lead product candidate TSC, that both adequately protect our intellectual property position for commercial purposes and extend the term of overall protection as compared to our existing issued patents, we may be reliant on these types of patent term extensions and similar exceptions for such protection during the ultimate commercialization of TSC. This limited protection could have a material and adverse effect on our business, financial condition, or results of operations.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We may not be able to obtain or enforce patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing, and marketing of health care products competitive with those that we are developing, and we face competition from a number of sources, such as pharmaceutical companies, generic drug companies, biotechnology companies and academic and research institutions. Accordingly, our ability to obtain and maintain patent protection in both the U.S. and non-U.S. jurisdictions will be critical to ability to successfully develop, obtain regulatory approval for, and, in particular, commercialize TSC and our other product candidates. These protections are and will be essential to preserving and protecting our novel inventions, proprietary developments, and trade secrets and to preventing third parties from infringing upon them. In particular, our ability to protect any of our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents in the U.S. and worldwide.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our patent portfolio includes patents and patent applications in the U.S. and other major markets covering our technology with varying scope, including issued U.S. patents related to composition of matter, formulation, methods of delivery, and methods of use&nbsp;and the scope of coverage vary from country to country. Although we believe that our intellectual property position is strong and are currently assessing our operations and existing portfolio for additional intellectual property opportunities, we do not have &#8211; and may be unable to obtain &#8211; patent protection for every aspect of our technology. For aspects of our technology for which we do not have patent coverage, or in countries where we do not have granted patents, we may not have any ability to prevent the unauthorized use of our technologies or technologies substantially similar to ours, and any patents that we may obtain in the future may be narrow in scope and thus easily circumvented by competitors. Further, in countries where we do not have granted patents, third parties may be able to make, use or sell products identical to or substantially similar to, our product candidates.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Due to legal standards relating to patentability, validity, enforceability and claim scope of patents covering pharmaceutical inventions, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. The patent application process, also known as patent prosecution, is expensive and time-consuming, and we may not be able to prepare, file, and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in an optimal manner. It is also possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to inadvertent prior public disclosures, proper priority claims, inventorship, claim scope, or patent term adjustments. If our current or future third party development partners are not fully cooperative or disagree with us as to the prosecution, maintenance, or enforcement of any patent rights, those patent rights could be compromised and we might not be able to prevent third parties from making, using and selling competing products. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Accordingly, we cannot guarantee that any patents will issue from any of our currently pending patent applications, which could impair our ability to prevent competition from third parties.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Even for aspects of our technology for which we have obtained, or obtain in the future, patent protection, the complexity of legal and factual questions underlying such claims means they may not provide us with sufficient protection for our product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies. We cannot guarantee that the claims of these patents are or will be held valid or enforceable by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. Third parties may design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize, our product candidates. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, patents have a limited lifespan, presenting further challenges in effectively protecting our technologies and associated commercial position. In the U.S., the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available under a variety of legislative and regulatory avenues but often the life afforded by these extensions and the protections they afford are often limited relative to full patent protection. The extensive period of time between patent filing and regulatory approval for a product candidate limits the time during which we can market a product candidate under patent protection, which may particularly affect the profitability of our early-stage product candidates. In particular, we have been developing TSC since the founding of Diffusion LLC in the early 2000s and, as a result, portions of our patent portfolio, including certain patents related to TSC&#8217;s composition of matter, will expire beginning in 2023. If the other issued patents in our portfolio currently or that may issue in the future are not adequate to protect our technologies, our competitive position may be harmed and we may face generic or other competition sooner than we otherwise would.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Furthermore, the laws of some foreign jurisdictions do not provide intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in those countries. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how by entering into confidentiality agreements with third parties, and intellectual property protection agreements with certain employees, consultants and advisors, third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our suppliers, manufacturers and other third parties. There can be no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secret information.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If we are unable to adequately obtain or enforce our patent and other intellectual property rights for any reason, it could materially and adversely effect our business, financial condition, or results of operations. For more information about our intellectual property and our competition, see the information included in <i>Part I </i>&#8211;<i> Item 1. Business </i>&#8211;<i> Products, Product Development, and Our Competition </i>of this Annual Report<i>.</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>If we become involved in lawsuits to protect or enforce our patents or other intellectual property, or if we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation could have a material adverse effect on our business, financial condition, or results of operations.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ultimate commercial success depends upon our ability to develop, manufacture, market, and sell our product candidates and use our proprietary technologies in the U.S. and non-U.S. markets. In order to do so, it is critical that we prevent third parties from infringing on our intellectual property rights and that we operate our business without infringing on the intellectual property rights of others.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">However, numerous U.S. and non-U.S. issued patents and pending patent applications owned by third parties exist in fields relating to TSC and our other product candidates, their potential methods of delivery, potential indications they may be used to treat, and their other features, and, as more patents are issued over time, the risk increases that others may assert that our product candidates, technologies, or methods of delivery or use infringe their patent or other intellectual property rights, or that we discover a third party infringing on our rights. Moreover, it is not always clear to industry participants, including us, which patents cover various drugs, biologics, drug delivery systems, or their methods of use, which of these patents may be valid and enforceable, and what inventions or technologies may be claimed by non-public patent applications. Patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after their first non-provisional filing and publications in the scientific literature often lag behind actual discoveries, meaning we cannot be certain whether others, including our competitors, have filed patent applications for technology covered by patents or our pending applications and whether any such filing has priority over our own applications or patents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the biopharmaceutical and pharmaceutical industries in particular, there is a substantial amount of litigation involving patent and other intellectual property rights. This type of litigation may occur unexpectedly but may also be prompted by specific events, such as a patent application being made public by the USPTO or a non-U.S. governmental authority or under Paragraph IV of the Hatch-Waxman Amendments. For more information regarding the Hatch-Waxman Amendments and Paragraph IV thereunder, see the information in&nbsp;<i>Part I </i>&#8211;<i> Item 1. Business </i>&#8211;<i> Government Regulation </i>&#8211;<i> The Hatch-Waxman Amendments</i> of this Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of the date of this Annual Report, no litigation asserting infringement claims has been brought against us, nor have we filed such a claim against any third party.&nbsp; However, we cannot assure you that the development or future commercialization of any of our product candidates or other technologies will not result in claims that our activities infringe on the existing or future intellectual property rights of third parties.&nbsp; Furthermore, potential competitors may infringe our intellectual property, including our patents. For example, in the first quarter of 2021, we became aware of a third party affiliated with a former outside consultant of the Company which claims to be in early-stage development of a product candidate that purportedly may operate through a similar mechanism of action to TSC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We may be required to file infringement claims to stop third-party infringement or unauthorized use or, if a third party claims we are infringing on their rights, respond to such claims. This process can be expensive and time consuming, and could result in a court deciding that a patent of ours is not valid or is unenforceable, that a third party is not required to stop using a technology we believe infringe on our rights, significant costs, or the diversion of management&#8217;s time. An adverse determination in any litigation or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or amended such that they do not cover our product candidates in a manner sufficient to support our development and commercialization needs or that such product candidate needs to be significantly redesigned, or put our pending patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope. Further, some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, interference, derivation, or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to our patents or patent applications. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful in these proceedings, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and the diversion of management&#8217;s time. We may not be able to prevent all misappropriation of our proprietary rights, particularly in countries with a legal framework that offers limited intellectual property protections or where the costs of enforcement outweigh the commercial and other benefits of maintaining intellectual property protections.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings, including as a result of public announcements of the results of hearings, motions or other interim proceedings or developments, or public access to related documents. This type of disclosure could put us at a significant competitive disadvantage by disclosing important trade secrets or other proprietary information to our competitors and other third parties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any litigation or other challenge related to our intellectual property could materially and adversely effect our business, financial condition, or results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>General Risks Related to Our Intellectual Property</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our business, financial condition, or results of operations may also be materially adversely effected by a number of general risks related to our intellectual property that are not specific to our Company, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;As is common in the biopharmaceutical and pharmaceutical industries, some of our employees were formerly employed by companies in the industry, including our competitors or potential competitors, and some of our consultants actively work for other companies in the industry. As a result, although we have in place policies which prohibit the use of third-party confidential information in violation of any obligation to a former employer or otherwise, we may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their former employers or their former or current customers. In addition, if any of our current employees or consultants are engaged by a competitor in the future, it is possible that they may appropriate or otherwise improperly use our proprietary and confidential information. Any of the foregoing events could result in significant costs and the diversion of time and resources.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated as a result of any non-compliance with these requirements. We may also abandon certain intellectual property protections that we would otherwise maintain if we determine such protections are not expected to provide sufficient value relative to the cost of ongoing maintenance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Patent laws and other intellectual property protections available in the U.S., E.U., or other jurisdictions are subject to change. These changes may be unpredictable, weaken our overall intellectual property position, increase our costs related to maintenance and enforcement, or otherwise diminish the value of patents in general, thereby impairing our ability to protect our product candidates and maximize our return on investment thereon.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Business, Financial Position, Results of Operation, and Organizational Structure</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We will require additional capital to fund our operations which may not be available on acceptable terms or at all. If we fail to obtain necessary financing, we may be forced to delay or curtail our clinical trials and other development activities or be unable to complete the development and commercialization of our product candidates due to a lack of sufficient resources.</i></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Although we expect that our existing cash resources will enable us to fund our operating expenses and capital expenditure requirements, including expected costs related to the planned TSC Oxygenation Trials and our Planned Phase 2 Hypoxia-related Indication Trial, through 2023, we expect to continue to spend substantial amounts as we continue to develop TSC and our other product candidates, we will need to obtain additional financing in the future in order to complete the development of TSC and fund our other development and operational activities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We cannot be certain that the additional funding we will require will be available on acceptable terms or at all. Investors may demand significant discounts to market prices or that we agree to restrictive covenants or other limitations on our ability to operate our business, and conditions in the capital markets may make equity and debt financing more difficult to obtain or negatively impact our ability to complete a financing transaction at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back, discontinue the development or commercialization of one or more of our product candidates, or seek alternative financing opportunities such as collaborations or licensing opportunities. For example, prior to completing the May 2020 Offering and February 2021 Offering, we determined that we did not have adequate resources to fully support the randomized portion of the TSC GBM Trial and commencement of enrollment in the trial was suspended following the run-in portion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Furthermore, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves the associated risks and uncertainties. Although we have based this estimate on assumptions that we believe to be reasonable, they may prove to be wrong, we could utilize our available capital resources sooner than we currently expect, and actual results could vary greatly from our expectations expressed in this Annual Report as a result. The magnitude and timing of our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the number, development stage, and other characteristics of product candidates that we choose to develop, including any product candidates that we may in-license or otherwise acquire in the future;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the clinical development plans we establish for these product candidates;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the magnitude of costs associated with filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the initiation, progress, timing, costs, and results of clinical trials for such product candidates;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the outcome, timing and cost of regulatory approvals by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the cost and timing of completion of becoming a commercial organization; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the effect of competing technological and market developments.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We currently generate no revenue from the sale of products, have incurred significant losses since our inception, have a history of net losses and negative cash flow from operations, expect to incur losses for the foreseeable future, and may never become profitable. In addition, our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations. As a result, any investment in our common stock is speculative and risky.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are a clinical stage biotechnology company and, as a result, we have a limited operating history from which to assess how we will respond to competitive, economic, or other challenges to our business, and our business and prospects must be considered in light of the risks and uncertainties frequently encountered by similarly situated companies.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have limited cash resources, have generated substantial net losses and negative cash flow from operations since our inception, and we continue to incur significant research, development, and other expenses related to our ongoing operations, including the development of TSC and our other product candidates. To date, we have not yet obtained regulatory approvals for any of our product candidates and, accordingly, have not generated any revenues from the sale of products. We expect to continue to incur losses and negative cash flow for the foreseeable future.&nbsp;Furthermore, our future operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the delays in our product development programs including as a result of regulatory review, increased expenditures related to manufacturing or the enforcement of intellectual property rights, other litigation costs, changes in accounting policies, or other unanticipated events.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ability to generate sufficient revenues from TSC or any of our other product candidates, if approved, will depend on numerous factors described throughout this Annual Report. Even if we are able to successfully develop and receive regulatory approval for TSC or any of our other product candidates, we do not know if or when any such product will achieve commercial success or generate revenue for us, and we will incur significant costs associated with the commercialization that will need to be offset by revenue before achieving a profit. We may also in the future enter into collaboration agreements and license agreements with other companies that include milestone expenditures and payments, in which case our ability to generate revenue or achieve profitability may be dependent on the achievement of those milestones. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods, and our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity. Furthermore, due to the uncertainty of the drug development process, we are often unable to predict the timing or amount of increased expenses, or when we will be able to achieve or maintain profitability, if at all.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We will need to further increase the size and complexity of our organization in the future including, if TSC or any of our other product candidates are approved for commercial sale, establishing sales and marketing capabilities. We may experience difficulties in executing our growth strategy or managing any growth that we do experience if we are unable to recruit and retain talented individuals in key positions.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ability to succeed in the highly competitive pharmaceuticals industry depends upon our ability to attract and retain highly qualified personnel. As of the date of this Annual Report, we have 13 full-time employees and one part-time employee, including our new Senior Director of Quality Assurance hired during the first quarter of 2021. Particularly given our near-term plans for the TSC development program and our compliance requirements with the FDA, SEC, and other regulatory bodies, we believe that our current staffing levels are inadequate to support our future needs. We anticipate adding additional personnel to our team throughout the organization during 2021 in an effort to support the development of TSC, grow our business more generally, and optimize the size of our organization. In addition, assuming success in our planned clinical trials, we expect to further supplement and grow our scientific, clinical, regulatory, financial, and other human resources to support our planned research, development, and commercialization plans for TSC and our other product candidates..</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our ability to effectively manage our anticipated growth will depend on multiple factors, including, among others, our ability to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;effectively retain current talent and effectively recruit sufficient numbers of new talented employees;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;manage our third-party supply and manufacturing operations effectively and in a cost-effective manner,</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;while increasing production capabilities for our current product candidates to commercial levels;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;establish and maintain relationships with development and commercialization partners</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;manage our development and commercialization efforts effectively and in a cost-effective manner; and</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;continue to improve our operational, clinical, financial, management and regulatory compliance controls and reporting systems and procedures;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are highly dependent on our management and scientific personnel, including our executive officers, certain other key employees and consultants, and the members of our Board. The loss of the services of any of these individuals could impede, delay, or prevent completion of our planned clinical trials, regulatory approval, or commercialization of TSC or any of our other product candidates. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. All of our employees, including our executive officers with whom we have employment agreements, are employed on an at-will basis and their employment can be terminated by us or them at any time. As part of our efforts to retain our valuable employees, we, among other things, provide a generous salary and benefits package, as described in more detail in <i>Part I </i>&#8212;<i> Item 1. Business </i>&#8211;<i> Our People and Human Capital Resources </i>of this Annual Report</p>

<p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Nevertheless, we may be unable to attract or retain qualified management and other key personnel in the future due to the intense competition among biotechnology, pharmaceutical, and other businesses. There may be a limited number of persons with the requisite skills to serve in these positions, and we cannot assure you that we will be able to identify or employ qualified personnel for any such position on acceptable terms, if at all, and the high levels of competition within the industry may mean that we will be required to expend significant financial resources in our employee recruitment and retention efforts. Many of the other pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different risk profiles and longer histories in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will harm our ability to implement our business strategy and achieve our business objectives. Furthermore, as we currently have no marketed products, we currently have no sales or marketing personnel or capabilities. To commercialize TSC or any of our other product candidates, if approved, in the we will need to build our marketing, sales, distribution, and other related capabilities or arrange with third parties to perform these services, and we may not be successful in doing so.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, we have historically utilized the services of certain outside independent contractors to perform a number of critical functions for our company, including with respect to clinical development, regulatory matters, accounting, and human resources, a practice we expect to continue and may choose to expand in the future. We rely on these independent contractors and effectively managing our relationships with them is and will remain a priority. However, there can be no assurance that we will be able to manage these relationships effectively, that such contractors will be able or choose to continue working with us in the future, or that we will be able to find additional or replacement services if and as needed, on economically reasonable terms or at all.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we are not able to effectively manage our growth and expand our organization through a combination of effectively retaining our existing employees and third-party contractors and successfully recruiting new employees and contractors, we may be unable to effectively execute on our product development and other strategic plans, which my adversely effect our business, financial condition, or results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>If we decide to in-license or acquire one or more additional product candidates or otherwise enter into a strategic transaction, it could impact our liquidity, increase our expenses, and present significant distractions to our management team.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We currently only have two product candidates under active development, our lead product candidate, TSC, and our second product candidates, DFN-529. We may in the future implement a strategy to in-license or acquire one or more additional product candidates to supplement our pipeline. We may also consider a variety of other strategic transactions, including spin-offs, partnerships, joint ventures, restructurings, divestitures, business combinations, and minority investments. Any such transaction would expose us to a number of risks and uncertainties, including the potential incurrence of recurring, non-recurring (including unknown liabilities), or other charges (including amortization expenses, write-downs, or other impairment charges), increase of short- and long-term expenditures, or dilution our stockholders, as well as posing significant integration, implementation, or retention challenges and diverting our management team&#8217;s focus on other priorities, including the TSC development program. Any of the foregoing could have a material adverse effect on our business, financial condition, or results of operation. which could adversely affect our operations and financial results. There can be no assurance that we will undertake such a transaction or, if we do, that we will successfully complete the transaction or that the transaction will be additive to our business, financial condition, or results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Our ability to utilize our NOL carryforwards and other deferred tax assets may be limited as a result of past and future issuances of our common stock.</i></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2020, we had $11.7 million in federal and state NOL carryforwards available to reduce future taxable income, if any, for income tax purposes. If not utilized, the NOL carryforwards will begin expiring during the year ending December 31, 2034. Under Section 382 of the Tax Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50.0% change, measured by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-ownership change NOL carryforwards and other pre-ownership change tax attributes &#8211; such as research tax credits &#8211; to offset its post-ownership change income may be limited. In the year ended December 31, 2019, as a result of the issuance of a significant number of shares our common stock pursuant to the May 2019 Offering, November 2019 Offering, and December 2019 Offering, we performed an analysis under Section 382 of the Tax Code and, as a result of such analysis and a determination that such an ownership change had taken place, we reduced our NOL carryforwards. In the event we issue additional shares of common stock to fund our future development efforts and those issuances result in additional ownership changes for purposes of Section 382 of the Tax Code, as we did in the May 2020 Offering and the February 2021 Offering, our NOL carryforwards could be further reduced.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>General Risks Related to Our Business, Financial Condition, Results of Operations, and Organizational Structure</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our business, financial condition, or results of operations may also be materially adversely affected by a number of general risks related thereto and to our organizational structure that are not specific to our Company, including:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. Furthermore, our disclosure controls and procedures are subject to inherent limitations, human error, and other systematic breakdowns, and therefore may not prevent or detect all errors or acts of fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which could harm our business, financial condition, or results of operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;As our Company, the industry in which we operate, and the world-at-large become increasingly virtual, our acquisition and implementation of additional information technology solutions and our compliance with global privacy and data security requirements could result in additional costs and liabilities or inhibit our ability to collect and process data globally. Furthermore, any failure to comply with applicable requirements or best practices &#8211; as well as other events outside of our control &#8211; could result in a security breach or other disruption to our information technology systems, limit our capacity to effectively monitor and control our operations, compromise our or third parties&#8217; confidential information, or otherwise adversely affect our business, financial condition, or results of operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;We incur significant costs as a result of our public company status and devote substantial management time to operating as a public company, including complying with the applicable requirements of the Securities Act, the Exchange Act, the Dodd-Frank Act, SOX, and the rules and regulations of Nasdaq. If, in the future, we are required to include in our annual report an attestation of our independent registered public accounting firm regarding internal control over financial reporting, the amount of these compliance costs would increase significantly.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Although we have in place business continuity and disaster recovery plans, our business, financial condition, or results of operations could be negatively affected by volatility, disruptions, or other uncertainty caused by market fluctuations, economic downturns or unfavorable global economic conditions, pandemics, natural disasters or other catastrophic events, events of war, terrorism, or other man-made problems, or other geopolitical events outside of our control, including the COVID-19 pandemic and Brexit.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;If we fail to comply with applicable laws and regulations, including the healthcare laws and regulations described in&nbsp;<i>Part I </i>&#8211;<i> Item 1. Business </i>&#8211;<i> Certain Other Legislation and Regulations </i>&#8211;<i> Current Healthcare Laws and Regulations</i> of this Annual Report<i>&nbsp;</i>and applicable environmental, health, and safety laws and regulations, we could become subject to fines, penalties, or other consequences.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Ownership of Our Common Stock</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Our stock price is volatile and any investment in our securities may suffer a decline in value. In addition, this volatility may subject our business to additional risks, such as an increased risk of securities litigation or inability to meet the continued listing requirements of Nasdaq.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended December 31, 2020, the closing market price for our common stock varied between a high of $1.50 on July 21, 2020 and a low of $0.26 on March 16, 2020. As a result of fluctuations in the price of our common stock, you may be unable to sell shares or our common stock at or above the price you paid for them, even if your holding period is relatively short. The market price of our common stock is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market, industry and other factors, including the degree of analyst coverage of our stock, their valuations and recommendations, and whether any such analysts publish inaccurate or unfavorable research about our business. If the results of our business do not meet these analysts&#8217; forecasts, the expectations of investors or the financial guidance we provide to investors in any period, the market price of our common stock could decline. Furthermore, despite this volatility, due to the fact that we have never declared or paid cash dividends on our common stock and do not currently anticipate declaring or paying any cash dividends in the foreseeable future, we expect that only appreciation of the price of our common stock, if any, will provide a return to our stockholders for the foreseeable future.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Historically, the stock markets in general, and the markets for biotechnology stocks in particular, have experienced significant volatility that has at times been unrelated to the business, financial condition, or results of operations of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock and, consequently, adversely affect the price at which you are able to sell any shares of our common stock that you own. In the past, following periods of volatility in the market or significant price declines in individual securities or the market as a whole, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business, financial condition, or results of operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, our common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of our common stock on the Nasdaq Capital Market, we are required to meet certain listing requirements, including, among others, maintaining a minimum closing bid price for our common stock. Particularly given the historical volatility experienced by our common stock, there is no assurance that we will continue to meet the minimum closing price requirement and other listing requirements of Nasdaq.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We have funded our operations to date through the issuance of securities, including common stock, warrants to purchase common stock, convertible preferred stock, and convertible debt securities, and we expect that in the future we will need to raise additional capital through similar means to fund our continued development efforts for TSC and our other liquidity needs. Assuming funding is available on acceptable terms, any future issuance of common stock or securities convertible for or exchangeable into common stock will result in dilution to our existing stockholders and could depress the market price of our common stock. Furthermore, the terms of future financing transaction may contain provisions that restrict our operations or require us to relinquish certain rights to our product candidates or other technologies. </i></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Although we believe we have sufficient cash resources to fund the TSC Oxygenation Trials, our Planned Phase 2 Hypoxia-related Indication Trial, and our other operating expenses and capital expenditure requirements through 2023, we will in the future need to raise additional funds to continue our operations, fund additional clinical trials evaluating TSC and our other product candidates, and, if approved, commercializing TSC. We plan to continue to finance our operations with a combination of equity issuances, debt arrangements, and, potentially, licensing, or other partnering relationships.&nbsp; In addition, our Board may determine at any time to raise additional capital if it believes the terms are in the best interests of our stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accordingly, new issuances of a substantial number of shares of our common stock could occur at any time. For example, in February 2021, we issued 33,658,538 shares of our common stock in connection with the completion of the February 2021 Offering. Any issuance or sale of shares, or the perception in the market of an intent to issue or sell shares in the near-term, by the Company or holders of a large number of shares could reduce the market price of our common stock. We also cannot assure you that any such sale of common stock or other securities will be at a price per share that is equal to or greater than the price per share paid by you for our common stock. Furthermore, a depressed stock price could limit our ability to raise necessary capital through the sale of additional equity securities on terms that are acceptable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We may also seek additional capital through other methods, either alone or in combination with the issuance of additional securities, including debt financings, receivables or royalty financings, strategic partnerships and alliances, and licensing arrangements, any of which could be coupled with an equity component, such as warrants to purchase stock. The incurrence of indebtedness could result in increased fixed payment obligations, liens and other security interests being placed on certain of our assets, and certain restrictive covenants being imposed on the operation of our business, such as limitations on our ability to incur additional debt or acquire intellectual property rights. We may also in the future raise additional funds through strategic partnerships, alliances, and licensing arrangements with third parties, any of which could require us to relinquish valuable rights to TSC or our other product candidates. The restrictions imposed by any of these arrangement could materially decrease any potential returns on our investment in TSC or our other product candidates, or otherwise materially and adversely effect our business, financial condition, or results of operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Our organizational documents impose certain anti-takeover provisions and make the Delaware Chancery Court the exclusive forum for certain stockholder actions, which could depress the trading price of our common stock.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our certificate of incorporation, as amended, and our Bylaws contain provisions that may make the acquisition of our company, a proxy contest, or the nomination of a director candidate by a stockholder more difficult than such actions would be in the absence of such provisions, including that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">only our Board has the right to fill a vacancy on the Board created by an expansion or by the resignation, death, or removal of a director, which prevents stockholders from being able to fill vacancies on our Board;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">only our Chairman of the Board, our Chief Executive Officer, or a majority of our directors are authorized to call a special meeting of stockholders;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may issue undesignated preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval (notwithstanding any requirements imposed by the SEC or any exchange on which our common stock may now or in the future trade), and which may include rights superior to the rights of the holders of common stock;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our Board is expressly authorized to amend, restate, or repeal our Bylaws; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 3%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">advance notice is required with respect to any nominations for election to our Board or for proposing matters that can be acted upon by stockholders at any meeting of stockholder s.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for certain actions, including derivative actions brought on the Company's behalf, stockholder actions claiming breaches of a fiduciary duty owed by any of our directors or officers, and claims arising under our organizational documents, in each case, subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. Although this provision would not apply to any stockholder claims under the Exchange Act, there is uncertainty regarding whether a court would enforce such a forum selection provision as written would apply to stockholder claims under the Securities Act. Nevertheless, this forum selection provision may limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees, or agents, which may discourage lawsuits against us and such persons.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The limitations on certain stockholder rights imposed by these provisions could also depress the trading price of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 1B.</b></td>
			<td style="width: 88%;"><b>UNRESOLVED STAFF COMMENTS</b></td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">None.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 2.</b></td>
			<td style="width: 88%;"><b>PROPERTIES</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0px; text-indent: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">Our principal executive office is located in a leased facility in Charlottesville, Virginia, where we lease approximately 8,000 square feet of office space for approximately $10,000 per month. The current term of our Charlottesville lease will expire in April 2022.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 3.</b></td>
			<td style="width: 88%;"><b>LEGAL PROCEEDINGS</b></td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information in <i>Note 6, Commitments and Contingencies </i>&#8212;<i> Legal Proceedings</i> to our consolidated financial statements set forth in&nbsp;<i>Part II </i>&#8212;<i> Item 8 </i>&#8212;<i> Financial Statements</i> of this Annual Report is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, from time to time, we are subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. We record a liability in our consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when we have assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, we record the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. We disclose a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect our consolidated results of operations, financial position or cash flows.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 4.</b></td>
			<td style="width: 88%;"><b>MINE SAFETY DISCLOSURES</b></td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 5.</b></td>
			<td style="width: 88%;"><b>MARKET FOR REGISTRANT</b>&#8217;<b>S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Market Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our common stock trades publicly on the Nasdaq Capital Market under the symbol &#8220;DFFN.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Holders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of March 15, 2021, there were 353 record holders of our common stock. This does not include beneficial owners of our common stock whose stock is held in nominee or &#8220;street name&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dividends</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">To date, we have not declared or paid any cash dividends on our common stock and do not intend to do so in the near future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The information set forth in <i>Part III </i>&#8212;<i> Item 12 </i>&#8211;<i> Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i> of this Annual Report is incorporated herein by reference to the extent required by Item 201(d) of Regulation S-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Unregistered Sales of Equity Securities and Use of Proceeds</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">None</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">None.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 6.</b></td>
			<td style="width: 88%;"><b>SELECTED FINANCIAL DATA</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The information required by Item 6 of Form 10-K has been omitted from this Annual Report pursuant to the amendments to Regulation S-K adopted by the SEC on November 19, 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 7.</b></td>
			<td style="width: 88%;"><b>MANAGEMENT</b>&#8217;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Introduction</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This discussion and analysis contains information related to historical and prospective events intended to enable you to assess our business, financial condition, and results of operations. The information contained in this discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes contained elsewhere in this Annual Report, as well as the risks and uncertainties discussed in <i>Part I </i>&#8211;<i> Item 1A. Risk Factors </i>of this Annual Report.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Diffusion Pharmaceuticals: Enhancing Oxygen, Fueling Life</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to the areas where it is needed most. Our lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition to TSC, our product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR pathway inhibitor, is in early-stage development. We previously completed two Phase 1 clinical trials evaluating DFN-529 in age-related macular degeneration. DFN-529 was also previously in preclinical development in oncology, specifically GBM.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Highlights from 2020 and Early 2021</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td>
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Board &amp; Management Additions and Changes </i></b>- During the second half of 2020, our leadership team changed significantly. We appointed our new chief executive officer, Robert J. Cobuzzi, Jr., Ph.D., and our new general counsel, William Elder, in September 2020, followed by our new chief medical officer, Christopher Galloway, M.D., in October 2020. We also welcomed a new director, Jane Hollingsworth, to our Board in August 2020.&nbsp;&nbsp;Dr. Cobuzzi joined the Board in January 2020.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td>
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Initiation and Completion of TSC COVID Trial</i></b>&nbsp;- In September 2020, we announced the dosing of the first two patients in our TSC COVID Trial evaluating TSC in hospitalized COVID-19 patients at the NIID in Bucharest, Romania. On February 9, 2021, we completed dosing of the twenty-fourth and final patient in the TSC COVID Trial. No dose-limiting toxicities or serious adverse events were observed among any patients in the study, including those who received the highest dose of 1.5 mg/kg every 6 hours. Evaluation of secondary endpoint data is ongoing and we anticipate this data will be available early in the second quarter of 2021.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td>
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>February 2021 Equity Offering</i></b> - During the first quarter of 2021, we completed the February 2021 Offering resulting in aggregate gross net proceeds to the Company of approximately $34.5 million, before deducting underwriting discounts and commissions and offering expenses payable by us. In addition, during the period from January 1, 2021 through March l5, 2021, certain holders of warrants to purchase common stock cash exercised such warrants resulting in aggregate net proceeds to the Company of approximately $2.2 million. As a result, combined with our cash and cash equivalents as of December 31, 2020 of $18.5 million, we expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditures (including our planned clinical trials) through 2023.</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Strategic Priorities for 2021</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Since the founding of Diffusion LLC, we have been focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia. Prior to 2020, these efforts generated a substantial amount of data related to TSC, including data related to chemistry, manufacturing, and controls, preclinical safety and/or efficacy data in a wide array of experimental models, single dose safety, tolerability, and pharmacokinetic data, and clinical data and other information related to TSC's potential as a supplement to standard-of-care treatment in GBM, peripheral artery disease, and stroke.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In March 2020, the COVID-19 pandemic accelerated in the U.S. resulting in numerous delays and other challenges for biopharmaceutical companies conducting clinical studies in indications not related to COVID-19, including our TSC Stroke Trial. In early April 2020, we announced plans to initiate a clinical research program to evaluate TSC in patients with COVID-19 due to the anticipated persistence of the COVID-19 pandemic coupled with our belief in the potential of TSC to improve low tissue oxygen levels, a common symptom and complicating factor in the treatment of COVID-19. We believe this decision was both opportunistic and a natural extension of the previous development work conducted with TSC, and in September 2020 we commenced the TSC COVID Trial. &nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">38</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In November 2020, we announced that, following changes to our management team in the prior two months, we had initiated a thorough review of our then-existing development program for TSC and commenced plans to modify the program with the intent of accomplishing two principal strategic objectives:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;To optimize the clinical dose and dosing frequency for TSC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#8226;&nbsp;&nbsp;&nbsp;&nbsp;To evaluate TSC in clinical models designed to establish proof of concept for improvement in oxygenation.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The completion of the TSC COVID Trial in February 2021 provided the first multiple daily dose safety and tolerability data for TSC.&nbsp; We expect corresponding pharmacokinetic and other secondary endpoint data from this trial to be available early in the second quarter of 2021. Obtaining these data represents the first, major step in our ongoing efforts to implement our modified development strategy, intended to strategically gap-fill, supplement, and expand on our past development work in TSC, with the ultimate goal of maximizing the probability of regulatory approval and, if TSC is approved, commercial success.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the next twelve months, we intend to continue to execute our strategy and accomplish the following principal, strategic objectives, all of which we expect to be able to fund with cash-on-hand:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 18pt;"><b><i>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Complete the TSC Oxygenation Trials</i></b>&nbsp;&#8211;&nbsp;As described in more detail under the heading &#8212;<i>&nbsp;Our Anticipated Next Steps in the TSC Development Program: The TSC Oxygenation Trials</i>, the next phase in our development plan is to evaluate TSC's effects in clinical models of oxygenation in an effort to establish a dose-response relationship. We expect to commence the TSC TCOM Trial before the end of March 2021 with data expected in the second quarter of 2021, and we intend to commence both the TSC DLCO Trial and TSC Induced Hypoxia Trial in the third quarter of 2021 with data expected from each study expected within two months of their respective completion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;"><b><i>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Initiate Phase 2 Trial of TSC in Hypoxia-related Indication</i></b>&nbsp;&#8211;&nbsp;We believe positive data from one or more of the three TSC Oxygenation Trials would provide&nbsp;definitive evidence&nbsp;of TSC's enhancement of&nbsp;oxygenation, whether through increased uptake in the lungs, enhanced delivery, increased utilization at the tissue level, or some combination thereof.&nbsp;&nbsp;Positive data from any of these studies, if obtained, will guide the subsequent steps of our development strategy focused on demonstrating the clinical and therapeutic benefits of TSC in relevant patient populations on the hypoxia continuum. In particular, if successful in one or more of the three TSC Oxygenation Trials, we intend to initiate a Phase 2, controlled, clinical outcome study evaluating TSC in one or more&nbsp;appropriate hypoxia-related indications, which we refer to as our Planned Phase 2 Hypoxia-related Indication Trial,&nbsp;by the first quarter of 2022.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 18pt;"><b><i>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;Continue to Improve Our Efficiency and Effectiveness</i></b>&nbsp;&#8211;&nbsp;This will include evaluating, refining, and improving our policies, procedures, and processes related to chemistry, manufacturing, and controls, quality assurance, information technology, intellectual property, human capital, and other areas, including as described in more detail under the headings, &#8212;<i>&nbsp;Products, Product Development, and Our Competition</i>&nbsp;and &#8212;<i>&nbsp;Our People and Human Capital Resources</i>&nbsp;in <i>Part I </i>&#8211;<i>&nbsp;Item 1. Business</i>&nbsp;of this Annual Report.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Our Anticipated Next Steps in the TSC Development Program: The TSC Oxygenation Trials</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Following completion of the TSC COVID Trial in February 2021, the next step we have planned in the development of TSC is the design and execution of a trilogy of clinical studies using short-term, experimental models to evaluate the clinical effects of TSC on oxygenation. As of March 15, 2021, TSC has been administered to more than 180 subjects in our clinical trials. Data from these clinical trials have contributed significantly to our understanding of the safety, tolerability, and pharmacokinetics of TSC. In addition, post hoc analyses of two of our prior studies involving patients with peripheral artery disease with claudication and unresected GBM tumors have provided preliminary signals suggesting TSC's effect on oxygenation. However, neither of these studies was statistically powered to formally evaluate efficacy, and we therefore believe that further, robust clinical development of TSC requires a prospective exploration of the relationship between the level of exposure (dose) and response (change in oxygenation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">39</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To this end, we plan to execute the three, short-term TSC Oxygenation Trials during 2021, each of which we expect to conduct in the U.S.&nbsp;and fund with cash-on-hand. We believe positive data from any or more of the three TSC Oxygenation Trials would provide evidence of a definitive effect of TSC on oxygenation, whether through increased uptake in the lungs, enhanced delivery, increased utilization at the tissue level, or some combination thereof.&nbsp;Positive data from any of these studies, if obtained, will also guide the subsequent steps of our development strategy focused on demonstrating the clinical and therapeutic benefits of TSC in relevant patient populations across the hypoxia continuum.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Assuming success in one or more of the three TSC Oxygenation Trials, we expect to identify and announce the specific, hypoxia-related indications we will target in advancing TSC's development in the fourth quarter of 2021 and intend to initiate our Planned Phase 2 Hypoxia-related Indication Trial in the first quarter of 2022.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Financial Summary</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2020, we had a cash and cash equivalents balance of $18.5 million. We have incurred operating losses since inception, have not generated any product sales revenue, and have not achieved profitable operations. We incurred net losses of $14.2 million and $11.8 million for the years ended December 31, 2020 and 2019, respectively. To date, we have funded our operations and short-term liquidity needs primarily through the issuance and sale of common stock, warrants to purchase common stock, convertible debt, and convertible preferred stock. We expect to continue funding our operations through similar means for the foreseeable future, assuming the availability of additional capital, though we may enter into strategic partnerships or other alternative transactions in order to fund our ongoing capital requirements.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">40</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our accumulated deficit as of December 31, 2020, was $105.9 million and we expect to continue to incur substantial losses in future periods for the foreseeable future. We also anticipate that our operating expenses will increase substantially as we continue to advance the development of TSC, including any costs related to:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-size: 10pt; margin: 0px; font-family: &quot;Times New Roman&quot;; text-align: justify;">&#8226;</p>
			</td>
			<td>
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">our ongoing and planned clinical trials, including the ongoing and planned TSC Oxygenation Trials and our Planned&nbsp;Phase 2 Hypoxia-related Indication Trial;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td>
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any additional studies we may undertake, including other preclinical and clinical studies to support the filing of any NDA with the FDA;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td>
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">other research, development, and manufacturing activities designed to develop and optimize formulation, manufacturing processes, dosage, dose forms, and other characteristics prior to&nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#8226;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">regulatory approval;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td>
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the maintenance, expansion, and protection our global intellectual property portfolio;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p>
			</td>
			<td>
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the hiring of additional clinical, manufacturing, scientific, sales, or other personnel; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td>
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">investments in operational, financial, and management information systems.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of TSC, including the TSC TCOM Trial, the TSC VO2 Trial, and the TSC DLCO Trial. We expect that our existing cash and cash equivalents as of December 31, 2020, combined with the $36.7 million of aggregate gross proceeds received by the Company in connection with the completion of the February 2021 Offering (before deducting underwriting discounts and commissions and offering expenses payable by us) and the exercise of certain warrants to purchase common stock during the first quarter of 2021 prior to the date of this Annual Report, will enable us to fund our operating expenses and capital expenditure requirements, including expected costs related to the planned TSC Oxygenation Trials and our Planned Phase 2 Hypoxia-related Indication Trial through 2023.</p>

<p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Financial Operations Overview</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Revenues</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have not yet generated any revenue from product sales. We do not expect to generate revenue from product sales for the foreseeable future.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Research and Development Expense</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">R&amp;D expenses include, but are not limited to, third-party CRO arrangements and employee-related expenses, including salaries, benefits, stock-based compensation, and travel expense reimbursement. R&amp;D activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical studies. As we advance our product candidates, we expect the amount of R&amp;D costs will continue to increase for the foreseeable future. R&amp;D costs are charged to expense as incurred.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>General and Administrative Expense</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">G&amp;A expenses consist principally of salaries and related costs for executive and other personnel, including stock-based compensation, other employee benefit costs, expenses associated with investment bank and other financial advisory services, and travel expenses. Other G&amp;A expenses include, facility-related costs, communication expenses and professional fees for legal, patent prosecution and maintenance, consulting, accounting, and other professional services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Interest Income</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Interest income consists of interest earned from our cash and cash equivalents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">41</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><b><i>Income Tax Benefit (Expense)</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We recognize income tax benefit to utilize indefinite deferred tax liabilities as a source of income against indefinite lived portions of our deferred tax assets. Our NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of a greater than 50.0% cumulative change in the ownership interest of significant stockholders over a three year period, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. These limitations may, in certain cases, limit the amount of income tax benefit that can be utilized annually to offset taxable income or tax liabilities in future periods. The amount of the annual limitation is determined based on the Company&#8217;s value immediately prior to the ownership change, and subsequent ownership changes may further affect the limitation in future years. In 2019, due to the significant changes to our stockholder base as a result of the equity financing we completed during that year, we performed an analysis under Section 382 of the Internal Revenue Code and, as a result, reduced the magnitude of our NOL carryforwards to account for the ownership changes. In addition, the cumulative benefit of our NOLs was remeasured, resulting in tax expense recognized during the year ended December 31, 2019. We have not yet performed an analysis to determine whether or not ownership changes that have occurred in year ended December 31, 2020 give rise to any further limitations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>Critical Accounting Policies</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Certain of our critical accounting policies require estimates that involve the application of significant judgment by management in selecting the appropriate assumptions in determining the estimate. By their nature, these judgments are subject to an inherent degree of uncertainty. We develop these judgments based on our historical experience, terms of existing contracts, our observance of trends in the industry, and information available from other outside sources, as appropriate. Actual results may differ from these judgments under different assumptions or conditions. Different, reasonable estimates could have been used for the current period. Additionally, changes in accounting estimates are reasonably likely to occur from period to period. Both of these factors could have a material impact on the presentation of our financial condition, changes in financial condition, or results of operations. We believe the accounting policies described below are among the most critical to aid in fully understanding and evaluating our financial statements, as they require estimates which involve our most subjective or complex judgments.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Intangible Assets</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our sole intangible asset as of December 31, 2020 consisted of DFN-529, which was acquired in 2016 pursuant to our merger with RestorGenex Corporation and is accounted for as an IPR&amp;D intangible asset. The fair value of the IPR&amp;D asset was determined as of the acquisition date using the cost approach, often referred to as current replacement cost, which establishes a value based on the cost of reproducing or replacing the asset. The cost approach was chosen as we were not able to estimate an income stream attributable to the IPR&amp;D asset, given the fact that the related products had only completed limited preclinical and clinical trials and the timeline to commercial viability, if the FDA approval process were to be successful, is uncertain, would take a number of years, and the costs would be significant. As the development efforts for DFN-529 continue, based on the facts and circumstances at the time of a future valuation for the purposes of assessing impairment, it is possible that the value for the IPR&amp;D asset could be substantially reduced or eliminated, which could result in a maximum pre-tax charge to operations equal to the current carrying value of the asset, or $8.6 million as of December 31, 2020. We most recently tested the IPR&amp;D intangible asset for impairment on October 1, 2020, which is our annual impairment testing date. In addition to our annual impairment testing, upon the occurrence of certain triggering events, we may determine that an interim IPR&amp;D impairment analysis is warranted. There was no impairment to the IPR&amp;D asset during the years ended December 31, 2020 and 2019.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">42</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations for Year Ended December 31, 2020 Compared to Year Ended December 31, 2019 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table summarizes our results of operations for the years ended December 31, 2020 and 2019:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Change</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 55%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,427,667</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,619,597</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,808,070</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,444,109</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,834,284</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,609,825</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">103,168</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97,915</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,253</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Loss from operations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,974,944</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,551,796</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,423,148</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest income</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">114,257</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">85,302</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,955</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Loss from operations before income taxes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,860,687</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,466,494</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,394,193</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income tax benefit (expense)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,675,381</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(332,885</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,008,266</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(14,185,306</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11,799,379</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,385,927</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Research and development expenses were $9.4 million during the year ended December 31, 2020 compared to $6.6 million during the year ended December 31, 2019, an increase of 42.4%. A significant portion of this increase was attributable to the TSC COVID Trial, which was initiated in September 2020, and our related ramp-up, including a $1.1 million increase in manufacturing costs and a $2.2 million increase in clinical trial and other related R&amp;D expenses. Other R&amp;D costs, including share based compensation, also increased by $0.3 million. These increases were slightly offset by decreases of $0.3 million and $0.2 million related to the wind-down of our TSC GBM Trial and our TSC Stroke Trial, respectively and a decrease in salaries and wages expenses of $0.3 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">General and administrative expenses were $6.4 million during the year ended December 31, 2020 compared to $4.8 million during the year ended December 31, 2019, an increase of 33.3%. The increase in G&amp;A expense was primarily due to a $0.7 million increase in professional fees and a $0.9 million increase in salaries, wages, and stock-based compensation expense, including non-recurring expenses related to the retirement, resignation, and separation of our former Chief Executive Officer in the third quarter of 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Interest income increased slightly for the year ended December 31, 2020 compared to the year ended December 31, 2019 on an absolute basis due to our having a larger cash and cash equivalents balance and therefore earning more interest during the year ended December 31, 2020 compared to the year ended December 31, 2019.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the year ended December 31, 2020, we recognized an income tax benefit of $1.7 million to reflect the utilization of indefinite deferred tax liabilities as a source of income against indefinite lived portions of the our deferred tax assets. As a result of a deemed change in ownership under the provisions of Section 382 of the Tax Code, the cumulative benefit of our NOLs was remeasured during 2019 resulting in the reversal of an income tax benefit of $0.4 million recorded in 2018. Accordingly, net of a $0.1 million benefit related to losses incurred during the year, we recognized an income tax expense of $0.3 million for the year ended December 31, 2019.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Working Capital</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table summarizes our working capital as of December 31, 2020 and 2019:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,515,595</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,177,349</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses, deposits and other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">260,825</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">472,464</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,435,783</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,721,421</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Working capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,340,637</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,928,392</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We expect to continue to incur net losses for the foreseeable future. We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of TSC and our other product candidates, included the TSC Oxygenation Studies and our Planned Phase 2 Hypoxia-related Indication Trial, through 2023.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">43</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Cash Flows</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table sets forth our cash flows for the years ended December 31, 2020 and 2019:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash (used in) provided by:</p>
			</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(13,552,628</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,858,375</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Financing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,890,875</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,044,552</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,338,247</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,186,177</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Operating Activities</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the year ended December 31, 2020, net cash used in operating activities increased $3.7 million, or 37.5%, compared to the year ended December 31, 2019.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in operating activities of $13.6 million during the year ended December 31, 2020 was primarily attributable to our net loss of $14.2 million and a $1.7 million change in deferred income taxes. This amount was offset by our net change in operating assets and liabilities of $1.5 million, and non-cash charges comprised of $0.7 million of stock-based compensation expense and depreciation expense of $0.1 million.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in operating activities of $9.9 million during the year ended December 31, 2019 was primarily attributable to our net loss of $11.8 million and a $0.3 million change in deferred income taxes. This amount was offset by our net change in operating assets and liabilities of $1.0 million, and non-cash charges comprised of $0.5 million of stock-based compensation expense and depreciation expense of $0.1 million.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Investing Activities</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Cash flows from investing activities represent our sources and uses of cash from our investments, including purchases and sales of equipment and other assets. During each of the years ended December 31, 2020 and 2019, we had no such cash flows.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Financing Activities</i></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the year ended December 31, 2020, net cash provided by financing activities increased $1.8 million, or 11.5%, compared to the year ended December 31, 2019.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Net cash provided by financing activities of $17.9 million during the year ended December 31, 2020 was primarily attributable to the $10.8 million in proceeds (net of underwriting discounts and commissions payable by us) received in connection with the May 2020 Offering and $8.0 million in proceeds received in connection with the exercise of common stock warrants stock during the year. These cash inflows were offset in part by the payment of $1.0 million in additional financing costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Net cash provided by financing activities of $16.0 million during the during the year ended December 31, 2019 was primarily attributable to the $12.3 million in aggregate proceeds (net of underwriting discounts and commissions payable by us) received in connection with the May 2019 Offering, the November 2019 Offering, and the December 2019 Offering and $3.9 million in proceeds received in connection with the exercise of common stock warrants during the year. These cash inflows were offset in part by the payment of $0.2 million in additional financing costs.</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">44</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Capital Requirements</i></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We expect to continue to incur substantial expenses and generate significant operating losses as we continue to pursue our business strategy of developing TSC. Our operations have consumed substantial amounts of cash since inception and we expect to continue to spend substantial amounts of cash to advance the clinical development of TSC, DFN-529, and our other&nbsp; product candidates. As of the date of this Annual Report, most our cash resources for clinical development are dedicated to our ongoing and planned TSC Oxygenation Trials and our Planned Phase 2 Hypoxia-related Indication Trial. While we believe we have adequate cash resources to continue operations through 2023, we anticipate that we will need additional funding in order to complete development of TSC which, if available, could be obtained through additional capital raising transactions, entry into strategic partnerships or collaborations, or alternative financing arrangements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December&nbsp;31, 2020, we did not have any credit facilities in place under which we could borrow funds or any other sources of committed capital. In the future, we may seek to raise additional funds through various sources. However, we can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or be on terms acceptable to us. This risk may increase if economic and market conditions deteriorate. If we are unable to obtain additional financing when needed, we may need to terminate, significantly modify, or delay the development of TSC or our product candidates, or we may need to obtain funds through collaborations or otherwise on terms that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to raise adequate&nbsp;additional capital as and when required in the future, we could be forced to cease development activities and terminate our operations, and you could experience a complete loss of your investment.</p>

<p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To the extent that we raise additional capital in the future through the sale of our common stock or securities convertible or exchangeable for common stock such as common stock warrants, convertible preferred stock, or convertible debt instruments, the interests of our current stockholders may be diluted or otherwise impacted. In particular, specific rights granted to future holders of preferred stock or convertible debt securities may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The information in <i>Note 3, Basis of Presentation and Summary of Significant Accounting Policies</i> to our consolidated financial statements set forth in&nbsp;<i>Part II </i>&#8212;<i> Item 8 </i>&#8212;<i> Financial Statements</i>&nbsp;of this Annual Report is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 7A.</b></td>
			<td style="width: 88%;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As a "smaller reporting company" (as such term is defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information described in Item 305 of Regulation S-K and, accordingly, the information required by Item 6 of Form 10-K has been omitted from this Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">45</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 8.</b></td>
			<td style="width: 88%;"><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p>
			</td>
			<td style="vertical-align:bottom;width:12.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:86%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:12.9%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Report of Independent Registered Public Accounting Firm</p>
			</td>
			<td style="vertical-align:bottom;width:12.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">47</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:86%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:12.9%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Balance Sheets as of December 31, 2020 and 2019</p>
			</td>
			<td style="vertical-align:bottom;width:12.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">48</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:86%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:12.9%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Operations for the years ended December 31, 2020 and 2019</p>
			</td>
			<td style="vertical-align:bottom;width:12.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">49</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:86%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:12.9%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Changes in Stockholders&#8217;&nbsp;Equity&nbsp;for the years ended December 31, 2020 and 2019</p>
			</td>
			<td style="vertical-align:bottom;width:12.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">50</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:86%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:12.9%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019</p>
			</td>
			<td style="vertical-align:bottom;width:12.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">51</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:86%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:12.9%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes to the Consolidated Financial Statements for the years ended December 31, 2020 and 2019</p>
			</td>
			<td style="vertical-align:bottom;width:12.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">52</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">46</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Report of Independent Registered Public Accounting Firm</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the Stockholders and Board of Directors<br>
Diffusion Pharmaceuticals Inc.:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Opinion on the Consolidated Financial Statements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have audited the accompanying consolidated balance sheets of Diffusion Pharmaceuticals Inc. and subsidiaries (the Company) as of December&nbsp;31, 2020 and 2019, the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020 and 2019, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Basis for Opinion</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Critical Audit Matter</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated<i> </i>financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated<i> </i>financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated<i> </i>financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;"><i>Deemed dividend</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">As discussed in Note 7 to the consolidated financial statements, the Company entered into a warrant exercise agreement with an investor who held a previously outstanding warrant. The Company recognized a deemed dividend of $2.0 million to reflect the fair value of the consideration given as an inducement for the investor to exercise the warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">We identified the evaluation of the deemed dividend as a critical audit matter. A higher degree of auditor judgment was required to evaluate the application of the accounting guidance due to the unique nature of the transaction with the investor.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The following are the procedures we performed to address this critical audit matter. We read and evaluated the Company&#8217;s accounting memorandum that documented the business purpose, the terms of the agreements underlying the transaction, and the factors the Company considered in determining the applicable accounting treatment. We compared the facts and circumstances in the Company&#8217;s accounting memorandum to the agreements underlying the transaction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">/s/ KPMG LLP</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company&#8217;s auditor since 2015.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">McLean, Virginia<br>
March 16, 2021</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">47</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="4" id="175444" sectdesc="Balance Sheet">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-statement-type="balance-sheet" data-td-taggable-table="" data-td-v2v-id="1615409566662">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,515,595</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,177,349</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Prepaid expenses, deposits and other current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">260,825</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">472,464</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,776,420</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,649,813</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,198</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">252,366</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,639,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,639,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,162</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">247,043</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,771</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">322,301</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,729,551</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,110,523</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities and Stockholders</b>&#8217;<b> Equity</b></p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accounts payable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">545,844</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,251,412</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued expenses and other current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,776,470</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">358,532</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current operating lease liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">113,469</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">111,477</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,435,783</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,721,421</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">443,893</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,119,274</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Noncurrent operating lease liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,693</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">135,566</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,915,369</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,976,261</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commitments and Contingencies (Note 6)</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stockholders&#8217; Equity:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 64,015,441 and 33,480,365 shares issued and outstanding at December 31, 2020 and 2019, respectively</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64,016</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,481</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Additional paid-in capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,659,550</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">111,824,859</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accumulated deficit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105,909,384</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(91,724,078</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,814,182</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,134,262</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,729,551</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,110,523</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><i>See accompanying notes to consolidated financial statements.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">48</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="5" id="175445" sectdesc="Income Statement">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-statement-type="income" data-td-taggable-table="" data-td-v2v-id="1615409584573">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,427,667</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,619,597</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,444,109</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,834,284</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">103,168</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97,915</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Loss from operations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,974,944</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,551,796</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest income</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">114,257</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">85,302</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations before income taxes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,860,687</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,466,494</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income tax benefit (expense)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,675,381</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(332,885</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(14,185,306</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,799,379</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend arising from warrant exchange</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,950,378</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(16,135,684</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11,799,379</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Share information:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.30</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.76</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding, basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">53,831,973</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,706,509</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><i>See accompanying notes to consolidated financial statements.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">49</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="7" id="175446" sectdesc="Stockholders' Equity">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS</b>&#8217;<b> EQUITY </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-statement-type="stockholders-equity" data-td-taggable-table="" data-td-v2v-id="1615409594551">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="18" id=".amt.D6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stockholders' Equity</b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Common Stock</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Additional</b><br>
			<b>Paid-in</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b><br>
			<b>Stockholders'</b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><b>Shares</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><b>Amount</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><b>Capital</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><b>Deficit</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><b>Equity</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 40%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2018</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,376,230</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,377</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,532,881</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(79,924,699</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,611,559</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,688,276</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,688</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,905,207</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,917,895</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock upon exercise of warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,415,859</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,416</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,871,009</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,888,425</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">515,762</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">515,762</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,799,379</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,799,379</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,480,365</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,481</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">111,824,859</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(91,724,078</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,134,262</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock and warrants, net of issuance costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,428,572</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,429</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,330,202</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,341,631</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock upon exercise of warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,106,504</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,106</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,768,370</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,787,476</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">736,119</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">736,119</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,185,306</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,185,306</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,015,441</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,016</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,659,550</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(105,909,384</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,814,182</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><i>See accompanying notes to consolidated financial statements.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">50</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="8" id="175447" sectdesc="Cash Flows">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div data-td-statement-type="cash-flows" data-td-taggable-table="" data-td-v2v-id="1615409604375">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(14,185,306</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,799,379</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">103,168</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">97,915</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">736,119</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">515,762</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Change in deferred income taxes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,675,381</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">332,885</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Prepaid expenses, deposits and other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">518,169</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,774</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accounts payable, accrued expenses and other liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">950,602</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">567,668</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash used in operating activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,552,629</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,858,375</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows provided by financing activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from the sale of common stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,827,100</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from the sale of common stock, pre-funded warrants and warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,318,956</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from the exercise of common stock warrants and pre-funded warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,046,103</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,888,425</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Payment of offering costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(982,328</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(162,829</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by financing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,890,875</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,044,552</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,338,247</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,186,177</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at beginning of year</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,177,349</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,991,172</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at end of year</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,515,595</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,177,349</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Supplemental disclosure of non-cash investing and financing activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Offering costs in accounts payable and accrued expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">238,232</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Operating lease right of use asset and liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">334,205</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><i>See accompanying notes to consolidated financial statements.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">51</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175448" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409627264">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>1. Organization and Description of Business</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Diffusion Pharmaceuticals Inc., a Delaware corporation, an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to the areas where it is needed most. The Company&#8217;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to TSC, the Company's product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR pathway inhibitor, is in early-stage development. The Company previously completed two Phase 1 clinical trials evaluating DFN-529 in age-related macular degeneration. DFN-529 was also previously in preclinical development in oncology, specifically GBM.</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175449" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409641064">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>2. Liquidity</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has not generated any revenues from product sales and has funded operations primarily from the proceeds of public and private offerings of equity, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed, or at all, or that the Company&#8217;s research and development efforts will be successful.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. The Company does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered such arrangements or if it entered into such arrangements at later stages in the product development process.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The Company expects that its existing cash and cash equivalents as of December 31, 2020, combined with the proceeds received by the Company in connection with the completion of the February 2021 Offering and the exercise of certain warrants to purchase common stock during the first quarter of 2021 prior to the date of this Annual Report, will enable it to fund its operating expenses and capital expenditure requirements, including expected costs related to the planned TSC Oxygenation Trials and the Planned Phase 2 Hypoxia-related Indication Trial through 2023.</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175450" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409656745">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>3.</b>&nbsp;<b>Basis of Presentation and Summary of Significant Accounting Policies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Basis of Presentation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The accompanying consolidated&nbsp;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Use of Estimates</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">52</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Fair Value of Financial Instruments</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Concentration of Credit Risk</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Property and Equipment</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from 2 to 15 years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Long-Lived Assets</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets may not be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has not recognized any impairment of long-lived assets during the years ended December 31, 2020 and 2019.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Intangible Asset</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has an indefinite-lived IPR&amp;D asset, DFN-529, which has a balance of $8.6 million at both December 31, 2020 and December 31, 2019. DFN-529 is a PI3K/Akt/mTOR pathway inhibitor in preclinical development for oncology.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Intangible assets deemed to have indefinite lives are not amortized but rather are assessed for impairment annually on October 1 of the Company&#8217;s fiscal year or more frequently if impairment indicators exist. There was no impairment to the Company&#8217;s DFN-529 intangible asset recognized during the years ended December 31, 2020 and 2019.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Research and Development</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#8217;s behalf). Costs incurred for research and development are expensed as incurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company may record net prepaid or accrued expenses relating to these costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Upfront payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">53</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Patent Costs</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Income Taxes</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&nbsp;not&nbsp;that some portion or all of a deferred tax asset will&nbsp;not&nbsp;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&nbsp;not&nbsp;to be sustained.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">ASC 740-10 defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50.0% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Stock-based Compensation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the expected dividend yield and the fair value of the Company&#8217;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For certain stock option grants, the expected term was estimated using the &#8220;simplified method&#8221; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended December 31, 2020, it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. 10 years) of the stock option and therefore the Company began to use the contractual life as the expected term.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For stock price volatility, the Company uses a combination of their own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes no dividend yield because dividends are not expected to be paid in the near future, which is consistent with the Company&#8217;s history of not paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company accounts for forfeitures in the periods they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Net Loss Per Common Share</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">54</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409656739">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,100,112</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,385,141</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,240,204</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">309,276</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,340,316</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,694,417</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Recently Issued But Not Yet Adopted Accounting Pronouncements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): <i>Simplifying the Accounting for Income Taxes</i>. This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company is currently analyzing the impact of ASU No. 2019-12 on the consolidated financial statements.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In August 2018, the FASB issued ASU 2018-03, <i>Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurements, </i>which changes the fair value measurement disclosure requirements of ASC 820. The goal of the ASU is to improve the effectiveness of ASC 820's disclosure requirements. The Company adopted this standard in January 2020 and the adoption did not have a material impact on its related disclosures.</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175451" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409667796">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>4.</b>&nbsp;<b>Property and Equipment</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Property and equipment consists of the following:&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409667793">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">182,357</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">182,357</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and office equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151,442</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151,442</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">430,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">430,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">763,799</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">763,799</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: accumulated depreciation and amortization</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(614,601</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(511,433</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">149,198</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">252,366</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Depreciation and amortization expense was approximately $0.1 million for both the years ended December 31, 2020 and 2019.</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175452" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409680970">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>5.</b>&nbsp;<b>Accrued Expenses and Other Current Liabilities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Accrued expenses and other current liabilities consist of the following:</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409680967">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">653,899</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">182,708</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,809</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,338</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,055,398</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">57,378</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,364</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70,108</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,776,470</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">358,532</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">55</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
</div>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175453" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409700071">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>6.</b>&nbsp;<b>Commitments and Contingencies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Office Space Lease Commitment</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has a non-cancelable operating lease for office and laboratory space in Charlottesville, Virginia, which began in April 2017 and, as of December 31, 2020, has a remaining lease term of approximately 1.3 years. The discount rate used to account for the Company's operating lease is the Company&#8217;s estimated incremental borrowing rate of 10.0%. The original term of the lease ends in the second quarter of 2022 and the Company has an option to extend for another 5 years. This option to extend was not recognized as part of the Company's measurement of the right-of-use&nbsp;asset and operating lease liability as of December 31, 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Rent expense related to the Company's operating lease for both the years ended December&nbsp;31, 2020 and 2019 was approximately $0.1 million. Future minimum rental payments under the Company's non-cancelable operating lease at December&nbsp;31, 2020 were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409700069">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Rental</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Commitments</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 85%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">118,519</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,735</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">158,254</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,092</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">149,162</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Research and Development Arrangements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the course of normal business operations, the Company enters into agreements with universities and contract research organizations, or CROs, to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Defined Contribution Retirement Plan</i></b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has established its 401(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees may elect to contribute to the 401(k) Plan up to 90.00% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of 4.0% of the participant&#8217;s compensation. The Company made matching contributions under the 401(k) Plan of approximately $56,000 and $68,000 for the years ended December&nbsp;31, 2020 and 2019, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">56</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;"><b><i>Legal Proceedings</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company's legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#8217; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#8217;s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on April 14, 2015, the Court granted the Company&#8217;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. On November 19, 2018 at an Order to Show Cause Re Dismissal Hearing, the Court found sufficient grounds not to dismiss the case, and an arbitration hearing was scheduled for November 2020. In August 2020, due to the ongoing COVID-19 pandemic and related restrictions on gatherings in the State of California, the arbitration hearing was postponed to August 16, 2021. The Company believes this matter is without merit and intends to defend the arbitration vigorously. However, at this stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#8217;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#8217;s financial position.</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175454" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409713992">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>7.</b>&nbsp;<b>Stockholders' Equity and Common Stock Warrants</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>2020 Common Stock Offering</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2020, the Company completed the May 2020 Offering, a public offering of 11,428,572 shares of common stock for a purchase price of $1.05 per share for net proceeds of $10.3 million after deducting commissions, discounts, and other offering costs. In addition, at the closing of the May 2020 Offering, the Company issued warrants to purchase up to 571,429 shares of common stock to designees of the placement agent for the May 2020 Offering. The placement agent's warrants have an exercise price of $1.3125 per share and a term of five years from the date of issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Additionally, also in May 2020, the Company entered into a warrant exercise agreement with an investor who held a previously outstanding warrant to purchase up to an aggregate of 5,000,000 shares of our common stock at an exercise price of $0.35 per share(the Prior Warrant). In consideration for the exercise of the Prior Warrant for cash and an additional $0.125 per each share of common stock resulting from the exercise, the exercising investor received new unregistered warrants to purchase up to an aggregate of 5,000,000 shares of common stock in a private placement. The warrants are exercisable immediately at an exercise price of $0.5263 per share and exercisable until November 8, 2025. The Company recognized a deemed dividend of $2.0 million to reflect the consideration given as an inducement for the investor to exercise the warrants. This deemed dividend is recorded in the Company's consolidated statement of operations during the year ended December 31, 2020 as an increase to the net loss attributable to common stockholders for purposes of computing net loss per share, basic and diluted.&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In connection with the warrants exercised in May 2020, the Company issued warrants to purchase up to 250,000 shares of common stock to the placement agent with an exercise price of $0.5938 per share and otherwise have identical terms to the warrants issued to the investor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>2019 Common Stock Offerings</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In December 2019, Company completed the December 2019 Offering, an offering of 6,266,787 shares of its common stock and warrants to purchase 6,266,787 shares of common stock. The shares of common stock and warrants were sold for a combined purchase price of $0.5585 per share for net proceeds of $3.0 million. The December 2019 Offering warrants are exercisable beginning on the date of their issuance until June 13, 2025 at an initial exercise price equal to $0.4335 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, at the closing of the December 2019 Offering, the Company issued warrants to purchase up to 313,339 shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of $0.6981 per share and a term of five years from the date of issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">57</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In November 2019, the Company completed the November 2019 Offering, a registered direct public offering of 5,104,429 shares of its common stock, and 6,324,143 pre-funded warrants each to purchase one share of common stock, together with warrants to purchase up to 22,857,144 shares of common stock at a combined public offering price of $0.35 per share and associated warrants for total net proceeds of $3.3 million. The warrants were issued with an exercise price of $0.35 per warrant and are exercisable beginning on their date of issuance. Of the warrants issued, 11,428,572 have a term of 18 months and 11,428,572 have a term of 5 years. During the year ended December 31, 2019, 11,091,716 of those warrants were exercised for additional proceeds of $3.9 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, at the closing of the November 2019 Offering, the Company issued warrants to purchase up to 571,429 shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of $0.4375 per share and a term of five years from the date of issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In May 2019, the Company completed the May 2019 Offering, a registered direct public offering of 1,317,060 shares of common stock and a private placement of warrants to purchase 1,317,060 shares of common stock. The shares of common stock and warrants were sold for a combined purchase price of $4.895 for total net proceeds of $5.6 million. The warrants are exercisable beginning on the date of their issuance until November 29, 2024 at an initial exercise price equal to $5.00.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, at the closing of the May 2019 Offering, the Company issued warrants to purchase up to 65,853 shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of $6.11875 per share, a term of 5 years from the date of issuance and otherwise substantially similar terms to the form of the investor warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Common Stock Warrants</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During its evaluation of equity classification for the Company's common stock warrants issued in 2020 and 2019, the Company considered the conditions as prescribed within ASC 815-40, <i>Derivatives and Hedging, Contracts in an Entity</i>&#8217;<i>s own Equity</i>. The conditions within ASC 815-40 are not subject to a probability assessment. The warrants do not fall under the liability criteria within ASC 480,&nbsp;<i>Distinguishing Liabilities from Equity </i>as they are not puttable and do not represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock and would be classified in permanent equity if freestanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of December&nbsp;31, 2020, the Company had the following warrants outstanding to acquire shares of its common stock:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409713988">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Outstanding</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td colspan="3" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%; vertical-align: bottom;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Range of exercise</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price per share</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0); width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">903,870</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$33.30</td>
			<td id=".amt.3" style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 2022</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the January 2018 common stock offering</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,181,421</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;">$12.00</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;">-</td>
			<td colspan="1" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$15.00</p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">January 2023</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2019 Offering</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,382,913</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;">$5.00</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;">-</td>
			<td colspan="1" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$6.11875</p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">May and December 2024</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the November 2019 Offering</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">497,140</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;">$0.35</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;">-</td>
			<td colspan="1" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$0.4375</p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">May 2024</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the December 2019 Offering</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">313,339</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;">$0.4335</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;">-</td>
			<td colspan="1" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$0.6981</p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 2024 and June 2025</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Offering</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">571,429</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&nbsp;</td>
			<td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$1.31</td>
			<td id=".amt.3" style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 2025</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Investor Warrant Exercise</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,250,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;">$0.5263</td>
			<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;">-</td>
			<td colspan="1" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">$0.5938</p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 2025</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,100,112</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: right;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: center;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 4%;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;">&nbsp;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 13%;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">During the year ended December 31, 2020, no warrants expired and 19,106,504 warrants were exercised for gross proceeds of $8.0 million. During the year ended December 31, 2019, 1,767 warrants expired and 17,415,859 warrants were exercised for net proceeds of $3.9 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">58</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
</div>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175455" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409793290">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:12pt;"><b>8.</b>&nbsp;<b>Stock-Based Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;"><b><i>2015 Equity Plan</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to 4.0% of the total shares of the Company&#8217;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, 2,560,618 shares were added to the reserve as of January 1, 2021, which shares may be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the 2015 Equity Plan. As of December&nbsp;31, 2020, there were no shares of common stock available for future issuance under the 2015 Equity Plan. Further, the Company granted options to purchase 270,000 shares of common stock to employees during the year ended December&nbsp;31, 2020 that were granted outside of the 2015 Equity Plan as an inducement material to the employee&#8217;s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Generally, the options have a ten (10) year&nbsp;contractual term and vest in equal monthly installments over three (3) years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409793282">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b> </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">164,791</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,155</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">571,328</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">461,607</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">736,119</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">515,762</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table summarizes the activity related to all stock option:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409793284">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b><br>
			<b>Options</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b><br>
			<b>average</b><br>
			<b>exercise</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b><br>
			<b>per share</b> </b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b><br>
			<b>average</b><br>
			<b>remaining</b><br>
			<b>contractual</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life</b><br>
			<b>(in years)</b> </b></p>
			</td>
			<td id=".trail.D4" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b><br>
			<b>Intrinsic</b><br>
			<b>Value</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 52%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2019</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">203,736</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88.14</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117,270</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.62</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,583</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83.81</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(147</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">276.00</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">309,276</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">55.78</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">6.98</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">&#8212;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,931,100</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.68</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(172</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142.50</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,240,204</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.28</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.90</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">289,067</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,129,733</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15.64</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.28</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">219,010</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2020</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,240,204</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.28</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.90</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">289,067</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The weighted average grant date fair value of stock option awards granted was $0.64 and $2.16 during the years ended December&nbsp;31, 2020 and 2019, respectively. The total fair value of options vested during the years ended December&nbsp;31, 2020 and 2019 were $0.7 million and $0.6 million, respectively. No options were exercised during any of the periods presented. At December&nbsp;31, 2020, there was $0.8 million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&nbsp;2.2 years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">59</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The grant date fair value of employee stock options is determined using the Black-Scholes Model. The following assumptions were used during the years ended December&nbsp;31, 2020 and 2019:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409793287">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 66%;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td colspan="4" id=".amt.D4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".lead.D7" style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>
			<td colspan="3" id=".amt.D7" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 66%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.31&nbsp;</td>
			<td id=".amt.3" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td>
			<td id=".amt.4" style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10.00</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.25</td>
			<td id=".amt.6" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td>
			<td id=".amt.7" style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.77</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 66%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.4%</td>
			<td id=".amt.3" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td>
			<td id=".amt.4" style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.7%</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.9%</td>
			<td id=".amt.6" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td>
			<td id=".amt.7" style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.5%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 66%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">113.4%</td>
			<td id=".amt.3" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td>
			<td id=".amt.4" style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124.8%</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">112.4%</td>
			<td id=".amt.6" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td>
			<td id=".amt.7" style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">114.4%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 66%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.2" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;&nbsp;</td>
			<td id=".amt.3" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td>
			<td id=".amt.4" style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".amt.6" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td>
			<td id=".amt.7" style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Restricted Stock Unit Awards</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the year ended December&nbsp;31, 2020, the Company granted 153,000 restricted stock units to members of the board of directors of the Company. The weighted average grant date fair value of the restricted stock units granted during the year ended December&nbsp;31, 2020 was $0.65. The shares begin to vest 18 months after the grant date. The Company recognized approximately $18,000 in expense related to these units during the year ended December&nbsp;31, 2020. At December&nbsp;31, 2020, there was approximately $82,000 of unrecognized compensation cost that will be recognized over a weighted average period of 2.4 years.</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175456" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409805506">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>9.</b>&nbsp;<b> Income Taxes</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Since inception, the Company has incurred net losses, and until 2018, had not recorded any U.S. federal or state income tax benefits for the losses. In 2018, as a result of the change in net operating loss carryforward period associated with the 2017 Tax Act, the Company recognized an income tax benefit to reflect the adjustment allowed by the 2017 Tax Act to utilize indefinite deferred tax liabilities as a source of income against indefinite lived portions of the Company&#8217;s deferred tax assets. In 2019, as a result of a change in ownership under the provisions of Internal Revenue Code Section 382, the cumulative benefit of net operating losses was remeasured which resulted in tax expense to reverse the 2018 benefit recorded and record a benefit relative to losses incurred in 2019 after the date of the change in ownership.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse. &nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409805499">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax assets</b></p>
			</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,864,189</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,504,496</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,571,227</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,381,750</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">541,384</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81,700</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,394</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">63,589</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,709,631</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,187,898</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,906,646</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,051,440</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,818,179</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">167,993</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax liabilities</b></p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,223,678</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,223,678</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(38,394</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(63,589</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,262,072</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,287,267</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(443,893</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,119,274</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company does not have unrecognized tax benefits as of December&nbsp;31, 2020 or December 31, 2019. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">60</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company had NOL carryforwards for federal and state income tax purposes at December&nbsp;31, 2020 and 2019 of approximately:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409805501">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Combined NOL Carryforwards:</b></p>
			</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,013,388</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,844,972</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,007,966</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,844,972</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The pre-2018 net operating loss carryforwards begin expiring in 2020 for both federal and state income tax purposes. In November 2019, as a result of a change of ownership, under the provisions of Internal Revenue Code Section 382 and similar state provisions, the Company&#8217;s ability to utilize their net operating loss carryforwards to offset future income was limited. The Company recorded a valuation allowance against a portion of their deferred tax assets as of December 31, 2020 because of the uncertainty of their realization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1615409805503">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Rate reconciliation:</b></p>
			</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(21.0</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(21.0</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4.7</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.5</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.9</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.3</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.1</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(7.5</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.6</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.1</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total provision</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(10.5</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.0</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p>
			</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company&#8217;s 2017 to 2019 tax years remain open and subject to examination.</p>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175457" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409817797">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"><b>10. Related Party Transactions</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company&#8217;s Director of Information Technologies is the son of the Chairman of the Board of Directors and he has held that position since December 2014.</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="175458" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1615409837575">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>11.</b>&nbsp;<b>Subsequent Events</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b><i>2021 Warrant Exercises</i></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">From January 1, 2021 through March 15, 2021, warrants were exercised by multiple holders to purchase a total of 4,230,000 shares of the Company's common stock for aggregate gross proceeds of approximately $2.2 million.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>2021 Common Stock Offering</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In February 2021, the Company completed the February 2021 Offering in which it offered and sold 33,658,538 shares of its common stock in an underwritten, public offering for a purchase price to the public of $1.025 per share, inclusive of shares offered and sold pursuant to the exercise-in-full by the underwriter of its 30-day option to purchase additional shares. The February 2021 Offering resulted in aggregate net proceeds to the Company of $31.2 million, after deducting underwriting commissions, discounts, and expenses but prior to deducting other offering costs. In addition, at the closings of the February 2021 Offering, the Company issued to designees of the underwriter of the transaction warrants to purchase up to an aggregate of 1,682,927 shares of common stock to designees. The underwriter warrants have an exercise price of $1.28125 per share and a term of five years from the date of issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">61</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="12" id="175459" sectdesc="Other">&nbsp;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 9.</b></td>
			<td style="width: 88%;"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 9A.&nbsp;</b></td>
			<td style="width: 88%;"><b>CONTROLS AND PROCEDURES</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 45pt;">The term &#8220;disclosure controls and procedures&#8221; means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a &#8211; 15(e) and 15d &#8211; 15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Our principal executive officer and principal financial officer do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Management</b>&#8217;<b>s Report on Internal Control Over Financial Reporting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our Chief Executive Officer and Senior Vice President, Finance, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <i>Internal Control</i>&#8212;<i>Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Attestation Report of the Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">This report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. As a "smaller reporting company" (as such term is defined in Rule 12b-2 of the Exchange Act), pursuant to Section 989G of the Dodd-Frank Act, we are exempt from the requirement subjecting management&#8217;s report to attestation by our independent registered public accounting firm.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Change in Internal Control Over Financial Reporting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">There was no change in our internal control over financial reporting that occurred during our fourth quarter ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 9B.</b></td>
			<td style="width: 88%;"><b>OTHER INFORMATION</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">62</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART III</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 10.</b></td>
			<td style="width: 88%;"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information required by Item 10 of Form 10-K will be set forth in the Proxy Statement and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 11.</b></td>
			<td style="width: 88%;"><b>EXECUTIVE COMPENSATION</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information required by Item 11 of Form 10-K will be set forth in the Proxy Statement and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 12.</b></td>
			<td style="width: 88%;"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information required by Item 12 of Form 10-K will be set forth in the Proxy Statement and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 13.</b></td>
			<td style="width: 88%;"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information required by Item 13 of Form 10-K will be set forth in the Proxy Statement and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 14.</b></td>
			<td style="width: 88%;"><b>PRINCIPAL ACCOUNTING FEES AND SERVICES</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information required by Item 14 of Form 10-K will be set forth in the Proxy Statement and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">63</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART IV</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 15.</b></td>
			<td style="width: 88%;"><b>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 63pt;">1.&nbsp;Our financial statements are included in <i>Part II </i>&#8211;<i>&nbsp;Item 8. Financial Statements and Supplementary Data</i>&nbsp;of this Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 63pt;">2.&nbsp;All financial statement schedules have been omitted from this Item 15 as the required information is not applicable, is not present in amounts sufficient to require submission of such schedules, or because the information required is included in our financial statements or the related notes included in <i>Part II </i>&#8211;<i>&nbsp;Item 8. Financial Statements and Supplementary Data</i>&nbsp;of this Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 63pt;">3.&nbsp;The exhibits set forth in the following "Index to Exhibits" are filed with, furnished with, and/or incorporated herein by reference, as described thereon. A copy of any of such exhibit will be furnished at a reasonable cost, upon receipt from any person of a written request for any such exhibit. Such request should be sent to Diffusion Pharmaceuticals Inc., 1317 Carlton Avenue, Suite 200, Charlottesville, Virginia 22902, Attention: General Counsel.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 63pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">64</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>INDEX TO EXHIBITS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid black;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Exhibit</b><br>
			<b>No.</b></p>
			</td>
			<td style="vertical-align: top; width: 48%; border-bottom: 1px solid black;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Description</b></p>
			</td>
			<td style="vertical-align: top; width: 1%; border-bottom: 1px solid black; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; border-bottom: 1px solid black;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Method of Filing</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.1</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Certificate of Incorporation of Diffusion Pharmaceuticals Inc., as amended</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919005256/ex_137220.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 3.1 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.2</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Bylaws of Diffusion Pharmaceuticals Inc., as amended</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex3-4.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 3.4 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2015</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.1</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of 2017 Private Placement Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774917004538/ex4-1.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on March 15, 2017</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.2</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of 2018 Common Stock Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918000800/ex_103239.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on January 19, 2018</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.3</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of 2018 Underwriter's Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918000941/ex_103358.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.2 to the registrant&#8217;s current report on Form 8-K filed on January 22, 2018</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.4</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of May 2019 Common Stock Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919010905/ex_145858.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on May 28, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.5</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of May 2019 Placement Agent&#8217;s Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919010905/ex_145859.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.2 to the registrant&#8217;s current report on Form 8-K filed on May 28, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.6</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of November 2019 Series I Common Stock Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/ex_164781.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on November 13, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.7</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of November 2019 Series II Common Stock Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/ex_164782.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.2 to the registrant&#8217;s current report on Form 8-K filed on November 13, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.8</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of November 2019 Pre-Funded Common Stock Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/ex_164784.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.3 to the registrant&#8217;s current report on Form 8-K filed on November 13, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.9</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of November 2019 Placement Agent&#8217;s Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/ex_164785.htm" style="-sec-extract:exhibit;">Incorporated&nbsp;by&nbsp;reference&nbsp;to&nbsp;Exhibit&nbsp;4.4&nbsp;to&nbsp;the registrant&#8217;s current report on Form 8-K&nbsp;filed&nbsp;on November&nbsp;13,&nbsp;2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.10</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of December 2019 Common Stock Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919024424/ex_167361.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on December 13, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.11</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of December 2019 Placement Agent&#8217;s Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919024424/ex_167362.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.2 to the registrant&#8217;s current report on Form 8-K filed on December 13, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.12</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of May 2020 Common Stock Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920010091/ex_185437.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on May 8, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.13</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of May 2020 Placement Agent's Warrant (In Respect of Exercise Transaction)</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920010091/ex_185438.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.2 to the registrant&#8217;s current report on Form 8-K filed on May 8, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.14</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of May 2020 Placement Agent's Warrant (In Respect of Offering Transaction)</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920011442/ex_187389.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.3 to the registrant&#8217;s current report on Form 8-K filed on May 20, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.15</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of February 2021 Underwriter's Warrant</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774921003299/ex_227273.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed on February 18, 2021</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.16</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Description of Securities</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920005469/ex_176595.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 4.12 to the registrant's annual report on 10-K for the year ended December 31, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.1</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Employment Agreement dated as of September 8, 2020 by and between Robert J. Cobuzzi, Jr., Ph.D. and Diffusion Pharmaceuticals Inc.*</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920019460/ex_203251.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.2 to the registrant&#8217;s current report on Form 8-K filed on September 9, 2020</a></p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">65</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.2</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Amended and Restated Employment Agreement, dated as of September 21, 2018, by and between William Karl Hornung and Diffusion Pharmaceuticals Inc. *</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918017551/ex_124640.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.2 to the registrant's Current Report on Form 8-K filed September 27, 2018</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.3</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Employment Agreement, dated as of October 19, 2020, by and between Christopher D. Galloway, M.D. and Diffusion Pharmaceuticals Inc. *</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920021340/ex_207598.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed October 20, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.4</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Employment Agreement, dated as of September 23, 2020, by and between William Elder and Diffusion Pharmaceuticals Inc. *</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920020264/ex_205132.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed September 25, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.5</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Employment Agreement, dated as of September 6, 2016, by and between David G. Kalergis and Diffusion Pharmaceuticals Inc.*</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916038465/ex10-1.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed on September 8, 2016</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.6</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Separation Agreement dated as of September 8, 2020 by and between David G. Kalergis and Diffusion Pharmaceuticals Inc.*</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920019460/ex_203274.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed on September 9, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.7</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Employment Agreement, dated as of October 18, 2016, by and between John L. Gainer and Diffusion Pharmaceuticals Inc.*</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774917007493/ex10-18.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.18 to the registrant&#8217;s annual report on Form 10-K/A filed on April 28, 2017</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.8</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Separation Agreement, dated as of March 12, 2020, by and between John L. Gainer and Diffusion Pharmaceuticals Inc.*</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920005589/ex_177433.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed on March 18, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.9</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consulting Agreement, dated as of March 12, 2020, by and between John L. Gainer and Diffusion Pharmaceuticals Inc.*</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920005589/ex_177433.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.2 to the registrant&#8217;s current report on Form 8-K filed on March 18, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.1</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan**</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916033633/dffn20160607_def14a.htm" style="-sec-extract:exhibit;">Incorporated by reference to Appendix C to the registrants definitive proxy statement on Schedule 14A filed on June 10, 2016</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.11</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Amendment No. 1 to Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916033633/dffn20160607_def14a.htm" style="-sec-extract:exhibit;">Incorporated by reference to Appendix B to the registrants definitive proxy statement on Schedule 14A filed on June 10, 2016</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.12</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of Stock Option Award Agreement*</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918006050/ex_108103.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.5 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2017</a></td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.13</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of Diffusion Pharmaceuticals LLC Stock Option Award Agreement*</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex10-24.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.24 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2015</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.14</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of Indemnification Agreement between Diffusion Pharmaceuticals Inc. and each of its Directors and Officers*</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex10-3.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.3 to the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2015</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.15</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Form of Securities Purchase Agreement, dated as of May 18, 2020, by and among Diffusion Pharmaceuticals Inc. and the purchasers party thereto</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920011442/ex_187391.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed on May 20, 2020</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.16</p>
			</td>
			<td style="vertical-align: top; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Lease Agreement, dated March 31, 2017, by and between Diffusion Pharmaceuticals Inc. and One Carlton LLC</p>
			</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000105369117000015/lease1317carltonaveste400fu.htm" style="-sec-extract:exhibit;">Incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed on March 15, 2017</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">21.1</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Subsidiaries of Diffusion Pharmaceuticals Inc.</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_234335.htm" style="-sec-extract:exhibit;">Filed herewith</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">23.1</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consent of KPMG LLP, independent registered public accounting firm</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_234411.htm" style="-sec-extract:exhibit;">Filed herewith</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">31.1</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_234412.htm" style="-sec-extract:exhibit;">Filed herewith</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">31.2</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_234413.htm" style="-sec-extract:exhibit;">Filed herewith</a></p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">66</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">32.1</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_234414.htm" style="-sec-extract:exhibit;">Filed herewith</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 48%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">101</p>
			</td>
			<td style="vertical-align: bottom; width: 48%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The following materials from the registrant&#8217;s annual report on Form 10-K for the year ended December 31, 2020, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Filed herewith<br>
			&nbsp;</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicates a management contract or compensatory plan or arrangement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 12%;"><b>ITEM 16.</b></td>
			<td style="width: 88%;"><b>FORM 10-K SUMMARY</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">None.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">67</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 48%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Dated: March 16, 2021</p>
			</td>
			<td colspan="2" style="width: 3%;" valign="top" width="38%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
			</td>
			<td style="width: 14%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 48%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</p>
			</td>
			<td style="width: 14%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 48%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left; width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
			<td style="width: 14%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 48%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
			<td style="width: 14%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 48%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><i>President, Chief Executive Officer, and Director</i></p>
			</td>
			<td style="width: 14%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 48%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 3%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="35%"><i>(Principal Executive Officer)</i></td>
			<td style="width: 14%;" valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name and Signature</b></p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President, Chief Executive Officer, and Director</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 16, 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ William K. Hornung</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 16, 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">William K. Hornung</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial and Accounting Officer)</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ David G. Kalergis</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 16, 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">David G. Kalergis</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Robert Adams</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 16, 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Robert Adams</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Jane Hollingsworth</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 16, 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Jane Hollingsworth</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:37.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ John L. Gainer, Ph.D.</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 16, 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">John L. Gainer, Ph.D.</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:37.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Mark T. Giles</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 16, 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Mark T. Giles</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Alan Levin</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 16, 2021</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Alan Levin</p>
			</td>
			<td style="vertical-align:top;width:3.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:28.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:25.4%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">68</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ex_234335.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/15/2021 8:44:09 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_234335.htm</title>


</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 21.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:100%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 90%; margin-left: 0pt; margin-right: auto;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name of Subsidiary</b></p>
			</td>
			<td style="vertical-align: bottom; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>State or Other</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Jurisdiction of</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Incorporation or</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Organization</b></p>
			</td>
			<td style="vertical-align: bottom; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Direct or Indirect</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Ownership Interest by</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Company</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canterbury Laboratories, LLC</p>
			</td>
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">DE</p>
			</td>
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">100%</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Hygeia Therapeutics, Inc.</p>
			</td>
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">DE</p>
			</td>
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">100%</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Diffusion Pharmaceuticals LLC</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">VA</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">100%</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex_234411.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/16/2021 7:54:32 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_234411.htm</title>


</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin-bottom: 0; text-align: right; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin-bottom: 0; text-align: left; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board of Directors<br>
Diffusion Pharmaceuticals Inc.:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consent to the incorporation by reference in the registration statements (No. 333-206408, No. 333-206409, No. 333-218060, No. 333-226782, No. 333-233381, and No. 333-238233) on Form S-8, (No. 333-222203, No. 333-233686, No. 333-234234, No. 333-235670, and No. 333-238818) on Form S-1, and (No. 333-218062, No. 333-222879, No. 333-231541, and No. 333-249057) on Form S-3 of Diffusion Pharmaceuticals Inc. of our report dated March&nbsp;16, 2021, with respect to the consolidated balance sheets of Diffusion Pharmaceuticals Inc. as of December&nbsp;31, 2020 and 2019, and the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes, which report appears in the December&nbsp;31, 2020 annual report on Form 10-K of Diffusion Pharmaceuticals Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ KPMG LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">McLean, Virginia<br>
March 16, 2021</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex_234412.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/16/2021 7:57:18 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_234412.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0; text-align: right; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 31.1</b></font></p>

<p style="margin-bottom: 0; text-align: left; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>DIFFUSION PHARMACEUTICALS INC.</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>CERTIFICATION OF CEO PURSUANT TO SECTION 302 OF</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>THE SARBANES-OXLEY ACT OF 2002</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>CERTIFICATION</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Robert J. Cobuzzi, Jr., Ph.D., certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this annual report on Form 10-K of Diffusion Pharmaceuticals Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 16, 2021</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td align="left" style="text-align: left; width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Robert J. Cobuzzi, Jr., Ph.D.<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"> </font></p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">President and Chief Executive Officer</p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 30%;" valign="top" width="35%">(Principal Executive Officer)</td>
			<td style="width: 18%;" valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 216pt;text-indent:36pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex_234413.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/16/2021 8:05:37 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_234413.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0; text-align: right; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 31.2</b></font></p>

<p style="margin-bottom: 0; text-align: left; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>DIFFUSION PHARMACEUTICALS INC.</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>CERTIFICATION OF PFO PURSUANT TO SECTION 302 OF</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>THE SARBANES-OXLEY ACT OF 2002</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>CERTIFICATION</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, William K. Hornung, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this annual report on Form 10-K of Diffusion Pharmaceuticals Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 16, 2021</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td align="left" style="text-align: left; width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William K. Hornung<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"> </font></p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">William K. Hornung<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Chief Financial Officer</p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 30%;" valign="top" width="35%">(Principal Financial and Accounting Officer)</td>
			<td style="width: 18%;" valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex_234414.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/16/2021 8:10:49 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_234414.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0; text-align: right; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 32.1</b></font></p>

<p style="margin-bottom: 0; text-align: left; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>CERTIFICATION PURSUANT TO</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>18 U.S.C. SECTION 1350,</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>AS ADOPTED PURSUANT TO</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Annual Report on Form 10-K of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, Robert J. Cobuzzi, Jr., Ph.D. and William K. Hornung, President and Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 16, 2021</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td align="left" style="text-align: left; width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Robert J. Cobuzzi, Jr., Ph.D.<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"> </font></p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 30%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">President and Chief Executive Officer</p>
			</td>
			<td style="width: 18%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 30%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 18%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 30%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 18%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 30%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="35%">/s/&nbsp;William K. Hornung</td>
			<td style="width: 18%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 30%;" valign="top" width="35%">William K. Hornung</td>
			<td style="width: 18%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 30%;" valign="top" width="35%">Chief Financial Officer</td>
			<td style="width: 18%;" valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>dffn-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:19PM UTC 2021-03-16--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dffn="http://www.diffusionpharma.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="dffn-20201231.xsd" xlink:type="simple"/>
  <dei:AmendmentFlag contextRef="d_2020-01-01_2020-12-31" id="c-31">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2020-01-01_2020-12-31" id="c-16">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2020-01-01_2020-12-31" id="c-30">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2020-01-01_2020-12-31" id="c-29">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2020-01-01_2020-12-31" id="c-28">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2020-01-01_2020-12-31" id="c-27">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2020-01-01_2020-12-31" id="c-14">0001053691</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2021-03-12" decimals="INF" id="c-24" unitRef="xbrli-shares">101903979</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2020-01-01_2020-12-31" id="c-18">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="d_2020-01-01_2020-12-31" id="c-21">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFilerCategory contextRef="d_2020-01-01_2020-12-31" id="c-17">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityInteractiveDataCurrent contextRef="d_2020-01-01_2020-12-31" id="c-23">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityPublicFloat contextRef="i_2020-06-30" decimals="-5" id="c-25" unitRef="iso4217-usd">62400000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="d_2020-01-01_2020-12-31" id="c-13">Diffusion Pharmaceuticals Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="d_2020-01-01_2020-12-31" id="c-26">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="d_2020-01-01_2020-12-31" id="c-22">true</dei:EntitySmallBusiness>
  <dei:EntityVoluntaryFilers contextRef="d_2020-01-01_2020-12-31" id="c-19">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2020-01-01_2020-12-31" id="c-20">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:Security12bTitle contextRef="d_2020-01-01_2020-12-31" id="c-32">Common Stock, par value $0.001 per share</dei:Security12bTitle>
  <dei:TradingSymbol contextRef="d_2020-01-01_2020-12-31" id="c-15">dffn</dei:TradingSymbol>
  <dffn:AccruedClinicalStudiesExpensesCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883413" unitRef="iso4217-usd">1055398</dffn:AccruedClinicalStudiesExpensesCurrent>
  <dffn:AccruedClinicalStudiesExpensesCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883414" unitRef="iso4217-usd">57378</dffn:AccruedClinicalStudiesExpensesCurrent>
  <dffn:ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare contextRef="d_2020-05-01_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember" decimals="INF" id="c70883468" unitRef="iso4217-usd-per-xbrli-shares">0.125</dffn:ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare>
  <dffn:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="d_2019-01-01_2019-12-31_ClassOfWarrantOrRightAxis-WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" decimals="INF" id="c70883495" unitRef="xbrli-shares">11091716</dffn:ClassOfWarrantOrRightExercisedDuringPeriod>
  <dffn:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883523" unitRef="xbrli-shares">19106504</dffn:ClassOfWarrantOrRightExercisedDuringPeriod>
  <dffn:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883526" unitRef="xbrli-shares">17415859</dffn:ClassOfWarrantOrRightExercisedDuringPeriod>
  <dffn:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="d_2021-01-01_2021-03-15_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c70883764" unitRef="xbrli-shares">4230000</dffn:ClassOfWarrantOrRightExercisedDuringPeriod>
  <dffn:ClassOfWarrantOrRightIssuedDuringPeriod contextRef="d_2019-11-01_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" decimals="INF" id="c70883485" unitRef="xbrli-shares">6324143</dffn:ClassOfWarrantOrRightIssuedDuringPeriod>
  <dffn:ClassOfWarrantOrRightIssuedDuringPeriod contextRef="d_2019-11-01_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" decimals="INF" id="c70883491" unitRef="xbrli-shares">11428572</dffn:ClassOfWarrantOrRightIssuedDuringPeriod>
  <dffn:ClassOfWarrantOrRightIssuedDuringPeriod contextRef="d_2019-11-01_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" decimals="INF" id="c70883493" unitRef="xbrli-shares">11428572</dffn:ClassOfWarrantOrRightIssuedDuringPeriod>
  <dffn:ClassOfWarrantOrRightsExpired contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883522" unitRef="xbrli-shares">0</dffn:ClassOfWarrantOrRightsExpired>
  <dffn:ClassOfWarrantOrRightsExpired contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883525" unitRef="xbrli-shares">1767</dffn:ClassOfWarrantOrRightsExpired>
  <dffn:DeemedDividendFromWarrantExchange contextRef="d_2020-05-01_2020-05-31" decimals="-5" id="c70883471" unitRef="iso4217-usd">2000000</dffn:DeemedDividendFromWarrantExchange>
  <dffn:DeemedDividendFromWarrantExchange contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883188" unitRef="iso4217-usd">1950378</dffn:DeemedDividendFromWarrantExchange>
  <dffn:DeemedDividendFromWarrantExchange contextRef="d_2019-01-01_2019-12-31" id="c70883189" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:DeferredTaxAssetsCapitalizedCostsAndOther contextRef="i_2020-12-31" decimals="INF" id="c70883727" unitRef="iso4217-usd">10709631</dffn:DeferredTaxAssetsCapitalizedCostsAndOther>
  <dffn:DeferredTaxAssetsCapitalizedCostsAndOther contextRef="i_2019-12-31" decimals="INF" id="c70883728" unitRef="iso4217-usd">9187898</dffn:DeferredTaxAssetsCapitalizedCostsAndOther>
  <dffn:DeferredTaxAssetsLeaseLiability contextRef="i_2020-12-31" decimals="INF" id="c70883725" unitRef="iso4217-usd">38394</dffn:DeferredTaxAssetsLeaseLiability>
  <dffn:DeferredTaxAssetsLeaseLiability contextRef="i_2019-12-31" decimals="INF" id="c70883726" unitRef="iso4217-usd">63589</dffn:DeferredTaxAssetsLeaseLiability>
  <dffn:DeferredTaxAssetsOrphanDrugCredits contextRef="i_2020-12-31" decimals="INF" id="c70883723" unitRef="iso4217-usd">541384</dffn:DeferredTaxAssetsOrphanDrugCredits>
  <dffn:DeferredTaxAssetsOrphanDrugCredits contextRef="i_2019-12-31" decimals="INF" id="c70883724" unitRef="iso4217-usd">81700</dffn:DeferredTaxAssetsOrphanDrugCredits>
  <dffn:DeferredTaxLiabilitiesRightOfUseAsset contextRef="i_2020-12-31" decimals="INF" id="c70883736" unitRef="iso4217-usd">38394</dffn:DeferredTaxLiabilitiesRightOfUseAsset>
  <dffn:DeferredTaxLiabilitiesRightOfUseAsset contextRef="i_2019-12-31" decimals="INF" id="c70883737" unitRef="iso4217-usd">63589</dffn:DeferredTaxLiabilitiesRightOfUseAsset>
  <dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent contextRef="d_2020-01-01_2020-12-31" decimals="3" id="c70883750" unitRef="xbrli-pure">0.029</dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent>
  <dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent contextRef="d_2019-01-01_2019-12-31" decimals="3" id="c70883751" unitRef="xbrli-pure">-0.253</dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent>
  <dffn:LiquidityDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785628">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2.&lt;/div&gt; Liquidity&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; generated any revenues from product sales and has funded operations primarily from the proceeds of public and private offerings of equity, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;No&lt;/div&gt; assurance can be given that any such financing will be available when needed, or at all, or that the Company's research and development efforts will be successful.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;third&lt;/div&gt; parties and other strategic alliances and business transactions. The Company does &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; have any commitments to obtain additional funds and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;third&lt;/div&gt; parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;receive lower consideration upon commercialization of such products than if it had &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; entered such arrangements or if it entered into such arrangements at later stages in the product development process.&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company's product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company's control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company's financial condition and future operations. The Company expects that its existing cash and cash equivalents as of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020, &lt;/div&gt;combined with the proceeds received by the Company in connection with the completion of the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; February 2021 &lt;/div&gt;Offering and the exercise of certain warrants to purchase common stock during the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;first&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2021&lt;/div&gt; prior to the date of this Annual Report, will enable it to fund its operating expenses and capital expenditure requirements, including expected costs related to the planned TSC Oxygenation Trials and the Planned Phase &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2&lt;/div&gt; Hypoxia-related Indication Trial through &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2023.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</dffn:LiquidityDisclosureTextBlock>
  <dffn:OfferingCostsInAccountsPayable contextRef="d_2020-01-01_2020-12-31" id="c70883287" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:OfferingCostsInAccountsPayable contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883288" unitRef="iso4217-usd">238232</dffn:OfferingCostsInAccountsPayable>
  <dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EquityIncentivePlan2015Member" decimals="2" id="c70883572" unitRef="xbrli-pure">0.04</dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis>
  <dffn:PrepaidExpensesDepositsAndOtherAssets contextRef="i_2020-12-31" decimals="INF" id="c70883118" unitRef="iso4217-usd">260825</dffn:PrepaidExpensesDepositsAndOtherAssets>
  <dffn:PrepaidExpensesDepositsAndOtherAssets contextRef="i_2019-12-31" decimals="INF" id="c70883119" unitRef="iso4217-usd">472464</dffn:PrepaidExpensesDepositsAndOtherAssets>
  <dffn:ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants contextRef="d_2020-01-01_2020-12-31" id="c70883272" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883273" unitRef="iso4217-usd">12318956</dffn:ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants>
  <dffn:StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants contextRef="i_2019-11-30_SubsidiarySaleOfStockAxis-November2019PublicOfferingMember" decimals="INF" id="c70883487" unitRef="xbrli-shares">22857144</dffn:StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants>
  <dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883202" unitRef="xbrli-shares">12688276</dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts>
  <dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883227" unitRef="xbrli-shares">11428572</dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts>
  <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883203" unitRef="iso4217-usd">12688</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
  <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883204" unitRef="iso4217-usd">11905207</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
  <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c70883205" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883206" unitRef="iso4217-usd">11917895</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
  <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883228" unitRef="iso4217-usd">11429</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
  <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883229" unitRef="iso4217-usd">10330202</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
  <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c70883230" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883231" unitRef="iso4217-usd">10341631</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
  <dffn:UnderwriterOptionToPurchaseAdditionalSharesTerm contextRef="d_2021-02-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember" id="c70883770">P30D</dffn:UnderwriterOptionToPurchaseAdditionalSharesTerm>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785633">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5.&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;Accrued Expenses and Other Current Liabilities&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll and payroll related expenses&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;653,899&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;182,708&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued professional fees&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,809&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;48,338&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued clinical studies expenses&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,055,398&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;57,378&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;35,364&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;70,108&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,776,470&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;358,532&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883134" unitRef="iso4217-usd">545844</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883135" unitRef="iso4217-usd">1251412</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883411" unitRef="iso4217-usd">31809</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883412" unitRef="iso4217-usd">48338</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883409" unitRef="iso4217-usd">653899</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883410" unitRef="iso4217-usd">182708</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2020-12-31" decimals="INF" id="c70883403" unitRef="iso4217-usd">614601</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2019-12-31" decimals="INF" id="c70883404" unitRef="iso4217-usd">511433</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2020-12-31" decimals="INF" id="c70883162" unitRef="iso4217-usd">130659550</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2019-12-31" decimals="INF" id="c70883163" unitRef="iso4217-usd">111824859</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c70883213" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883214" unitRef="iso4217-usd">515762</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c70883215" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883216" unitRef="iso4217-usd">515762</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c70883238" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883239" unitRef="iso4217-usd">736119</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c70883240" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883241" unitRef="iso4217-usd">736119</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" decimals="INF" id="c70883616" unitRef="iso4217-usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c70883626" unitRef="iso4217-usd">164791</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c70883627" unitRef="iso4217-usd">54155</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="INF" id="c70883628" unitRef="iso4217-usd">571328</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="INF" id="c70883629" unitRef="iso4217-usd">461607</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883630" unitRef="iso4217-usd">736119</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883631" unitRef="iso4217-usd">515762</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" decimals="INF" id="c70883385" unitRef="xbrli-shares">9100112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2019-01-01_2019-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" decimals="INF" id="c70883386" unitRef="xbrli-shares">22385141</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" decimals="INF" id="c70883387" unitRef="xbrli-shares">2240204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2019-01-01_2019-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" decimals="INF" id="c70883388" unitRef="xbrli-shares">309276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883389" unitRef="xbrli-shares">11340316</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883390" unitRef="xbrli-shares">22694417</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2020-12-31" decimals="INF" id="c70883130" unitRef="iso4217-usd">27729551</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2019-12-31" decimals="INF" id="c70883131" unitRef="iso4217-usd">24110523</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883120" unitRef="iso4217-usd">18776420</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883121" unitRef="iso4217-usd">14649813</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883312">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The accompanying consolidated&amp;nbsp;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2020-12-31" decimals="INF" id="c70883116" unitRef="iso4217-usd">18515595</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2019-12-31" decimals="INF" id="c70883117" unitRef="iso4217-usd">14177349</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883320">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;The Company considers any highly liquid investments, such as money market funds, with an original maturity of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;three&lt;/div&gt; months or less to be cash and cash equivalents.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="i_2019-12-31" decimals="INF" id="c70883282" unitRef="iso4217-usd">14177349</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="i_2018-12-31" decimals="INF" id="c70883283" unitRef="iso4217-usd">7991172</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="i_2020-12-31" decimals="INF" id="c70883284" unitRef="iso4217-usd">18515595</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883280" unitRef="iso4217-usd">4338247</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883281" unitRef="iso4217-usd">6186177</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" decimals="INF" id="c70883464" unitRef="iso4217-usd-per-xbrli-shares">1.3125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember" decimals="INF" id="c70883467" unitRef="iso4217-usd-per-xbrli-shares">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member" decimals="INF" id="c70883470" unitRef="iso4217-usd-per-xbrli-shares">0.5263</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember" decimals="INF" id="c70883473" unitRef="iso4217-usd-per-xbrli-shares">0.5938</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2019-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" decimals="INF" id="c70883479" unitRef="iso4217-usd-per-xbrli-shares">0.4335</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2019-12-31_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" decimals="INF" id="c70883481" unitRef="iso4217-usd-per-xbrli-shares">0.6981</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" decimals="INF" id="c70883490" unitRef="iso4217-usd-per-xbrli-shares">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2019-11-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" decimals="INF" id="c70883498" unitRef="iso4217-usd-per-xbrli-shares">0.4375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2019-05-31_SubsidiarySaleOfStockAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" decimals="INF" id="c70883504" unitRef="iso4217-usd-per-xbrli-shares">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2019-05-31_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" decimals="INF" id="c70883506" unitRef="iso4217-usd-per-xbrli-shares">6.11875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c70883773" unitRef="iso4217-usd-per-xbrli-shares">1.28125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember" decimals="INF" id="c70883531" unitRef="iso4217-usd-per-xbrli-shares">33.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MinimumMember" decimals="INF" id="c70883535" unitRef="iso4217-usd-per-xbrli-shares">12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" id="c70883536" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MaximumMember" decimals="INF" id="c70883537" unitRef="iso4217-usd-per-xbrli-shares">15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember" decimals="INF" id="c70883540" unitRef="iso4217-usd-per-xbrli-shares">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember" decimals="INF" id="c70883542" unitRef="iso4217-usd-per-xbrli-shares">6.11875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember_RangeAxis-MinimumMember" decimals="INF" id="c70883545" unitRef="iso4217-usd-per-xbrli-shares">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember_RangeAxis-MaximumMember" decimals="INF" id="c70883547" unitRef="iso4217-usd-per-xbrli-shares">0.4375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MinimumMember" decimals="INF" id="c70883550" unitRef="iso4217-usd-per-xbrli-shares">0.4335</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" id="c70883551" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MaximumMember" decimals="INF" id="c70883552" unitRef="iso4217-usd-per-xbrli-shares">0.6981</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" decimals="INF" id="c70883556" unitRef="iso4217-usd-per-xbrli-shares">1.31</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember_RangeAxis-MinimumMember" decimals="INF" id="c70883560" unitRef="iso4217-usd-per-xbrli-shares">0.5263</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember_RangeAxis-MaximumMember" decimals="INF" id="c70883562" unitRef="iso4217-usd-per-xbrli-shares">0.5938</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" decimals="INF" id="c70883486" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" decimals="INF" id="c70883463" unitRef="xbrli-shares">571429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember" decimals="INF" id="c70883466" unitRef="xbrli-shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member" decimals="INF" id="c70883469" unitRef="xbrli-shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember" decimals="INF" id="c70883472" unitRef="xbrli-shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2019-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" decimals="INF" id="c70883476" unitRef="xbrli-shares">6266787</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2019-12-31_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" decimals="INF" id="c70883480" unitRef="xbrli-shares">313339</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2019-11-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" decimals="INF" id="c70883497" unitRef="xbrli-shares">571429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2019-05-31_SubsidiarySaleOfStockAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" decimals="INF" id="c70883501" unitRef="xbrli-shares">1317060</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2019-05-31_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" decimals="INF" id="c70883505" unitRef="xbrli-shares">65853</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c70883772" unitRef="xbrli-shares">1682927</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember" decimals="INF" id="c70883529" unitRef="xbrli-shares">903870</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" decimals="INF" id="c70883534" unitRef="xbrli-shares">1181421</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" decimals="INF" id="c70883539" unitRef="xbrli-shares">1382913</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" decimals="INF" id="c70883544" unitRef="xbrli-shares">497140</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" decimals="INF" id="c70883549" unitRef="xbrli-shares">313339</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" decimals="INF" id="c70883554" unitRef="xbrli-shares">571429</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember" decimals="INF" id="c70883559" unitRef="xbrli-shares">4250000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2020-12-31" decimals="INF" id="c70883564" unitRef="xbrli-shares">9100112</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2020-12-31" id="c70883149" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2019-12-31" id="c70883150" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785635">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;6.&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;Commitments and Contingencies&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Office Space Lease Commitment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has a non-cancelable operating lease for office and laboratory space in Charlottesville, Virginia, which began in &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; April 2017 &lt;/div&gt;and, as of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020, &lt;/div&gt;has a remaining lease term of approximately &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1.3&lt;/div&gt; years. The discount rate used to account for the Company's operating lease is the Company's estimated incremental borrowing rate of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10.0%.&lt;/div&gt; The original term of the lease ends in the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;second&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2022&lt;/div&gt; and the Company has an option to extend for another &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5&lt;/div&gt; years. This option to extend was &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; recognized as part of the Company's measurement of the right-of-use&amp;nbsp;asset and operating lease liability as of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Rent expense related to the Company's operating lease for both the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt; was approximately &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.1&lt;/div&gt;&lt;/div&gt; million. Future minimum rental payments under the Company's non-cancelable operating lease at &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; were as follows:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Rental&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;118,519&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;39,735&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;158,254&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: imputed interest&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(9,092&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;149,162&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Arrangements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In the course of normal business operations, the Company enters into agreements with universities and contract research organizations, or CROs, to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;require upfront payments and long-term commitments of cash.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Defined Contribution Retirement Plan&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has established its &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;401&lt;/div&gt;(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;elect to contribute to the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;401&lt;/div&gt;(k) Plan up to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;90.00%&lt;/div&gt; of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;4.0%&lt;/div&gt; of the participant's compensation. The Company made matching contributions under the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;401&lt;/div&gt;(k) Plan of approximately &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$56,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$68,000&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"&gt;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Legal Proceedings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; August 7, 2014, &lt;/div&gt;a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company's legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp;amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;BC553996&lt;/div&gt;). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys' fees and costs. On &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 30, 2014, &lt;/div&gt;the Company filed a petition to compel arbitration and a motion to stay the action. On &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; April 1, 2015, &lt;/div&gt;the plaintiff filed a petition in opposition to the Company's petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; April 14, 2015, &lt;/div&gt;the Court granted the Company's petition to compel arbitration and a motion to stay the action. On &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; January 8, 2016, &lt;/div&gt;the plaintiff filed an arbitration demand with the American Arbitration Association. On &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; November 19, 2018 &lt;/div&gt;at an Order to Show Cause Re Dismissal Hearing, the Court found sufficient grounds &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; to dismiss the case, and an arbitration hearing was scheduled for &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; November 2020. &lt;/div&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; August 2020, &lt;/div&gt;due to the ongoing COVID-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;19&lt;/div&gt; pandemic and related restrictions on gatherings in the State of California, the arbitration hearing was postponed to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; August 16, 2021. &lt;/div&gt;The Company believes this matter is without merit and intends to defend the arbitration vigorously. However, at this stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;have on the Company's financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company's financial position.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2020-12-31" decimals="INF" id="c70883154" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2019-12-31" decimals="INF" id="c70883155" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2020-12-31" decimals="INF" id="c70883156" unitRef="xbrli-shares">1000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2019-12-31" decimals="INF" id="c70883157" unitRef="xbrli-shares">1000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2020-12-31" decimals="INF" id="c70883158" unitRef="xbrli-shares">64015441</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2019-12-31" decimals="INF" id="c70883159" unitRef="xbrli-shares">33480365</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2020-12-31" decimals="INF" id="c70883160" unitRef="xbrli-shares">64015441</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2019-12-31" decimals="INF" id="c70883161" unitRef="xbrli-shares">33480365</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2020-12-31" decimals="INF" id="c70883152" unitRef="iso4217-usd">64016</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2019-12-31" decimals="INF" id="c70883153" unitRef="iso4217-usd">33481</us-gaap:CommonStockValue>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2020-01-01_2020-12-31" id="c70883318">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Concentration of Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883260" unitRef="iso4217-usd">-1675381</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883261" unitRef="iso4217-usd">332885</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="i_2020-12-31" decimals="INF" id="c70883738" unitRef="iso4217-usd">2262072</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="i_2019-12-31" decimals="INF" id="c70883739" unitRef="iso4217-usd">2287267</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="i_2020-12-31" decimals="INF" id="c70883142" unitRef="iso4217-usd">443893</us-gaap:DeferredIncomeTaxLiabilitiesNet>
  <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="i_2019-12-31" decimals="INF" id="c70883143" unitRef="iso4217-usd">2119274</us-gaap:DeferredIncomeTaxLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2020-12-31" decimals="INF" id="c70883731" unitRef="iso4217-usd">1818179</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2019-12-31" decimals="INF" id="c70883732" unitRef="iso4217-usd">167993</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2020-12-31" decimals="INF" id="c70883719" unitRef="iso4217-usd">3864189</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2019-12-31" decimals="INF" id="c70883720" unitRef="iso4217-usd">1504496</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2020-12-31" decimals="INF" id="c70883721" unitRef="iso4217-usd">1571227</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2019-12-31" decimals="INF" id="c70883722" unitRef="iso4217-usd">1381750</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2020-12-31" decimals="INF" id="c70883729" unitRef="iso4217-usd">14906646</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2019-12-31" decimals="INF" id="c70883730" unitRef="iso4217-usd">12051440</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilities contextRef="i_2020-12-31" decimals="INF" id="c70883740" unitRef="iso4217-usd">443893</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities contextRef="i_2019-12-31" decimals="INF" id="c70883741" unitRef="iso4217-usd">2119274</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="i_2020-12-31" decimals="INF" id="c70883734" unitRef="iso4217-usd">2223678</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="i_2019-12-31" decimals="INF" id="c70883735" unitRef="iso4217-usd">2223678</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883437" unitRef="iso4217-usd">56000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883439" unitRef="iso4217-usd">68000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="d_2020-01-01_2020-12-31" decimals="2" id="c70884241" unitRef="xbrli-pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="d_2020-01-01_2020-12-31" decimals="2" id="c70883434" unitRef="xbrli-pure">0.9</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:Depreciation contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883392" unitRef="iso4217-usd">103168</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883394" unitRef="iso4217-usd">97915</us-gaap:Depreciation>
  <us-gaap:DepreciationNonproduction contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883175" unitRef="iso4217-usd">103168</us-gaap:DepreciationNonproduction>
  <us-gaap:DepreciationNonproduction contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883176" unitRef="iso4217-usd">97915</us-gaap:DepreciationNonproduction>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785639">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:12pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2015&lt;/div&gt; Equity Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2015&lt;/div&gt; Equity Plan provides for increases to the number of shares reserved for issuance thereunder each &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; January 1 &lt;/div&gt;equal to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;4.0%&lt;/div&gt; of the total shares of the Company's common stock outstanding as of the immediately preceding &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, &lt;/div&gt;unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2,560,618&lt;/div&gt; shares were added to the reserve as of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; January 1, 2021, &lt;/div&gt;which shares &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2015&lt;/div&gt; Equity Plan. As of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020,&lt;/div&gt; there were &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;no&lt;/div&gt; shares of common stock available for future issuance under the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2015&lt;/div&gt; Equity Plan. Further, the Company granted options to purchase &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;270,000&lt;/div&gt; shares of common stock to employees during the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; that were granted outside of the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2015&lt;/div&gt; Equity Plan as an inducement material to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5635&lt;/div&gt;(c)(&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;4&lt;/div&gt;). Generally, the options have a &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;ten&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10&lt;/div&gt;) year&amp;nbsp;contractual term and vest in equal monthly installments over &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;three&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;3&lt;/div&gt;) years.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;164,791&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;54,155&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;571,328&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;461,607&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;736,119&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;515,762&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following table summarizes the activity related to all stock option:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;average&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;price&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;per share&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;average&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;remaining&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;life&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;(in years)&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;Intrinsic&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2019&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;203,736&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;88.14&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;117,270&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2.62&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(11,583&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;83.81&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(147&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;276.00&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2019&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;309,276&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;55.78&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;6.98&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,931,100&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;0.68&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(172&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;142.50&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2020&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2,240,204&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.28&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.90&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;289,067&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2020&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,129,733&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;15.64&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.28&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;219,010&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and expected to vest at December 31, 2020&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2,240,204&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.28&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.90&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;289,067&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The weighted average grant date fair value of stock option awards granted was &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.64&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$2.16&lt;/div&gt; during the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019,&lt;/div&gt; respectively. The total fair value of options vested during the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt; were &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.7&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.6&lt;/div&gt; million, respectively. &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;No&lt;/div&gt;&lt;/div&gt; options were exercised during any of the periods presented. At &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020,&lt;/div&gt; there was &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.8&lt;/div&gt; million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&amp;nbsp;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2.2&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"&gt;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The grant date fair value of employee stock options is determined using the Black-Scholes Model. The following assumptions were used during the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5.31&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10.00&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5.25&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5.77&lt;/div&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;0.4%&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1.7%&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1.9%&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2.5%&lt;/div&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;113.4%&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;124.8%&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;112.4%&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;114.4%&lt;/div&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" rowspan="1" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Stock Unit Awards&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020,&lt;/div&gt; the Company granted &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;153,000&lt;/div&gt; restricted stock units to members of the board of directors of the Company. The weighted average grant date fair value of the restricted stock units granted during the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.65.&lt;/div&gt; The shares begin to vest &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;18&lt;/div&gt; months after the grant date. The Company recognized approximately &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$18,000&lt;/div&gt; in expense related to these units during the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020.&lt;/div&gt; At &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020,&lt;/div&gt; there was approximately &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$82,000&lt;/div&gt; of unrecognized compensation cost that will be recognized over a weighted average period of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2.4&lt;/div&gt; years.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883193" unitRef="iso4217-usd-per-xbrli-shares">-0.30</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883194" unitRef="iso4217-usd-per-xbrli-shares">-1.76</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883195" unitRef="iso4217-usd-per-xbrli-shares">53831973</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883196" unitRef="iso4217-usd-per-xbrli-shares">6706509</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883336">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Common Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; included in the calculation as the impact is anti-dilutive.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"&gt;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;9,100,112&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;22,385,141&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2,240,204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;309,276&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;11,340,316&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;22,694,417&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2020-01-01_2020-12-31" decimals="3" id="c70883758" unitRef="xbrli-pure">-0.105</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2019-01-01_2019-12-31" decimals="3" id="c70883759" unitRef="xbrli-pure">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2020-01-01_2020-12-31" decimals="3" id="c70883746" unitRef="xbrli-pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2019-01-01_2019-12-31" decimals="3" id="c70883747" unitRef="xbrli-pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2020-01-01_2020-12-31" decimals="3" id="c70883752" unitRef="xbrli-pure">0.181</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2019-01-01_2019-12-31" decimals="3" id="c70883753" unitRef="xbrli-pure">-0.075</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2020-01-01_2020-12-31" id="c70883754" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2019-01-01_2019-12-31" decimals="3" id="c70883755" unitRef="xbrli-pure">0.086</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="d_2020-01-01_2020-12-31" id="c70883756" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="d_2019-01-01_2019-12-31" decimals="3" id="c70883757" unitRef="xbrli-pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="d_2020-01-01_2020-12-31" decimals="3" id="c70883748" unitRef="xbrli-pure">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="d_2019-01-01_2019-12-31" decimals="3" id="c70883749" unitRef="xbrli-pure">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c70883603" unitRef="iso4217-usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" decimals="INF" id="c70883621" unitRef="iso4217-usd">82000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c70883604">P2Y73D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" id="c70883622">P2Y146D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2020-01-01_2020-12-31" id="c70883316">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The carrying amounts of the Company's financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883173" unitRef="iso4217-usd">6444109</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883174" unitRef="iso4217-usd">4834284</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883326">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Intangible Asset&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has an indefinite-lived IPR&amp;amp;D asset, DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529,&lt;/div&gt; which has a balance of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$8.6&lt;/div&gt;&lt;/div&gt; million at both &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2019. &lt;/div&gt;DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529&lt;/div&gt; is a &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;PI3K/Akt/mTOR&lt;/div&gt; pathway inhibitor in preclinical development for oncology.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Intangible assets deemed to have indefinite lives are &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; amortized but rather are assessed for impairment annually on &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; October 1 &lt;/div&gt;of the Company's fiscal year or more frequently if impairment indicators exist. There was &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;no&lt;/div&gt;&lt;/div&gt; impairment to the Company's DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529&lt;/div&gt; intangible asset recognized during the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="d_2019-01-01_2019-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InprocessResearchAndDevelopmentAssetMember" decimals="-3" id="c70883339" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="d_2020-01-01_2020-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InprocessResearchAndDevelopmentAssetMember" decimals="-3" id="c70883377" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883324">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Long-Lived Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; recognized any impairment of long-lived assets during the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883182" unitRef="iso4217-usd">-15860687</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883183" unitRef="iso4217-usd">-11466494</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785643">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;9.&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt; Income Taxes&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Since inception, the Company has incurred net losses, and until &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2018,&lt;/div&gt; had &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; recorded any U.S. federal or state income tax benefits for the losses. In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2018,&lt;/div&gt; as a result of the change in net operating loss carryforward period associated with the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2017&lt;/div&gt; Tax Act, the Company recognized an income tax benefit to reflect the adjustment allowed by the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2017&lt;/div&gt; Tax Act to utilize indefinite deferred tax liabilities as a source of income against indefinite lived portions of the Company's deferred tax assets. In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019,&lt;/div&gt; as a result of a change in ownership under the provisions of Internal Revenue Code Section &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;382,&lt;/div&gt; the cumulative benefit of net operating losses was remeasured which resulted in tax expense to reverse the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2018&lt;/div&gt; benefit recorded and record a benefit relative to losses incurred in &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt; after the date of the change in ownership.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse. &amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;3,864,189&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,504,496&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,571,227&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,381,750&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan Drug credits&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;541,384&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;81,700&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Lease liability&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;38,394&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;63,589&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Capitalized start-up costs and other&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10,709,631&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;9,187,898&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(14,906,646&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(12,051,440&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,818,179&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;167,993&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,223,678&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,223,678&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Right of use asset&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(38,394&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(63,589&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,262,072&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,287,267&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax liability&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(443,893&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;"&gt;)&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,119,274&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company does &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt;&lt;/div&gt; have unrecognized tax benefits as of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; or &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2019. &lt;/div&gt;The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"&gt;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company had NOL carryforwards for federal and state income tax purposes at &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt; of approximately:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Combined NOL Carryforwards:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;15,013,388&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5,844,972&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;15,007,966&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5,844,972&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The pre-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2018&lt;/div&gt; net operating loss carryforwards begin expiring in &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; for both federal and state income tax purposes. In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; November 2019, &lt;/div&gt;as a result of a change of ownership, under the provisions of Internal Revenue Code Section &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;382&lt;/div&gt; and similar state provisions, the Company's ability to utilize their net operating loss carryforwards to offset future income was limited. The Company recorded a valuation allowance against a portion of their deferred tax assets as of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;because of the uncertainty of their realization.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Rate reconciliation:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal tax benefit at statutory rate&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(21.0&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(21.0&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State tax, net of Federal benefit&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(4.7&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2.5&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan drug credit&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2.9&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;25.3&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;18.1&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(7.5&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock compensation&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.6&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid black;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;0.1&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total provision&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(10.5&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;3.0&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company's &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2017&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt; tax years remain open and subject to examination.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883184" unitRef="iso4217-usd">-1675381</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883185" unitRef="iso4217-usd">332885</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883333">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&amp;nbsp;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt;&amp;nbsp;that some portion or all of a deferred tax asset will&amp;nbsp;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt;&amp;nbsp;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&amp;nbsp;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt;&amp;nbsp;to be sustained.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;740&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10&lt;/div&gt; defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;recognize the tax benefit from an uncertain tax position only if it is more likely than &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;50.0%&lt;/div&gt; likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;740&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10,&lt;/div&gt; the Company's policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883265" unitRef="iso4217-usd">950602</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883266" unitRef="iso4217-usd">567668</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883263" unitRef="iso4217-usd">-518169</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883264" unitRef="iso4217-usd">-426774</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="i_2020-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InprocessResearchAndDevelopmentAssetMember" decimals="-3" id="c70883329" unitRef="iso4217-usd">8600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="i_2019-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InprocessResearchAndDevelopmentAssetMember" decimals="-3" id="c70883376" unitRef="iso4217-usd">8600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="i_2020-12-31" decimals="INF" id="c70883124" unitRef="iso4217-usd">8639000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="i_2019-12-31" decimals="INF" id="c70883125" unitRef="iso4217-usd">8639000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883180" unitRef="iso4217-usd">114257</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883181" unitRef="iso4217-usd">85302</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:LegalCostsPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883330">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patent Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
  <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="i_2020-12-31" decimals="2" id="c70883421" unitRef="xbrli-pure">0.1</us-gaap:LesseeOperatingLeaseDiscountRate>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-5">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Rental&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;118,519&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;39,735&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;158,254&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: imputed interest&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(9,092&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;149,162&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="i_2020-12-31" decimals="INF" id="c70883455" unitRef="iso4217-usd">158254</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="i_2020-12-31" decimals="INF" id="c70883453" unitRef="iso4217-usd">118519</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="i_2020-12-31" decimals="INF" id="c70883454" unitRef="iso4217-usd">39735</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="i_2020-12-31" decimals="INF" id="c70883456" unitRef="iso4217-usd">9092</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="i_2020-12-31" id="c70883420">P1Y109D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
  <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="i_2020-12-31" id="c70883424">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
  <us-gaap:Liabilities contextRef="i_2020-12-31" decimals="INF" id="c70883146" unitRef="iso4217-usd">2915369</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="i_2019-12-31" decimals="INF" id="c70883147" unitRef="iso4217-usd">3976261</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2020-12-31" decimals="INF" id="c70883168" unitRef="iso4217-usd">27729551</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2019-12-31" decimals="INF" id="c70883169" unitRef="iso4217-usd">24110523</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883140" unitRef="iso4217-usd">2435783</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883141" unitRef="iso4217-usd">1721421</us-gaap:LiabilitiesCurrent>
  <us-gaap:NatureOfOperations contextRef="d_2020-01-01_2020-12-31" id="s1785627">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1.&lt;/div&gt; Organization and Description of Business&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Diffusion Pharmaceuticals Inc., a Delaware corporation, an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to the areas where it is needed most. The Company's lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's most intractable and difficult-to-treat conditions.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In addition to TSC, the Company's product candidate DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529,&lt;/div&gt; a novel, allosteric &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;PI3K/Akt/mTOR&lt;/div&gt; pathway inhibitor, is in early-stage development. The Company previously completed &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;two&lt;/div&gt; Phase &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1&lt;/div&gt; clinical trials evaluating DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529&lt;/div&gt; in age-related macular degeneration. DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529&lt;/div&gt; was also previously in preclinical development in oncology, specifically GBM.&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883278" unitRef="iso4217-usd">17890875</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883279" unitRef="iso4217-usd">16044552</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883267" unitRef="iso4217-usd">-13552629</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883268" unitRef="iso4217-usd">-9858375</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883186" unitRef="iso4217-usd">-14185306</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883187" unitRef="iso4217-usd">-11799379</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c70883218" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c70883219" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c70883220" unitRef="iso4217-usd">-11799379</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c70883243" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c70883244" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c70883245" unitRef="iso4217-usd">-14185306</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883190" unitRef="iso4217-usd">-16135684</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883191" unitRef="iso4217-usd">-11799379</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883338">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently Issued But &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;Not&lt;/div&gt; Yet Adopted Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 2019, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;12,&lt;/div&gt; Income Taxes (Topic &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;740&lt;/div&gt;): &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/div&gt;. This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 15, 2020 &lt;/div&gt;and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; been issued and interim periods therein. The Company is currently analyzing the impact of ASU &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;12&lt;/div&gt; on the consolidated financial statements.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; August 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;03,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurements, &lt;/div&gt;which changes the fair value measurement disclosure requirements of ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;820.&lt;/div&gt; The goal of the ASU is to improve the effectiveness of ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;820's&lt;/div&gt; disclosure requirements. The Company adopted this standard in &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; January 2020 &lt;/div&gt;and the adoption did &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; have a material impact on its related disclosures.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OpenTaxYear contextRef="d_2020-01-01_2020-12-31" id="c70883716">2017 2018 2019</us-gaap:OpenTaxYear>
  <us-gaap:OperatingIncomeLoss contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883177" unitRef="iso4217-usd">-15974944</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883178" unitRef="iso4217-usd">-11551796</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseExpense contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883429" unitRef="iso4217-usd">100000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883449" unitRef="iso4217-usd">100000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseLiability contextRef="i_2020-12-31" decimals="INF" id="c70883457" unitRef="iso4217-usd">149162</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiabilityCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883138" unitRef="iso4217-usd">113469</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883139" unitRef="iso4217-usd">111477</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="i_2020-12-31" decimals="INF" id="c70883144" unitRef="iso4217-usd">35693</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="i_2019-12-31" decimals="INF" id="c70883145" unitRef="iso4217-usd">135566</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="i_2020-12-31" decimals="INF" id="c70883126" unitRef="iso4217-usd">149162</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="i_2019-12-31" decimals="INF" id="c70883127" unitRef="iso4217-usd">247043</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="INF" id="c70883742" unitRef="iso4217-usd">15013388</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2019-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="INF" id="c70883743" unitRef="iso4217-usd">5844972</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="INF" id="c70883744" unitRef="iso4217-usd">15007966</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2019-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="INF" id="c70883745" unitRef="iso4217-usd">5844972</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883417" unitRef="iso4217-usd">1776470</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883418" unitRef="iso4217-usd">358532</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2020-12-31" decimals="INF" id="c70883128" unitRef="iso4217-usd">15771</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2019-12-31" decimals="INF" id="c70883129" unitRef="iso4217-usd">322301</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-4">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll and payroll related expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;653,899&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;182,708&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,809&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;48,338&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued clinical studies expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,055,398&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;57,378&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;35,364&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;70,108&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,776,470&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;358,532&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
  <us-gaap:OtherSundryLiabilitiesCurrent contextRef="i_2020-12-31" decimals="INF" id="c70883415" unitRef="iso4217-usd">35364</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:OtherSundryLiabilitiesCurrent contextRef="i_2019-12-31" decimals="INF" id="c70883416" unitRef="iso4217-usd">70108</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:PaymentsOfFinancingCosts contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883276" unitRef="iso4217-usd">982328</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsOfFinancingCosts contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883277" unitRef="iso4217-usd">162829</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2021-02-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember" decimals="-6" id="c70883305" unitRef="iso4217-usd">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember" decimals="-5" id="c70883462" unitRef="iso4217-usd">10300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2021-02-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember" decimals="-5" id="c70883771" unitRef="iso4217-usd">31200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883270" unitRef="iso4217-usd">10827100</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2019-01-01_2019-12-31" id="c70883271" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="d_2019-12-01_2019-12-31_SubsidiarySaleOfStockAxis-December2019PublicOfferingMember" decimals="-5" id="c70883478" unitRef="iso4217-usd">3000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="d_2019-11-01_2019-11-30_SubsidiarySaleOfStockAxis-November2019PublicOfferingMember" decimals="-5" id="c70883489" unitRef="iso4217-usd">3300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="d_2019-05-01_2019-05-31_SubsidiarySaleOfStockAxis-May2019PublicOfferingMember" decimals="-5" id="c70883503" unitRef="iso4217-usd">5600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2021-01-01_2021-03-12_SubsequentEventTypeAxis-SubsequentEventMember" decimals="-6" id="c70883309" unitRef="iso4217-usd">2000000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2019-01-01_2019-12-31_ClassOfWarrantOrRightAxis-WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" decimals="-5" id="c70883496" unitRef="iso4217-usd">3900000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883524" unitRef="iso4217-usd">8046103</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883527" unitRef="iso4217-usd">3888425</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2021-01-01_2021-03-15_SubsequentEventTypeAxis-SubsequentEventMember" decimals="-5" id="c70883766" unitRef="iso4217-usd">2200000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785631">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;4.&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;Property and equipment consists of the following:&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;182,357&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;182,357&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;151,442&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;151,442&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;430,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;430,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;763,799&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;763,799&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(614,601&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(511,433&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;149,198&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;252,366&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;Depreciation and amortization expense was approximately &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.1&lt;/div&gt; million for both the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" decimals="INF" id="c70883395" unitRef="iso4217-usd">182357</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" decimals="INF" id="c70883396" unitRef="iso4217-usd">182357</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="INF" id="c70883397" unitRef="iso4217-usd">151442</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="INF" id="c70883398" unitRef="iso4217-usd">151442</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="INF" id="c70883399" unitRef="iso4217-usd">430000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="INF" id="c70883400" unitRef="iso4217-usd">430000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2020-12-31" decimals="INF" id="c70883401" unitRef="iso4217-usd">763799</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2019-12-31" decimals="INF" id="c70883402" unitRef="iso4217-usd">763799</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2020-12-31" decimals="INF" id="c70883405" unitRef="iso4217-usd">149198</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2019-12-31" decimals="INF" id="c70883406" unitRef="iso4217-usd">252366</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c70883322">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;15&lt;/div&gt; years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-3">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;182,357&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;182,357&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;151,442&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;151,442&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;430,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;430,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;763,799&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;763,799&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(614,601&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(511,433&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;149,198&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;252,366&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember" id="c70883317">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" id="c70883319">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785647">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10.&lt;/div&gt; Related Party Transactions&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company's Director of Information Technologies is the son of the Chairman of the Board of Directors and he has held that position since &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 2014.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883171" unitRef="iso4217-usd">9427667</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883172" unitRef="iso4217-usd">6619597</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2020-01-01_2020-12-31" id="c70883328">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company's behalf). Costs incurred for research and development are expensed as incurred.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;At the end of the reporting period, the Company compares payments made to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;third&lt;/div&gt;-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;record net prepaid or accrued expenses relating to these costs.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;Upfront payments made to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;third&lt;/div&gt; parties who perform research and development services on the Company's behalf are expensed as services are rendered.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2020-12-31" decimals="INF" id="c70883164" unitRef="iso4217-usd">-105909384</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2019-12-31" decimals="INF" id="c70883165" unitRef="iso4217-usd">-91724078</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="d_2020-01-01_2020-12-31" id="c70883289" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883290" unitRef="iso4217-usd">334205</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-2">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;9,100,112&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;22,385,141&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2,240,204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;309,276&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;11,340,316&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;22,694,417&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-10">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;3,864,189&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,504,496&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,571,227&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,381,750&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan Drug credits&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;541,384&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;81,700&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Lease liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;38,394&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;63,589&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Capitalized start-up costs and other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10,709,631&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;9,187,898&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(14,906,646&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(12,051,440&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,818,179&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;167,993&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,223,678&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,223,678&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Right of use asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(38,394&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(63,589&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,262,072&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,287,267&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(443,893&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2,119,274&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-12">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Rate reconciliation:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal tax benefit at statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(21.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(21.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State tax, net of Federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(4.7&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan drug credit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(2.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;25.3&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;18.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(7.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid black;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;0.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total provision&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(10.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;3.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-7">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;164,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;54,155&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;571,328&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;461,607&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;736,119&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;515,762&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-8">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;average&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;price&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;per share&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;average&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;remaining&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;life&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;(in years)&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;Intrinsic&lt;/div&gt;&lt;br /&gt; &lt;div style="display: inline; font-weight: bold;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2019&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;203,736&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;88.14&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;117,270&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2.62&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(11,583&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;83.81&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(147&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;276.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2019&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;309,276&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;55.78&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;6.98&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,931,100&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;0.68&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;(172&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;142.50&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2,240,204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.28&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.90&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;289,067&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,129,733&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;15.64&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.28&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;219,010&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and expected to vest at December 31, 2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2,240,204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.28&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;8.90&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;289,067&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-9">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5.31&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5.25&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5.77&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;0.4%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1.7%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1.9%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2.5%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;113.4%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;124.8%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;112.4%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;114.4%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" rowspan="1" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-6">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%; vertical-align: bottom;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;price per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0); width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Expiration dates&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in 2017 related to Series A convertible preferred stock offering&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;903,870&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$33.30&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;March 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in 2018 related to the January 2018 common stock offering&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,181,421&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$12.00&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$15.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;January 2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2019 Offering&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,382,913&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$5.00&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$6.11875&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;May and December 2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the November 2019 Offering&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;497,140&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.35&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.4375&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;May 2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the December 2019 Offering&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;313,339&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.4335&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.6981&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;December 2024 and June 2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2020 Offering&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;571,429&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$1.31&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;March 2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2020 Investor Warrant Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;4,250,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.5263&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.5938&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;November 2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;9,100,112&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 4%;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 13%;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883258" unitRef="iso4217-usd">736119</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883259" unitRef="iso4217-usd">515762</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c70883587">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" id="c70883615">P1Y180D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" decimals="INF" id="c70883611" unitRef="xbrli-shares">153000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" decimals="INF" id="c70883614" unitRef="iso4217-usd-per-xbrli-shares">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember" id="c70883690" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" id="c70883692" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2019-01-01_2019-12-31_RangeAxis-MinimumMember" id="c70883693" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2019-01-01_2019-12-31_RangeAxis-MaximumMember" id="c70883695" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember" decimals="3" id="c70883684" unitRef="xbrli-pure">1.134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" decimals="3" id="c70883686" unitRef="xbrli-pure">1.248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2019-01-01_2019-12-31_RangeAxis-MinimumMember" decimals="3" id="c70883687" unitRef="xbrli-pure">1.124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2019-01-01_2019-12-31_RangeAxis-MaximumMember" decimals="3" id="c70883689" unitRef="xbrli-pure">1.144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember" decimals="3" id="c70883678" unitRef="xbrli-pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" decimals="3" id="c70883680" unitRef="xbrli-pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2019-01-01_2019-12-31_RangeAxis-MinimumMember" decimals="3" id="c70883681" unitRef="xbrli-pure">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2019-01-01_2019-12-31_RangeAxis-MaximumMember" decimals="3" id="c70883683" unitRef="xbrli-pure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2021-01-01_2021-01-01_PlanNameAxis-EquityIncentivePlan2015Member_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c70883573" unitRef="xbrli-shares">2560618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2020-12-31_PlanNameAxis-EquityIncentivePlan2015Member" decimals="INF" id="c70883577" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2020-12-31" decimals="INF" id="c70883664" unitRef="xbrli-shares">1129733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2020-12-31" decimals="INF" id="c70883665" unitRef="iso4217-usd-per-xbrli-shares">15.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883644" unitRef="xbrli-shares">147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883656" unitRef="xbrli-shares">172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883640" unitRef="xbrli-shares">11583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-OutsideOfThe2015EquityPlanMember" decimals="INF" id="c70883579" unitRef="xbrli-shares">270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883636" unitRef="xbrli-shares">117270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883652" unitRef="xbrli-shares">1931100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883589" unitRef="iso4217-usd-per-xbrli-shares">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883590" unitRef="iso4217-usd-per-xbrli-shares">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2019-12-31" id="c70883651" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2020-12-31" decimals="INF" id="c70883663" unitRef="iso4217-usd">289067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2018-12-31" decimals="INF" id="c70883632" unitRef="xbrli-shares">203736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2019-12-31" decimals="INF" id="c70883648" unitRef="xbrli-shares">309276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2020-12-31" decimals="INF" id="c70883660" unitRef="xbrli-shares">2240204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2018-12-31" decimals="INF" id="c70883633" unitRef="iso4217-usd-per-xbrli-shares">88.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2019-12-31" decimals="INF" id="c70883649" unitRef="iso4217-usd-per-xbrli-shares">55.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2020-12-31" decimals="INF" id="c70883661" unitRef="iso4217-usd-per-xbrli-shares">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="i_2020-12-31" decimals="INF" id="c70883671" unitRef="iso4217-usd">289067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="i_2020-12-31" decimals="INF" id="c70883668" unitRef="xbrli-shares">2240204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="i_2020-12-31" decimals="INF" id="c70883669" unitRef="iso4217-usd-per-xbrli-shares">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883645" unitRef="iso4217-usd-per-xbrli-shares">276</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883657" unitRef="iso4217-usd-per-xbrli-shares">142.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883641" unitRef="iso4217-usd-per-xbrli-shares">83.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883637" unitRef="iso4217-usd-per-xbrli-shares">2.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883653" unitRef="iso4217-usd-per-xbrli-shares">0.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2020-01-01_2020-12-31" id="c70883334">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company's common stock, the expected term of the Company's stock options, the expected dividend yield and the fair value of the Company's common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For certain stock option grants, the expected term was estimated using the &amp;#x201c;simplified method&amp;#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020, &lt;/div&gt;it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10&lt;/div&gt; years) of the stock option and therefore the Company began to use the contractual life as the expected term.&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For stock price volatility, the Company uses a combination of their own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;no&lt;/div&gt; dividend yield because dividends are &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; expected to be paid in the near future, which is consistent with the Company's history of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company accounts for forfeitures in the periods they occur.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c70883585">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c70883354">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember" id="c70883672">P5Y113D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" id="c70883674">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2019-01-01_2019-12-31_RangeAxis-MinimumMember" id="c70883675">P5Y91D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2019-01-01_2019-12-31_RangeAxis-MaximumMember" id="c70883677">P5Y281D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2020-12-31" decimals="INF" id="c70883667" unitRef="iso4217-usd">219010</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2020-01-01_2020-12-31" id="c70883666">P8Y102D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2019-01-01_2019-12-31" id="c70883650">P6Y357D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2020-01-01_2020-12-31" id="c70883662">P8Y328D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2020-01-01_2020-12-31" id="c70883670">P8Y328D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883597" unitRef="iso4217-usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883598" unitRef="iso4217-usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember" decimals="INF" id="c70883461" unitRef="iso4217-usd-per-xbrli-shares">1.05</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2019-12-31_SubsidiarySaleOfStockAxis-December2019PublicOfferingMember" decimals="INF" id="c70883477" unitRef="iso4217-usd-per-xbrli-shares">0.5585</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2019-11-30_SubsidiarySaleOfStockAxis-November2019PublicOfferingMember" decimals="INF" id="c70883488" unitRef="iso4217-usd-per-xbrli-shares">0.35</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2019-05-31_SubsidiarySaleOfStockAxis-May2019PublicOfferingMember" decimals="INF" id="c70883502" unitRef="iso4217-usd-per-xbrli-shares">4.895</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember" decimals="INF" id="c70883769" unitRef="iso4217-usd-per-xbrli-shares">1.025</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesOutstanding contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883197" unitRef="xbrli-shares">3376230</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883222" unitRef="xbrli-shares">33480365</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883247" unitRef="xbrli-shares">64015441</us-gaap:SharesOutstanding>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785629">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;3.&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The accompanying consolidated&amp;nbsp;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The carrying amounts of the Company's financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Concentration of Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company considers any highly liquid investments, such as money market funds, with an original maturity of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;three&lt;/div&gt; months or less to be cash and cash equivalents.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;15&lt;/div&gt; years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Long-Lived Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; recognized any impairment of long-lived assets during the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Intangible Asset&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has an indefinite-lived IPR&amp;amp;D asset, DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529,&lt;/div&gt; which has a balance of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$8.6&lt;/div&gt;&lt;/div&gt; million at both &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2019. &lt;/div&gt;DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529&lt;/div&gt; is a &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;PI3K/Akt/mTOR&lt;/div&gt; pathway inhibitor in preclinical development for oncology.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Intangible assets deemed to have indefinite lives are &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; amortized but rather are assessed for impairment annually on &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; October 1 &lt;/div&gt;of the Company's fiscal year or more frequently if impairment indicators exist. There was &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;no&lt;/div&gt;&lt;/div&gt; impairment to the Company's DFN-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;529&lt;/div&gt; intangible asset recognized during the years ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company's behalf). Costs incurred for research and development are expensed as incurred.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;At the end of the reporting period, the Company compares payments made to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;third&lt;/div&gt;-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;record net prepaid or accrued expenses relating to these costs.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;Upfront payments made to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;third&lt;/div&gt; parties who perform research and development services on the Company's behalf are expensed as services are rendered.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patent Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&amp;nbsp;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt;&amp;nbsp;that some portion or all of a deferred tax asset will&amp;nbsp;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt;&amp;nbsp;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&amp;nbsp;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt;&amp;nbsp;to be sustained.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;740&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10&lt;/div&gt; defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; may &lt;/div&gt;recognize the tax benefit from an uncertain tax position only if it is more likely than &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;50.0%&lt;/div&gt; likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;740&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10,&lt;/div&gt; the Company's policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company's common stock, the expected term of the Company's stock options, the expected dividend yield and the fair value of the Company's common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For certain stock option grants, the expected term was estimated using the &amp;#x201c;simplified method&amp;#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020, &lt;/div&gt;it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;10&lt;/div&gt; years) of the stock option and therefore the Company began to use the contractual life as the expected term.&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For stock price volatility, the Company uses a combination of their own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;no&lt;/div&gt; dividend yield because dividends are &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; expected to be paid in the near future, which is consistent with the Company's history of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company accounts for forfeitures in the periods they occur.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Common Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; included in the calculation as the impact is anti-dilutive.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"&gt;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;9,100,112&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;22,385,141&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2,240,204&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;309,276&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;11,340,316&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;22,694,417&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently Issued But &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;Not&lt;/div&gt; Yet Adopted Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 2019, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;12,&lt;/div&gt; Income Taxes (Topic &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;740&lt;/div&gt;): &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/div&gt;. This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 15, 2020 &lt;/div&gt;and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; been issued and interim periods therein. The Company is currently analyzing the impact of ASU &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;12&lt;/div&gt; on the consolidated financial statements.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; August 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;03,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurements, &lt;/div&gt;which changes the fair value measurement disclosure requirements of ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;820.&lt;/div&gt; The goal of the ASU is to improve the effectiveness of ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;820's&lt;/div&gt; disclosure requirements. The Company adopted this standard in &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; January 2020 &lt;/div&gt;and the adoption did &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; have a material impact on its related disclosures.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883207" unitRef="xbrli-shares">17415859</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883232" unitRef="xbrli-shares">19106504</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember" decimals="INF" id="c70883460" unitRef="xbrli-shares">11428572</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2019-12-01_2019-12-31_SubsidiarySaleOfStockAxis-December2019PublicOfferingMember" decimals="INF" id="c70883475" unitRef="xbrli-shares">6266787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2019-11-01_2019-11-30_SubsidiarySaleOfStockAxis-November2019PublicOfferingMember" decimals="INF" id="c70883484" unitRef="xbrli-shares">5104429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2019-05-01_2019-05-31_SubsidiarySaleOfStockAxis-May2019PublicOfferingMember" decimals="INF" id="c70883500" unitRef="xbrli-shares">1317060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2021-02-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember" decimals="INF" id="c70883768" unitRef="xbrli-shares">33658538</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883599" unitRef="xbrli-shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883600" unitRef="xbrli-shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883208" unitRef="iso4217-usd">17416</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883209" unitRef="iso4217-usd">3871009</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c70883210" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2019-01-01_2019-12-31" decimals="INF" id="c70883211" unitRef="iso4217-usd">3888425</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883233" unitRef="iso4217-usd">19106</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883234" unitRef="iso4217-usd">7768370</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c70883235" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2020-01-01_2020-12-31" decimals="INF" id="c70883236" unitRef="iso4217-usd">7787476</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockholdersEquity contextRef="i_2020-12-31" decimals="INF" id="c70883166" unitRef="iso4217-usd">24814182</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2019-12-31" decimals="INF" id="c70883167" unitRef="iso4217-usd">20134262</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883198" unitRef="iso4217-usd">3377</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883199" unitRef="iso4217-usd">95532881</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c70883200" unitRef="iso4217-usd">-79924699</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2018-12-31" decimals="INF" id="c70883201" unitRef="iso4217-usd">15611559</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883223" unitRef="iso4217-usd">33481</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883224" unitRef="iso4217-usd">111824859</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c70883225" unitRef="iso4217-usd">-91724078</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2019-12-31" decimals="INF" id="c70883226" unitRef="iso4217-usd">20134262</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c70883248" unitRef="iso4217-usd">64016</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c70883249" unitRef="iso4217-usd">130659550</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c70883250" unitRef="iso4217-usd">-105909384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2020-12-31" decimals="INF" id="c70883251" unitRef="iso4217-usd">24814182</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785637">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;7.&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;Stockholders' Equity and Common Stock Warrants&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; Common Stock Offering&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2020, &lt;/div&gt;the Company completed the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2020 &lt;/div&gt;Offering, a public offering of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;11,428,572&lt;/div&gt; shares of common stock for a purchase price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$1.05&lt;/div&gt; per share for net proceeds of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$10.3&lt;/div&gt; million after deducting commissions, discounts, and other offering costs. In addition, at the closing of the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2020 &lt;/div&gt;Offering, the Company issued warrants to purchase up to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;571,429&lt;/div&gt; shares of common stock to designees of the placement agent for the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2020 &lt;/div&gt;Offering. The placement agent's warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$1.3125&lt;/div&gt; per share and a term of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;five&lt;/div&gt; years from the date of issuance.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Additionally, also in &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2020, &lt;/div&gt;the Company entered into a warrant exercise agreement with an investor who held a previously outstanding warrant to purchase up to an aggregate of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5,000,000&lt;/div&gt; shares of our common stock at an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.35&lt;/div&gt; per share(the Prior Warrant). In consideration for the exercise of the Prior Warrant for cash and an additional &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.125&lt;/div&gt; per each share of common stock resulting from the exercise, the exercising investor received new unregistered warrants to purchase up to an aggregate of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5,000,000&lt;/div&gt; shares of common stock in a private placement. The warrants are exercisable immediately at an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.5263&lt;/div&gt; per share and exercisable until &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; November 8, 2025. &lt;/div&gt;The Company recognized a deemed dividend of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$2.0&lt;/div&gt; million to reflect the consideration given as an inducement for the investor to exercise the warrants. This deemed dividend is recorded in the Company's consolidated statement of operations during the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020 &lt;/div&gt;as an increase to the net loss attributable to common stockholders for purposes of computing net loss per share, basic and diluted.&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In connection with the warrants exercised in &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2020, &lt;/div&gt;the Company issued warrants to purchase up to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;250,000&lt;/div&gt; shares of common stock to the placement agent with an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.5938&lt;/div&gt; per share and otherwise have identical terms to the warrants issued to the investor.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019&lt;/div&gt; Common Stock Offerings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 2019, &lt;/div&gt;Company completed the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 2019 &lt;/div&gt;Offering, an offering of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;6,266,787&lt;/div&gt; shares of its common stock and warrants to purchase &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;6,266,787&lt;/div&gt; shares of common stock. The shares of common stock and warrants were sold for a combined purchase price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.5585&lt;/div&gt; per share for net proceeds of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$3.0&lt;/div&gt; million. The &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 2019 &lt;/div&gt;Offering warrants are exercisable beginning on the date of their issuance until &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; June 13, 2025 &lt;/div&gt;at an initial exercise price equal to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.4335&lt;/div&gt; per share.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In addition, at the closing of the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 2019 &lt;/div&gt;Offering, the Company issued warrants to purchase up to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;313,339&lt;/div&gt; shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.6981&lt;/div&gt; per share and a term of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;five&lt;/div&gt; years from the date of issuance.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"&gt;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; November 2019, &lt;/div&gt;the Company completed the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; November 2019 &lt;/div&gt;Offering, a registered direct public offering of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5,104,429&lt;/div&gt; shares of its common stock, and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;6,324,143&lt;/div&gt; pre-funded warrants each to purchase &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;one&lt;/div&gt; share of common stock, together with warrants to purchase up to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;22,857,144&lt;/div&gt; shares of common stock at a combined public offering price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.35&lt;/div&gt; per share and associated warrants for total net proceeds of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$3.3&lt;/div&gt; million. The warrants were issued with an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.35&lt;/div&gt; per warrant and are exercisable beginning on their date of issuance. Of the warrants issued, &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;11,428,572&lt;/div&gt; have a term of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;18&lt;/div&gt; months and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;11,428,572&lt;/div&gt; have a term of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5&lt;/div&gt; years. During the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2019, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;11,091,716&lt;/div&gt; of those warrants were exercised for additional proceeds of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$3.9&lt;/div&gt; million.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In addition, at the closing of the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; November 2019 &lt;/div&gt;Offering, the Company issued warrants to purchase up to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;571,429&lt;/div&gt; shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.4375&lt;/div&gt; per share and a term of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;five&lt;/div&gt; years from the date of issuance.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2019, &lt;/div&gt;the Company completed the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2019 &lt;/div&gt;Offering, a registered direct public offering of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,317,060&lt;/div&gt; shares of common stock and a private placement of warrants to purchase &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,317,060&lt;/div&gt; shares of common stock. The shares of common stock and warrants were sold for a combined purchase price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$4.895&lt;/div&gt; for total net proceeds of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$5.6&lt;/div&gt; million. The warrants are exercisable beginning on the date of their issuance until &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; November 29, 2024 &lt;/div&gt;at an initial exercise price equal to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$5.00.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In addition, at the closing of the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; May 2019 &lt;/div&gt;Offering, the Company issued warrants to purchase up to &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;65,853&lt;/div&gt; shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$6.11875&lt;/div&gt; per share, a term of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5&lt;/div&gt; years from the date of issuance and otherwise substantially similar terms to the form of the investor warrant.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Common Stock Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;During its evaluation of equity classification for the Company's common stock warrants issued in &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2019,&lt;/div&gt; the Company considered the conditions as prescribed within ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;815&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;40,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Derivatives and Hedging, Contracts in an Entity&lt;/div&gt;'&lt;div style="display: inline; font-style: italic;"&gt;s own Equity&lt;/div&gt;. The conditions within ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;815&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;40&lt;/div&gt; are &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; subject to a probability assessment. The warrants do &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; fall under the liability criteria within ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;480,&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic;"&gt;Distinguishing Liabilities from Equity &lt;/div&gt;as they are &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; puttable and do &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;not&lt;/div&gt; represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;815,&lt;/div&gt; but are eligible for the scope exception as they are indexed to the Company's own stock and would be classified in permanent equity if freestanding.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2020,&lt;/div&gt; the Company had the following warrants outstanding to acquire shares of its common stock:&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"&gt;    &lt;tr style="vertical-align: bottom;"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td colspan="3" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%; vertical-align: bottom;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;price per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0); width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Expiration dates&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in 2017 related to Series A convertible preferred stock offering&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;903,870&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$33.30&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;March 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in 2018 related to the January 2018 common stock offering&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,181,421&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$12.00&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt;  &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$15.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;January 2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2019 Offering&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,382,913&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$5.00&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt;  &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$6.11875&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;May and December 2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the November 2019 Offering&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;497,140&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.35&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt;  &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.4375&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;May 2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the December 2019 Offering&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;313,339&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.4335&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt;  &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.6981&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;December 2024 and June 2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2020 Offering&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;571,429&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$1.31&lt;/div&gt;&lt;/td&gt;  &lt;td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;March 2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2020 Investor Warrant Exercise&lt;/div&gt; &lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;4,250,000&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.5263&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;-&lt;/div&gt;&lt;/td&gt;  &lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$0.5938&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;November 2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;  &lt;/tr&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;9,100,112&lt;/div&gt;&lt;/td&gt;  &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 4%;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt;  &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 13%;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;  &lt;/tr&gt;    &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2020, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;no&lt;/div&gt; warrants expired and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;19,106,504&lt;/div&gt; warrants were exercised for gross proceeds of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$8.0&lt;/div&gt; million. During the year ended &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; December 31, 2019, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,767&lt;/div&gt; warrants expired and &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;17,415,859&lt;/div&gt; warrants were exercised for net proceeds of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$3.9&lt;/div&gt; million.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="d_2020-01-01_2020-12-31" id="s1785648">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;11.&lt;/div&gt;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2021&lt;/div&gt; Warrant Exercises&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;From &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; January 1, 2021 &lt;/div&gt;through &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; March 15, 2021, &lt;/div&gt;warrants were exercised by multiple holders to purchase a total of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;4,230,000&lt;/div&gt; shares of the Company's common stock for aggregate gross proceeds of approximately &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$2.2&lt;/div&gt; million.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;2021&lt;/div&gt; Common Stock Offering&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; February 2021, &lt;/div&gt;the Company completed the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; February 2021 &lt;/div&gt;Offering in which it offered and sold &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;33,658,538&lt;/div&gt; shares of its common stock in an underwritten, public offering for a purchase price to the public of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$1.025&lt;/div&gt; per share, inclusive of shares offered and sold pursuant to the exercise-in-full by the underwriter of its &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;30&lt;/div&gt;-day option to purchase additional shares. The &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; February 2021 &lt;/div&gt;Offering resulted in aggregate net proceeds to the Company of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$31.2&lt;/div&gt; million, after deducting underwriting commissions, discounts, and expenses but prior to deducting other offering costs. In addition, at the closings of the &lt;div style="display: inline; font-style: italic; font: inherit;"&gt; February 2021 &lt;/div&gt;Offering, the Company issued to designees of the underwriter of the transaction warrants to purchase up to an aggregate of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;1,682,927&lt;/div&gt; shares of common stock to designees. The underwriter warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;$1.28125&lt;/div&gt; per share and a term of &lt;div style="display: inline; font-style: italic; font: inherit;"&gt;five&lt;/div&gt; years from the date of issuance.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="d_2020-01-01_2020-12-31" id="c-11">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Combined NOL Carryforwards:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;15,013,388&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5,844,972&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;15,007,966&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font: inherit;"&gt;5,844,972&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2019-12-31" decimals="-3" id="c70883706" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2020-12-31" decimals="-3" id="c70883718" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UseOfEstimates contextRef="d_2020-01-01_2020-12-31" id="c70883314">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/div&gt; &lt;div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" id="c70883465">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2019-12-31_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" id="c70883482">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" id="c70883492">P1Y180D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" id="c70883494">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2019-11-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" id="c70883499">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2019-05-31_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember" id="c70883507">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" id="c70883774">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2019-01-01_2019-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_ClassOfWarrantOrRightAxis-WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InprocessResearchAndDevelopmentAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:InprocessResearchAndDevelopmentAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-05-01_2019-05-31_SubsidiarySaleOfStockAxis-May2019PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:May2019PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-11-01_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-11-01_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-11-01_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-11-01_2019-11-30_SubsidiarySaleOfStockAxis-November2019PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:November2019PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-12-01_2019-12-31_SubsidiarySaleOfStockAxis-December2019PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:December2019PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InprocessResearchAndDevelopmentAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:InprocessResearchAndDevelopmentAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_PlanNameAxis-EquityIncentivePlan2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_PlanNameAxis-OutsideOfThe2015EquityPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:OutsideOfThe2015EquityPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-05-01_2020-05-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-05-01_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PriorWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:TheMay2020OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2021-01-01_2021-01-01_PlanNameAxis-EquityIncentivePlan2015Member_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2021-01-01_2021-03-12_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2021-01-01_2021-03-15_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2021-02-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-01</xbrli:startDate>
      <xbrli:endDate>2021-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2021-02-01_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:PublicOfferingInclusiveOfUnderwriterSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-01</xbrli:startDate>
      <xbrli:endDate>2021-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-05-31_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PlacementAgentWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-05-31_SubsidiarySaleOfStockAxis-May2019PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:May2019PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-05-31_SubsidiarySaleOfStockAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-11-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PlacementAgentWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-11-30_ClassOfWarrantOrRightAxis-WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-11-30_SubsidiarySaleOfStockAxis-November2019PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:November2019PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_ClassOfWarrantOrRightAxis-PlacementAgentWarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PlacementAgentWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InprocessResearchAndDevelopmentAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:InprocessResearchAndDevelopmentAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dffn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-12-31_SubsidiarySaleOfStockAxis-December2019PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:December2019PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:NewWarrantsIssuedMay82020Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PriorWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020OfferingWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020PAWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dffn:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:TheMay2020OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020InvestorWarrantExerciseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020InvestorWarrantExerciseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020InvestorWarrantExerciseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020OfferingWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsAttachedToSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InprocessResearchAndDevelopmentAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:InprocessResearchAndDevelopmentAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_PlanNameAxis-EquityIncentivePlan2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dffn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2021-02-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:PublicOfferingInclusiveOfUnderwriterSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2021-03-12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>dffn-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:19PM UTC 2021-03-16--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dffn="http://www.diffusionpharma.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diffusionpharma.com/20201231">
  <xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.diffusionpharma.com/20201231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-equity" roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-changes-in-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-description-of-business" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-1-organization-and-description-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accrued-expenses-and-other-current-liabilities" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-commitments-and-contingencies-" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-common-stock-warrants" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-related-party-transactions" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-10-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-subsequent-events" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.diffusionpharma.com/20201231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-tables" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 4 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accrued-expenses-and-other-current-liabilities-tables" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 5 - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-commitments-and-contingencies-tables" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 6 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-common-stock-warrants-tables" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-tables" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 8 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-tables" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 9 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-details-textual" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 2 - Liquidity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-details-textual" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 4 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-property-and-equipment-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 4 - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 5 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-commitments-and-contingencies-details-textual" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 6 - Commitments and Contingencies - Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-details-textual" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 8 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-stock-option-activity-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-fair-value-assumptions-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-details-textual" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 9 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-operating-loss-carryforwards-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-operating-loss-carryforwards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 9 - Income Taxes - Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 9 - Income Taxes - Reconciliation of Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-subsequent-events-details-textual" roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 11 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dffn_AccruedClinicalStudiesExpensesCurrent" name="AccruedClinicalStudiesExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" name="ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightsExpired" name="ClassOfWarrantOrRightsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_December2019PublicOfferingMember" name="December2019PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_DeemedDividendFromWarrantExchange" name="DeemedDividendFromWarrantExchange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" name="DeferredTaxAssetsCapitalizedCostsAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_DeferredTaxAssetsOrphanDrugCredits" name="DeferredTaxAssetsOrphanDrugCredits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" name="EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_EquityIncentivePlan2015Member" name="EquityIncentivePlan2015Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_HCWainwrightAndCoLLCMember" name="HCWainwrightAndCoLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_InprocessResearchAndDevelopmentAssetMember" name="InprocessResearchAndDevelopmentAssetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_May2019PublicOfferingMember" name="May2019PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NewWarrantsIssuedMay82020Member" name="NewWarrantsIssuedMay82020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_November2019PublicOfferingMember" name="November2019PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_OfferingCostsInAccountsPayable" name="OfferingCostsInAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_OutsideOfThe2015EquityPlanMember" name="OutsideOfThe2015EquityPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" name="PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_PlacementAgentWarrantMember" name="PlacementAgentWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_PrepaidExpensesDepositsAndOtherAssets" name="PrepaidExpensesDepositsAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_PriorWarrantMember" name="PriorWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" name="ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" name="PublicOfferingInclusiveOfUnderwriterSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" name="StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" name="StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020InvestorWarrantExerciseMember" name="TheMay2020InvestorWarrantExerciseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020OfferingMember" name="TheMay2020OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020OfferingWarrantsMember" name="TheMay2020OfferingWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020PAWarrantsMember" name="TheMay2020PAWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" name="UnderwriterOptionToPurchaseAdditionalSharesTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" name="UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" name="WarrantsAttachedToSeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" name="WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" name="WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" name="WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" name="WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" name="WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" name="WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details" name="statement-statement-note-4-property-and-equipment-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-property-and-equipment-tables" name="statement-statement-note-4-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" name="statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables" name="statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" name="statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-6-commitments-and-contingencies-tables" name="statement-statement-note-6-commitments-and-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" name="statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" name="statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details" name="statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" name="statement-statement-note-8-stockbased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" name="statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-stockbased-compensation-tables" name="statement-statement-note-8-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details" name="statement-statement-note-9-income-taxes-operating-loss-carryforwards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" name="statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-9-income-taxes-tables" name="statement-statement-note-9-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>dffn-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:19PM UTC 2021-03-16--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsLeaseLiability" xlink:label="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-operations" xlink:href="dffn-20201231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_DepreciationNonproduction" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="dffn_DeemedDividendFromWarrantExchange" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dffn-20201231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:label="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-property-and-equipment-details" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20201231.xsd#statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets" xlink:href="dffn-20201231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>dffn-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:19PM UTC 2021-03-16--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-10-related-party-transactions" xlink:href="dffn-20201231.xsd#statement-note-10-related-party-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-10-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities" xlink:href="dffn-20201231.xsd#statement-note-5-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-1-organization-and-description-of-business" xlink:href="dffn-20201231.xsd#statement-note-1-organization-and-description-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-1-organization-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-document-and-entity-information" xlink:href="dffn-20201231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity" xlink:href="dffn-20201231.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dffn_LiquidityDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="dffn-20201231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_InprocessResearchAndDevelopmentAssetMember" xlink:label="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:href="dffn-20201231.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_December2019PublicOfferingMember" xlink:label="dffn_December2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_May2019PublicOfferingMember" xlink:label="dffn_May2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_November2019PublicOfferingMember" xlink:label="dffn_November2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PlacementAgentWarrantMember" xlink:label="dffn_PlacementAgentWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_TheMay2020OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_PriorWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_NewWarrantsIssuedMay82020Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020PAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_December2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_PlacementAgentWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_November2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_May2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_OutsideOfThe2015EquityPlanMember" xlink:label="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events" xlink:href="dffn-20201231.xsd#statement-note-11-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-significant-accounting-policies-policies" xlink:href="dffn-20201231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="dffn-20201231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-tables" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:href="dffn-20201231.xsd#statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-tables" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:href="dffn-20201231.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-tables" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-tables" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity-details-textual" xlink:href="dffn-20201231.xsd#statement-note-2-liquidity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dffn-20201231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_InprocessResearchAndDevelopmentAssetMember" xlink:label="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-details-textual" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-details-textual" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:href="dffn-20201231.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_December2019PublicOfferingMember" xlink:label="dffn_December2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_May2019PublicOfferingMember" xlink:label="dffn_May2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_November2019PublicOfferingMember" xlink:label="dffn_November2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PlacementAgentWarrantMember" xlink:label="dffn_PlacementAgentWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_TheMay2020OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_PriorWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_NewWarrantsIssuedMay82020Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020PAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_December2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_PlacementAgentWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_November2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_May2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeemedDividendFromWarrantExchange" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightsExpired" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-details-textual" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_OutsideOfThe2015EquityPlanMember" xlink:label="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-details-textual" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events-details-textual" xlink:href="dffn-20201231.xsd#statement-note-11-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dffn-20201231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="dffn-20201231.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsLeaseLiability" xlink:label="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-operations" xlink:href="dffn-20201231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationNonproduction" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="dffn_DeemedDividendFromWarrantExchange" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dffn-20201231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_OfferingCostsInAccountsPayable" xlink:label="dffn_OfferingCostsInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:label="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_OfferingCostsInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="dffn-20201231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-property-and-equipment-details" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_LaboratoryEquipmentMember" xlink:label="dffn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dffn_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20201231.xsd#statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets" xlink:href="dffn-20201231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="dffn-20201231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>dffn-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:19PM UTC 2021-03-16--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DocumentAndEntityInformation" xlink:label="dffn_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dffn_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DocumentAndEntityInformation" xlink:to="dffn_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dffn_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="dffn_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-significant-accounting-policies-policies" xlink:label="dffn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-significant-accounting-policies-policies" xlink:to="dffn_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-4-property-and-equipment-tables" xlink:label="dffn_statement-statement-note-4-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-property-and-equipment-tables" xlink:to="dffn_statement-statement-note-4-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:label="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:to="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-6-commitments-and-contingencies-tables" xlink:label="dffn_statement-statement-note-6-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-6-commitments-and-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-6-commitments-and-contingencies-tables" xlink:to="dffn_statement-statement-note-6-commitments-and-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Common Stock Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:to="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:to="dffn_statement-statement-note-8-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-9-income-taxes-tables" xlink:label="dffn_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-9-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-9-income-taxes-tables" xlink:to="dffn_statement-statement-note-9-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details" xlink:label="dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Property and Equipment - Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details" xlink:to="dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:label="dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Commitments and Contingencies - Future Minimum Rental Payments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:to="dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dffn_LiquidityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Disclosure [Text Block]</link:label>
    <link:label xlink:label="dffn_LiquidityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the liquidity of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_LiquidityDisclosureTextBlock" xlink:to="dffn_LiquidityDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Attached to Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrants that are attached to Series A Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:to="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:to="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:to="dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:label="dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Operating Loss Carryforwards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:to="dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:label="dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Reconciliation of Income Tax Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:to="dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatements" xlink:label="dffn_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dffn_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NotesToFinancialStatements" xlink:to="dffn_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dffn_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="dffn_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRenewalTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering, Inclusive of Underwriter Shares [Member]</link:label>
    <link:label xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding a public offering, inclusive of shares offered and sold pursuant to the exercise-in-full by the underwriter of its option to purchase additional shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average remaining contractual life (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 64,015,441 and 33,480,365 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 Offering [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the May 2020 offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020OfferingMember" xlink:to="dffn_TheMay2020OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020OfferingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 Offering Warrants [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020OfferingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the May 2020 offering warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020OfferingWarrantsMember" xlink:to="dffn_TheMay2020OfferingWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_PriorWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Warrant [Member]</link:label>
    <link:label xlink:label="dffn_PriorWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the prior warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PriorWarrantMember" xlink:to="dffn_PriorWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeemedDividendFromWarrantExchange-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_DeemedDividendFromWarrantExchange</link:label>
    <link:label xlink:label="dffn_DeemedDividendFromWarrantExchange-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed Dividend From Warrant Exchange</link:label>
    <link:label xlink:label="dffn_DeemedDividendFromWarrantExchange-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from warrant exchange</link:label>
    <link:label xlink:label="dffn_DeemedDividendFromWarrantExchange-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of deemed dividend from the exchange of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeemedDividendFromWarrantExchange" xlink:to="dffn_DeemedDividendFromWarrantExchange-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseDiscountRate</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exchange, Additional Consideration Per Share (in dollars per share)</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">the amount of additional consideration per share given in the exchange of a class of warrant or right.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:to="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other current assets</link:label>
    <link:label xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 Investor Warrant Exercise [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the May 2020 Investor Warrant Exercise.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedSalariesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and payroll related expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:label xlink:label="dffn_EquityIncentivePlan2015Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:label xlink:label="dffn_EquityIncentivePlan2015Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the 2015 equity incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EquityIncentivePlan2015Member" xlink:to="dffn_EquityIncentivePlan2015Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PlacementAgentWarrantMember" xlink:label="dffn_PlacementAgentWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_PlacementAgentWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Placement Agent Warrant [Member]</link:label>
    <link:label xlink:label="dffn_PlacementAgentWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to placement agent warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PlacementAgentWarrantMember" xlink:to="dffn_PlacementAgentWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with May 2019 Public Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to warrants issued in connection with May 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020PAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 PA Warrants [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020PAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the May 2020 PA Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020PAWarrantsMember" xlink:to="dffn_TheMay2020PAWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_May2019PublicOfferingMember" xlink:label="dffn_May2019PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_May2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">May 2019 Public Offering [Member]</link:label>
    <link:label xlink:label="dffn_May2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the May 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_May2019PublicOfferingMember" xlink:to="dffn_May2019PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:label xlink:label="dffn_NewWarrantsIssuedMay82020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Warrants Issued May 8, 2020 [Member]</link:label>
    <link:label xlink:label="dffn_NewWarrantsIssuedMay82020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents new unregistered warrants (the "New Warrants") issued May 8, 2020.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NewWarrantsIssuedMay82020Member" xlink:to="dffn_NewWarrantsIssuedMay82020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 6)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:label xlink:label="srt_DirectorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible asset</link:label>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherSundryLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</link:label>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</link:label>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of common stock warrants and pre-funded warrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of common stock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock warrants, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_AccruedClinicalStudiesExpensesCurrent</link:label>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical studies expenses</link:label>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_InprocessResearchAndDevelopmentAssetMember" xlink:label="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_InprocessResearchAndDevelopmentAssetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In-Process Research and Development Asset [Member]</link:label>
    <link:label xlink:label="dffn_InprocessResearchAndDevelopmentAssetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to indefinite-lived intangible asset known as "In-Process Research and Development Asset (IPR&amp;D) called RES-529".</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:to="dffn_InprocessResearchAndDevelopmentAssetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_OutsideOfThe2015EquityPlanMember" xlink:label="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_OutsideOfThe2015EquityPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside of the 2015 Equity Plan [Member]</link:label>
    <link:label xlink:label="dffn_OutsideOfThe2015EquityPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding awards issued outside of the 2015 Equity Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_OutsideOfThe2015EquityPlanMember" xlink:to="dffn_OutsideOfThe2015EquityPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_DeferredTaxLiabilitiesRightOfUseAsset</link:label>
    <link:label xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right-of-use asset.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="dffn_DeferredTaxLiabilitiesRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsLeaseLiability" xlink:label="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsLeaseLiability" xlink:to="dffn_DeferredTaxAssetsLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_November2019PublicOfferingMember" xlink:label="dffn_November2019PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_November2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">November 2019 Public Offering [Member]</link:label>
    <link:label xlink:label="dffn_November2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the November 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_November2019PublicOfferingMember" xlink:to="dffn_November2019PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the December 2019 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the December 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_December2019PublicOfferingMember" xlink:label="dffn_December2019PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_December2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2019 Public Offering [Member]</link:label>
    <link:label xlink:label="dffn_December2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the December 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_December2019PublicOfferingMember" xlink:to="dffn_December2019PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightsExpired</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Rights, Expired (in shares)</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants or rights expired.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightsExpired" xlink:to="dffn_ClassOfWarrantOrRightsExpired-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right of use asset and liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_OfferingCostsInAccountsPayable" xlink:label="dffn_OfferingCostsInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="dffn_OfferingCostsInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering costs in accounts payable and accrued expenses</link:label>
    <link:label xlink:label="dffn_OfferingCostsInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount in Accounts Payable from offering costs in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_OfferingCostsInAccountsPayable" xlink:to="dffn_OfferingCostsInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationNonproduction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationNonproduction</link:label>
    <link:label xlink:label="us-gaap_DepreciationNonproduction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_LaboratoryEquipmentMember" xlink:label="dffn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="dffn_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tangible personal property used in a laboratory setting.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_LaboratoryEquipmentMember" xlink:to="dffn_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period (in shares)</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="dffn_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the January 2018 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the January 2018 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs</link:label>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of common stock and warrants issued during the period, net of issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants</link:label>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock and Warrants Issued During Period, Number of Securities Called by Stock and Warrants (in shares)</link:label>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of securities called by stock and warrants issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">State tax, net of Federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the November 2019 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the November 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)</link:label>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of shares and warrants issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows provided by financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants with 5 Years Term Issued in Connection with the November 2019 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants with 5 years term issued in connection to the November 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:to="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants with 18 Months Term Issued in Connection with the November 2019 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants with 18 months term issued in connection to the November 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:to="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:type="locator"/>
    <link:label xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm</link:label>
    <link:label xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriter Option to Purchase Additional Shares, Term (Day)</link:label>
    <link:label xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the term of the underwiter's option to purchase additional shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:to="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:label="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of common stock, pre-funded warrants and warrants</link:label>
    <link:label xlink:label="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the sale of common stock, pref-funded warrants, and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:to="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized start-up costs and other</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized costs and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orphan Drug credits</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to the orphan drug credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]</link:label>
    <link:label xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to warrants issued to designees of the underwriter in connection with the February 2021 common stock offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="locator"/>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent</link:label>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit</link:label>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_HCWainwrightAndCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">H.C Wainwright &amp; Co., LLC [Member]</link:label>
    <link:label xlink:label="dffn_HCWainwrightAndCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_HCWainwrightAndCoLLCMember" xlink:to="dffn_HCWainwrightAndCoLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>dffn-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:19PM UTC 2021-03-16--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-10-related-party-transactions" xlink:href="dffn-20201231.xsd#statement-note-10-related-party-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-10-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities" xlink:href="dffn-20201231.xsd#statement-note-5-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-1-organization-and-description-of-business" xlink:href="dffn-20201231.xsd#statement-note-1-organization-and-description-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-1-organization-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-document-and-entity-information" xlink:href="dffn-20201231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity" xlink:href="dffn-20201231.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dffn_LiquidityDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="dffn-20201231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_InprocessResearchAndDevelopmentAssetMember" xlink:label="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:href="dffn-20201231.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_December2019PublicOfferingMember" xlink:label="dffn_December2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_May2019PublicOfferingMember" xlink:label="dffn_May2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_November2019PublicOfferingMember" xlink:label="dffn_November2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PlacementAgentWarrantMember" xlink:label="dffn_PlacementAgentWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_TheMay2020OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_PriorWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_NewWarrantsIssuedMay82020Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020PAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_December2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_PlacementAgentWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_November2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_May2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_OutsideOfThe2015EquityPlanMember" xlink:label="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events" xlink:href="dffn-20201231.xsd#statement-note-11-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-significant-accounting-policies-policies" xlink:href="dffn-20201231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-significant-accounting-policies-policies" xlink:label="dffn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="dffn-20201231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-tables" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-4-property-and-equipment-tables" xlink:label="dffn_statement-statement-note-4-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:href="dffn-20201231.xsd#statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:label="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-tables" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-6-commitments-and-contingencies-tables" xlink:label="dffn_statement-statement-note-6-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-6-commitments-and-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:href="dffn-20201231.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-tables" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-tables" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-9-income-taxes-tables" xlink:label="dffn_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-9-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity-details-textual" xlink:href="dffn-20201231.xsd#statement-note-2-liquidity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dffn-20201231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_InprocessResearchAndDevelopmentAssetMember" xlink:label="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_InprocessResearchAndDevelopmentAssetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-details-textual" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-details-textual" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:href="dffn-20201231.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_December2019PublicOfferingMember" xlink:label="dffn_December2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_May2019PublicOfferingMember" xlink:label="dffn_May2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_November2019PublicOfferingMember" xlink:label="dffn_November2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PlacementAgentWarrantMember" xlink:label="dffn_PlacementAgentWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_TheMay2020OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_PriorWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_NewWarrantsIssuedMay82020Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020PAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_December2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_PlacementAgentWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_November2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_May2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeemedDividendFromWarrantExchange-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightsExpired-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-details-textual" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_OutsideOfThe2015EquityPlanMember" xlink:label="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_OutsideOfThe2015EquityPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-details-textual" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events-details-textual" xlink:href="dffn-20201231.xsd#statement-note-11-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dffn-20201231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:href="dffn-20201231.xsd#statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:label="dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="dffn-20201231.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsLeaseLiability" xlink:label="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset-n8" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxLiabilitiesRightOfUseAsset-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities-n10" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:label="dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-9-income-taxes-operating-loss-carryforwards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dffn-20201231.xsd#statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-n8" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:label="dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-operations" xlink:href="dffn-20201231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationNonproduction-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="dffn_DeemedDividendFromWarrantExchange-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dffn-20201231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_OfferingCostsInAccountsPayable" xlink:label="dffn_OfferingCostsInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:label="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-5" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_OfferingCostsInAccountsPayable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="dffn-20201231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-property-and-equipment-details" xlink:href="dffn-20201231.xsd#statement-note-4-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_LaboratoryEquipmentMember" xlink:label="dffn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details" xlink:label="dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-property-and-equipment-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="dffn_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20201231.xsd#statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="dffn-20201231.xsd#statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets" xlink:href="dffn-20201231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="dffn-20201231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20201231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>dffn20201231_10kimg001.gif
<TEXT>
begin 644 dffn20201231_10kimg001.gif
M1TE&.#EA$P%5 /<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M8GW&E@%B[*<A2)ADMUUH_X&U0F\)_9:)A6"I( 8T"!%C87F?J2!A8V+@MUV
M6XQH4"8):G<#@T*"Y!]Y-_[H)%M,";3:0.E-EZ![!STXW V]$9,)> 2]R!Y;
MO27V99($*;,%=S$DAV9(+PX859&SP7# 7 FN!YF;"<7)G'X(*1-&G72M<,,P
M"L5U8ILBOEEAD3$D&,8RCH(D29&601F&&&AP*L91GV&*HH0)#7.49S%H5:I\
M2&%Y4#VGK?\' PX(35E?8YF$ 0-^DD0C9:4=^6F<?A0*9!-+/1&*(EB2*<22
M2XV&":&AT0JD3%(H8FFKH_4H,XQ+P(:TY(TX((E>K-S-NM$D.*Y574+$@+H=
MHN$V6"]))<H9(D-B0KA64\66E5 : <XI!FDQ46@6BE!J<J_ !?D:T;9OC@O#
M#97-V% F!3.G64&;-38EDHHJF)E"I@H(:$'FBOQKK2]_?-<^]$3#DC[U4/P>
MR 9)W"+-] 0M=,XCA;P0SM <ZY"P<_)F;D*3^(@CJ01I,IB76(-))6)HZ1E#
M&%8CYN4P88^;G21C?QG>,E<3%C:X@;K=]F!E>:EE5&A,H@QC#1+_$S;9@ L5
M\)0XX]Q..[TP8HOBBO?2CCOT$.V1W'_+O(\RDFB)AB8Z[U-R@/LVI(^3Q U$
MX7*XX7:;CIP!L(+7H.G6W>PJW(EJJ,+9GENS^R03@V<!S(Z;JP5-XGILR*L%
M\SX]S>ZU:#"(P?M \:I^)P"B4:T<T(G78D@MMH!?R_CA,\*+.SAW1$_JHL4&
M *67HX6;K"O2BY!_ T9?[9 P1C7;E-@"S0U60#4TR$DX!S21=B!DOVNQ)P;:
M"U,"-^,SFO4K?\P!0 3/<D#B34AF]&@'(\CW#5C40ANU> 4X7I%"6X2O%T'K
MR(E@(!1BZ(IT=H+@MBXHG(-!;!^LBLKT_S2C';90[3$=8]AQ,C6FX83'AC.D
M6OIX8B@F9LAT ED&&EZ'0!/-93\S6981$U*/8?#"A&BL10EKD0U;?$.%+'Q%
M^&PAF8#%;"@P8LM+N@@62(%FB .)2_Y"YQ!)U$E>:WF#Y>J!K1P=L6,!\M"B
M@@B9 S107NN)X$ XMBB$<'*2>EK99CAH(K(4JS$YHX<+:V%"6V2#E6QT(PO#
MA\(YVJ(=EKM( /TWB1LJ44\W:)3%BG0 ,3Q-(>QRTKL&XB1+$@0[B_)1NIH$
M)2_&@'?QVHMQ-$G%+EZ,9\K82R37<B=,'>!D!;F6-BW#37J,T(0K7*,;;2''
M\*DPEG($WS$G0O^/ =I@@7R<(0$/PK2,[8\@,2%&GHZS3(%@,D9'G!^AJFF9
M.\4 /W7RHWP,8"<8<,Y:7^$C-_<Q#*G5Q2#826)O!M/+2*G @_&#W8X0>@OP
MM1&.MG1<+U:9QC:"#X8:V25=?#0;BS(1+$_[7%LT]A!ER(DM5$G3FK9C@.FQ
M=!):F@M3)H&)21S&JX:Y"A/9DC?#3$(2HP2H_8:D%DE>T736C* ^L)J,@SA0
M01!$Z(2&X<)7O!$<XH/%,!*&LW/0<GPFE.,BT(<11G+Q>;S)1.:>2LZU5FB0
M^PP4>Q+T5H=^2"XW8-U!#&FBAAHD7B<Z5$+NRJ21?C([IPT@?M#Y$-?_P,Z#
M^E@E+&%YRP\2A*^N#.X;P5</<U70(2%5YGD4VC^\&<1BL2-D0ZK$GL[68Y+<
M+)F%3%N0E,D)D-3[BIQ<R\7YQ,Q/'O(A0P*F3@86I![N6 0L2O@-WO;"(#FK
MQQQ3^$9;@&.Q!+&C3)KX-8*VRUT&R==TC F1*@UH109I)&A$^UQE@84JA!.(
MC?!:H-7> %+L+!5^,$87@TA'*FW)A( CELZ\D/@RQ--'+\ WRWO:@AXQF9([
M7'A3P+)P&)*KB%#!$JVD=&PUT$T*4QWBU!1%=2#]-%%5>;:/+<X'1 OQKG&V
M %X-BS<[E@U36[>$'C[.12N9?5E[CZ,]5=XS_YYRO"^5:;9?5I;0A9U;[T,%
MF)"[@>:YN3.H7A5"F67QQB"LHG!!!#D?[J;I1"KH<*!>O,T^21(L!]FE)'NC
MC-_LDY138UE?6YC/=B0,(6=\(PI-"#YW8"2YN>,3_XX:@_V42#L,%AWS@H>G
M&/R3MD1D$S>AV1Q'#T3+SNGRY9285T^6ERZ=%4@R#[P60TW"8:L-(M7*&#[Z
M!I<1KDZ(/O@*R_IJPQ:+0%*>&R0##,)4("=&$9*7!:*#+OK2?"F(A*.BZ&<J
M,*K;VO"RPDRE+P]GI"5E4E00@@/_L8G?-PA*H PNKTF0IATT1BSYTKP/=]AY
MOJTL!&,%<LK\TNSDN?\42!A #!9@/]JD:X%?("\DW84LP\A2^>)[EQ@I@GLN
M>!8JIE,0"5K)V"J;VO$Y\PPUG6@;:X#^PA$.5(,>'!3L )(>R$[A"-A:/JU8
M.?/X8?]:BW!#F1Z"&48OAO$XD@LD&J@D.FADW5U1-6TU_6).KA52+&7L1CL-
MVG=HL^M%]6IV65O0WBCE/D8JH]=CM<I+J Y,+?3 FB[:XC8+V=C*&R^D'>%[
M)3WIR0A<:J:X9G3A*EW("Y^'5%9IL-<^;'1I& @XF5T,PW$5@D04N?RZ4NXR
ML4&79<;?0-E0U([V I:)O[?%Z0.)AIAD95'UF#:;';/LC,$!\N%Z7F:-D1C_
MZ.6H0M&_(MQE5)SX1K]^(+M]']&887M6=:'C,BU2O+&W9M*30[K<";P2QA;]
M-A IQ5 Z(W!LYF$:Q19T]UO5%R ;,V3&,65I<GERD0D7IUMMU$8 MF(?0VXX
MQ8$X)A"\P'ZMQ$)H9 N#51"O%VL) 0KMDB#FHE2")F[,1&WTH1P+Y$P'P0C*
M5'P"<GRKM29>\V[,XWS"$6 *011FQF^QER8]TB3;1@\M=%/BXVJV0B'A,U_T
M] US%###H'ZLIWKR]'TD)U0,2'_M@G>+LG<*$4"2Y'-PR&_9]8#^HUZV0EW'
M@2AY>#=0%3.-06RPM3PHY2]101J"LBC$HTJC]U=R_\0+'DARJX13C\@@]" )
M=&2)/%4+C.!^ V%U>?2$!Z%0M2=S L%HZG$ D[(09U%>4H<0UZ4G=N)S5K8=
MQ@9O122$@8(NPA%,=M5<W]0@D5@A_]%9#M9:!K%?]U1/#.(S,2%")_1QX&-9
M,21J:@0^Y[ 9]! &VH1Y]&<B\W8B8:!N:3(,H,@F-)00<Q@# [4A8U5@A+:.
MB3=G529-R)$E&+1P$P%0=I2()Q)!?+6,7BA'PV 34^)?K91"@&4+KC:,4F)8
MKV!"0#40*]<Q+D<ELAAS!>$&_C<7.' >]1 -+=$\"711(Q5ES6$ M#A#CH8K
MQJ=L^[ DLA(5>F,L9Y$B?Y\V)"IV1U(" #@W%RVF+',A130S0J/'0K74D*='
M,S,V/BAT4[;0"QD68/0P#.LWD?"W;VGH2886 ^&X+)(@"9.0-VB0.4>!&U<&
M&FAP2@?!'0/$30331<5T@-IF'QC21V A!I*0!I)PCI.$CV(P"<.P#$A"#WYV
M:!6HB <Q8UTX7[S5#C@6=AA'3RLD/N#3#I&X&CMU4VL%*UXDBJ<%.S#_8(J>
MHQX29E2TD42Y<XL"X2\4F$N2L$YRP9I:=AFZF(>^]([3-$YWY'!<HI=Y(P9=
M R,JF4[M!B,VH$F,N$9P!$NWP N]L%,T5E^NQ$HJ:)!8U"!B-TLCIQE0!R,-
M.!#)P'(YQ(9=N2B25![)T3F4-A<#>(K5UT,\225!Y'.-,0D:A2(+A9?;46:0
M@1^P<V'[X8_;T10CTU=N%(W[M:"DMGX<1Q#2R7KF8G"7 9HOLV'Y(V"HB%>@
M88\#8@!9YRSHB6V%N$2TR7C75'R[H9I@ :*X!X%8A'L !:"@ 0" Y(\%LVU0
MY@Y&"4?])8TFU$;UU4HM@U\3LIWAPSO%(D;S_X<0":<=-$(0XZ%PZ)DN!R )
M#JEO3?*>I=DN2S:*K!*B7)E 3+1''6,N\=$N2;0"F&!7?DD7([4/H$=/-&9/
M].57^91/6*D0,4$/B["%M0!#YH)(GW&1UL)SMK=H;6%W 8HG44*( 19-1F<0
M:=JBK)D)\D*CO$,Q^!-0;2$9>KA0%:0/[:E T,9-:K) 9#&5]%""<W1/:02H
M+B1GZT4S=5H+MW!,\A>>E^5_41&EF]0DE00C-Q!QS;)N!(%S_Y1O@'9IU1&)
M"/A\2E<0FF!DHD(FC1$O%\,<DZIA!=A'1\4EU8*2J&&$!.$.K@I+\31ZLSJ"
MOB5[1=F%+K1/L%:H\/^R*"H@8,J0"6G0*3Z! T:Q%&&P*3B@EXF!$6'U)8<A
M6=$R#&^PL! ;9J:XKPG[5<.@?P.!55B!%#=0L.>A#YH 5E_R)3M4%$@!%4=1
ML :B$&PSL@NK-K4:-'SEJJH'G9#9$!02=N$#/K!P8UDXLBYK&-6RKX>!"4 ;
MIR2!L1F!K!'1+2WQH$W[$GO#M [!M$)3.#NC$,"Z8_MU/CM#M4;S,!.!K%0K
MMA*1I0A106C'"QJ7JU)B1\<5MC.3<K<"J=#1.65+$6@[$6RIG71J0N<S-$(#
MM1"QMQJB,W WMW9+MUDK>T'6$7D[:(PK$S1##+;$0N!@#M"YN=%)CHH;N0__
M [HFT;<V.#$J$3 [-IU^98(M!&!FJVM\2A%R^[IGFQ"[A[;'%4)_2HGVY$:=
M1[AO)R6D2;O$&[H(P:/KMWKK!SZ+);K%^[RLD:4!4T%V5)4ZA3CM< XZI5-J
MY[P5$3*&"[TJ@;>O\A$N,[GE>VHY]C+36[XJ<5SABQ+>BQ+A.[P@$;F[!XOZ
MN[\7H3.G!F4O,;_BVUB2V[B-);4.$;^ET6DMT<"2^R(?.< W0;H$@23Y2Q'-
MTRP*3"/U  T*_*Y'@Q&N\2E2P24'^TP   !A=L$+\<$2##*:$ 9IH+00P3$
M8*A+XQ-45ZO7D<(=TATIW&PY,P:X$1XN_,)I>Q!1__H2.Y?"<H6SV2EF&K00
M++P/89#"X8%*(5P24:,"6D$3AJ0"*AQ(V -(FT$I6HQ*MH(P8*>$QD(0IFA'
M*Q8P<KP]+ ;"=&S (%S!:)$& G8# ,"E^S"\[<NX-FRN\"H08E#&6WP3DH ;
MVI,) # ;!%C$>GP0%PRL>SR?%,$W=*O)6P&_>KP:OK)B6DP]!@  #>@E5/,T
M,8'& Z')P2O%$>0K4!N%^K<MOR' 0Q+($20&8KP5QE.<[X41%#,EOG*^,5'%
M!"'+$F$3NT<:^9M6-XPP'D$:P:'*L(M28FR?5/PJIVP1QL.#!"$) 3#&5>8Z
M3[05:SQ[G1;%Z+$W/:,/</\38"VAQ 11SZS(Q+8BDOM#,15$&0" R(&RP_%L
MQ!(TQ5F+P*9AR7"<)C )T<YL%;X\)#"@T(^<CHL<Q)KD'RF<PF*J4*RST621
M'E/,"!\]T F#!A^-98_KT1\= _;3C\"<TK4F.6<AQAP=9)EPS@UXQ0# $X&L
M&RG=%-!@/*Q#&B^2T@#P+C>9TJ:UU,23!CJ=PF\1B2S]FB8M&9FP A_MBY9C
M%D =TS"!$2RM:/"!Q0+!TA DQA>ET\"VT9=QSFN5#$5\Q;6#*,J &^8X/P?@
MQ-<R/T#<4(LL-4X,,FF0PM($ .'1U9,,%BE,6^PRT!$6R!J6.L*!T9#\:$$L
M%5C_IAE>G2,I_#+-I]#+ACV7$=3S"<RU1I\ D QR#0/GO (@>1:=76(9$37M
M2! NE;&8C8%:U!V[?3G'EZVAQ=@#L0Q08FU@DAZUX\5"$1<&(",R\A(O AM6
MQ2(:!L@I^C'&XQVDXB74TQVYYB 5S1.IW( U'<O9'"),+-0!L%8IK#^;U-B$
MA!W>(2V4+=0P@"5GDA!9?4FI(P;#$ W#D!<^:4>/' #?03U(^Q"/3&'T?-SN
MH0]G#=9";0 &VB<IS#O9W-3IU!T:7LX \->2/<F7*L:DLM=-'2WZ@ --+<OD
MG;$J;A X$!N<'4$93:)7/-P-<<4'P'PU[E @_A"LS3O._WW#^A;,4J()* XG
M 0 BA=$(@.R3F_'=$=0=HC2*@.S4W9&.G'TD!4$;YC([G'S:Z+3(,*!L3D7,
MO\77%;+?G"'&:7+1IF4\,FTM 1!I$M'%I++4? +,&,X0/8+<QA(5JATF?TTJ
M5]S:A0OA@<S4D(PD;+T?AIG@(.,EG?(5^6TM=EYF , ((//7IA5:7IGIF."O
MGRX0V$,K!4P,D#P8A>$EA\T\M?X>, X#^=P=#<C2'G6*C+P\,S$,DM IH74
MI#(,B^[;#'ZQ]#@0B^SHIQUMP^#5;K+7+W7)%,+!L[PTV.,I8I &SKYHP8["
MCDXA,0S$'\WGAZKDB-@=+J?ELO_<Z.=ACNKN.C=L$WY7Y BQX+)]46HQW2GL
M'C:LWA==Y^X>)B5.+QO=$$L2TX'LWQ?M*BQMU1+G6ZN!!K!A/_T$ $%B.=E\
M,K!^I8I;2 N/ONE,VSMCVZ+TW6URL=7CU&+L028-;*@C!@+6'3<0,/C=W\,
M#2$/;[AQ,JL!'QSU-26\%)]"+Y--*HT!U&EB[2!C/&ON4+7#$$#\'2[QR,U&
M4E[=RDL=Q.&Q>]$>'B8=;8#.WP\NSN>-3),<9F5O+=/]5J/CD_3YV9Q=ZK@A
MRS@@%EN1S3'@,X'M0\J0RK?XR-+5=_KM06*@&PA_YYN]#QNM,X\\XILTR1*O
MS:>U<DS_CA :K]6F?EKP;BT#+Q)4C[3F+>W&LL@K$_>N_2X";7'I=-$V/^-C
M[I._T?!Y/Q"P\60$A1N;ZDDIW(" K.M4(AL>Y.OT8D#Q?<E671#-M]M+/5*%
M3OT.?=H-I0]2;2R!C,,94=H//LQ#E/I;4>4%82.=CN:@CO.WO_.D8>I1&NVD
M@?[J%0;G;(3[[OWMGH.NG>@ L4]9# !H].U#B# 3@!69$!(C&"/AQ(0 5*"A
M.,D  $P),Q&<1)%B#!42]QVDB$:%@6$)Z444";%@PAL 8C@4B?#@LIP]1:*Q
MB=/G/J QE%%<%@: F*/[Q-AL>E*I"AP)E0$ $)+BP)DG=1(,_R.R9HQZ")4:
M=?D4@*2$F@# 0#N17L*B0A.6G0@#!H"HRIZ2G*ALKYB$*"4%34C0 .&>6 FC
M)+:W8<)A6(5&/:AIK]:<?XE9)7E#9*:];!5B#1,58=-E8F (Q3MT8B85 .SV
M/!RC94JH"#75UJV,& Z; ,*N)B@&)>BE(I.KWG<6Y4>;Q)0E^[LTZF$ !R19
M5Z:)L4""*L2 )Y8)S6Z$D[JKR)0^!MR-A9W61D-L&,]][@^PAX8DX\#S"R<Q
M-F)*&=**$XHZSL008QAEEAF&( "&.I"ONV(PP*2)9,(H(;5BF$0X988)42.&
MH).-+JS86XXBM9I"B9ZG4A-QH^+@(_](M(<V,BVPO4)TZ0#C8D,HHJC4*LX
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;9(679KIIIV]5^.>GIVY1:JJOQOIJJ[$."  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>dffn20201231_10kimg003.gif
<TEXT>
begin 644 dffn20201231_10kimg003.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M57TPAC'DY*E.6+S=%3F&NRQ&QXMUHHT,;&:SH7%L!3@ F@RN* .:70IZ-E/
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MGDB%>5D\N'M(,&JR,5 >BI0+7S,=)(,["Z 10QQ-&M$!!%#-! @W1&H,Q2A
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M.]&(!TN^MR30V:V((!*IRI$^33VVT-$UX*''7=L8IX )!,B_J5 24[67FWP
M&C"*KUNV*K "'X&)6EL+"UP\A[P)F& U*C@LK)M1ETT[ZM$!!? H8B6**DH
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M 0IOFKXMJ-K3F;L+4)(DH4E_M @VOM6-K!%?]9< X%D(H $$V!R.FAZ'801
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M*YY.G(J(W2I\7>/N(;K,GE5#IR1FZL)BB81!;X>Q0ZA[BN5>V3QD@?&E%YM
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M,F%HLH\^F4PFG:F::'K#GS?@P%U>>-6E'E[DF>>MM]/M19=Z?RWS7@P'J 7
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MK$)"%G*(.!N1<R9%)Q'8 0X>)N8>578A/.M9!'2P@A4@Q7]$^C("08B#.>.
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MAE\T0D--Y*(D1D4.X&PDBK9,52!=!W,!'F.9G[A\A[BX9'B4QP[M#F",8O]
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M?.9IGO+@6=Z;O6Y/NQ@0_]+DA ZP9U$J2+YTQ5=EK(!<*SQJ!9Z A5:H!5L
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MS[8EL]F:Z("'>?3_VO9,URM^MHN^A:GF(LT%X+2^69[[5'406$#/] Q.XU;
M>%N3(O3ZEB!QC459, );!( !J/ *1+4.A,F:S(5& ,5.V(^%@AU _\581V:D
M)+-@]"'<R&JD+ LUPQ'@L#6T> HW<XXU<TH:R)=%M??:@'$5\TZPBH$>"=VA
M_6-Z/"@5*YO7[=UZL[.R5J(HRIUW0/:W*0^U:E)!J^$MNB\M0O0*8NG<3@]2
MZO0HA__VEA)RC+O5%G1VO@'6BW.(C5UT.<V(QTB<7AV< N$G;<]TD=^VC3S
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M[&7[HQ__'"AB=4$ M\O].2_./>YTESO=?ZP[;@7W1?5\(T'B'A,,(5'= !!
MNV7B (.J!+@Q2^GP6N*2B$7@CQLI,YP22A(!R2!B*Z$)BCI"<)HX?'?S!(E,
M.#>\E8C!N^,,W_BR$L/&(ON\72$+0<ET9$\&("R]/X"C;087'"Q<>TJRR7_Q
M\IO2#%A1F=X,^ORGI\H$,#'FT_FF@[/*Y<?Z:XUVC5ON=^'<:+ PGVI4U5H>
M8@&?H>5W4BL:E*$,8$_BZB?^3#B/[7I8Z<JGM4(LX6C,V2J+G9#%/M(N)U9
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M! "+*/#W N"VK%4B8F#ABD=%[K-/3:( #6=Q-$L^J(W&R,Y[EK4[_L:[K(-
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MR9[E(  %41A6.VG'/$Y,?!4#"9'^@)(MN,^WZNL5^FJ9$Z D!7^X+''+?!D
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M,H4  N L[J%)(L>2,B))J)8A$3$#%M!@_J?_.?61+2MY/3+R+PEV:!!0="H
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M27AR\J4FJUAA!1EBT'+@@1&208P<Q*C")1D4R,%EEV7_Z#C$GF: BBJJ($B
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MG%-4=ZN->^J)1?S@@%N@&ZY$BRO&JG4K#69,78&&D2!UM7%V\\K=*^88+T;
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M^X& T0@AT% MZ)@B(:(;AK*-%@RS@*LL=P*\,$HG+N*R)=,BB6*/:=F;O.-
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M[PTDD$L.OA03?BH"""-.]C&X($$HZ=0B30F=9!-*Q1X;;( XF81&&/S)]!"
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MQ##"(LQ2CRZK\*@99A64&B(/C:7%'$4='.(/1R[-;H2H3,54^+'J;4A*SB:
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M?+#J)L.$0DE(O!(S:L:]*$+S!ARVN"@N& *(0<ZV,MKBSHMPP*A&LVC$*4M
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M!=],[(,8Q[E)D_N,@S> 9Q(3U\0^,B& &$S";&E, WA(H@EE<&08Q&@+F[<
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M6+8"6$TG ^D'8&>U'@TT'LSF=BO@*WR'=W>S+=V6<]Y'/_&%)_/!)DJD1(5
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B1[L5-'5\_4%H-'538WC!RN6[1*$702R\$=?*Y6@0 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>dffn20201231_10kimg004.gif
<TEXT>
begin 644 dffn20201231_10kimg004.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M0S18J,086O&*6%1&#IHW)PZH[&),\.+*_+4<Z C(5F. !@L59$'PH<V+<*H
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M#N@G$>(#DGAE^H8VM:./$[9!@.)(VK$<%",Y881AH())G=,ZR,%Y +)!&_0
M11!Y)5)?H/(F7S19YO0H18 B:0 SYZ@=/G!O[O,&[0)S[))>CZ1!%8(K?N(K
MI7*,_09PDK4Q?A5&BX<T*__T81^F#!XX3T=@8D )=(\B?'2R>J&%B_?T<"06
ME$4X2@+R= +T.Q^7A8R"3R-(+B3X5R;(E"=X2DH7<DEW=.:ACGT"/C%88BPW
MA3"HE/G$<A600"/W*U+C4UE(<_T#9@V4(.'AA@G@'.!QA@[ID!G"*'PY %2E
MA66V52M&B'+&BL*H:,$(4;#XF(W9AWHH9\DE(6ZG06XB+BDP E(P FY%>$V
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M@H5QSP,S%@ $&:<MPN<S.6:>MBJ9L>JJ?+ABL'J*+:8)9/, HZA< Q,I<_(
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M.ZSY:JPI!GHE+[7\FPP?*+\I,IDPA><B I*;Q?O0!*X<"N(2#:<PQ7?@RJ;
M3_36-G0"V4:+M.N2+1.J'?PQ(-=QLI2M/H[C+8I7B?((U++)B)U8>(4'X8#E
M*.##104BR%BHGTQ+>7,"!U5$17A4+\M"VE)JVB]H@?DD?"/=VA;9ZY6,[<L
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M5C7:XS0/C "Q^P"'7+P_[-[]X>!-U:F/)Y?.BB/ C;D.:FI.0U49'#5%_^#
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M(Q!1NX@BW,/5 1P=$SM^ IPQ,!XTJ!NP*!J&JD'>X9V%^@K8PCI0"S7NNHB
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M9#Q<&9@14@PTF\IXWL!(PD!2A#?@3J3NAJ@'),<RH,!,)L1@GE?)H $XF(2
MJG.WP@!3+=+1]WPZO)- 7O@-/R ?^3S[4E]ZIW.%F0J]BI28!EPE!^\1S:E\
M^9AO7BI-V8IP4YJ2\IA*1W$Y6)F"*/,RQL&A*Z2;T(M'/((C6,"GE1NN=?^
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M54)QWN=M&6%(8(F0A;51YU0ID(](BI841DS!2HS81S,NA;5I2O]9RII0HP7
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M9 ("Q!,':1%LT^7XI$F J('B0 8$YD#JZ/8Y&29O^W:G$GN(<%T]D2J\L/Q
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M,I9VAPKI)FHJDMIU9,-,QW4'59#;XAA $:  ?3(]T\T$N$[2@?](7FAJ=K'
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ML4%4K.+>A=@!_S&X76I>0R$<$4K'::JQ *.1)E  CB-2)^1))(>UAHYJ)4;
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M@1C>(*TR1&^*IP@[:1A"*!,V(;WT: !9 XUF2@8T00S6!X/X+%IZ80N2C K
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M)]1$I3KB-GQ,*X[  <+"JO1!JX"+T92AGW2#G+8MK.SH/E["!^PFY&+O#8S
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M0JQ2?**+[@H$BRD3K(26_])419RT(S: 0))R;B+N093R*4\U:-<)#FXP 01
M!ZQ2]B[#,D8)F/C-#RTD7)*A/=C# ?5V0QQP7\#FD\!I'[;.2ASC4T@B2YKN
M,UU5)R3!R!(U42^JJ*K@(,IP"Q*".3T'-3SBGP(J#2IB+RYF'V)I8P_$04=&
M@[RD,EQB,Q$ER02BJ)"#@)IU&2BO=M\$NP#I3US",E['-0_@G:IS'S1!*GCW
MXBIB(GPB26L"6K)U\F[,@(9AHSYS,(=EGX@DH>S -(7W80KR6R2"8\Z23E*B
M<*33.,R-=LEBT<JBJZ0G5-DU8[$DAN(5" P2/='J/#,I0EW),Z9V]WJOU!ZF
M-DZX#QE%("088X/ 4V$'HXB$:$"@4MJZJ&4:F(&#:(BRCT%7S6=4HB@HX"_\
MT4)_:$!"%OND+:TP"6LZ! ? K(4JMMA,@RC@"EOI 5^TZI/_5'1IF,-''0[!
MGL8H+XDE@/9M<> ]ILMHF= !*;"X@#1J<&22\@-X&J) ?/*5R@M.JZ0Y>WAZ
MAF1'K@,([,470'#4\#43GA) 348[NF,&/N0!C ?>BN!BRN5/@,D$H<,(ZN7>
M L0\/B'BW&./P=9.-0$&* QZP@N;5"O:&H"B$@4 HF0?AD%5+6I5^U(%+'>"
M:$6U' <E'%0TA*XOSDP41_ B9N-J:P8(^$9+7$>#<$"G^)*CHJ0>%JTTJY,L
M!@J%B"0EZ%(F<D4R)H)Y724-5%9+<J (CH )FJ /FH /<H+R#*\ZG3E;F8,8
M5%%Z5R JQ*,H.&A94@!G0B$:Q*@B_S ":U2X?C8HK 8P)3C@%XTC6G9+]++*
M#G"#0G+C&%O-?L0Q#1ZFN9S/^> *"!R$0WJA0P+:,SAD7W5/0.13@QM#;0P8
M)'3G+RJK0%O&]Q[X.RBCUPYT0E4F#?A"V#KKCCHB)#I&.P@DC#Z6@3V#V3"&
M;(MU)+-&!&GEV0ZD"$1&EP[#9 C$G1<MD<2B.LLB%';1197%0M Y0X BDVIO
M,L@#B>]4NNJ- J,#DHQKJD^G),Q6/64 *>E4$R8A0+B:BOX&QAQLBS%GX3CB
M!UCPE< 8/?!*XB!(GTOD,M3@2T$$"!*P]MRTC4^GXOX$8#[)/-!CC]<CCXW6
M/7;T 8GA"?]U A0(5K7 2SR0S \D^P\N*@SV@1$@&5$HNY7/APH:-5)_PE34
M9F\.]P$":$HL0P>THS(DPHQ:(KQD22CLXW@S:"!310;2CE$ 8 7"@":8XZIF
M55IJ=QE"@DBRXDA^P%(>(%=0Y@#&P"88[18A8B*,H GT) 6F +OQQ Y.879+
MDUK"0'H'PC@H0KZ>(S>B:@3L0 UN>BA 4:B^]SXT%S5D !C)0JM(:+<H4&>N
MXAB%C_ADXSYNR*Y,1CX(Y4\V33X(A$Y)C8][@4KS2O<NHW,,V#M%VJCGJ(N2
M#]7@L67JK"0UE'M_*#!8AF5*>D ^U%CL4?7P"/PFQC.""(Q*B]?_ C)X*OH[
M[N4-1(J,< >EN ,="_*0>HN1HZ41'RHE!L4"ODL'0.>4EJ0L'Q9 /LEH(_!H
M63("5V,H8^1)IV8/!]1&^T*,R^6TI(TV&@QJH!0#5X). =N\C*E ^.++M88E
M*BD-;+"_=.!/L(B*\K@]R+*-"84LJ11L#MN(.PEL.>23Q$9L-@1/@V5[Q2AN
M4#D\#D*R)9L*$E4%&B&W([DS!6*W)2@I5)9P$R13WHMO:*HF-J9*MF.Y;V<E
MWHLR#QD_=))7F2F"*,K(*!E?; *KU%=]JW/1HN$-.."@E 4ZDYOIP@,!T" G
M+!)645'B>N.ZLWL$LAN[F> .@GTTJ<61_Z67FH/$B2XB([ BP_)$69B (;&F
M[%A"I!C*6%SN+JJ*G8=1&4YA9L)5)$+&-"3&(N2W0"[)>$+.(-N8T^R*/><&
MX?+5E<:87V/)+/^HPO'(H8LO0@%#LJ3L,_1(R,14P7]HA '#' \VV"+&6(PE
M) S8+E1+8>71^GXHXSV#96!\L#Q92]=J&CLD#58XASA8G]8/]@Y2]&8V:6Y@
M&;A:#<8@!R @ 4"$<1A' ""@"8))Y:=BJ2.N7XHP&:Z<T==COU%.W8QK $FB
M.W10N<##KH;!E=P:@KZC4[0IPU"DAU<B73B$X=\\$_;7<\N6-05,:G^ O_HK
MP A1;*58BE^23?^'@3TB[F[=-"S=5+H.^VL$.2PT3CPBHGU.QH$00($0U0_^
MP-(O*H$X/9(O*@:X" <4 J/*NRB&(E,N27X< $Y4,[1H&P'0+(^Z0M*U8RH0
MH 'LZ3"<Q#LZ30PD2@4:6;BC932#O2RB 10JX$FY;4]4XP$J9=EO( T*Z-GI
M@?*DI3GZT+JM/07$_]I3 %O/=VD$R '% %I](MJD$*K,Z4A0("L, YP9:R6Z
M OX^(CMDH_4!XL<!  !B*(.V3%DT9?64.506BH,1$1R85.3 H0B'#4 J_-A0
MP4%(-)K@O#&"\B1*.$9^&&$)Y,<D39DRT<Q$J>;-834GZ?29:6:F'Q7_/'*H
ML-'(!J5 -E@H2A2'#Y^2WDS"Y'/2R8M 6L)QJ1)(D329TF2M.BFMI#1I<!2%
MNN$CT@H@B[S%835H4$F9)/DDR]=L4$UB1'[\X3*-D30LX:31-&D831P.*ENN
MC",'8J]%NG[51,]AIH(  @PXC?IT@@$)5M-H?80#18Q'*^#0I(Q8[MS$,BD;
M!JHWL4_$@!L'I6EBAQ'+1SAWOEQ$!XPQC:@I8@3(2;$_8I+EJ4GS9K%=N_]P
M(%'V=.8C1!R1SB%V1IHW<=;4^]/'9I?=.R/.<5\:.;"6P _7/98)3^#Q5%-Q
M#3Z826^215C3A,(1EPF&FABW828Q$ 0 #C\\_Y"# S@<<  .#$4SB0I4^ $C
MC"]20445-*K@8HXT[KBC"E7$D(-B*"%V0P $'5!9!3D4U557**'D0!K[T+,/
M#@C@\(!;.% F0P,/6.!4!4:(J20%#UB&H@P.Y+"D> ]4<$033#1AA!A4A$%/
M-/5 HPE;C!&SD$/+T+,,4D:,T(0((TSA7!,C,#&F PA$N<R4RBS3T#X,(02'
M;$VD,$(*GZ8PQ12DGLI$*-&$MD\]F6R!8ZRQ N"E2!588 1M[3F*J'-,6)##
MD\)ZAV)E(Q(%55$/# 3 #?6$%MI#RA *2J>T8:3442"!1!0%)FJ2'*1O>/;2
M2IS]0!8Q/C&822^# ?_%$U#RED547""!^5:R(YJ8%AII86+6&]@]BE(1+)W$
MDAHO%:$&65GM9959:)Q' ;+)VM7175:MY9=5#Z>EUR1\T;M42R8/:1W#-MG$
M$QI;-M! BB(B]L-7*2\&AT/[I$%: *VQ!O0 !)RFP,\# #%=KA80Y0!NNVF2
M##%1*Z.)U+A)IDR$50/7Z7/20;?K<AB)Z:3"V67'G4PVM858=6[3_ !M\,'7
M00?P;:2&9)$E:).['0(E8-L_^(>8#X+-I,9J ^3@V,HK]T8AY!)V2#E/NCVT
M(,N18]A;UD82Y$!,/F2)0 P!B+'//IG0Z,>,,LK88ZQ4Z'@CC2MTEVN3B^'_
M$,,66U;VP .=/7G$DS]HDOH^;Z2X)F59HKAD!1V!N72RE!V@)F5*$H58W(KZ
M"H>-DO3Y %$Q ;A,0GEJ\@,'([C?:Q,H("I=2R.^H:DRFM(#S:7K;Z H1S&!
M41.9" H^9:H4V"$A^R!&&'!T(UFI   R,%.]<)6>(^PJ@&-J&_&,<(3C14,,
MD[),^8*'F0\59$\)24A#'K(,4V0K/1O@P&$\HBS*V&1.YF))2LH%A\Y\Y3$,
MH@1X[C,AH:QK7F]P2U'B@D,HOH4". C87[)RDB:X#R7:(9>YC%"$'W@L+V;A
M2\?&X !OE>E-#G@ !3SB ,.!["Q!L0I6,H&&D)5%_R.Y$^)BRF6PQ53()L2@
M#[BVA)C.#,^//W (/29!&@&H9@8)R($.U(!)(' @"#][0*XX\)0'/,8ANAE&
M;D!AG*Q9;3A62X9DB&$']S7G.6"CS=F&EQV88"<FZ.K-S,#H)/+8[TW7>I_=
MCHF1#:CA/BL#2D_P0XDW!,X\Y@G2,V>RF@3,H$/N8A>%=')$R2Q(9\E+733T
MP4J6=>A"Q( ##D 4(B"4KT16.D ,H+&/7KBH=:]K78]6("N ULA%-UK!Q,ZF
M22!TY'C[T$1F?J 9)TD$A&>#PZKVL8P8,,]$")!9&_,%TC-)ZD2489.2E/0F
M(SCJ4XAZ0Q56\$M-9B<';_^(EC+@8*A'[:I7]*.-DO0G*$+Q+WT:T: (')6>
M7!FA TQ8U*)$ (H&PJIV. + K [PIC<U!2-V&\&A?-4$)GWP"$PHWC*B09G+
M5*8!F%D609PUK;A*ZW*A*()=0G*FD*S1!Y6QR40(EA(@P&2P+0EC$6RR-YPH
MZ&$)4N(S<W*>\^BUC2)QP'E,E(:-_2LM6SDJ&,L%1".<1&$'VEA0L&*6-/@E
M#3Y(JXER(*++X,4G_BI+4-* %:U\K"9BP0@3PG@S'\+D#<?3G#AUDX8&Y$ _
MZ/HC2Q(#BF7H@V<W* BX-I$^H9X5%"C1 ="^Y)'C/01JQ @.*D]9G."0-T+!
M\4W_>9?ZM97"3Y:@Q)UUN/@2A?J'+ ZEF<E<<IWJN,4"%KC6=*XE%@IU:$+#
M$,I]'O8&\=",+4&Y"E#&P!H!3"(GCJ,)Y"KW39H,(QK)DY;^DK>A#8%"P<!I
M"PX, "++0I0"]!P(,32U(W_.B$<JT(*L9J<C@L; /+CJBI@@>CQCE4]Z9Q,6
M!SIRX]0I0P8!0-$! F 092 )2Q5XTY*"=[TT3'E2E!E=B422*$<==01'2$,,
M1&0!A9X-HJ"Y5!J0$A_WJ7E7[HN-$98&P] @A"&@P(A['O44.5-4(J("%1.6
M\4""1G %,=#H"MBZY%LE53HB.%2N'A"3.$^4HJ*UTN^V_X2BTEWI1 0Q" LO
MY4CU"<I^-/N=;&UBASEY52QF0]C"O%*=XFIN,"L;!H?Y=FR?](FO)OI!;%V+
M S28UF%YS%531< $80;2)3[<I6C_<ENL &P2_FI+LVF&F,SL13!^X<MN04:6
M-&@D/>3!SI.$Y$,B%GO%O7FM?_D#!^TTTAW0@.2'4*</N9IX&:#81#83  =P
M/40W%(^:*3?$RJ@EHVJJY%"U G@$"SQ @^RA#4?PN\BN$.XQ:9"QG,U6GI:4
MB"[7XFHRWW"3R#!VB?CY&%LF[# ]J@%H8[B)NWS!MV]^.$$;.G%NF/F@2FF*
MZ9+9.#'>( -4@P@'\AS1ECH:@/\3;X%'.N[1[*H@P=FI'4=<;U^3NK/0W[&)
MQKK#;Y,J@#RGM^7-DR"Q\DJ()<JB"0?U4)VI381X3WZ/4:'J])HTTQD;+NT!
M;TB(,H@B$45]-<UV\_-1?G#6T+AP6M%X Z[>UX2E.8FBQ8L-H^34(JKBZ,VP
M+5&*WB0]CMB<"=-Q3TCLR_JR0BD&#I !Z4J'HA,Y8 5OW5-<13_7A.R'9F?>
M$LX+>6TY]?!)#%M8=3*"<W=!J%W,5!<SYU66'(2QUN>) 1K,0NZR^*6.?VTJ
M2A0C7- >3*8>NR.Y_[\6;:$9S$6 561;:U%'#^-N-1$8\V81]I,PX](8*S$6
M'D9U4*/_"3<@8VTS+HH$!&FP$/5@<  0!I8':PI'>ABV&IK0/Q.7&Y] -3%8
M7KI1-1BB2L1!7IH "D< !!"0 )*4 "KU/N\#2@R#'683<"BA,+PT#$T$>?SQ
M7]E!,Z.C:29G 6^@!C0Q"9"S,N*7<]>D%\2%2,9216^ !F*  V- 20.P3<]T
M'S?Q8993$TX'3ELC8A&B#_L0#1<('(5A69\#  @ 4;9Q)JQV8O2P CS"8T F
M:1*$(Y26=3^@>D36/27E%IHA/44@:F>#*S15#_K 0*DC==)5*6EP &QE&==C
M3X"B/YF )),R*9[$ 2NE4XYB!"6R))((=\XF!H*2!E^B*X?"_WN/8C=*M30_
M0 SJ PV$8F=<A1+E@U#"@A(5@2@W $$$I0) 8EF%B"1)4A0%IE08X6=ME(L*
M-6H4Q24<=2(ITE&3PBPQH%VP9E,/T5SRAFY;<AO%41)SHBC%4RZ"%5HNP1T8
M\0-O"!2]<!-:>'[QHA=L@V[IEAG]LA>Z%136QE1>Q6VY]"0!MQUV]6T5ED>3
M !AF@8;,]9 _T%I],4=9<15!!V$UI%2%I1T;63!FDUD20B%8,P:T=Y)C(5X'
M,1H'MRJR=H*DI S%0'3+4'&7HQM38TJI%"%/EQNI1 R;H 8S@!H*H!JS.!T'
M5G>W%&R(@2 SHU^Z\X$T0Q-I<))P4/]L#\:%B*5'/G=F74:7E449F4$!K4$
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ME_ZR%N2&2!*&;K#E,&\0&/X7EYF@!K\I IWF'V"D,"HQ@0H3<0JV<<-02 U
M&>BV?N@25-35++$I* _A#M(2#0/R@Y?C-%"3&PD)"K^!&^GT@KJQ"9I !C](
M($#S,[,X&V#2%8HQDP#9'SF@;%CB7_5&'NAB@9J <X[3$W<(A@T6EUK1<F8"
M4D4!/*F9 XH#(/C!3!:8="?6&Y638G)X$ZE##R)&$VKB SD B,Q#&?6)(I6B
M/_C4"^'IB)Q)(S;"=BK5!$S59;F(&#B45E>"B^18JS%QG"6"/(0"_PVT&9ND
MJ#_10 QI( 9B(&TW]D+3HCU+]DE>U2@ZA9$F<D+5E(;C92L%)A&]UP&?E!Y=
MUCR:0*67(HF?=%*\JE#O&1\H<01Q@ /7.#O$AZ=*@FJ3@JC<8P&:*)U%<"5K
MLCV22)I-@@,-$ ,(T  R8&62 CSO"'TG:(++(&]=]*2(X0 W@ /JQ00F&BH%
MDU\0*A;V4T <P%_J=$1:R"#.A$4S\Y#,M27QEQ8LF0G*L6:=)E@A"W-!E(03
M94<B>4>J518X0&,>BF3.9A:Y%3)YL5MO4$.=%IT&TGWF4C.?M1+"@:#EI0R3
M<+&(A&0B<H+Z,()B,&C/9V*YL:E",P!BMO\;-"B&RV6 N6%U5O>E5XD:BI,
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M"G "!D" P4S2"!''T.W81Y-,*122L()P_=:M^(@32L"!,^&IIQR,Z#S$4P_
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M/. !VE_$ ,62:>4QM7'3")35@7W=K'69T0UK"!*5J4"E(6^LV;>&54B;71%
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M#>T448E AY8I^45W5*EO+\?@%M?=Z,,6D!T<3!0Y^ZPF:$O3G< 61 RA9'-
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MD,R1A-9A$!_@L'=B.MD8+0*J  IP"APX2_<ZCR*!-C+D *>KG=Q R:!9O1\
MF!WS0VU:(P<8GEF2D =P+I+P(MDH I:JD@%:O0@[$RHX@*S2I/_AI-%[%3J1
MD DANBKY&UU)O&B[/GP1KS/;*67"C@VK$/](35",C#;Z 1ERO(Y"$S& P_F
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M'3&1%_L1BK&N^DJ/!/BPK_NZLP*%?; #;I4G:;H/BCQ,P^$=H4BHFVP QSP
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MI$P)CL&1D'Q\@'2<'(C4')W;, XS7TD.YMZEB,$V.:%\([.&#)C87%%^TJH
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M,8NR";KB0Y?"]"X&!S"=BURT A>I #/NBQ*5#G.C&^WH1S=:9J6FX!D'!.
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M:S2D01DT0U=-Z->H+8'U44: PYN>YI'@*/@VDJ">BPYPF"N-&"S_-%Z[?M)
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M%B@VAA!QP!M HF XY=]P3UPEPR0 0#M=70Q %J;DTLVD!!,(I^M I&;82F5
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M<'5KO8%"-X8KI?''P53 N1*#NBX$6^% ,0P#5\9F2*0!+/XJB !!131? B
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M'IG7>V1A_X!K'-(%7<58] >@-?)& (I 34+,U*S-TA,Q3%D5\-U&N9@89/=
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MG I%--4#.@P4,9;$0 U39G)K)F)B,\&QH-2I")!-.9RUL,%"_X4*.2H\P.$
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M)$V.UBX&!SB[4:F WWZ//?>L+@(_!(Z[H9Z@B<KV*!]^* )"WL\4;;0$6AA
MSB')LE,\>CWB2*U1^10T)"#T:J%01&5H[ W)&AL#TA\2SL$''&18_QC[1AG.
M/@T?Z-V/U%\[RB$! =H\="];$WJHUHH$8O4B^R-*:%4-&0BK<K6_!XV$ \L;
M%:A LI$BB 4E79&@2[P2$PL:A1YOD-8-:E(/H4 'A$8!A2;20*.9Y48Z^C!7
MB)1U+*^$#D2F00IF:*@9I51&+L'A&?Q&DX;S?20P@1G,8 )#'+90@%(.BTSV
M&@.'X)QL+44D8L5 <B.44()->DF#V4QC-CMUSETFBZ): ,.6VNSF![_1A&W
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M<$DY#(.@7;5M&J$NJYHT')2AYZWXB)C13->&Z7G?(FE2# !8 0Q6H )K:D3
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MP+GZPS_.HD!;,#V,( 9DP$STPVY0+@?"H!#" %/H9>-:4$NR9 IDJT&,0*=
MP[X&KJ=$5,+QTL6^0@>^($\LVD\EWH"2(L9,-,MT;B:V1L!M^NVVZ@,.?.8X
M8H &M84&D<*-<O !Y&<O@ PTGE*3E"TE_'-W7LQT<LU>NM('&(V$9J!-@,QZ
MSL3HLC0-9@8+LV>)N-"',('2& H'C+#>WDEX[M*D>L:'?&@OU3 Q(> O&14P
M"_4_DLY1X"?L$G,AS XO3$<N5W$JVH<#;'/N'J\E0@<F> M-W*A;;HVF0/_S
M[_KDAG[@)MQA6>)L$UUB-6]U)3T02#ZA3E2#YB9#PG+(+B"D,']2$]PTR$PC
M.1LF#9H.TR+*TLSG%G/Q%+N3.'X1&$<@"% ,4=2 BSSL6]EQL#[$+)K3B'PQ
M)-(30MP(J-3 -VA$.+*1 S!K;'*S 28!V'04693A/HLM/XN-^L3 ;!SE3!9R
M54#E6J6F 5N$0:QD)."@6'SDEOKLX9#G6[]M,GBK*O=/(\1&;1)GE]RC">XB
M0L)&LG[C!U8 .U; 7P*CO&2K:AB)18PR2*;**7&*[M"EU$ P\F H$WAF8^D"
M4DS'MW[%/!BDO!XPDHQ /-,@ &9'&1R,*,8$%'#_3'(L3"\$@!*6X21:0DFJ
M"GD6Q<5>[$@?,V*,\-(LC1)$0RS=R:1X9YVR%$*(C#%FC*"$D^ENC,A^( &R
MZ%#$L@78[D6^"E,D ?1*8PS@AZ0B8H"J;"[")U/<$D.AK%(Q],;PA0)8\2X@
MQ0C5)L3,31,&42R(*;3TKG?<%9TJ9!9#4ZLJ(!.$\J@NR"6.Z:88-()$D.&6
MS<-2(Q-ZP1UQ8 "M4G<*$RD'8 8LA5G?,5*$[CC3 /26%1,>AE'BC]5X#T$2
M@T&6RP@L; P*Z?:.)SR@Z?9B(S-\\:PJ!BCRXP?*!;K*2M..Z_B.0Q)5$4H0
M  V$II;R[$3NLV^HH)6,_TT=AT&@;D-",$DYL)&YK*1AWT:YFH*H],M(DNV9
MP.A7FX9WVX]G%G+_Q"9 7Y9U8A0PJI)*+H1F2(M#8H!>K$0"S0L%^DVV<@LO
MSNQ8-,?NCLE8+O,U82Z^A&N[4G SB14'4M!37%6;D!9!4\ ([& HAD%^90 H
MP+'@TB#4+&Q^BJ>6QB(K?"3F#HGFIK (W-4*U=)T*&!P<T");,PQUI;J#B4Y
MPM@_U-*'',.'N!!3;DQ3).$-$I=+[W(T8"1?X-)Y'8JAB(Q2(:)2Q:[>U,2[
M;NS&DO-0ATP-!NHN=O,NZ*U3-F(NYXZ_1O=OO@('QI;").O\(/'O:&@S8!4F
M0/]CSF("M&CWF'HD+"JV-;0O$WR!=Y'"DA^79X(N.+%'[V D\RB%49:5H"K-
MF+5'KKJSK@0&:?_E"%"%U'BW:3[',3JLP[Z6D\BHKJ1H_M*3,]@U*A@R7NGJ
M,##K1N[E # 2M+("<[1"&<@1._+S.OBF.U;+,]3P"DW)*J'D5SJ P B,0=@&
M)#P"8H<+>6;35UM+0GE7=S_C/P3.3%:%^\R+/1:) O'#MVB$1&^$"U:V( U#
M1KL):]1#D0"NWD(W*PC':^]M5$FD_* )!+$B="6,IGF++F)D_Y2C = MFP*C
M11D$06J"'KX$3,3DJ' G!^0GQ1"@4D3$6*RJ_3X#>-7_X J_V'<@)%/QPLP<
M8R\G 5H1MTW>!$Y(:0K5LFZS9Z'0QU&6U3'&X F3TITP=)+7TGF=%X_OV.G2
M('%U@%*Q,E+65#B7[I@C@Y$= P<:8'/!Y\7F<EB^+88<SR5 03-Y([+<-456
MMU4K9JM^0$>X!S^()3H<+UD@;U1_- C%PTXF@;54FZ%RP'<XPTPF]U3\2A?5
M '@-:N_JMGP8"C*$\](BJJ&P)PUNAIRO-3$ Y@@>X,(\#R ;IF%*K<\""Q0,
M2V5>+ULY8+'HA3.6(1IJABXNHV N2WX!;U5V\WYG27_M2RQ(2S^;I#MZ,Q.H
MNF3[8V;L2 5U;"E"8B !!WQ#_U>"#;J>!M:6-2'[!*HQ9"@3_'@5^0\"V6-K
MUD/!YGL_WG@%I.])?L63.K3C9+9!U*UW>J<D$K"=7\BTMP*:M")8L8DS'(<S
M*A2VN=%T@$A>8JM%*D26Z&$25$!^P^")]<@E;((2>'!^-NIQ@!=G?38J38U@
M%W&=WOAW[D)A%CE:\30Y*6$,#L5-1X-G_D--\$*)&'FA%@HRG-=1. ]5W"G_
M-I<MZWB.W[*NY=A1=',W\06QU]2'WJ!P\12B'@-/'P4O7JQ,L9I8CD<VV;ET
M\:-WBBX'474,(E$TV4*W4$3XD&)STT"60@LL,)-!A>0KOM>+&#HU2J,T(.9E
M<%NY@_\,]1:[4_YCVXQ93QW%JX]3,O#D+)K".:7(,"S >/="#3IL7 58H4]C
M7#\L=;89,1HD/6\(J+ P2F8$T.1(?G-@"97C ";A$*4*IZ+):-*Q.P*).W @
M18I !WA#H\7&*C,OC59M)-2@)"88M0'\8P8V(,VF82RE01V%L=.((Q#G2;%F
MVIK@/CC69($ *(M-!>#Q)KFFHA?':E  ,'QK_Q[ L&:$*B:(1.8++$)0N%[C
M%#]"O1SGFF8DF("R=(JVV ?#QF6"272<)]RL)FZBSI:A:ME$*1$E!RI$"<<F
M$[)BP\+C6S=S$:]P ,$'%AD&]'H[K2UM8V0 :Q$E 531![[_:JL#FY'OO*V3
MVL+^:=3F+7P NZOWLG#!/)!]Z"X>('/5YT^+D)(KS:L9AD\A WTD8W-O^V7@
M]@#;W7M/1#R\"Q2P[7'JU%U1%ZPTZ._*Z-6BHA5MXTAQ()Z(9BMJ2LRXRZ%\
MU9 BV'>U9Z#&X,7P;S00H%'VMD+1Y$B5B(GH.&TS82\?PV'&0 PF\=G9QHB(
MXYE'8U4C8TPO>%$\PW>5'#M?J[+JZGR-(!JB02F (#<2&7BI9!FO5;R/PP$L
MP.SQA;-$RQ_!:W3%(AER?#N,C3L"  =\(R0R6FT*T( S"P[*XOS2/W0!9YH;
M.B!GF4ANSS$^QI8_0S+4D%YNQHBG_XU)5P0@1/QPD.,'D") . "I\$,&%3\/
MJ:RH8($#!R8=1#1)T41CBA%-1F@T8H0AD(45C7!0N;*()F69E W3E(P8J)G#
M;FJ:F4R3CPH55@I5Z  !#AP5@!A<^@/'"A4 '#@H,E3$$2,;&A!;IDP9L2TJ
MH ((($# C!QCQJC1!"?'@+<)X.;H8-%"$: .)H$BEBD3WTS#,FGJ.VE8FH(_
M$A],DSCQ44V3)KV1/"F39$F6,4?NJV;&VP%QXSX @M7"#PICTEB>E :SI$FO
M,^40 />M@K<Y<BAMF@,'FDF_T4B:G 83<-AI)KF1C(,"0Z#0?P"57H$"CLF3
M?\/.U#K3Z__ADX[B:)R8\8\BB04'#KQ3$]_$/QO[D-KXX$$C:EQ. A CJA&Z
M'%@0#30#/9"#,ON\H4PTJBT#S3Y=*0,-,<K0LT\TQ/@PAC*0'8 @/0@2$UA?
MO?1E(F&6]8484S_DD$!H,JA6666)H7<0BPSE( 9WF5U&663+S8C=45(Y8)%%
M(G! 5T9,CF !: /(,)B)E05&R4PF8NE7EH.Q1]61=(W @9AB'C%@11Q4L,P^
M/N10 0Z:O!'4D4J.T,$! .2)% X/X'  #EYQ**A?-+7GES*,4*%H%8I*I$(.
M*HG904D/_& $:98NQ9 #.*C7GB;ML<<>8.H!ME-?70IVHJHECCC_Y8Q;"I8&
M4!:H9(1&N&XDPA0C<(0"2!4<X*9T2BF% Z,0*;I"##\(916N(T3+A$@AI;F4
M4D&Q-.:D1>SUTI9\P633,.+^\,"<0DW*01$(.&!@8DG]8!H.886U0@#T59"#
M _V)$2$]Q(25YU@(?#8 ;;2]"&5H1XA@ZP8<_+ !#FF(ZRF)J&;B WGD%=2;
M&)7%]IIVW%'&8V2:> ;E6P(\4"M6'%B7QF3&):=:&C,($%H+*Z_8YGPX'"=)
M<L*Q]IIJ0T<V'W0,;2#=!A7<Y70%#Z#16F5HE&R<R:PUP.?/',-WZF [@<+=
M Q3("S'$ZPY4D'GY_9#&,IGP%U5&%AFQ_\\R%3C0)BC[_*#)/IF\(<;@^U#8
M%80(-D7X#_NDD0;A@^M3ZF"5]0)9BC.&G5A<H"$@ ^?<M<C4;KLU]4-F)X<\
MH^N6I2$>#ONB2Y<(3"IIT1$/0)G#,)2L2B7P69KXUZC$P-$LF!S@/J9%^X12
MUP^ -]4IJ$6@R:3#>.;I -4.''# 2R**FQ-.A0:6Z$-^)$L%L]-:-0(3$1NT
MT*4*&91#GS_PA1.IIG+5J#+6%_^I*C &'%7P2E0E%%7I#=(YTA%&8(1H?40*
MO0J)1BA8!'SQ23HM<HJB_/"'1JW  <NSB)@ZPD*1'"%BIDD(=2P2$B8TC()P
MV!*'>N(55;E'&?]O<)<1:C6F:37," ,A2*6PU10 U.N)4%1!#-P1H64,0P54
M$$L 5O89T'$Q!T>@GT4VH!*H_< '[ND+EK1D&4W(KF,M IH#)K,:&64B2%O+
MA':,\P8@]&YA<%E>$9Q&L<AH1C8& UU<SA)'\3A !C@8FB1;4QS6&$<[;T##
M]^XRR I +'M4<5J:[I*UY!C29MN1$0XX];,<M*DQ.5!-J2CTAN9L8&VV$HH1
M[H(8],@M%-#83W\<@)$C14,9?3-7XWRPIMZ\9!_0"%3BUH0&R$%C<#.+' X@
M)+E)[,2;#D01=U:D/RB)KE,HTH3G.,:0';WN-R5;CAXKDYQ,',5<TMG_5P[2
MQ3SG*41A DC#,"KCBS869DK$"QXQ*F,H "J/3K=;$@<N%+4'.*!Q.1#,E.#P
M)8O0I7M1V5?X_#43#A&C)\,@QB?X$JY)C! B[:-"%2Q%)I%0T +G6LJE#)(C
M!UP,7+$:&ZD,^)<#@I.AWFP@JD8TB:+*2EY#Z0A(/ (2%.BJ"1$+@ H"0#NC
MQ*!1,6T?1%2 %*&($2.X<UC$&!)#GN;2IA7D !QDPM*5I@$-1_&!Y%8)%!HJ
M:5H<P"H0I%*[W"3G*0*+8KW()2)B  PL PN (E<6FH7%U6%J50C4JD:,AI+J
M2J@23V]62=H;N',2F*CD:^B)-5A)QE*7JLW"_R!5QHD5QV8YJTT+0$>0,^YK
ME9QR@-6.0UQ* H<[0_N))SW9K))P &) @%A)S-B=4GK',I-9[0TX!5PW1:T"
M)5G=J6922^A$ER7HS=L&>ON#-RP#1,*,"IB,4+W>0J@\T P:@B#467T@* T/
MF)PF@/N&?13A ?L A46;HBI8D>ZU(/R!#LPI P0X^##C@9?GWD89S1@.!S>
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M3_2T&O:$0E%C$1W58B#'5T 1<<E&/Q0D)B+P8R(7(?%E)'3B-*"@":  "F\
M*1SB7E[Q$O2P$_N5=Z" 0LL "B4!"LM@!S]P"E)($7AQ. _&.LSQ Y5E%#*B
M/$Q3AA1@4?L20JO#&O048MQ5;0=@,^-!3N1!6F\@.3=#.IH@ _&6 WV'(J:'
M>C<65)Y7=]QQAX/Q(=&@#_\7 A-'-A-)%2>3,3  \"<QL1<XH1,H11-^L5+K
MPWL0 2G69U6!UG&5YB[[4SO7,0RBLB5L]#^"41BQ2!B#.%!U!DZ94%!XQCF!
M 2M]QA(W6(HV%6@.8P2(I@)5H 7D!U-_(%9AU2A;D!-P$$06Q2?4MC_%MSP3
M-%7<2#]S%1-I\"<F82GV\4%,QFG)UQ$K 6M(1BZWAWLKD$6Y-X]9-##;M S+
M8!-J8"[[,P,+>$28E3?/M2YX(4M^(8LH$CQN1!)#\5SW]@- $AFI!!Z:H1KB
MAEE-< 0)$&-0HC,DX4<<N9%]*'1L"$&AM!(%!S,8.%Q9TV^3D38,L2XBN!*9
MQ3;_$A-+L8,#8G 4*+@<$(1Q0T$_R-<\*E$$001PRR:0S=,P#C,_'< $W1(H
MRE /:& W#O!"1V(!;[).UH,@75%27O$&FA *?/(<:[4!6EF&Y\(I#I1',Z()
M;A$7,B!T!*B%%(&6MV0!RV9&4D$Q7H@#1D$0G/);#G #5G,4XY@Z#-$4=D1T
ME:$&H!$7DA-+R;$3;G<JE2%W;E=GQ0.+=.9@H)54IY>+F= ?>>(OW;=2.H$^
M6/(7Q+ ((Y1[*_ #P<A"')$"';=+92@=FH=C7*(E<C>+;*:+4T)ZXG1Z?T%G
M[0%! IDDP>AZ&?$#,7!K]9)[SRA6$4$%BR H>QB8JY1U_Z?V/4M&/QPW58-6
M0T8P$\3@?,-R$@B1&.=20;=B4S7$C2\DEJ*R$^ GC_P9F^[S:'D2 Q'2%0QY
M%0Q)G@U#E#^FEYN"!B(R)9XBB\RY8KHT1@Q1=3>C&2&3(CA@<$J2)#:D \)6
M60G@(N8&.@C0392T?Q4JDT/!$#Y0,K\1)++S/3/HH0%)E$-Q&JHQ.XW4=?#B
M@D%I$<C7$>KF ,[A28-$I!?QE"+QE,78%8I3-\-$)T!!ATI1$'V2"=' 7RO5
M%:#P6DU3$7.")@&"ED#GET172=QA3A57&;2R8A6!)GI)IJ^F;<#A-=SU6[]U
M;>5%'DB4.KW1'1)9,M*&=J%3*?^DA09O '?'*4Y_ 1D[!HEN)E1VUF8 E GX
M-R.4. D< E2'5RJ@*@;T^#Z1P@0L]"N[,HPOA$0J81HN@3ZA\BH!U)FD4SR9
M8R(E\DW2IH>&L9,ZZ29Y0Q?RB7TK(9V-0GY@Q3[8&58JH#FLJ SA2#O!913Z
M E[@%29218Q2)5<QL8+M"5Z8,EBH9F@ME"LKD4.S) G[*7Z,QGN*,C W ")=
ML0Q+FG&X\V?(AI+KHI4RXT9H, 8X(+!QYD;X:@1G)9 8>#/;L6U6<U>2\0!?
M@EDV=00N8C!PD3"U81:Q=!2_ 4$%AR3[2G!8802QA!Q'DUI("D)#H7&WXK(&
M]R9X]77_'#,>W.$<(7LK'%=$>*..E)(V^ IHSQ(_3VD$+]$5]) &5GDDRZ8\
MEU:S:=!8/10NQ !!;D*F=+(2>GFF:=DW[$88*&@9*B, )%D9*(&6 :*46<N@
M_G=<#D=:#^ #>_);0<,;'!.HCI$9W=9ML',8"@,:]!4]30$X]>"HN;H3RZ /
M"U5CJ*<)NZJI/D2:XK29=&:: ( &,K&:*[4E/1%Z@#$)6,0HX=< *A$_(3$_
M'\$$O#(M8B04\\*3;T9WGH=4ES-0FU-4T49GMJM4X=$N,8  XH-"9NHPMZ,D
M)?%5\[B?[^J,S4@%C!"J[I$&[9)UX'DNJ':.&F%5D_=IA,(I_TND4T!@%\*J
M$EBE:JN**TF20V,S#+<G$?*HK _1C-@I%C$P;Y(#09[DHMJBK^C%7$6Q,1GF
M&+13.#(IE K:LA9Q8BA(3VA0$+3S,P^P 50AE%#:!$ P  B0@(JDL0.@&XWA
ML068-VJ%67_&$K>D5\C!&HYT:IZ$%9E%GMIR%WVI.F%S3RU,DT29$16$$<CW
ME"N1I"V(PUB%*T[:/'.E.#WXJM2S#$4886A&,<JP%YW(4G[Q!N>2)G61MG2*
MQ4QC43<C'C>@DVH0EP*0 WHV*T%!H6M[I@$R'=<5'F_8&UO)74&SDXG)(B=K
M2A-9./3V/:&!  _ <W+"$!#2A2EB(?_BA)F D;M4(FV?.8BN18D5PU*;V(J3
M&BI@,7Y9U*$K) *XR1$> 2WR*9"$"9AJ-A/0:AFHG*EL-YJ02T"XR#F0L<*
M";Q?1Z&V8HR+EGOPRXPPY7B*$HV96%*R<P# :ZUW6;I%9&A358P[YGQLE3WV
M,1#ENL/,+%4D(6TL!0/M*G[.Z(P/(18' $MO G%K(\(-&4K4P2GK1%HLD23P
M_&<Y:,)CEARO\08"&S9/1P$IT3P^O$) D# <'&\S\ /[2!X5B&P8^3P&3'")
M01GB\4I- 9/-^1\C##.DY4KM_#T%)UT;5[Z!ML,Z#!T2QZ0:L<S(-E<\6'(
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M3%DR8I^($0,U3!/_297*5 Y+J6E8)DV9$'*PL &G00L&>>I,:"'A P<R<OS
M\2/'@P$)!CS(D<-'#AQ)*_C$FM5@!ZP]$_Z8E"9350<YRN(PB\/!6K9MDZ)!
MDT:2W$EHZDYR,RFL@PH;<OH$DD" FGUP>A8I7,&!LGW*,F5J/(EQIGKZ,DW2
MM(\8IGK[,A&+AG%2IF7[DLG,7$_ROIJ7'X^N"T V  H2)8X0<<3@#['$WN"H
M\*,"D!_"J6ZADKQ*!8H<1@@4T40$;NG2(W)HR.%'V0=*?W1WH/9!WYX]<09/
MTQKVZTPS:3Z^7--]IC=CMIN%6OP'<:45S(J=!!/8Q%!!A>22\\.//ZCP_Z,*
M/Y)389B9)I&DEV%.HDFESS+\1*8-B?GL#0>Z2Z@ABHS K2&NBI!O)4V428,J
M[GSX01--MJN@IX8*(@BB@H!X39->PBBP2",+/#"Y/Q)D\@\59'/ 1.P..D@Q
M"A(*;H.^?MA N.W62JHX_HHSJXB%FA.(H($*6M.@ABI(2HSBBOA!C2* *"(-
M_8C:0,J"LG.3 QW8TD],.O7C*[N'TF2B Q$<)<@A[#8H8JVC?L@3TT+5VD G
M,_O423O%T JS.#TS58J"'SC0R<1''V4BM^B<@\X()K TT\R)1FB.(8.*L ,D
M920!X 8 <,@()% P*LFE96&"UL67Y,L$CJ XN/]**YYV$DZQM2C(P;\<!' *
M@4N+>T M!WKBJEWGWN5*6X,J>$,2O<A"RX&IU!VQWP>("B^-,201(PV[[)J+
MPM^"RA%;@W00((=]QGV ,%"(@DPCR*"99!_/)GLLLGV@*?BQ- Z0 600&\MD
MLO7T<JTCV7Y8DU>()-(R#3BFT@]/((BCJHH#<7"S9A$$BE6ZYR0]B"APA>./
M*!*QE3([WAYK<1+WM![-E\>&&8V23/KKR[^RH!X.B."0LNNRT88A$$D&YV;R
M0!4RG!9K#4$T*4/4^B9&DS3:0F#$57F$B,5E/VRYIC0>A\/O[X+S2<4IC7BO
MO;@-//+( Q]D,L$G 6C_ $W ^A0N/"Q_$ I+Q0XHM5!$F</.Y@[8I,CFYHSP
M-+R>?S""M^#U\X&O/B%:R$V@$,(!@9XS';XJ5D]\M]&C;[?^"%\-\OUYXM30
MCX('@-"IS^G+QN%Q?64O=$0MS8?H1%EM7GH@7BN@P*]6IZP<*R->Q B,..(1
MD!"#)"@Y"0)/@Z&2@ A$*Z$),83CL)UTQ2=EPU):+I4#IPS 7,/[#E+X$BAX
MR<LGY4%/&NXBAJJHA5\/$!_^8 @P'(@A+O8Z6%@D89<T *=A?JD<$#*CB1G,
M #++*$*ZH@&V21"C,?0(C<<T,1HG0J,>:O&8QY01'F74PX$>:YEF7 .;O&1B
M_S8 ^,'1</.<VV''".'IC@6 8 0YKLHX,3C0"FA'D-OA)CHWDY2)B!(5UJ'K
M.R/*4784R9.K]<(UF1#;:-@#2?AD(EQ7$<HABS.<GBTE?6/,Q.8,A" &U>U!
M6YA)36KBP/:T;$/3@F5,8!0 !+AP+>,QT0_@X"'4O(1Q%VH/*.@SN6R=+W*N
MT80DBD0%SG5.;J1L$!4*(;,#-(>$O$O(E52UNN!0 $P]E)V>1,B[B<AJ5K!Z
M%7;B-ZHYI<$([IP3F7#0G?U5S5,) 1,:V*<?'.0O4 69#D4<A4Z#_&D[#Z!1
M&NBD4$UYYTH5*$).5M47L[PA$ST\"HWT(Q47;@ (K/^:$D1$*I%S2N=/6/)H
MJ'PT)83@[PW+R(AH!H@L9Z%$)# AB4D:"#A7IG(F;\"24"AHGA.>9RCA<8!2
M!".8'(SI!QJ=)U;B!9$.&($K@"+JO%28%['T\ !L(4H%8(BE&;(E+F@0 PMK
M:!>]H&$\Y-%*\(PB@P%PT"AO2 .()OG(^;1'<+"CB8VB,3@<H $^&LH<?"3A
MFC3(C#9-P$U!I),;[G4'>,.Y4_"( R>A,;,!;A(IB@0*4-U@1ZQEX20G9?25
M:Y(0+.JI)&8D>=@;/< O$35"0N9Y%.+(<6TXN,P;1L.( @'@F:4$W8.J( E6
M^G1#O-00M%RIU\#9$BU1063_<#3Q+&G%Y"5]>X]*;/0&]KTA<F*[#-Q4L )F
M,K.91DH2*:4)-]F4[B$4*5]#4J<8_ GG2N$!KB9PH-%"2>4!9E(DK&@5T(=,
M22<#EM-^#D6G,17O*GTA9_E8A:6J3,([LCN*65:EJ#8>C2'UBY1/NF<H(*1A
M3,"9:)>TU$VZU"4\4O'.OM:2$$]53E9\O-Z)"2+6+$V/2E4:$<_2]Z)E$*LC
M86 624YS$6+ I,K>7=P#023>-XPGI>8AZH6QE2/\@>DH3!%,Q?93X+!NQ2'N
MRDIY6.45;.%U+G/I85OP=\FW$GDMM6RL PX0@P:@#+AZNA*=LU)5"SQ , .
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M -:M.<E65GU252 \  %,58, !#  '(P!O8]\I";$,")-5VM?D3]H#/&9KA^
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M<KH.G6.5(O#1Q]%+KRL8"E&WKVJ>&\BTLEPLMH(92;*7T1@<H0LJG\R*!N.
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M!$  <G%= 2@]$ZR*_VB@!^+D,3';Y)^8%YPH#EZ5C0TP,0:+E-P"$_^8M>Z
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MQ%P8$2@721112A0Y6.*$(U:'GD78K1C<,%L 0,4*5!R7''3-.=?+#;$=<-!
M'.40F'L^W:40 C<<<*!PUCGU!D=E!>E#0NX!911:.*"ET UI2,(66Y)X.::8
M4(FAT)9X-2!&5XR@P8A5C8 I9QIB1.G01FR]X5-""FFY$0597B6F)).$F89?
M>%70D$8Y;'175V4:>EU4A?8DI4$#W16E#P+AP"%P*9JD23+9*=01$ 7U!/]
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M\3Y9_7U"^MV<O%_EH4;K7; IHV(50KV%TQKBM*5FA"$64?DM" XY6\ ,,<(
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M3RES<'1%1ZA!"BES:_O(]@VW)JD #+0=F#W=;=.("B2CKRRD13W8D_SC>CS
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M.JK\ $@82M,/A.23(M1-3A58TIP@DJ0-'*D"/N"?EC2G)4:<!4?M6Q^RR.0
M#TW)3$ J)0Y\0LLXB2A.L(,3G!:RI!2%T68V8X@![W)DD^\ 3SQ:Y.)X&O_U
MJ .@*0=*<65#&H(I*9GJ(C]1&5XX$KU18:HDIQKAW6S"/\+\*%;B>Y6L>C*Z
M8 74)X'CW4YXDCX6?9)#3O$5 F0@@Y7@( <IX=]LYM(_KVPN1FNY@0418$&;
MH&$,Z>J40W-DF/[YA5PX0(W%+D@3F=X ;V,QC+GB!0!+RJ8R*>Q,%?[%0BJL
M@%\ LU)65!.Q)[KE-.;*EG1J2$T?PM N&7,.<) SG.8DYSC#08YR..:Q+;B%
M-ODKJQ:]LR@K%K(N3+N+-[OSQNW4;#J^DPW&YKB%W4B-:LPAT,C^: L^'D<Y
M8AB&V&)PJ+*IJ4@459W;HKF0.#5DD0AA9$56^;G_P>$%857*2QJ015$RD:E]
M18E+&L1 2@TES@$Y<)SCW@:GR(TJ(=Q+RQAPB5HMI:$H@4O@-0MRO6%BB +E
MK"5F:<NZMTG61"$J@E;(6I4)@BY'#U ;*<4@UYO9+*V@(-X@8Z \BB+S2-G#
ME$*FY!.>0.6-?4G# QZP*8-@*GKM=,#?:A)2</5O$I08@Z]: JOQ)4 &#_A!
MFP1:T)J<M+7C-1\R6\NK!"#35BP)#+DPG&&(RH"B8S#+M/;I+#3@DW>W6BB'
MBGNFWL'E+F,0  0I416J7%!P]]2)4,24E1K.)1-B<]0(ZWHOGPZYJ/[B3V+(
MFI>^3<M_-U4,)B2CFJ9&_XR'ZYKR71B1UY,Y!SEXY*J!]N@UOP(G9=2$HM%B
M5I;P](*[,V/:-[<)5[)]TU##4&-UV.R[/F6B"C"H0FYZ$^@A%E% "RK0@1B$
MH 8=QQ#;FA!<AP$'XGJH=.4%$31C%[LED2@AC;O(C@:%VG1!I0'I,F!K*$!1
MU?ZV?V] T]F$=!/,NM*5DY6<9*-)ZUE")9-IV&5NP2(&'+$/F:V1@4XN8J8*
MR'=T%1#H16BI)$F22--PF^0/!K87PN  N X@"(? C8,TC/'.VR&/>R11O 9P
MJ#7!.M%Y.54L7G%8;ZA)@P_:)%^23.DDV&S-4+P2EF7990PRZ*=+ )H#89&I
ML?]%4NU)#3[A!-@*X>0*7X!?E8# B \P'8?)^%P548J*P:(?QL$-RM?NUCP
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MXE[%PBP.,,('@BX,X69.5F*%7#+P D&.? PN!._KOGRI_ S,^6S"O?[BQ1#
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MO=$%GMD5?=BS_=8K_A[@;5W<?1WC2_WB!WC2XQWC'UX31'[0&;[0QUW7 P(
!.P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>dffn20201231_10kimg005.gif
<TEXT>
begin 644 dffn20201231_10kimg005.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MAO6<A(81&I_$,DF2Q"@-,7W$A@UK-TS8L%["VD6EEXQ>.V7MDKE+]K1GIDE
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MZ:V0]LM)LABL:PH^ "(3B$8__P0T4$')$PF'%0S0+I-Z]!GF!I,.F(3(2=Z
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MA\BSQ%&*B6>AAXRS-5)JDM23P)?#%,<0M=#;ARD9MM!C1IN3A#=(N8(XBY7
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MF&3J!"0]QW9TLC*#SBD]1VT,PT[% "-DL(^,G6.6C_DR;7"]H,T96 !S8\,
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M,6]![@J4N[(BZJ9W[-20Y\B;X-I:!9>3D,N$)K$6KG:RDI>I3UC/:+GJ@/8
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M=GO7=H$7=\%U<A$Q!6V(%1MC=Y 3-0NM'OB&PE 2,O;S(^I")/#C4;^B'M1
M 50W?,TV <27?,WV?,<7?<7W?,V7?=77;&$6>0?S0X4I/!"")B3A%:VC=Z0E
M7R/"/D.T<-0$954J  ",0R6W.,@@!PA =5E7!W0@!R)8!V9@@B7X@BTX@S%X
M@S48@KE7?O.1O6XPM&! %VGE*K52(J1WD9:70B!#$X;L!_F)*:=,#6B ?'6@
M:S"B&);!:WK8AY>A&)2!A[V&AX68B'?8AWD8(WJX:X!Q4]MV-],"*8X7A 'M
M,^$L (JR)6+87H]/6EXR[L3D8Q6#1/\9->+\TR 73PUF@ R&9%/V[UL^^-,
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MD8!J.8W_'_;'PW^"XV]$A.KKIP)MS7:>F)66UWYZ!^!;@LRQD?CC>?OK7!F
M,MY(Q=5;*TT.0_T;AK@!8A*.& %BQ+@A1@P:1IDR24*3<&&:-!#1$-N',:/&
MC1P[>OP(,J3(D21+FCR),J7*E2Q;NGP),Z;,F1F5H<$Q!DV:3)-X8D(3AE'/
M80W%W# H(Y.^C\0&QC@@IF?#3 O12)+$T^&D-#C0:*()-JS8L63+FCV+-JU:
MD<K&*$PS2=(D3).&S<TT;)@FGI-NK+B!(Q/(3&*>AD'3D*A=N7A[3DR3,(VR
MM90K6[Z,.;/FS2Z5<8U*L2=6O(KQ$L9Q5,S%C\MNQL 1=2A>_TQXL<J5"QG-
M9,Z\>_O^#3RX\'W*!.Z<A"8N:6*9F!.=)&9@U]T>H0E$+69JK\1SYU+<"5GR
M\/'DRYL_CUZC9X5[T23'^XE8,F5Z,T$. WO2LI"$N<!.KEAID\25G280B9=>
M@@HNR&"#,'D&6W.0)4:,,A42Y1 .,B#T54B:<!6#0K(]1]=#:3 7G44.KLAB
MBRXJJ$Q"@6DRS$)X:3+?,!829I1"U'UDG5$RO$>,7GEE0E=VS,$VQH\O/@EE
ME%*B!6&(-(:623(5TL@3&C*$.$DT(M63"6HA8J4C?30B)TE[,G2UVI1RSDEG
MG2;9),:&S1&&587R,0?143AHLI1(Q/]$%R)B>B7#Y55[8B<&*'9.2FFE<VJ"
M: P6.:2H,IEXBEQA5I)$F*",[*0CA@HUA\8*KZEH::RRSIK@,(A"U9 D4>%%
M7U$#(2382*#D>9 8HUE(%"-HBG' :]G1"FVTTO*6R1A'!7 #46*$@96%R?"T
M;4$XQ,F?4=@:V]PPGSBD$',Q .!LA]/.2V^]8YT6@P$JU&54G_'9A<93P)*$
MJ4%@\DH,<F%DEPE!SBIE;\023XQ2<:BM$( !/06<7:I(%N9J8"-YB@,.S8I!
MFW.$:5HC  88)$8:^U%,<\TV[[-,F08! ( 8ML+@,X[,00=#LSA,XJ1'T,7@
MZ@U],OI0B+;_ E 08$C?C'76\Z[W%,]A&*B"HL1\4B.S*E@M9DB>'74 T&(7
M!31A/!MT=-):WXTWG3$Z-;=# 821"8W,91+&"LT.:?=&>S_UMU3TZ1KW#3R+
M*T;B>5^..8O$N)8QO+8:$)6.>$%F0-65LV74NS&$D49>7(810';OPGL 0I9G
MCGONYQ7<;-^2  !XELSI:H#A(9+K4<$[XX FJ&&$+<GLE >K>_76EU=J #S#
M2]A?=0W>UPHOOT;]1SH? , *84@UN.1RS5[TJ-?/3[]O.N_,O20OXP6*JE0;
M7;Z.1$,@3$,?\QI"G[ZH(#N2HQK,/E6_"$JP,A;K6M\8\3>+U$<2'C<(  RJ
M-HEZ@(0> 3N  >!U@Z$,[RGOXUFS#B"R"?_*<(9E@4RSM < &/0$7MUZCAA<
M:! $>:0M1\$8  XXC/X%+&P-VQ[=KD;#*$KQ)<4YRO;RQT,N484@'SR($#NR
MN:[I"UU["A@ >C([ !@-BE-LHQM+4H^;',!P?9O$R_K$ES!0K70ANEU3GJ("
M[=T +NE"@PH.T$(7>N]V;VSD&SUCD!/.+2X>S,ZWMNA!>+T&>1O1&=5RB,2B
MO,LADCRD%QGIR%1&D8@$60'/-):)XB%F>)/0H_;$%<!.WF".DHR!<HHD!EEF
MPI6?#"(J58E,"=ID9Y)< 5UR&#2 S0Y]KQD&:R:!OP"<32K:RB%RKO@4YLTL
MF>24XN)P"  5I"'_>CTSC5QV.3F#9&*<&]$' ='',X6,1FYG-.,K_]*D<@J4
MAF%\%PXU-@F7*:E+[U(!'X]6*(XL(WKXY%D*9:-'7Z)A>P$(F22..="07FYM
MO)Q<U-KY'*!\LG0II*=&])$&@VB3:DZ3S0\-L,[MG?"4(NWI_#;WI2O"(#E>
M<R<VMR>^0494<3&59#I3F+(FQD!7''V9#-CHTSKM9ZOZV(\RO%J/:"BC'M"H
MQS+*.IEE3&:L8B6K6=&*L[6&=:QE/6L]TBK7MM85KFHESES=:E>\^E6O;[UK
M7 =+U\(*EJV)#>QA&0M8ON:UL9)%;&0-VU?([M6L726.M6XX.86\JT#@_Y*<
M]N88@Q-%(ZRL76UK9(J^@B2G)P)))T4FY\#IM!:S@NVK;WL+W,/^5KC!':YQ
MBXM<XBKWN,M-+G.?Z]SH-G>ZT*5N6CO[$DVH@0QI(,-VO_M=[XI7#>$M;WG'
M>U[PCA>]ZU5O>M/K7?B2M[WQI>]\WVM?^>HWO_S%KW_IFX,<R$  "" P@7,P
M P$(0 8!;O" "XP !,P@!^+M;GC', ,($Q@!#)YP@!^,8 /+H, SF($.OCN&
M^]IWQ?)EL8M;#.,7RSC&-)ZQC6N,XQN_.+QDD)1+*)&  0P@R$,6,I&#C&0A
M%SG)15YRDYU\9",[6<I,CC*3H2QE+%.YR59^<O^2HZQE+7>9R&+>,IF_G&4T
MFWG*:AXRF95,@"MO><E!5L"3"9!E+W,9RG@>,Y;1#.@_"SK0A!ZTH0N-Z$,K
M.M&,7K2C&UUH)0>9$MFE@0YT8&E,7]K$FL[TI3O]:4V#.M26]K2H2QWJ45\Z
MTZ@FM:A7#6M3J_K4KXZUJV<]:U;7.M>V=K6I=2UK5+=:UYR&=:ISH.M+YP#4
MR-9TLY6M@V6_^M>?SC2G3?QL&C1;VZ7>MK>[#6Y,?UO<X>8VN<]M[G2/6]WE
M7K>[VPUO=+];WO%F-[WO;>]\CUO<I,[!)EX2#6(L0Q-?)08HE%$,96P"X<H
M186*0? *A<)/FEC&E@J][G"!$]Q"$]^2Q1LN<&)$?!D.M]#"/6XAAR=\X\7(
MN,(MU/"$BYSA)8<XS!>>\F)<W.(9'SC,)VZABE?(X18?^<:)T7%E5#SEQ%BY
MA4CNIY/'/.@TK]# _01TD"OCZ4\/^<=#SO"F%SSL __XQ-4J](_K?!D);SO7
M9:Y6L3/<XB1/N,_M+O"YYQWO:N6[WOM><,#3_>^$][OA U]XQ!]^\(O?N^(?
:SWC(.S[RE)^\Y05_^<137N\,A[N\1!(0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>dffn20201231_10kimg006.gif
<TEXT>
begin 644 dffn20201231_10kimg006.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MLV,7O:=!"K:A@%HUXXY!9L4-C1J['CQ2$^^CGX+!V8JWQIG U'5,/-8+9GU
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MSZ<,*HB#L==_)DB"_L=_*E""*\ "2\@"3$B"2BB"';A_0GA\-_!\,5& <6$
M5=B%7HA_D_]0@5IX U\8>_M'@D\(A2/HA$[8 BS@AFP8AVHH@ONG E/8@:J'
M@F6(>FA0$RI"#/:WAX(XB+*7!OL ))^7@<2GAZC'B'B8AZOGB(V8@DW(AB4H
M@G%X!2VPB6\8AW$(AT_H@51HAZ=GAX08 ]&V$L]'#%Q(B*[XBJL7AKU'@V58
MAU)HBY4HA[FXB;QX!4YH!4ZHB;S(B6DH@E%(A2<(B:XGB?@G"3)1@,H0B+ X
MC:^X@U97#XI(?*:8>MN(>MT( -UH@L9(@DB(B9Z8B\+H KSHB9W8 L*XCD_(
MA$[8A"-8CGL8 UH8$[1(C<?G@?QHA5A(=6GPA>.HBU*(AK_HB</_R(O &(]M
MN(GJJ(Z@J)#G6(]V^(VKAY'X!QPP$8W_:'QGJ(8?27S62'4>685KR(83.8)'
MV(0-V0)6X(Z;F([$J(8/"9'NR (ON9#$&(I!V(6R"!/9.)*V9X[SZ(\F2)2O
M)P96IP_2>(.8.(QOV)"7B) ZV88J^88P.8_U"(4WZ89P"(SI*)$]V96/*(1]
MJ(]*N8RN-X*;. !P:(0A>(9KR7H]"'7$@)(K@).;V)!IF(1)N(1-N)4Q>966
M:)%%6(D-Z9<W&9$\>9@?R(&MQXS'%Y0NL0QD6)<M:8Q2>) !P (N0 "AR8F"
MN88E>)9*&0-6IPFTAX)V2)EF&  RT *A_RF1\\B$(IB;5MF)MUF:7<E_2KB$
M*XF0"_F.M%F3=$B$9HB:MV>9+4$/FLE_;#@ AZF$M$D !? "!#"1[&B$=7F7
M3S>4*Q@ 4>D"MLF5<TF$!;F8<EB,9\B9"$F5\;B+C7F<<5F,-5B2+L&:'YF8
M@SD YMD"U&F);>@"!5  HGF>-^F$4EB75C<,LJ>1JO>:WJB'0;B&$.D",X">
M'PB.J!>"\EB8,$F/7:F&-HF5Z(F0]*B5 0J/<<F2WLB :?D2:#"-*"B=N]@"
MVBF:8*F0USF:W F1V]D"N;F6X.ETXJEZK8AZ2PJ2G_F&9 F,Z9EZRIF28 F6
M5B"8\"F8N,F&[_](H+XY@DFHDCQIGRWPD[#WC1*J>L[)$OM8AL )G(,)AYLH
MF@1  SWYB0+:HA,II$#ZFW/)CU:7EVP)>TMZJ*EWJ'-*ED]8ATW:DL'8B]4I
M@C' I3+@E5HID[JX O;7?\9XDV/)HT_(G$,X>VVZ$C4ZB"7(CM?IHE+9GKE8
MD<(Y "^ H.K8FPP:@M-XI$V7I!Z:IJ3:EE'YJO5X *T' Y_: C- EAN*F[B(
MGI0:C#/ EP9YD?I'@C' A$)ZH-NIJPZHGRWQIEV8K)P(EK5YJ_+(FR9:FBR
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M5"??RXB,(MC!-2#7%["=A/NA +&"Q4""+&*P$$BP!0T=;J*0<()'S[Y/)4R
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MOY]T<K&K3'#TC*LZ >B0S:-*)"S.M/;J$[_!YEK@@@Z,Z*"#V>2*"T(7(%2
MA@AH( #3A<["\# X"UC@/Z%P2JS4-!\KCR Z]W013U=?A356634;YJDCCW(J
M-Z7$&@BM FI(T(7VF I /($.6@&\R%I8=J@<C&"BCGV@6<+*%+Z,(AIHH@"A
MRRM'2*$)$<25(@0IC !B!@)R.I,WR59@;*D.6?!5@0)^BL%'^VX]"HU9LZJ/
MU?'"RDTO .,R<\4TDS28 !TB.*)11B]X&((==, 8_V,@T#5"!PAHF"&!&6C
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MQYLHJU&YN3IJ#.")C070P&ESX=@AK..18A+5R:3H-VDVZJP0XS.,4=[,S5[
M9MQ<PX8SJ5$553B,RF[>K$K3N"K@/R*5/(7+/\I3SC'@.\@[!'H@!D8P+Q4R
MS71BKGE)S=\H/^2#4JK#"PYQ0<?07;>C2*^HGSW2">/-F8LF%L%9,A:PE]H;
M%*05%![L07I!E&GCN0<]@B-(2=I 20M5*M?)W;@LK]/4)I1ANIJB&:SB21@
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MT=S<\-U,RFG(!E3(AFEPA6Q(!6R8AE<@A!5PN!@(L8:#2JO6;1WM,!!KPRT
MUCKTA7W@5803 ^P,6B3+D 5G$N 187.]MO%*F<>.NO'E0H%A#2?'D_4FWH!E
MFBB.K=1!D_[8:X60F7X%]9D."@WL;]+[I5!/84SZQZ11.M@-=3&CIL;X:>*E
M5//JG;RM\_>-AC'FU(;-9H95:FPH]&DP=$,?=%1X9W&V:AW-1N/FQFU<.$@?
MAGVH0V&:!"OHPX0K*6I=H=>S.6VR"9O@[._M<5>NWFC=I<LH;UM)"L'V/1=Y
M3;":\F$>E$3=/+9%&8>:.;*0NYC,R(2Y_R9?REV.E+V9FIG-*Y3U><WY*5,
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M)9>PT=/.;^?TALYOO;DS7#O$&-<.-,2\@LHK_ZZ\\N8KA<"IA7@%0720185
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MUPI"$3XRGUU X:::-@.[+ A G@(;7E86D_:)ZXG)*NB4*K3*FXU&!>OM8?V
M>-B;81:D5@%68%[&O)H""VM%6JD50S/+& *+!K)3EAA+)*6;RHQFI'7?VC3T
M8 "TML(6K@T]] >O.K81J6]T8]Z408]%0&(1D2!Q)!2QBQ1OP2*_U:HM$L*0
MC%3_P8*9BU@,QNJ>]CS.8R:![A;T8\G[T,<+43NB3!T;&,K@C@6NB]U2>)@C
M3][R1JRBDF!3626,#D^^\UU?$9\5NR$="X:"K5H+_((9[#%M*.*:97]=J.:H
M[6P% FB6S)AU%69^N6WQNS"@ RV6W<AVMG.$;3:'48]DG.$,9F@TI!U]!C!4
MP4]E70@Y_P@1/-G8Q@WS=,3*:A(06A*Z]\GG?!H1$[ZR0+QS!68+2):J.-,D
M!B-Z%M/(C#NKV/JT:!/C5*C$9;J]LL_LNTD,4C>C(REY:PZZUF4T-=.HV7#
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MDNT$/@*D$&((#VEGN>2HI6K)ZM7+O<R+,QI';]##,F2")HBJJ(XJJ8K!Y,2
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MM5Z:#,,S4<*09WJ05_;IQB<*,H0Z6>G0;X=H(U>HD5W (BR></'S!I&XE+
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M^>(DRA=U^^.""ABJEH07K@/=4UYY&?':=@//YA="1A5KRV)4H^U\-9L3/^B
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MWP+P*Y_\_V49"%+7<L<UP0Z72\+UNUBZ#)"^<1QX&A3L.,"'YX%[$&M"&3&
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MLAQU2J4\\!L_D>(H;J;^3!-NT2@XTBZW,,U>"MY6BB')3<W@31.( 2Z' 0U
M\84X$L0V(2&3,!,H@1U5K&]Z$L1P\J5&43-[K,:V\1B)+1.\T!2)@=BB:1ZP
M\:6^<E6P\1J+C1CRTA1GJGI,41\: 19#[!93<QA7[!B)8L4 <Q)4K#17"@9U
M$Q?QDOPF(3'[1AC2(,2&H1Q[LQC#LL/F,A1>49X^<3"5 0W(3S;?@ 1-3,2&
M(=MZ3*58;#93K-AN_U$L5RP;MQ(]AD$2CG$8B@'$4JHU."QCOJP=E,T=5LPA
M:TREB$$?&K(I]Z$76.J%YJ$GPQ(SPW$8BL) W3+% E0?CE#&$NV%V@$OG<D(
M7PK$9&P8_C((=Y#.QN#+FG(;V7+#AB^E8-!$K6>F4' 2C ((K0ZEJ"P-B+,U
M/S(-;M% #9,H+K,II?/#/I$:>^%ZDJ$A#=0X;50?7 H.9JK&>B$4FA(V1Q0V
MHZ%!6],O):$\<8D$MRPL.<Q!>_(L2Y :Z:$1AJ\>&O0306P9>(%* Q36E TG
M<6G#7J@,Z>$-@G >=JP\C6W?G/0RXY,]UA(GKU1*/303ZD%%7R@A,\9 B_\"
M$^0)&^F!,:DQS8PSW&0,-K$1WO2R2W?L%1TR8ZPQ&1AA4O$R50\S,U=P&#PJ
M+VLO%"!S'^:AQE2,*'@AV_!+IVHO++_,4OU&"3&!W% *.\LP&@!4FE 3PV14
M2FD2/3<LW)[3Q.3I%3.F2;&Q'EB,%]5,1/M&1>T-,S$3&P$TU'I!PU2L&)X4
MQ%#PRPQ-$JAHD[0G",LM-[\NV[RU/:D5$S:AT3"U]OH46(4AVW8U";M4I8QS
M4_UFD^"M1J$Q45\C*:]1":$AF\@-,#ERIUP2!@>T&'NA2TTL(0$3W(CA.]-R
M&%!R0J,30N&M'$UL.U/SCLBM2]]@&'96IU9VGI3_X6]@ZZ4@UF]2](6>-%X7
MJ$FM[AAW*MQH-E-+,Q2^3,5LD>)\%(N*5A]"LV]Z82C\AF-A,YMVED?EK1<R
M]F>W452+K0SU 0WFJ3A!3#]O<3L9 11$%3#)$A:38:7$;$[KP66%8<?22 F%
M<5=5+!E$E1&T1\723$ZALQAC%M)6;$YCML/F=%-A4Q*H%&G94U3_UF+)Y-%8
MTBB,2K[\)L68PAESLAF90B8-MBCJ03\U 6QO%);"ULRJZ$;5CUJ6X7I@-YU:
MK(J"]Z!N;(' ]M'J 3Z+%[^4@G1S4IYVEQGY9H:TLBBH\1AGB'HM;LB6M[/\
M!ABO%RDZ]"=O%SY%E[E4_PS%7#$4W:XQTW<:12PE1^>EH'%LX[>^4#=_Q^IZ
M]0%]^3> !7B ";B #?B $3B!%7B!$]@9M4=QL_9&X5$SP4Q9\='K /C,.HN6
M=O(IQA<5<:1B-ZLP4Q,VM><SH;'B:&D5H^*#&9B\Y!0("Y-%DR(3;K#][$TN
MS4W:AD'6<K(DP[%QJ:AQ,>R$;W(>/?(3I1%Z*RY[AE,[C>J6A,XH*#1\G8)[
M_<<H8G);1;AT,BJ'R8]NMY&+NPX<ASC%SEAYC=@@P_?1#))U]>:%Z:O]OO,-
M3-@]&+,?5^H^I517>;3VQ"#;>.$&;_0O;?$YG_88LZDZ 1/>Q&"1P0PZT2 #
MH?]!06M7IX8,"#/!)8%3&#/F*QTW$X:OZS353*,AQ(HV8X>1-TM9-7GS*ZM4
MFBRU245,8(_BI4!!D]&S-UDLF^!R8_MVTIH).&%STE*4&,!M&-'3A>5XME;V
M&8>A-.4),N7R7]=S'E<,%(+9%DGQE-\SQK#S"%FJ3%<6)R'V*8=U9:4T$^).
M-<=/V]PU'-_30+\2*?'2?=D2'-V2Q>P9GD',ZM  I<22$BSL#7J!2E4*7G'W
MBHQU%^^XD&'10)400X50"7$RW,CMA2 V$^Y35R<A(==Y/$<5GYL9O'9W'S !
M6'>U_;"S,-.L'-/@E@!T&#;!.955VX2*BE1J&?+!Q)384$Q-$3-A,PE353.+
M3:7,$R=S]7VYU$NE,S_?,PEEU&]XDXIVRNI>T"C*4%ZQ4#IU4U<I(5F#MEA#
M#9J45E<?%'OQ4H\LTS=ME%*SEQJ;5$Z+]2N7TZ=]6ETEM*3M2Y.5\U79LO9
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M+@JE3T0B38*:5CL1 Q-?G.USTG<HG66>18$%" V -K;%US(D3OB>1@II(II
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8F,0LIC&/B<QD*G.9S&RF,Y\)314%!  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>rider.jpg
<TEXT>
begin 644 rider.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .PU$2
M  0    !   .PP       8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( 2$"F@,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI\W_  5T_P"#CS3_ (8W4DMUX/\ #>LQ^&IHD<[8]-TQ7N-1 [ R2K<KD?\
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MVA/CMX>_9C^"/BCX@>*[K['X>\):=+J-[(!EV5!PB#^*1VVHJ]V91WK^=?\
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MW5@^KQVNKV3Z';:G).K321R6[3 +*?-DC1E9B-^?U<H **** "BBB@ HHHH
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MQC\/_AFNI3PZ7>:SK6O:6VD:OK6M:A/J.IZK;OS(DL\K%@KM\Q5-B XVJH
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M+7P?X=L-!AF@AMI%M@V9(X=_E!BQ).WS'Y//S'.:[*@ HHHH **** "BBB@
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MSK'#"ADD=C@(H&23]!4RDHIRD[)#2;=D8_Q!^(6F_#3P[)J6I3;(U^6.-?\
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MM3VM+5*23U2E9Z/:2:U23?A\39#_ &;7BZ+YJ517A+NNWJOQ33'5_*;_ ,'
M/_*8#XU?]A"R_P#3;:5_5E7\[G_!Q'_P2H^,VF?M?_$#XZ:7X:D\4?#SQ/);
MW;W>CAKF?1Q%:PP,+J$#>BYC)\Q0R $993Q7]A>!>88;"Y]46)J*'/3<8W=K
MRYX.ROU:3LNO0_.^(*<YX=<JO9W?W,F_X--?C%X4^&?[7OCW3/$7B+1]#O\
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M )N]^ECQ>U_8?\-QPXFU36I)/[RO&H_+8:Q?$W[#*"%FT779/,'2.]B!4_\
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M8XFB[2<%"_E4E&F_PDSZ7@_"QQ&<4*<]KW_\!3E^AJ?L5> TTSP?>>()8_\
M2=4E,,+$<K"AP<?5\Y_W17KOBSQ7IO@3POJ6MZU?6NEZ/H]M)>WMY<R".&UA
MC4N\CL>%55!))Z 5S_[/]HME\%_#:)]UK)'_ !;+']2:\M_;$T_4OC)\2_ O
MPQTM--N([J&^\9:G;7[,+.^33?(%E:W 4%C ^H7-I(X )9+5UP0Q%>QX6Y'0
MRGA/+\'05OW4)/SE-*<G\Y-_*QS<2XR>*S2O5G_,TO1.R_!'$_$W]J_XF:QX
M$U/XB:*="\"^"_"ZV.LC1-8LC<>(M>TJ2Z"/=W49=!IEO)"D[1AE>;]T6<Q%
M7B'R+_P3<UKQ1X(^/_Q(\.^#]8TWPOJWQ:\;K-I>IW6FK?K>Z1%/XIO&OK>$
MN@G@9H8(S*K;0+E<,&9#7=>(O%?Q!^+/Q3\0?$*X^*UPG@WP'K&H^!_%VH>$
M/#"6.H:E86&GW>IWR2&62=8;5;F".WM)1^^)NKAO.VS("[QA\ /&?P'\-_\
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M/7RJ3RZ7/@_=?W_G<^#_  G_ ,$:;[PUI_DMXZLYO<:8R_\ M2M7_AT9>?\
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M"E[''XA\:^)(=?TMM/;4+W5XII);.2+2XT5&CB5-JQ:19*I Y <DL7+4Q_\
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MG]?_ &5_V@-:\$Z;)%'XB@#Z+::7KNFO\0<Z[JCK)J'G&/5O*+1Q&:>TGV#
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MZ,-RNIX(([@U%H^CV?AW2+73]/M;>QL+&%+>VMK>(10V\2 *B(B@!550
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '\B/_!4C_@J[^TU\,?\
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M%%%=!S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>#_XJOQ[B\S_ *:?K5J$2X_Y:?K7DULKC#9L]BCPC1GO4?W(_7P?M-_#D_\
M,]^$?_!M!_\ %4?\-,?#O_H>O"/_ (-H/_BJ_(N(2_\ 33]:L*)<_P#+3]:\
M:M[FQZM'@'#SWJR^Y'ZW?\-*_#O_ *'KPC_X-H/_ (JC_AI/X>G_ )GCPG_X
M-H/_ (JOR602Y_Y:?K4RB4#_ ):?K7C8C,YT]DCTZ7AGA9_\OI?<C]8_^&D_
MA[_T/'A/_P &T'_Q5#_M+?#N-2S>.O"*J.I.K0<?^/5^3O[[_II^M<KXQ\1M
M=7OV&*1MD)!F.>K?W?P_G6F0XC%YICHX2C!);REK[L5N_P!%YM')G? .79;A
M'B:M>5]HJRUD]E^K\D?L2/VG/APW3QYX//\ W%X/_BJ>/VEOAVW_ #/7A'_P
M;0?_ !5?CAI99CQN-;ED)/\ ;KZ3,\OEA;\L[_+_ ()Y&6\'X;%)7G)?=_D?
MKG_PTI\//^AX\)_^#6#_ .*KBOC_ /ML^$/AE\-+Z_T/7]%UW6I!Y-E;6ETE
MQB0@X=PI.$7J<XR<+D9S7YH1>;M_Y:?K4CJ[J0P8_6OROB+B;&8>A.G0LI--
M)ZZ>>^_8^\RGPKR]UH5:U24HIIN.EGY-[V?43Q%XAO/%>N76I:A<275Y>RM-
M-+(<M(S$DDGU))->L?L7_LQW'[1/Q)C6ZCEC\.Z45FU"=?EW#/RQ*?[SD$9[
M ,>V#YQ\//ASJGQ/\;:?H.DV[7%]J,HBB7H!W))[  $D]@">@K]4O@'\%-,^
M 7PUL?#^FJK-$/,NKC;AKJ<@;G/Y  =E '.,U^1\!<(SS?'.MBE^YIN\K_:E
MOR^=]Y>7JC[+Q$XPCDF 6'PKM7J*T;?9CLY6Z6VCY^C1T%IX'T6PM8X(=(TV
M.&%!'&BVR!44#  X["O-OVR/#.FVO[,OBZ2+3[&.1;1<,D"AA^]3OBO7:\Q_
M;+&?V8_%W_7JG_HU*_HW,J=.&#JR45I&73LF?S7D%:I+-,,G)ZU(=?[R/R;\
MBCR*N>5_G%'E?YQ7X3_:;[G]A>P*?D4>15SRO\XH\K_.*/[3?</8'VU_P2D\
M(Z7KO@'Q0VH:;I]\T=W %:XMDD*C$G0L#7UA_P *S\-_]"_H?_@#%_\ $U\R
M?\$EEV_#_P 5?]?<'\I*^MZ_8^&:=*MEE*I**;:?1=V?RUQ_7JT\_P 1",FD
MG'J_Y8GC/[4G[(FA_&[X:3VNEZ;INFZ]9!IM/GA@2$,^.8G*@?*V ,]B >0"
M#^9OB#0;SPOK5UI]_;R6MY9RM#-%(NUD93@@CU!&*_9BODW_ (*,_LECQCH\
MWCSP_:C^U+&/.JPQCFYA4?ZX?[2 8;U4 \;3GX7Q*X+6)H_VI@8_O(+WDE\4
M5U]8_BO1(^O\+N.)86NLIQ\OW<W[C;^&3Z7_ )9?A+U;/F']DK]I2^_9P^),
M-ZN^;1KXK!J5J#_K8\_>';>N25)]QD!C7Z;:)\2- \1:1:W]GK&FS6MY$LT3
MBX4;E89'!.1]#R*_'J.UD+X,;?+U&*N^=<(JA6F Z  FOE_#KB7%X*C+"M<U
M-N\4WL^MO)]N^O5W_1... <)G-:.+YW3J)6;2OS+I=76J[]M.BM^P7_"7:3_
M -!33_\ P)3_ !H_X2[2?^@II_\ X$I_C7X\S/>;>MS^M9UZ]Y@\W7YM7[UE
M>(J8RVT?Q_R/R?'>'-+#_P#+]O\ [=7_ ,D?LM_PE^D_]!33O_ E/\:7_A+M
M)_Z"FG_^!*?XU^).KWEQ'\K33*>X+&M7P5XMN-43[%)-,UU$/D^8DR+_ (BO
M8SS+\5@,#]?I)5(Q^);.*[];J^_;?:]O&ROA/"8K&K!5:[A*7POE33?;XE9]
MN^V]K_M#_P )=I/_ $%-/_\  E/\:/\ A+M)_P"@II__ ($I_C7X_;+[TN_R
M:C9??W;O\FKXVCQ$ZGV/Q_X!]74\)X1_YB7_ . ?_;'[ ?\ "7Z3_P!!33O_
M  )3_&C_ (3#2?\ H*:=_P"!*?XU^/4BWV.EU_X]4;+?>EU^35[%''>TZ'#4
M\,X1_P"8A_\ @'_VQ^Q'_"8Z3_T%--_\"4_QH_X3'2/^@IIO_@2G^-?CC(M]
MCI=?^/5 ZWV.EU_X]7K4:?.>?5X!C#_E\_\ P'_[8_97_A,M'_Z"NF_^!*?X
MT?\ "9Z./^8MIO\ X$I_C7XPS"^_Z>O_ !ZJ\JWN.EU_X]7J4<I4_M?A_P $
M\RMPC&'_ "]?_@/_  3]I?\ A-='_P"@MIG_ (%)_C1_PFNC?]!;3/\ P*3_
M !K\3I5O<]+K_P >JK.MYMZ773_:KU*/"ZG_ ,O/P_X)Y5;(U3^W^'_!/VZ_
MX3?11_S%]+_\"D_QH_X3C1?^@QI?_@5'_C7X;S+>;NEU_P"/52N%O/2Z_P#'
MJ]"GP3&?_+Y_^ _\$\FMA_9]3]U/^$ZT0?\ ,8TK_P "X_\ &D_X3S0_^@SI
M/_@7'_C7X.W2WGI<_P#CU8/B;4[JQAV+]H\Z3IU^4>M>IA_#=59**KO_ ,!_
M^V/!QV:1PL'4FM%YG[_?\+!T'_H.:/\ ^!D?^-'_  L'0?\ H.:/_P"!D?\
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MMI=^?)//;QS*T1GV6Y13(K*IDW8)45]15\=?\%?/^0E^RE_V<'X9_P#1&H4
M&J_\$T_B18:7<SK^V9^TMNAB:09_X1X] 3_T"ZY#_@A3\#M9\2? 'P[^TIXX
M^)'C;XA_$;XV^"='BU5];^QK;:=#;/<S116R6\$9"![J4_.7)SUK[PN[5+ZU
MDAD&8YD*, <9!&#7QKX0_P""$OP9^'OABQT3P_XH^/FA:+ID0@L]/T_XLZ_:
MVMI&.B1QI=!44=@ !0!P?_!+O_@FE\:OV2?VN?%7C+Q]XJTO4=+O]+U"QU/4
M;3Q'J6I7?Q'OI]1%S;:K>VEP!!82VUL#;B.W+ ^8P!"*H/&?$W]BSQA\$/\
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MYE8?W(Q\QSP3M7C=FNK X.KBZ\,-05Y2=E_79;OR,<1B(4*<JM1V25V?&O\
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MJ5JG+.VQ5&JY.S+][>1Z?:O-*=L<8R2!FL[_ (3;3_\ GJ__ '[/^%2>+O\
MD7+K_='\Q7 WUR+*PN)F:.-8(GD+2DB-=JDY;'.T8R<<XS58[&5*,U&%M@JU
M)1=D=U_PFVG_ //5_P#OV?\ "C_A-M/_ .>K_P#?L_X5^/WP7_X+.?$>U-K;
MZ\-%^(GBBUDN]/U&ST@V-GX9N[Z6_P! M;3[#JEO]H,]JBZL9-_RRKDQS1EU
M!J_\7O\ @NSXP\0>#_%/A_PCX#T7PMXNTOP%JVOWNJW>OK<+HE[:#44_T:"2
M +>)YUB JL5D99MY0*C&L_K6*OLOZ^8O:5/(_7+_ (3;3_\ GJ__ '[/^%'_
M  FVG_\ /5_^_9_PKX)_9[_X*M'XSZC\<VU#P')X:T/X+:;J-\VHW>JJ\UX;
M":>&9+FTCC:>WW^1YR,D<BF*0 ;F&#Y?\./^"[&I_$6T\.7=K\)["XT^XO3!
MK]U;>)'/V2 Z]9:,DUDC6V;EF>_AEV2&+"I(,YQF/KF*[+^OF+VM3L?J-_PF
MVG_\]7_[]G_"D?QGILBE6D9E/!!C//Z5^5WPR_X*V^//C=^SY^U?\2-)M_#&
MCQ_#'X?Z=XB\*:1#<KJW]D7<L&HO)'?MY<1%T&MX1+:MD1,I4,=QK-^"'_!:
MWX@:+XGT7P)XX\ 1^)/%TNMZK9ZG,UQ;Z!>Z;:V]XEM%'+;;Y+>2]576XD2"
M9E:WE@:/<TF!7UO%=EI_P_<?M)^1^K__  E&D?[/_?D_X4^/QCIL2X5V4>@B
M(_I7Y-^#_P#@X;O/&7@WP[?6/P@TW5K[Q%J-K!$VE^,HI=*$4VF6VH-:_;98
M8HUU.-;CRGMGVJKQMEZZ+PI_P6VUCXL?M,Z'X+\-^%_ ]EX?'Q'L_"&J:WJ>
MM7,<,UI=PZMY0CWV\9AO//TMTV.I5VDBC7/F>8H\9B^J7]?,7M*G8_43_A-M
M/_YZO_W[/^%'_";:?_SU?_OV?\*_+7XW_P#!5GQQ\ OVN/B5IOV[0_'&B>!_
M%MYH\OPWTO1A_P )(FBV_AA-7;6$N4D+!5N<P-YT7EL) %;>,&<?\%XFTBWT
M^;4?ASH^I6<DNMV\E]X9\4'6;76+BPTZ*_BATO9;B2X$JR21-/(B012VTJ%]
MVT%?7,5:Z2_KYA[2H?J'_P )MI__ #U?_OV?\*/^$VT__GJ__?L_X5^:?Q,_
MX*B>-_%W_!,S_A='A^S\'_#C58/$ZZ?=B]URPU)+W2XT,\\FF/.\5O+>O#_J
M[:Y,;%HY5QN,>?/_ (S_ /!:;QE\2-9U+X=_"G3=/T_Q$MQX<BA\3W0DAO($
MO-4TRRNDET^XM76"Z/\ :";5_?1Q@R?-(4 )'%XI]%_7S#VE3R/UL_X3;3_^
M>K_]^S_A1_PFVG_\]7_[]G_"ORA\(?\ !;[XE?&5_!-]X0^$/A6ST_Q'K.HZ
M4EEKGBOR[O5I8]'N;ZTL$:.(_9=0>:V:$Q31X>1D5,AF=/3?$?\ P65L;?\
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M_%[X':?\*]'^"MI#J'C+X@:]J.EPVC:3!J+7;P:1=WD$>V>>"..)IH(Q+*9
MR1>8RAF !\M\6?\ !9GQK\-O&FEZ'K'P7TF\N+[QCJ/@U9[3Q:L$5U<:6;./
M42IGA2..1I+L&WC:4^8D$I+*0N<XX[$R2:M_7S)52;VL?IE_PFVG_P#/5_\
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MM&HY*[.6N?C)H-I<R0R7$PDA<HP$#\$'![4S_A=GA_\ Y^9O_ =_\*\>U_\
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M,<=N=0CO) $F*NEO<:;/;R.K%?,>'!*N&!]9K]E_7S#^P\JZU)?>O\C]+O\
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M^&=3M_BW\1O#?Q'U6XNA)8W>C>%#X?CM(=@!C:,W-QYC%LG=N7@XQWK\_O\
M@HE^QY\;/BK^UW\1O$GP_P#!?CH?!9CHG_"R_"EKXL6QN?C3Y7EEO[(7)^R?
M9[?9%,?-MOM@C,/&WS&_0#]E:'XV0^%]4_X7=<?"RXUK[4/[./@>WOX;46^P
M9\X7CNQDWY^Z0,8[U\!_\%#]#^/UW^UU\1)/AK;_ !]_X4*QT;_A;$&E7#KJ
MFHX6/=_PAX?,RXM?+%Y]G9 X#+%^^#$@'T[_ ,%M46+_ ((X_M!+'"]NB^ K
MX+$_WHQY7"GD\CIU/UKZ?\(?\B;I?_7E%_Z *^8/^"VVW_ASC^T%Y8F5/^$#
MOMHFW>8!Y7&[=SN]<\YZU]/^$/\ D3=+_P"O*+_T 4 <,>M!&1@@$'@@CK3C
M$V?NM^5'E-_=;\J^,LSRR-((XC'MBA7R1MCQ&!Y0]%X^4=.!Z5Q?QP^(OA7]
MFWX&>*/'7B#388_#7@/2KK6[R.RTZ.26*"-"\WDQ\ NR@C (W=S7<>4W]UOR
MKD?CY\$M)_:/^!OC#X>^(?[0CT'QMI%QHNH/92>5<I!.A1S&Y5@K@'@E2 >Q
MIQWUV&?*7C7_ (+C_!WP/XFL='G\*^*VU?4K33+J.U:+3%<2ZA?M:VD)=;EX
MRS%)+@N'*1HHW$2,$KU_P_\ \%!O@3XF\(6FI:AXL\*://=>'[?7+C2[[R+B
M]L=/ED A\Y8/-3!9E*HK-]Y6 QS6=X;_ ."8G@O0]1TZ^N=>\;:M?Z9+X?EB
MGGDL[;(T2_N[^Q0QVUM%$%$M[,'VH"ZA>0V6/(:=_P $7OAWX>^'.I>$=%\:
M?%S0?#.L6^EI?Z=8ZS L-]<:>D,4%U*&MR7=H((X9(R?)=0<Q[N:Z+47IJ7[
MAZY;_ML? K7?$MIX8B^(_P .[W4-8AM;BWL%NX98[Q+B#[1;GH8R7A D4$[M
MFTX *UR?QV_X*0_"?X&7N@7M]8Z]XGTKQ-X4?QNWB#PYH2:I96.@0RP1-J5S
M(&$GV93<1-E$D(0[L8!(\K^(W_!#;P;<_LE^+OA/X)\7^--#T;Q5'I.V#4[M
M;NTTR\LC8Q'5(1''',MZ]I8K#D2"++L?+ 9A7L7[1'_!-OP'^TAK>AS:AJ'C
M3P_I.B^%9? LVCZ!J$=C9:QH,LL$LFG7/[II/*8VT2GRGC8H&7.&-'+236K#
MW23Q=_P45_9^\!>,;/2;SQ]X3;6M8\2VGA\PVML9Y1J,RRO;O,53A#]GE G.
M4#(5W9! ZC]EG6OA'XE^$DVB_"6Y\,ZEX.\/ZA<6=Q9Z<3-#9W<DANIEE67+
M^8[S^<2^2WFAP2"#7CVD?\$;/AOX>^).K^+K#Q1\4K3Q!J>NV>OPWB:S$TNE
MR6L]]+%! S0%O) U&ZBQ(798C&JLOEJ1Z3^Q-^P?X3_8.\)>(])\)ZEXMUI?
M%6HQ:IJ%WK]VEW=2S16L5JAWI&F?W4*;F;<SMN9F)8U,HT^7W6P=K:'L0TZU
M"E?LMIM(((\A,$$;2,8Z%>#ZCCI3[>VBM(ECAAAAC7HD2!%'T XJ7RF_NM^5
M'E-_=;\JPU,QM=QX-_Y%Z'ZM_,UQ/E-_=;\J[;P<,>'X?JW7ZFO3RK^,_3_(
MZ,/\0[Q=_P BY=?[H_F*X4'%=WXM&?#MU_NC^8KAO*;^ZWY49M_%7I^K#$?$
M58=(L[:%8XK&QBCC)*HENBJI)W$@ 8&6 )QU(!ZBN!OOV1?ACJ?QWA^)UQX'
MT&;Q];HJQZP\3&12L+P*_E[O*\P0RR1B0IO"2,N[!(KTCRF_NM^5'E-_=;\J
M\U.2V,-2O'IUM%=S7"6MJEQ= ">585$DX P-[8RV!P,YP*;;Z19VD2QPV-C#
M'& %2.W154 @@  8&" ?J >U6O*;^ZWY4>4W]UORI:B*Z:;:HLBK:VB+<$F4
M"%0)2222PQ\V223G.<GUKYO\?_\ !1?X2>%_C#XR\!?$+1=:\&1>$8XAJFO>
M)=-M;?1I%O4G2V,,ZS-*[7,=M<;-D>[9 Y;8%KZ8\IO[K?E7S[\??^";/@O]
MH+XK:EXZNM;\=>&_&&H"P6+5-#OHH9=/%I9ZC9#R5DAD3][;:I=QR;U;.Y"N
MQE!.M/EO[Y4;=2G\(OVP?V?_  OHT/P_T_4O"/@[1/"FOQ>"?#EA>RP"TU62
M"TL9();(Y</#Y=[:1I,Y!+NHW$LNZUJW_!2']GV'PAJ>K:/XZ\&^*)(;'4=8
M@LM*,<EQK,EA!-<SI S*L<EP%@E*@MN)1R#\K$<39_\ !$?X*:-XN\/ZQIMO
MXFL9/#5VL]I;236U]:M L6G1K:M'<P2#RU_LNU977$RMYA$@W#:>(O\ @BI\
M*?%'_"$QW6M?$AK#P#X;/AC3+#^UHC;>0;>^MS,RF$E9VCU&X#-&4#E8BP8H
M*TM2>MV5[IM2?\%9/@V_A/PSXE\.7G_"56WB^.!?.T62TDGLY7OM-LC;7(,B
MR^9')JELS *RA 3NY0-H?!O_ (*=_L__ !2\3QZ+9>*M!\.^)--L([U=/U**
M&W:UAGMY[HK#/&6@8_9[::600R$!5.<G(',>'_\ @B]\+=%FM;JZUSXD:WJT
M-Q%<3:GJ.J0R75X89M'D@639 J;8DT.PB7:JDHLFXLS[AS7QM_X(=>!_'_P*
MU#P1X?\ $7B?2[;5H?#EA<MJ,XN8XK?2;R20SQ>6B.MW)9W%Y:;@XC*7!W(2
M,E\M%Z:A[A]A>&)= \6^#-.O-(AT>^\/ZK;Q:A8M!;QFTN8I )8YD7;MPP97
M#8SR#6DVFVK7<EP;6T-Q,0TDI@7S)",8+-C)(P,$GC ]!4MO816%M%;VML+:
MUMT6*"&--JPQJ JH!V 4  >@I_E-_=;\JYM3,IG1+'$F+&R7SI3.Y2!%9I<8
M\W(&?,_V_O>]9'P[^$OACX2_#71_!OAO0=-TGPKX?MTM-.TN.'?;VL2'*J ^
M<X;)R2222<YYKH_*;^ZWY4>4W]UORHU#4KMIEJT;*UI9LCJ593 A5E; 8$8Y
M!P,CO@9Z"I(H4MXPD<<<:+T5%"J/H!Q4GE-_=;\J/*;^ZWY4K,#I?AU_J[S_
M 'E_D:P-5_Y"ES_UU;^9KH/AVI6.\R"/F7J/8U@:I&QU.X^5O]:W;W-=];_=
M:?S_ #-I_P .)4:))'5F1&:,Y1BH)0],@]N..*BN-+M+Q%6:SLYE643JLD".
M%D'20 C[X_O=?>K/E-_=;\J/*;^ZWY5P:F)7_LVU_P"?2SZ8_P!0GN/3W(_$
M^IH_L^VW;OLMKNSG/DKG/'.<>P_[Y'H*L>4W]UORH\IO[K?E1J!5.C6+2;S8
MV)?9Y6XVR;MG)VYQ]WD\=.3ZU@?\(3X3^'/BOQ5X^:RT_2M7UBPMUU_6G9@\
MUI8I*81(Q)"QPK),0% 'SL3DG-=3Y3?W6_*L/XF?#ZW^*GPW\0>%[ZXU:PL_
M$FFW&EW%SIERUI>V\<\31L\$R_-'*H8E7'*D TU<9YCH7[>/[/\ XBUKP]I]
MC\3/AW)J7C:Z>+2;4W$<=QJEQYS6[J$90PD\Y#$0X#;P%/)7//\ A/\ X*:?
M!/QAX=^+?B32=>L]1\)_!.&RN-:\0Z? EW:7!N8Y)$2T\O+RRAEV;0H+22KM
MW;LUQ_PY_P""*'PC^'&ERVL=]XZU1;JXM+JZDO;^'=<O;ZO'JZY\N!  ]S&
MP4#,9(&#\U=%\*O^"4'PU^&'P1\?_#V;4/'7BCPY\1M*TW0[\:SJBM<V-EIL
M!@T^&UEABC,7V>/9L<[GW1(Q).2>CEH^9?N'/_$/_@K-\)?@KH7AZ^\8>!_'
MGA5M:O+ZP@M;OP_8-<V:6WV5KB1TBN'&W-["#%&6F+^8IBW*15CQ!_P6$^ _
MA^V\17E[+K@OO"/Q 7X6W-J=$5KXZC(TB[X5+9-D?)F)ER!B)@5S@'G_ !#_
M ,$*_A/XSTJZAUSQ%\2M6N]4U;4M7U:_EN=/CN-7DU"ULK6Z60)9+'&6BL+?
M]["D<P<R/YF]RU;.K_\ !$[X*ZUXRN_$$L/BY=5O(KJ)IEU%3M^T:R-8+C,9
M_>)-OA1SEA;RNA))W"K4.MP]P]R\"?L@_#/X0_%W7_&WA[P1H6D^,/$+3#4M
M4A1FEF,LRS3; S%(O,F19'\M5WNJL<D"N[_L>R$OF?8;#S-@CW_9DW;1T7.,
M[1DX'09JY,9)YFD96W.Q8X4]Z;Y3?W6_*N5\SW(U9#:64&GP^7;V\%O&69RD
M,:QJ68Y9L* ,D\D]33G@CE8,\<;L 5!9 Q /4 GL>_K4GE-_=;\J/*;^ZWY4
MM1%>XTRUNT59K.SF5%V*LD".%4=% (X P.!QQ4[,7;)Y-+Y3?W6_*CRF_NM^
M5%F!=\+_ /(PVG^^?Y&N]K@_#$;#Q!:_*WWSU'L:[RO?RG^$_7]$=F'^$^<M
M?_Y#]_\ ]?,O_H9JI5O7_P#D/W__ %\R_P#H9JI7!+<_<*/P+T1RGQ?^!/@O
M]H+PY;Z/XZ\*Z#XOTJSNEO8+35K-+J&&=59!(JL,!@KNN?1V'0FL?7OV2/A;
MXHU+[9J'P]\'W5Q_9(T$LVF1JK:>(VC6U*@!3$L;,BJ1A58@8!Q7H=%/F:V"
M5&$G>21Y[XE_9)^%OC.UOX=6^'OA#48M4^T&[6XTR-_M!GN([J9B2,[GN(HI
M2PYWQJV<@&O-?BQ=?LO? _Q;I/@CQ98?#CP_JFJ168M-.?3 JP1>5)IEHTC1
MH4MD,<TMK$\K(")'12237T97S7^T;_P3XNOCU\5?%VJ6OCR3P[X7^*&FZ+I'
MC?2/[%2\N-1MM+NI)X/LER95^RLZRO&Y:.48(90K<U5.6OO,Y<53E&/-1@FS
MK'^#O[/OP=U[P_J1\/\ PM\/:E;75MH.CW BM8IEN52X:WM8SU,VR6Z*J?F(
MDDZ[CG/^'7[.7[..J^ ]%NM"\"_#.VT.]7^V-/AGTN&T8"XMUM3(8)@KIO@=
M(2KJ/D*(1C:*^:/@#_P1-U#0](L=>\5:[X.L?%UGXBL]:@L+?PQ%>Z?&EKJ6
MJ7(^U,9%-Y<RQ:CL^T?NS&L42[6"9-^X_P""!/A'5O"ZV>J>*+'6-2CT@Z1'
MJ=YX;BEN44>'$T:%@S2D_NID%ZHSQ* !@@/6ON?S,XX_6'%-4%]Z/JCP1\/O
M@WXA\!V_A72]"\*MH'AG5KQK?2+JT\I;.]@::"XFCBF 8[=TZ^:H*E6;#%>:
M\[_:^^%/[,_ASX#"R^(%IX9\,>%_&C+I-G?Z59EKBY8V<:%+=[>.1N;*P2-B
M%*^1!M)VBO+_ !W_ ,$56\?:CJ377Q*MQ;WVF>(K&&;_ (1=#J5A+K%XUU+/
M'="X#-M&R$HX93$UP%V-,S#TK3/^"=^K>"/@=\*?#G@[QQI?A?Q!\*_%5YXK
ML]1.@S:A8SS74-]%+&+6:[WJN+YV \XJ&3[H4[0O=3OS%2C7E%P=);>7ET^_
MJ>A>!_@1\!?$/PQBLO#GA?X8W7A#Q-X=C2."RM[9K/4M&,SW2$ ??M_/EDF#
M]!(Y;(;FM31_V</@[=6NEV-AX-^'MQ#:^'9]%T^WALK:0+HUP^9H(U .;65R
M2V,JS$DDDG/RG8_\$)= T(1V-KXT34-#AT@V0CU70_,U&XF;29=,DBDO(9XI
M%TZ0327#6<00"<AED &*Z'X+?\$<(/AI\8=-\7:Q\3->\07EKH4.DO=VD,NB
MZG;21V?V0FTGM9T2&%H]I,;1.=P9MVYRU#Y?Y@A[?1.@OO6QZ+X"TO\ 97\3
M?&R/P_HFD_#:7QY\)?M)MUET[R[K0?LMR'N&AGF0 ^1<3*79';RVFY*[^?0/
M%_[._P %O$_Q&U+Q9KOA+X<WGBK4-,:VO]5O+>V^V3V4T+0'S)#SL>$M'O/5
M"5SMXKYE^)G_  1#T_QQXG\6:Q9?$C5K&]\7ZG>:C?+=V+WT4JR:E8ZA;PD-
M."H5K,QSM&4-TLJE\-$IKF_B+_P14UC2].TV/P9XA\'S0/=^%[>^TG4]!>ZT
MV2'3)X6>ZN$N;F:2X"Q1>6MJLD:2(P#EF57I^XW\1-\1!/FHI^EOE^A])?$O
M]@/X)?$N^MX[C2=*T1;?0]=MH+/1;F'3HTM]9@AMK^]5(P")'BA1!,,*-S<$
MG--^"_[!/P-^$/AC1=,L])T7Q)-&]\^GW^M74-Y>2I-DW,,14*GV=?F_<QH(
MX\L0JEF)^>V_X(,V*^&&T5?B=<26?_"-MHRWLWAZ-M529M%ET@HMSYP*Z:$E
M:<6(&!*J_O,"MSQE_P $1])US4-0CT/QTO@W1[]?$5ND.CZ"L<UC9ZM&R_8H
M"9C%%#%(PERD2R,0RAU61A2O';F#DJWY_8*_JO+_ "/I:;]D'X,^-CI>J'X>
M^ M5^QR0W5A>)I\,RHT45O#$Z.N0=D=I:HO) %M%CE%PNI_L0_!S6=/UBUN_
MA?X'N+?Q!,;C4HWTJ(B\D-PUR7;C[WGN\N1CYW8]S47[%_[,,'[(/P(M?!<%
MY9WQCO[O49IK2WFMX'EN)#(^R.6:9D!/) ?;DDA5SBO5JRE)IV3/0IT8R@G4
M@DWNCROQ_P#L2?"GXD>#;[0;[P/H-KI^HH(YO[/MELY=GV:*S9%>, HK6D,=
MLP7&81LX%>J*H10JJJJHP HP .P%%%3S-[FT:<(N\4%>@?L]?\A_4?\ KW7_
M -"KS^O0/V>O^0_J/_7NO_H5;X7^*CS,^_Y%]7T7YH]8HHHKW#\J"OF?_@J)
M^S]XX^-OPR^'.M?#O2;'Q)XH^$OQ$T?Q]!H%S?II_P#PD$=GYT<MI'<.#'#*
MT=PS(TGR;D ) .1],44 ?'G_  W;^TY_T8[XW_\ #E^%_P#Y*H_X;M_:<_Z,
M=\;_ /AR_"__ ,E5]AT4 ?'G_#=O[3G_ $8[XW_\.7X7_P#DJC_ANW]IS_HQ
MWQO_ .'+\+__ "57V'10!^>'[9'C7]J+]O;]E_QK\&8_V3]5^'J_$K3FT&?Q
M-KOQ"T.ZL-#AF(66YDAM)I)Y=B;B$C0EF ' )(_0?1]/_LG2+6U#>9]EA2+=
MC&[: ,_I5BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,&?X8Z#<SR22:9;M)(Q=F.>2>2>M-
M_P"%5>'O^@5;_K_C7045G[*'9?<=?]H8I:*I+[W_ )G/_P#"JO#W_0*M_P!?
M\:/^%5>'O^@5;_K_ (UT%%'L8?RK[A_VABO^?DO_  )_YG/_ /"JO#W_ $"K
M?]?\:/\ A57A[_H%6_Z_XUT%%'L8?RK[@_M#%?\ /R7_ ($_\SG_ /A57A[_
M *!5O^O^-'_"JO#W_0*M_P!?\:Z"BCV,/Y5]P?VABO\ GY+_ ,"?^9S_ /PJ
MKP]_T"K?]?\ &C_A57A[_H%6_P"O^-=!11[&'\J^X/[0Q7_/R7_@3_S.?_X5
M5X>_Z!5O^O\ C1_PJKP]_P! JW_7_&N@HH]C#^5?<']H8K_GY+_P)_YG/_\
M"JO#W_0*M_U_QH_X55X>_P"@5;_K_C7044>QA_*ON#^T,5_S\E_X$_\ ,Y__
M (55X>_Z!5O^O^-'_"JO#W_0*M_U_P :Z"BCV,/Y5]P?VABO^?DO_ G_ )G/
M_P#"JO#W_0*M_P!?\:/^%5>'O^@5;_K_ (UT%%'L8?RK[@_M#%?\_)?^!/\
MS.?_ .%5>'O^@5;_ *_XT?\ "JO#W_0*M_U_QKH**/8P_E7W!_:&*_Y^2_\
M G_F<_\ \*J\/?\ 0*M_U_QJ]H?@[3/#4TDEC9Q6SR+M8KGYA6E135."=TD1
M/&8B<>6<Y-=FV%%%%6<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716313809400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Diffusion Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">dffn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,903,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716319834088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 18,515,595<span></span>
</td>
<td class="nump">$ 14,177,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PrepaidExpensesDepositsAndOtherAssets', window );">Prepaid expenses, deposits and other current assets</a></td>
<td class="nump">260,825<span></span>
</td>
<td class="nump">472,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,776,420<span></span>
</td>
<td class="nump">14,649,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">149,198<span></span>
</td>
<td class="nump">252,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible asset</a></td>
<td class="nump">8,639,000<span></span>
</td>
<td class="nump">8,639,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">149,162<span></span>
</td>
<td class="nump">247,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">15,771<span></span>
</td>
<td class="nump">322,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">27,729,551<span></span>
</td>
<td class="nump">24,110,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">545,844<span></span>
</td>
<td class="nump">1,251,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,776,470<span></span>
</td>
<td class="nump">358,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">113,469<span></span>
</td>
<td class="nump">111,477<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,435,783<span></span>
</td>
<td class="nump">1,721,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">443,893<span></span>
</td>
<td class="nump">2,119,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liability</a></td>
<td class="nump">35,693<span></span>
</td>
<td class="nump">135,566<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,915,369<span></span>
</td>
<td class="nump">3,976,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 64,015,441 and 33,480,365 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">64,016<span></span>
</td>
<td class="nump">33,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">130,659,550<span></span>
</td>
<td class="nump">111,824,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(105,909,384)<span></span>
</td>
<td class="num">(91,724,078)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">24,814,182<span></span>
</td>
<td class="nump">20,134,262<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 27,729,551<span></span>
</td>
<td class="nump">$ 24,110,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PrepaidExpensesDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PrepaidExpensesDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317515176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">64,015,441<span></span>
</td>
<td class="nump">33,480,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">64,015,441<span></span>
</td>
<td class="nump">33,480,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716319738008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 9,427,667<span></span>
</td>
<td class="nump">$ 6,619,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,444,109<span></span>
</td>
<td class="nump">4,834,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">103,168<span></span>
</td>
<td class="nump">97,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,974,944)<span></span>
</td>
<td class="num">(11,551,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">114,257<span></span>
</td>
<td class="nump">85,302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(15,860,687)<span></span>
</td>
<td class="num">(11,466,494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">1,675,381<span></span>
</td>
<td class="num">(332,885)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,185,306)<span></span>
</td>
<td class="num">(11,799,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeemedDividendFromWarrantExchange', window );">Deemed dividend arising from warrant exchange</a></td>
<td class="num">(1,950,378)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (16,135,684)<span></span>
</td>
<td class="num">$ (11,799,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (1.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Weighted average shares outstanding, basic and diluted (in dollars per share)</a></td>
<td class="nump">$ 53,831,973<span></span>
</td>
<td class="nump">$ 6,706,509<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeemedDividendFromWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend from the exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeemedDividendFromWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716314057752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">3,376,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 3,377<span></span>
</td>
<td class="nump">$ 95,532,881<span></span>
</td>
<td class="num">$ (79,924,699)<span></span>
</td>
<td class="nump">$ 15,611,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts', window );">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)</a></td>
<td class="nump">12,688,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts', window );">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs</a></td>
<td class="nump">$ 12,688<span></span>
</td>
<td class="nump">11,905,207<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,917,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="nump">17,415,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 17,416<span></span>
</td>
<td class="nump">3,871,009<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,888,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">515,762<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">515,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,799,379)<span></span>
</td>
<td class="num">(11,799,379)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">33,480,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 33,481<span></span>
</td>
<td class="nump">111,824,859<span></span>
</td>
<td class="num">(91,724,078)<span></span>
</td>
<td class="nump">20,134,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts', window );">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)</a></td>
<td class="nump">11,428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts', window );">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs</a></td>
<td class="nump">$ 11,429<span></span>
</td>
<td class="nump">10,330,202<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,341,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="nump">19,106,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 19,106<span></span>
</td>
<td class="nump">7,768,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,787,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">736,119<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">736,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,185,306)<span></span>
</td>
<td class="num">(14,185,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">64,015,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 64,016<span></span>
</td>
<td class="nump">$ 130,659,550<span></span>
</td>
<td class="num">$ (105,909,384)<span></span>
</td>
<td class="nump">$ 24,814,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of shares and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of common stock and warrants issued during the period, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716319734968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,185,306)<span></span>
</td>
<td class="num">$ (11,799,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">103,168<span></span>
</td>
<td class="nump">97,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">736,119<span></span>
</td>
<td class="nump">515,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Change in deferred income taxes</a></td>
<td class="num">(1,675,381)<span></span>
</td>
<td class="nump">332,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, deposits and other assets</a></td>
<td class="nump">518,169<span></span>
</td>
<td class="nump">426,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="nump">950,602<span></span>
</td>
<td class="nump">567,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,552,629)<span></span>
</td>
<td class="num">(9,858,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="nump">10,827,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants', window );">Proceeds from the sale of common stock, pre-funded warrants and warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,318,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of common stock warrants and pre-funded warrants</a></td>
<td class="nump">8,046,103<span></span>
</td>
<td class="nump">3,888,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of offering costs</a></td>
<td class="num">(982,328)<span></span>
</td>
<td class="num">(162,829)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,890,875<span></span>
</td>
<td class="nump">16,044,552<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">4,338,247<span></span>
</td>
<td class="nump">6,186,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">14,177,349<span></span>
</td>
<td class="nump">7,991,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">18,515,595<span></span>
</td>
<td class="nump">14,177,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_OfferingCostsInAccountsPayable', window );">Offering costs in accounts payable and accrued expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">238,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use asset and liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 334,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_OfferingCostsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount in Accounts Payable from offering costs in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_OfferingCostsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of common stock, pref-funded warrants, and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716395762424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div> Organization and Description of Business</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Diffusion Pharmaceuticals Inc., a Delaware corporation, an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to the areas where it is needed most. The Company's lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's most intractable and difficult-to-treat conditions.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to TSC, the Company's product candidate DFN-<div style="display: inline; font-style: italic; font: inherit;">529,</div> a novel, allosteric <div style="display: inline; font-style: italic; font: inherit;">PI3K/Akt/mTOR</div> pathway inhibitor, is in early-stage development. The Company previously completed <div style="display: inline; font-style: italic; font: inherit;">two</div> Phase <div style="display: inline; font-style: italic; font: inherit;">1</div> clinical trials evaluating DFN-<div style="display: inline; font-style: italic; font: inherit;">529</div> in age-related macular degeneration. DFN-<div style="display: inline; font-style: italic; font: inherit;">529</div> was also previously in preclinical development in oncology, specifically GBM.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317608744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_LiquidityDisclosureTextBlock', window );">Liquidity Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div> Liquidity</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> generated any revenues from product sales and has funded operations primarily from the proceeds of public and private offerings of equity, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. <div style="display: inline; font-style: italic; font: inherit;">No</div> assurance can be given that any such financing will be available when needed, or at all, or that the Company's research and development efforts will be successful.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with <div style="display: inline; font-style: italic; font: inherit;">third</div> parties and other strategic alliances and business transactions. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> have any commitments to obtain additional funds and <div style="display: inline; font-style: italic; font: inherit;"> may </div>be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with <div style="display: inline; font-style: italic; font: inherit;">third</div> parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it <div style="display: inline; font-style: italic; font: inherit;"> may </div>receive lower consideration upon commercialization of such products than if it had <div style="display: inline; font-style: italic; font: inherit;">not</div> entered such arrangements or if it entered into such arrangements at later stages in the product development process.</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company's product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company's control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company's financial condition and future operations. The Company expects that its existing cash and cash equivalents as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>combined with the proceeds received by the Company in connection with the completion of the <div style="display: inline; font-style: italic; font: inherit;"> February 2021 </div>Offering and the exercise of certain warrants to purchase common stock during the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2021</div> prior to the date of this Annual Report, will enable it to fund its operating expenses and capital expenditure requirements, including expected costs related to the planned TSC Oxygenation Trials and the Planned Phase <div style="display: inline; font-style: italic; font: inherit;">2</div> Hypoxia-related Indication Trial through <div style="display: inline; font-style: italic; font: inherit;">2023.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidity of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716392992200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">3.</div></div>&nbsp;<div style="display: inline; font-weight: bold;">Basis of Presentation and Summary of Significant Accounting Policies</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The accompanying consolidated&nbsp;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div>  <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair Value of Financial Instruments</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The carrying amounts of the Company's financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of <div style="display: inline; font-style: italic; font: inherit;">three</div> months or less to be cash and cash equivalents.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from <div style="display: inline; font-style: italic; font: inherit;">2</div> to <div style="display: inline; font-style: italic; font: inherit;">15</div> years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Long-Lived Assets</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> recognized any impairment of long-lived assets during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Intangible Asset</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has an indefinite-lived IPR&amp;D asset, DFN-<div style="display: inline; font-style: italic; font: inherit;">529,</div> which has a balance of <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$8.6</div></div> million at both <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>DFN-<div style="display: inline; font-style: italic; font: inherit;">529</div> is a <div style="display: inline; font-style: italic; font: inherit;">PI3K/Akt/mTOR</div> pathway inhibitor in preclinical development for oncology.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Intangible assets deemed to have indefinite lives are <div style="display: inline; font-style: italic; font: inherit;">not</div> amortized but rather are assessed for impairment annually on <div style="display: inline; font-style: italic; font: inherit;"> October 1 </div>of the Company's fiscal year or more frequently if impairment indicators exist. There was <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">no</div></div> impairment to the Company's DFN-<div style="display: inline; font-style: italic; font: inherit;">529</div> intangible asset recognized during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company's behalf). Costs incurred for research and development are expensed as incurred.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">At the end of the reporting period, the Company compares payments made to <div style="display: inline; font-style: italic; font: inherit;">third</div>-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>record net prepaid or accrued expenses relating to these costs.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Upfront payments made to <div style="display: inline; font-style: italic; font: inherit;">third</div> parties who perform research and development services on the Company's behalf are expensed as services are rendered.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div>  <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patent Costs</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&nbsp;<div style="display: inline; font-style: italic; font: inherit;">not</div>&nbsp;that some portion or all of a deferred tax asset will&nbsp;<div style="display: inline; font-style: italic; font: inherit;">not</div>&nbsp;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&nbsp;<div style="display: inline; font-style: italic; font: inherit;">not</div>&nbsp;to be sustained.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">ASC <div style="display: inline; font-style: italic; font: inherit;">740</div>-<div style="display: inline; font-style: italic; font: inherit;">10</div> defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>recognize the tax benefit from an uncertain tax position only if it is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than <div style="display: inline; font-style: italic; font: inherit;">50.0%</div> likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC <div style="display: inline; font-style: italic; font: inherit;">740</div>-<div style="display: inline; font-style: italic; font: inherit;">10,</div> the Company's policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-based Compensation</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company's common stock, the expected term of the Company's stock options, the expected dividend yield and the fair value of the Company's common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For certain stock option grants, the expected term was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. <div style="display: inline; font-style: italic; font: inherit;">10</div> years) of the stock option and therefore the Company began to use the contractual life as the expected term.</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For stock price volatility, the Company uses a combination of their own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes <div style="display: inline; font-style: italic; font: inherit;">no</div> dividend yield because dividends are <div style="display: inline; font-style: italic; font: inherit;">not</div> expected to be paid in the near future, which is consistent with the Company's history of <div style="display: inline; font-style: italic; font: inherit;">not</div> paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company accounts for forfeitures in the periods they occur.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Common Share</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the calculation as the impact is anti-dilutive.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div>  <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9,100,112</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">22,385,141</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,240,204</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">309,276</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,340,316</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">22,694,417</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently Issued But <div style="display: inline; font-style: italic; font: inherit;">Not</div> Yet Adopted Accounting Pronouncements</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> December 2019, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12,</div> Income Taxes (Topic <div style="display: inline; font-style: italic; font: inherit;">740</div>): <div style="display: inline; font-style: italic;">Simplifying the Accounting for Income Taxes</div>. This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2020 </div>and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have <div style="display: inline; font-style: italic; font: inherit;">not</div> been issued and interim periods therein. The Company is currently analyzing the impact of ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12</div> on the consolidated financial statements.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently Adopted Accounting Pronouncements</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> August 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">03,</div> <div style="display: inline; font-style: italic;">Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurements, </div>which changes the fair value measurement disclosure requirements of ASC <div style="display: inline; font-style: italic; font: inherit;">820.</div> The goal of the ASU is to improve the effectiveness of ASC <div style="display: inline; font-style: italic; font: inherit;">820's</div> disclosure requirements. The Company adopted this standard in <div style="display: inline; font-style: italic; font: inherit;"> January 2020 </div>and the adoption did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a material impact on its related disclosures.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716393085608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">4.</div></div>&nbsp;<div style="display: inline; font-weight: bold;">Property and Equipment</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Property and equipment consists of the following:&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">182,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">182,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and office equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">151,442</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">151,442</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">430,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">430,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">763,799</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">763,799</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: accumulated depreciation and amortization</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(614,601</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(511,433</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">149,198</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">252,366</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Depreciation and amortization expense was approximately <div style="display: inline; font-style: italic; font: inherit;">$0.1</div> million for both the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317737704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">5.</div></div>&nbsp;<div style="display: inline; font-weight: bold;">Accrued Expenses and Other Current Liabilities</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Accrued expenses and other current liabilities consist of the following:</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">653,899</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">182,708</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">31,809</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">48,338</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,055,398</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">57,378</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">35,364</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">70,108</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,776,470</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">358,532</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317721480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">6.</div></div>&nbsp;<div style="display: inline; font-weight: bold;">Commitments and Contingencies</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Office Space Lease Commitment</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has a non-cancelable operating lease for office and laboratory space in Charlottesville, Virginia, which began in <div style="display: inline; font-style: italic; font: inherit;"> April 2017 </div>and, as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>has a remaining lease term of approximately <div style="display: inline; font-style: italic; font: inherit;">1.3</div> years. The discount rate used to account for the Company's operating lease is the Company's estimated incremental borrowing rate of <div style="display: inline; font-style: italic; font: inherit;">10.0%.</div> The original term of the lease ends in the <div style="display: inline; font-style: italic; font: inherit;">second</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2022</div> and the Company has an option to extend for another <div style="display: inline; font-style: italic; font: inherit;">5</div> years. This option to extend was <div style="display: inline; font-style: italic; font: inherit;">not</div> recognized as part of the Company's measurement of the right-of-use&nbsp;asset and operating lease liability as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Rent expense related to the Company's operating lease for both the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019</div> was approximately <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$0.1</div></div> million. Future minimum rental payments under the Company's non-cancelable operating lease at <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> were as follows:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Rental</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Commitments</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">118,519</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">39,735</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">158,254</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(9,092</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">149,162</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Arrangements</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the course of normal business operations, the Company enters into agreements with universities and contract research organizations, or CROs, to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which <div style="display: inline; font-style: italic; font: inherit;"> may </div>require upfront payments and long-term commitments of cash.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Defined Contribution Retirement Plan</div></div>&nbsp;</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has established its <div style="display: inline; font-style: italic; font: inherit;">401</div>(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees <div style="display: inline; font-style: italic; font: inherit;"> may </div>elect to contribute to the <div style="display: inline; font-style: italic; font: inherit;">401</div>(k) Plan up to <div style="display: inline; font-style: italic; font: inherit;">90.00%</div> of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of <div style="display: inline; font-style: italic; font: inherit;">4.0%</div> of the participant's compensation. The Company made matching contributions under the <div style="display: inline; font-style: italic; font: inherit;">401</div>(k) Plan of approximately <div style="display: inline; font-style: italic; font: inherit;">$56,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$68,000</div> for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div>  <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Legal Proceedings</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> August 7, 2014, </div>a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company's legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">BC553996</div>). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys' fees and costs. On <div style="display: inline; font-style: italic; font: inherit;"> December 30, 2014, </div>the Company filed a petition to compel arbitration and a motion to stay the action. On <div style="display: inline; font-style: italic; font: inherit;"> April 1, 2015, </div>the plaintiff filed a petition in opposition to the Company's petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on <div style="display: inline; font-style: italic; font: inherit;"> April 14, 2015, </div>the Court granted the Company's petition to compel arbitration and a motion to stay the action. On <div style="display: inline; font-style: italic; font: inherit;"> January 8, 2016, </div>the plaintiff filed an arbitration demand with the American Arbitration Association. On <div style="display: inline; font-style: italic; font: inherit;"> November 19, 2018 </div>at an Order to Show Cause Re Dismissal Hearing, the Court found sufficient grounds <div style="display: inline; font-style: italic; font: inherit;">not</div> to dismiss the case, and an arbitration hearing was scheduled for <div style="display: inline; font-style: italic; font: inherit;"> November 2020. </div>In <div style="display: inline; font-style: italic; font: inherit;"> August 2020, </div>due to the ongoing COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic and related restrictions on gatherings in the State of California, the arbitration hearing was postponed to <div style="display: inline; font-style: italic; font: inherit;"> August 16, 2021. </div>The Company believes this matter is without merit and intends to defend the arbitration vigorously. However, at this stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter <div style="display: inline; font-style: italic; font: inherit;"> may </div>have on the Company's financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company's financial position.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317768904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">7.</div></div>&nbsp;<div style="display: inline; font-weight: bold;">Stockholders' Equity and Common Stock Warrants</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2020</div> Common Stock Offering</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In <div style="display: inline; font-style: italic; font: inherit;"> May 2020, </div>the Company completed the <div style="display: inline; font-style: italic; font: inherit;"> May 2020 </div>Offering, a public offering of <div style="display: inline; font-style: italic; font: inherit;">11,428,572</div> shares of common stock for a purchase price of <div style="display: inline; font-style: italic; font: inherit;">$1.05</div> per share for net proceeds of <div style="display: inline; font-style: italic; font: inherit;">$10.3</div> million after deducting commissions, discounts, and other offering costs. In addition, at the closing of the <div style="display: inline; font-style: italic; font: inherit;"> May 2020 </div>Offering, the Company issued warrants to purchase up to <div style="display: inline; font-style: italic; font: inherit;">571,429</div> shares of common stock to designees of the placement agent for the <div style="display: inline; font-style: italic; font: inherit;"> May 2020 </div>Offering. The placement agent's warrants have an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$1.3125</div> per share and a term of <div style="display: inline; font-style: italic; font: inherit;">five</div> years from the date of issuance.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Additionally, also in <div style="display: inline; font-style: italic; font: inherit;"> May 2020, </div>the Company entered into a warrant exercise agreement with an investor who held a previously outstanding warrant to purchase up to an aggregate of <div style="display: inline; font-style: italic; font: inherit;">5,000,000</div> shares of our common stock at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.35</div> per share(the Prior Warrant). In consideration for the exercise of the Prior Warrant for cash and an additional <div style="display: inline; font-style: italic; font: inherit;">$0.125</div> per each share of common stock resulting from the exercise, the exercising investor received new unregistered warrants to purchase up to an aggregate of <div style="display: inline; font-style: italic; font: inherit;">5,000,000</div> shares of common stock in a private placement. The warrants are exercisable immediately at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.5263</div> per share and exercisable until <div style="display: inline; font-style: italic; font: inherit;"> November 8, 2025. </div>The Company recognized a deemed dividend of <div style="display: inline; font-style: italic; font: inherit;">$2.0</div> million to reflect the consideration given as an inducement for the investor to exercise the warrants. This deemed dividend is recorded in the Company's consolidated statement of operations during the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>as an increase to the net loss attributable to common stockholders for purposes of computing net loss per share, basic and diluted.&nbsp;&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In connection with the warrants exercised in <div style="display: inline; font-style: italic; font: inherit;"> May 2020, </div>the Company issued warrants to purchase up to <div style="display: inline; font-style: italic; font: inherit;">250,000</div> shares of common stock to the placement agent with an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.5938</div> per share and otherwise have identical terms to the warrants issued to the investor.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2019</div> Common Stock Offerings</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> December 2019, </div>Company completed the <div style="display: inline; font-style: italic; font: inherit;"> December 2019 </div>Offering, an offering of <div style="display: inline; font-style: italic; font: inherit;">6,266,787</div> shares of its common stock and warrants to purchase <div style="display: inline; font-style: italic; font: inherit;">6,266,787</div> shares of common stock. The shares of common stock and warrants were sold for a combined purchase price of <div style="display: inline; font-style: italic; font: inherit;">$0.5585</div> per share for net proceeds of <div style="display: inline; font-style: italic; font: inherit;">$3.0</div> million. The <div style="display: inline; font-style: italic; font: inherit;"> December 2019 </div>Offering warrants are exercisable beginning on the date of their issuance until <div style="display: inline; font-style: italic; font: inherit;"> June 13, 2025 </div>at an initial exercise price equal to <div style="display: inline; font-style: italic; font: inherit;">$0.4335</div> per share.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, at the closing of the <div style="display: inline; font-style: italic; font: inherit;"> December 2019 </div>Offering, the Company issued warrants to purchase up to <div style="display: inline; font-style: italic; font: inherit;">313,339</div> shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.6981</div> per share and a term of <div style="display: inline; font-style: italic; font: inherit;">five</div> years from the date of issuance.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div>  <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> November 2019, </div>the Company completed the <div style="display: inline; font-style: italic; font: inherit;"> November 2019 </div>Offering, a registered direct public offering of <div style="display: inline; font-style: italic; font: inherit;">5,104,429</div> shares of its common stock, and <div style="display: inline; font-style: italic; font: inherit;">6,324,143</div> pre-funded warrants each to purchase <div style="display: inline; font-style: italic; font: inherit;">one</div> share of common stock, together with warrants to purchase up to <div style="display: inline; font-style: italic; font: inherit;">22,857,144</div> shares of common stock at a combined public offering price of <div style="display: inline; font-style: italic; font: inherit;">$0.35</div> per share and associated warrants for total net proceeds of <div style="display: inline; font-style: italic; font: inherit;">$3.3</div> million. The warrants were issued with an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.35</div> per warrant and are exercisable beginning on their date of issuance. Of the warrants issued, <div style="display: inline; font-style: italic; font: inherit;">11,428,572</div> have a term of <div style="display: inline; font-style: italic; font: inherit;">18</div> months and <div style="display: inline; font-style: italic; font: inherit;">11,428,572</div> have a term of <div style="display: inline; font-style: italic; font: inherit;">5</div> years. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div><div style="display: inline; font-style: italic; font: inherit;">11,091,716</div> of those warrants were exercised for additional proceeds of <div style="display: inline; font-style: italic; font: inherit;">$3.9</div> million.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, at the closing of the <div style="display: inline; font-style: italic; font: inherit;"> November 2019 </div>Offering, the Company issued warrants to purchase up to <div style="display: inline; font-style: italic; font: inherit;">571,429</div> shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.4375</div> per share and a term of <div style="display: inline; font-style: italic; font: inherit;">five</div> years from the date of issuance.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> May 2019, </div>the Company completed the <div style="display: inline; font-style: italic; font: inherit;"> May 2019 </div>Offering, a registered direct public offering of <div style="display: inline; font-style: italic; font: inherit;">1,317,060</div> shares of common stock and a private placement of warrants to purchase <div style="display: inline; font-style: italic; font: inherit;">1,317,060</div> shares of common stock. The shares of common stock and warrants were sold for a combined purchase price of <div style="display: inline; font-style: italic; font: inherit;">$4.895</div> for total net proceeds of <div style="display: inline; font-style: italic; font: inherit;">$5.6</div> million. The warrants are exercisable beginning on the date of their issuance until <div style="display: inline; font-style: italic; font: inherit;"> November 29, 2024 </div>at an initial exercise price equal to <div style="display: inline; font-style: italic; font: inherit;">$5.00.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, at the closing of the <div style="display: inline; font-style: italic; font: inherit;"> May 2019 </div>Offering, the Company issued warrants to purchase up to <div style="display: inline; font-style: italic; font: inherit;">65,853</div> shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$6.11875</div> per share, a term of <div style="display: inline; font-style: italic; font: inherit;">5</div> years from the date of issuance and otherwise substantially similar terms to the form of the investor warrant.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Common Stock Warrants</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During its evaluation of equity classification for the Company's common stock warrants issued in <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company considered the conditions as prescribed within ASC <div style="display: inline; font-style: italic; font: inherit;">815</div>-<div style="display: inline; font-style: italic; font: inherit;">40,</div> <div style="display: inline; font-style: italic;">Derivatives and Hedging, Contracts in an Entity</div>'<div style="display: inline; font-style: italic;">s own Equity</div>. The conditions within ASC <div style="display: inline; font-style: italic; font: inherit;">815</div>-<div style="display: inline; font-style: italic; font: inherit;">40</div> are <div style="display: inline; font-style: italic; font: inherit;">not</div> subject to a probability assessment. The warrants do <div style="display: inline; font-style: italic; font: inherit;">not</div> fall under the liability criteria within ASC <div style="display: inline; font-style: italic; font: inherit;">480,</div>&nbsp;<div style="display: inline; font-style: italic;">Distinguishing Liabilities from Equity </div>as they are <div style="display: inline; font-style: italic; font: inherit;">not</div> puttable and do <div style="display: inline; font-style: italic; font: inherit;">not</div> represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC <div style="display: inline; font-style: italic; font: inherit;">815,</div> but are eligible for the scope exception as they are indexed to the Company's own stock and would be classified in permanent equity if freestanding.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020,</div> the Company had the following warrants outstanding to acquire shares of its common stock:</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td colspan="3" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%; vertical-align: bottom;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price per share</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0); width: 1%;">&nbsp;</td>  <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;">Expiration dates</div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">903,870</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">$33.30</div></td>  <td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">March 2022</div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the January 2018 common stock offering</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,181,421</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$12.00</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td>  <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$15.00</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">January 2023</div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2019 Offering</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,382,913</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$5.00</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td>  <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$6.11875</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">May and December 2024</div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the November 2019 Offering</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">497,140</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$0.35</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td>  <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$0.4375</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">May 2024</div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the December 2019 Offering</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">313,339</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$0.4335</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td>  <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$0.6981</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">December 2024 and June 2025</div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Offering</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">571,429</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">$1.31</div></td>  <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">March 2025</div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Investor Warrant Exercise</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,250,000</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$0.5263</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td>  <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$0.5938</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>  <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">November 2025</div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,100,112</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 13%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  </tr>    </table> </div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div><div style="display: inline; font-style: italic; font: inherit;">no</div> warrants expired and <div style="display: inline; font-style: italic; font: inherit;">19,106,504</div> warrants were exercised for gross proceeds of <div style="display: inline; font-style: italic; font: inherit;">$8.0</div> million. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div><div style="display: inline; font-style: italic; font: inherit;">1,767</div> warrants expired and <div style="display: inline; font-style: italic; font: inherit;">17,415,859</div> warrants were exercised for net proceeds of <div style="display: inline; font-style: italic; font: inherit;">$3.9</div> million.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716396046616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:12pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">8.</div></div>&nbsp;<div style="display: inline; font-weight: bold;">Stock-Based Compensation</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2015</div> Equity Plan</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The <div style="display: inline; font-style: italic; font: inherit;">2015</div> Equity Plan provides for increases to the number of shares reserved for issuance thereunder each <div style="display: inline; font-style: italic; font: inherit;"> January 1 </div>equal to <div style="display: inline; font-style: italic; font: inherit;">4.0%</div> of the total shares of the Company's common stock outstanding as of the immediately preceding <div style="display: inline; font-style: italic; font: inherit;"> December 31, </div>unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, <div style="display: inline; font-style: italic; font: inherit;">2,560,618</div> shares were added to the reserve as of <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2021, </div>which shares <div style="display: inline; font-style: italic; font: inherit;"> may </div>be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Equity Plan. As of <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020,</div> there were <div style="display: inline; font-style: italic; font: inherit;">no</div> shares of common stock available for future issuance under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Equity Plan. Further, the Company granted options to purchase <div style="display: inline; font-style: italic; font: inherit;">270,000</div> shares of common stock to employees during the year ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> that were granted outside of the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Equity Plan as an inducement material to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule <div style="display: inline; font-style: italic; font: inherit;">5635</div>(c)(<div style="display: inline; font-style: italic; font: inherit;">4</div>). Generally, the options have a <div style="display: inline; font-style: italic; font: inherit;">ten</div> (<div style="display: inline; font-style: italic; font: inherit;">10</div>) year&nbsp;contractual term and vest in equal monthly installments over <div style="display: inline; font-style: italic; font: inherit;">three</div> (<div style="display: inline; font-style: italic; font: inherit;">3</div>) years.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended</div> </div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">164,791</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,155</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">571,328</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">461,607</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">736,119</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">515,762</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table summarizes the activity related to all stock option:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div><br /> <div style="display: inline; font-weight: bold;">Options</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div><br /> <div style="display: inline; font-weight: bold;">average</div><br /> <div style="display: inline; font-weight: bold;">exercise</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price</div><br /> <div style="display: inline; font-weight: bold;">per share</div> </div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div><br /> <div style="display: inline; font-weight: bold;">average</div><br /> <div style="display: inline; font-weight: bold;">remaining</div><br /> <div style="display: inline; font-weight: bold;">contractual</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">life</div><br /> <div style="display: inline; font-weight: bold;">(in years)</div> </div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate</div><br /> <div style="display: inline; font-weight: bold;">Intrinsic</div><br /> <div style="display: inline; font-weight: bold;">Value</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2019</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">203,736</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">88.14</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">117,270</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.62</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(11,583</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">83.81</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(147</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">276.00</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">309,276</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">55.78</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">6.98</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,931,100</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.68</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(172</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">142.50</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,240,204</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8.28</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">8.90</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">289,067</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,129,733</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">15.64</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">8.28</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">219,010</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2020</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,240,204</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8.28</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">8.90</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">289,067</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The weighted average grant date fair value of stock option awards granted was <div style="display: inline; font-style: italic; font: inherit;">$0.64</div> and <div style="display: inline; font-style: italic; font: inherit;">$2.16</div> during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively. The total fair value of options vested during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019</div> were <div style="display: inline; font-style: italic; font: inherit;">$0.7</div> million and <div style="display: inline; font-style: italic; font: inherit;">$0.6</div> million, respectively. <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">No</div></div> options were exercised during any of the periods presented. At <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020,</div> there was <div style="display: inline; font-style: italic; font: inherit;">$0.8</div> million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&nbsp;<div style="display: inline; font-style: italic; font: inherit;">2.2</div> years.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div>  <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The grant date fair value of employee stock options is determined using the Black-Scholes Model. The following assumptions were used during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td>  <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.31&nbsp;</div></td>  <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10.00</div></td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.25</div></td>  <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.77</div></td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.4%</div></td>  <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.7%</div></td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.9%</div></td>  <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.5%</div></td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">113.4%</div></td>  <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">124.8%</div></td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">112.4%</div></td>  <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">114.4%</div></td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td>  <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>  <td colspan="2" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;&nbsp;</div></td>  <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>  <td style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Stock Unit Awards</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020,</div> the Company granted <div style="display: inline; font-style: italic; font: inherit;">153,000</div> restricted stock units to members of the board of directors of the Company. The weighted average grant date fair value of the restricted stock units granted during the year ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> was <div style="display: inline; font-style: italic; font: inherit;">$0.65.</div> The shares begin to vest <div style="display: inline; font-style: italic; font: inherit;">18</div> months after the grant date. The Company recognized approximately <div style="display: inline; font-style: italic; font: inherit;">$18,000</div> in expense related to these units during the year ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020.</div> At <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020,</div> there was approximately <div style="display: inline; font-style: italic; font: inherit;">$82,000</div> of unrecognized compensation cost that will be recognized over a weighted average period of <div style="display: inline; font-style: italic; font: inherit;">2.4</div> years.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716393048856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">9.</div></div>&nbsp;<div style="display: inline; font-weight: bold;"> Income Taxes</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Since inception, the Company has incurred net losses, and until <div style="display: inline; font-style: italic; font: inherit;">2018,</div> had <div style="display: inline; font-style: italic; font: inherit;">not</div> recorded any U.S. federal or state income tax benefits for the losses. In <div style="display: inline; font-style: italic; font: inherit;">2018,</div> as a result of the change in net operating loss carryforward period associated with the <div style="display: inline; font-style: italic; font: inherit;">2017</div> Tax Act, the Company recognized an income tax benefit to reflect the adjustment allowed by the <div style="display: inline; font-style: italic; font: inherit;">2017</div> Tax Act to utilize indefinite deferred tax liabilities as a source of income against indefinite lived portions of the Company's deferred tax assets. In <div style="display: inline; font-style: italic; font: inherit;">2019,</div> as a result of a change in ownership under the provisions of Internal Revenue Code Section <div style="display: inline; font-style: italic; font: inherit;">382,</div> the cumulative benefit of net operating losses was remeasured which resulted in tax expense to reverse the <div style="display: inline; font-style: italic; font: inherit;">2018</div> benefit recorded and record a benefit relative to losses incurred in <div style="display: inline; font-style: italic; font: inherit;">2019</div> after the date of the change in ownership.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse. &nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Deferred tax assets</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2019</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,864,189</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,504,496</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,571,227</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,381,750</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">541,384</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">81,700</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease liability</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,394</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">63,589</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10,709,631</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9,187,898</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(14,906,646</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(12,051,440</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,818,179</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">167,993</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td>&nbsp;</td>  <td>&nbsp;</td>  <td>&nbsp;</td>  <td>&nbsp;</td>  <td>&nbsp;</td>  <td>&nbsp;</td>  <td>&nbsp;</td>  <td>&nbsp;</td>  <td>&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Deferred tax liabilities</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>  <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,223,678</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,223,678</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(38,394</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(63,589</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,262,072</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,287,267</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td>&nbsp;</td>  <td style="padding-bottom: 1px;">&nbsp;</td>  <td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>  <td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(443,893</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;">)</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,119,274</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company does <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">not</div></div> have unrecognized tax benefits as of <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> or <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div>  <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company had NOL carryforwards for federal and state income tax purposes at <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019</div> of approximately:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Combined NOL Carryforwards:</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15,013,388</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5,844,972</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15,007,966</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5,844,972</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The pre-<div style="display: inline; font-style: italic; font: inherit;">2018</div> net operating loss carryforwards begin expiring in <div style="display: inline; font-style: italic; font: inherit;">2020</div> for both federal and state income tax purposes. In <div style="display: inline; font-style: italic; font: inherit;"> November 2019, </div>as a result of a change of ownership, under the provisions of Internal Revenue Code Section <div style="display: inline; font-style: italic; font: inherit;">382</div> and similar state provisions, the Company's ability to utilize their net operating loss carryforwards to offset future income was limited. The Company recorded a valuation allowance against a portion of their deferred tax assets as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>because of the uncertainty of their realization.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;">    <tr style="vertical-align: bottom;">  <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Rate reconciliation:</div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black;">&nbsp;</td>  <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td>  <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2019</div></div></div> </td>  <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(21.0</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(21.0</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(4.7</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2.5</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2.9</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">25.3</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">18.1</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(7.5</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</div> </td>  <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8.6</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td>  <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid black;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">0.1</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td>  </tr>  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total provision</div></div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(10.5</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">&nbsp;</td>  <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>  <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3.0</div></td>  <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td>  </tr>    </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company's <div style="display: inline; font-style: italic; font: inherit;">2017</div> to <div style="display: inline; font-style: italic; font: inherit;">2019</div> tax years remain open and subject to examination.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317768904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">10.</div> Related Party Transactions</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company's Director of Information Technologies is the son of the Chairman of the Board of Directors and he has held that position since <div style="display: inline; font-style: italic; font: inherit;"> December 2014.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716393105176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">11.</div></div>&nbsp;<div style="display: inline; font-weight: bold;">Subsequent Events</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2021</div> Warrant Exercises</div></div></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">From <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2021 </div>through <div style="display: inline; font-style: italic; font: inherit;"> March 15, 2021, </div>warrants were exercised by multiple holders to purchase a total of <div style="display: inline; font-style: italic; font: inherit;">4,230,000</div> shares of the Company's common stock for aggregate gross proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$2.2</div> million.</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2021</div> Common Stock Offering</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <div style="display: inline; font-style: italic; font: inherit;"> February 2021, </div>the Company completed the <div style="display: inline; font-style: italic; font: inherit;"> February 2021 </div>Offering in which it offered and sold <div style="display: inline; font-style: italic; font: inherit;">33,658,538</div> shares of its common stock in an underwritten, public offering for a purchase price to the public of <div style="display: inline; font-style: italic; font: inherit;">$1.025</div> per share, inclusive of shares offered and sold pursuant to the exercise-in-full by the underwriter of its <div style="display: inline; font-style: italic; font: inherit;">30</div>-day option to purchase additional shares. The <div style="display: inline; font-style: italic; font: inherit;"> February 2021 </div>Offering resulted in aggregate net proceeds to the Company of <div style="display: inline; font-style: italic; font: inherit;">$31.2</div> million, after deducting underwriting commissions, discounts, and expenses but prior to deducting other offering costs. In addition, at the closings of the <div style="display: inline; font-style: italic; font: inherit;"> February 2021 </div>Offering, the Company issued to designees of the underwriter of the transaction warrants to purchase up to an aggregate of <div style="display: inline; font-style: italic; font: inherit;">1,682,927</div> shares of common stock to designees. The underwriter warrants have an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$1.28125</div> per share and a term of <div style="display: inline; font-style: italic; font: inherit;">five</div> years from the date of issuance.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716313870920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The accompanying consolidated&nbsp;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair Value of Financial Instruments</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The carrying amounts of the Company's financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of <div style="display: inline; font-style: italic; font: inherit;">three</div> months or less to be cash and cash equivalents.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from <div style="display: inline; font-style: italic; font: inherit;">2</div> to <div style="display: inline; font-style: italic; font: inherit;">15</div> years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Long-Lived Assets</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> recognized any impairment of long-lived assets during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Intangible Asset</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has an indefinite-lived IPR&amp;D asset, DFN-<div style="display: inline; font-style: italic; font: inherit;">529,</div> which has a balance of <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$8.6</div></div> million at both <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>DFN-<div style="display: inline; font-style: italic; font: inherit;">529</div> is a <div style="display: inline; font-style: italic; font: inherit;">PI3K/Akt/mTOR</div> pathway inhibitor in preclinical development for oncology.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Intangible assets deemed to have indefinite lives are <div style="display: inline; font-style: italic; font: inherit;">not</div> amortized but rather are assessed for impairment annually on <div style="display: inline; font-style: italic; font: inherit;"> October 1 </div>of the Company's fiscal year or more frequently if impairment indicators exist. There was <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">no</div></div> impairment to the Company's DFN-<div style="display: inline; font-style: italic; font: inherit;">529</div> intangible asset recognized during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company's behalf). Costs incurred for research and development are expensed as incurred.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">At the end of the reporting period, the Company compares payments made to <div style="display: inline; font-style: italic; font: inherit;">third</div>-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>record net prepaid or accrued expenses relating to these costs.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Upfront payments made to <div style="display: inline; font-style: italic; font: inherit;">third</div> parties who perform research and development services on the Company's behalf are expensed as services are rendered.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patent Costs</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&nbsp;<div style="display: inline; font-style: italic; font: inherit;">not</div>&nbsp;that some portion or all of a deferred tax asset will&nbsp;<div style="display: inline; font-style: italic; font: inherit;">not</div>&nbsp;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&nbsp;<div style="display: inline; font-style: italic; font: inherit;">not</div>&nbsp;to be sustained.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">ASC <div style="display: inline; font-style: italic; font: inherit;">740</div>-<div style="display: inline; font-style: italic; font: inherit;">10</div> defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>recognize the tax benefit from an uncertain tax position only if it is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than <div style="display: inline; font-style: italic; font: inherit;">50.0%</div> likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC <div style="display: inline; font-style: italic; font: inherit;">740</div>-<div style="display: inline; font-style: italic; font: inherit;">10,</div> the Company's policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.</div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-based Compensation</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company's common stock, the expected term of the Company's stock options, the expected dividend yield and the fair value of the Company's common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For certain stock option grants, the expected term was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. <div style="display: inline; font-style: italic; font: inherit;">10</div> years) of the stock option and therefore the Company began to use the contractual life as the expected term.</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For stock price volatility, the Company uses a combination of their own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes <div style="display: inline; font-style: italic; font: inherit;">no</div> dividend yield because dividends are <div style="display: inline; font-style: italic; font: inherit;">not</div> expected to be paid in the near future, which is consistent with the Company's history of <div style="display: inline; font-style: italic; font: inherit;">not</div> paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company accounts for forfeitures in the periods they occur.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Common Share</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the calculation as the impact is anti-dilutive.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9,100,112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">22,385,141</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,240,204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">309,276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,340,316</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">22,694,417</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently Issued But <div style="display: inline; font-style: italic; font: inherit;">Not</div> Yet Adopted Accounting Pronouncements</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> December 2019, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12,</div> Income Taxes (Topic <div style="display: inline; font-style: italic; font: inherit;">740</div>): <div style="display: inline; font-style: italic;">Simplifying the Accounting for Income Taxes</div>. This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2020 </div>and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have <div style="display: inline; font-style: italic; font: inherit;">not</div> been issued and interim periods therein. The Company is currently analyzing the impact of ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12</div> on the consolidated financial statements.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently Adopted Accounting Pronouncements</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <div style="display: inline; font-style: italic; font: inherit;"> August 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">03,</div> <div style="display: inline; font-style: italic;">Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurements, </div>which changes the fair value measurement disclosure requirements of ASC <div style="display: inline; font-style: italic; font: inherit;">820.</div> The goal of the ASU is to improve the effectiveness of ASC <div style="display: inline; font-style: italic; font: inherit;">820's</div> disclosure requirements. The Company adopted this standard in <div style="display: inline; font-style: italic; font: inherit;"> January 2020 </div>and the adoption did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a material impact on its related disclosures.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317720920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9,100,112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">22,385,141</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,240,204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">309,276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,340,316</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">22,694,417</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317525752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">182,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">182,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and office equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">151,442</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">151,442</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">430,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">430,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">763,799</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">763,799</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: accumulated depreciation and amortization</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(614,601</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(511,433</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">149,198</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">252,366</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716393147736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">653,899</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">182,708</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">31,809</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">48,338</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,055,398</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">57,378</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">35,364</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">70,108</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,776,470</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">358,532</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317706232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Rental</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Commitments</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">118,519</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">39,735</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">158,254</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(9,092</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">149,162</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317770024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%; vertical-align: bottom;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price per share</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;">Expiration dates</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">903,870</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">$33.30</div></td> <td style="width: 4%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">March 2022</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the January 2018 common stock offering</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,181,421</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$12.00</div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$15.00</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">January 2023</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2019 Offering</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,382,913</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$5.00</div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$6.11875</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">May and December 2024</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the November 2019 Offering</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">497,140</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$0.35</div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$0.4375</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">May 2024</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the December 2019 Offering</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">313,339</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$0.4335</div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$0.6981</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">December 2024 and June 2025</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Offering</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">571,429</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">$1.31</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">March 2025</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Investor Warrant Exercise</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,250,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$0.5263</div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font: inherit;">$0.5938</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-style: italic; font: inherit;">November 2025</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 57%;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,100,112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 13%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716320821672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended</div> </div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">164,791</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,155</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">571,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">461,607</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">736,119</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">515,762</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div><br /> <div style="display: inline; font-weight: bold;">Options</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div><br /> <div style="display: inline; font-weight: bold;">average</div><br /> <div style="display: inline; font-weight: bold;">exercise</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price</div><br /> <div style="display: inline; font-weight: bold;">per share</div> </div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div><br /> <div style="display: inline; font-weight: bold;">average</div><br /> <div style="display: inline; font-weight: bold;">remaining</div><br /> <div style="display: inline; font-weight: bold;">contractual</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">life</div><br /> <div style="display: inline; font-weight: bold;">(in years)</div> </div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate</div><br /> <div style="display: inline; font-weight: bold;">Intrinsic</div><br /> <div style="display: inline; font-weight: bold;">Value</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">203,736</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">88.14</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">117,270</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(11,583</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">83.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(147</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">276.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">309,276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">55.78</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">6.98</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,931,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.68</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(172</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">142.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,240,204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8.28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">8.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">289,067</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,129,733</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">15.64</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">8.28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">219,010</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,240,204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8.28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">8.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">289,067</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.31&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10.00</div></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.25</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.77</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.4%</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.7%</div></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.9%</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.5%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" rowspan="1" style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">113.4%</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">124.8%</div></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">112.4%</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">114.4%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td> <td colspan="2" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317752584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Deferred tax assets</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,864,189</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,504,496</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,571,227</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,381,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">541,384</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">81,700</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease liability</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,394</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">63,589</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10,709,631</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9,187,898</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(14,906,646</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(12,051,440</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,818,179</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">167,993</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Deferred tax liabilities</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,223,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,223,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(38,394</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(63,589</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,262,072</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,287,267</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td style="padding-bottom: 1px;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(443,893</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,119,274</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Operating Loss Carryforwards [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Combined NOL Carryforwards:</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15,013,388</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5,844,972</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15,007,966</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5,844,972</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Rate reconciliation:</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(21.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(21.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(4.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">25.3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">18.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(7.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid black;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">0.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total provision</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(10.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">)%</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</div> </td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716316078376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,827,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,046,103<span></span>
</td>
<td class="nump">$ 3,888,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716314213176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance</a></td>
<td class="nump">$ 8,639,000<span></span>
</td>
<td class="nump">$ 8,639,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_InprocessResearchAndDevelopmentAssetMember', window );">In-Process Research and Development Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance</a></td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">5 years 113 days<span></span>
</td>
<td class="text">5 years 91 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">5 years 281 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_InprocessResearchAndDevelopmentAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_InprocessResearchAndDevelopmentAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716393070184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">11,340,316<span></span>
</td>
<td class="nump">22,694,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">9,100,112<span></span>
</td>
<td class="nump">22,385,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2,240,204<span></span>
</td>
<td class="nump">309,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716321689256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="nump">$ 103,168<span></span>
</td>
<td class="nump">$ 97,915<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716316081960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Property and Equipment - Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 763,799<span></span>
</td>
<td class="nump">$ 763,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(614,601)<span></span>
</td>
<td class="num">(511,433)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">149,198<span></span>
</td>
<td class="nump">252,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dffn_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">182,357<span></span>
</td>
<td class="nump">182,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">151,442<span></span>
</td>
<td class="nump">151,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dffn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dffn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716321697704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and payroll related expenses</a></td>
<td class="nump">$ 653,899<span></span>
</td>
<td class="nump">$ 182,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">31,809<span></span>
</td>
<td class="nump">48,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_AccruedClinicalStudiesExpensesCurrent', window );">Accrued clinical studies expenses</a></td>
<td class="nump">1,055,398<span></span>
</td>
<td class="nump">57,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">35,364<span></span>
</td>
<td class="nump">70,108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,776,470<span></span>
</td>
<td class="nump">$ 358,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AccruedClinicalStudiesExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AccruedClinicalStudiesExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716400314824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term (Year)</a></td>
<td class="text">1 year 109 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317631032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Commitments and Contingencies - Future Minimum Rental Payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 118,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">39,735<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">158,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(9,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="nump">$ 149,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716309849784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,827,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeemedDividendFromWarrantExchange', window );">Deemed Dividend From Warrant Exchange</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,950,378<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,106,504<span></span>
</td>
<td class="nump">17,415,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,046,103<span></span>
</td>
<td class="nump">$ 3,888,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightsExpired', window );">Class of Warrant or Rights, Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember', window );">The May 2020 Offering Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 1.3125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_PriorWarrantMember', window );">Prior Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare', window );">Class of Warrant or Right, Exchange, Additional Consideration Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_NewWarrantsIssuedMay82020Member', window );">New Warrants Issued May 8, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.5263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020PAWarrantsMember', window );">The May 2020 PA Warrants [Member] | H.C Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.5938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember', window );">Warrants Issued in Connection with the December 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,266,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,266,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.4335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_PlacementAgentWarrantMember', window );">Placement Agent Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,339<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="nump">65,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6981<span></span>
</td>
<td class="nump">$ 0.4375<span></span>
</td>
<td class="nump">$ 6.11875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember', window );">Warrants Issued in Connection with the November 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,324,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember', window );">Warrants with 18 Months Term Issued in Connection with the November 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember', window );">Warrants with 5 Years Term Issued in Connection with the November 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,091,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_TheMay2020OfferingMember', window );">The May 2020 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">11,428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_December2019PublicOfferingMember', window );">December 2019 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,266,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_November2019PublicOfferingMember', window );">November 2019 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,104,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants', window );">Stock and Warrants Issued During Period, Number of Securities Called by Stock and Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,857,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_May2019PublicOfferingMember', window );">May 2019 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,317,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,317,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>the amount of additional consideration per share given in the exchange of a class of warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeemedDividendFromWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend from the exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeemedDividendFromWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities called by stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockAndWarrantsIssuedDuringPeriodNumberOfSecuritiesCalledByStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_PriorWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_PriorWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_NewWarrantsIssuedMay82020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_NewWarrantsIssuedMay82020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dffn_HCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dffn_HCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_PlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_PlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsWith18MonthsTermIssuedInConnectionWithTheNovember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsWith5YearsTermIssuedInConnectionWithTheNovember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_TheMay2020OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_TheMay2020OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_December2019PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_December2019PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_November2019PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_November2019PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_May2019PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_May2019PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716315049928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">9,100,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember', window );">Warrants Attached to Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">903,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 33.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember', window );">Warrants Issued in Connection with the January 2018 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">1,181,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember', window );">Warrants Issued in Connection with the January 2018 Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember', window );">Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">1,382,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.11875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember', window );">Warrants Issued in Connection with the November 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">497,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember', window );">Warrants Issued in Connection with the November 2019 Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember', window );">Warrants Issued in Connection with the November 2019 Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.4375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember', window );">Warrants Issued in Connection with the December 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">313,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember', window );">Warrants Issued in Connection with the December 2019 Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">0.4335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember', window );">Warrants Issued in Connection with the December 2019 Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.6981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember', window );">The May 2020 Offering Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 1.3125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember', window );">The May 2020 Investor Warrant Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">4,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember', window );">The May 2020 Investor Warrant Exercise [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.5263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember', window );">The May 2020 Investor Warrant Exercise [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.5938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716315352840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,931,100<span></span>
</td>
<td class="nump">117,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 736,119<span></span>
</td>
<td class="nump">$ 515,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 73 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 146 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member', window );">Equity Incentive Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis', window );">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member', window );">Equity Incentive Plan 2015 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">2,560,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_OutsideOfThe2015EquityPlanMember', window );">Outside of the 2015 Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dffn_OutsideOfThe2015EquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dffn_OutsideOfThe2015EquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716395951176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 736,119<span></span>
</td>
<td class="nump">$ 515,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">164,791<span></span>
</td>
<td class="nump">54,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 571,328<span></span>
</td>
<td class="nump">$ 461,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716309765528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number (in shares)</a></td>
<td class="nump">309,276<span></span>
</td>
<td class="nump">203,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 55.78<span></span>
</td>
<td class="nump">$ 88.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,931,100<span></span>
</td>
<td class="nump">117,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted-average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 142.50<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted-average remaining contractual life (Year)</a></td>
<td class="text">8 years 328 days<span></span>
</td>
<td class="text">6 years 357 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 289,067<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number (in shares)</a></td>
<td class="nump">2,240,204<span></span>
</td>
<td class="nump">309,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="nump">$ 55.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted-average remaining contractual life (Year)</a></td>
<td class="text">8 years 328 days<span></span>
</td>
<td class="text">6 years 357 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">1,129,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual life (Year)</a></td>
<td class="text">8 years 102 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 219,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">2,240,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted-average remaining contractual life (Year)</a></td>
<td class="text">8 years 328 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value</a></td>
<td class="nump">$ 289,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716319777208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">5 years 113 days<span></span>
</td>
<td class="text">5 years 91 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">113.40%<span></span>
</td>
<td class="nump">112.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">5 years 281 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">124.80%<span></span>
</td>
<td class="nump">114.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317729816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2017 2018 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716314218408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,864,189<span></span>
</td>
<td class="nump">$ 1,504,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,571,227<span></span>
</td>
<td class="nump">1,381,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsOrphanDrugCredits', window );">Orphan Drug credits</a></td>
<td class="nump">541,384<span></span>
</td>
<td class="nump">81,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">38,394<span></span>
</td>
<td class="nump">63,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsCapitalizedCostsAndOther', window );">Capitalized start-up costs and other</a></td>
<td class="nump">10,709,631<span></span>
</td>
<td class="nump">9,187,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(14,906,646)<span></span>
</td>
<td class="num">(12,051,440)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">1,818,179<span></span>
</td>
<td class="nump">167,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,223,678)<span></span>
</td>
<td class="num">(2,223,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(38,394)<span></span>
</td>
<td class="num">(63,589)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(2,262,072)<span></span>
</td>
<td class="num">(2,287,267)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (443,893)<span></span>
</td>
<td class="num">$ (2,119,274)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsCapitalizedCostsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized costs and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsCapitalizedCostsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to the orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716317653784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Operating Loss Carryforwards (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 15,013,388<span></span>
</td>
<td class="nump">$ 5,844,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 15,007,966<span></span>
</td>
<td class="nump">$ 5,844,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716403388520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Reconciliation of Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of Federal benefit</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent', window );">Orphan drug credit</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="nump">25.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">18.10%<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision</a></td>
<td class="num">(10.50%)<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139716315221976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Subsequent Events (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,106,504<span></span>
</td>
<td class="nump">17,415,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,046,103<span></span>
</td>
<td class="nump">$ 3,888,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,827,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">1,682,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 1.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Public Offering, Inclusive of Underwriter Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">33,658,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 1.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm', window );">Underwriter Option to Purchase Additional Shares, Term (Day)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of the underwiter's option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_PublicOfferingInclusiveOfUnderwriterSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_PublicOfferingInclusiveOfUnderwriterSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MRPTE$97F!7@>"Z%W-R9!]9^(\7]02P,$%     @ 2*]P4FR-A8]@!0  E1,
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MI->H-A,@8V\40]+#.!0C+ K8R!=/6HC)),3?F_TSGI+)$!R/(MS#-I2BA-
M^['AH*OPP0D;9QS=7OU54**())SW$?HD&<8!).((R ,:PB=5Z%R).Y4KJ^1D
MF<9=Y<=DTOOW::IKJ,MH*YX%Y+DW F3@%V<\9JSO_U .$PXEFHRXW[$)GJ83
M0%G5LBO0GK)\$!FO#W2(S96]J+]-/8*4QYR.^=!Q#)XFF9=/Z*J?L*J\1[F$
M!JL%_NR%/20+C"D+DSYJGQQF432"NF,5_&]HY5B0AYQ!&.513/MP/>02$<S(
MV&[NR 5/L\NU7$O FB%5IKJ0R(JG$:Q#QF",QLD JH=9,$Y(-,+7N.,6/$TN
MGW69_J><&#()Y>$0^% ,4\['*!%WA(.G&6>7$L=2P4,E">9TF+E#09I$(0G'
M4J%C'3Q-.U>Z*)1US<6N7D O[T(LRQ0PH[>?M94H]#?ODX;=Z'AAMB*5ES.8
M#8VL'N1LA;QM_/\W]+JA[UB-!).$<6MU^FVC\TQ6YL<?8H*C=^@C-%OV>8HW
M2$=(!!\-+HR9QBTS1V^"\R# P"$5@CZ_EA<(SZ&S>?E#9B,J5[5KN]&5^EMF
M[U#(Y@'F<\9P\W$HG;,XF-.0OP@K8US);RI];0TT8IG;(,(B&']D<0>U_V6"
M:H3<+#2'T=EL93/[YM[-LW?K,-U"%N"PEY4>,4I9/)*3Y&#0.D*W6:;<? X;
MR$T<9ZJ$"6FK8$-YP7H(E08A#$:\3UL^48QCPF(^,AR1CGW)4?:MBSIO9N!,
MKE6JO#TF&3+G&30_29#0N-\J^&03H  61/$(W(YHR331[NJ3.=@ /S5SAK^:
M$L_4!A^:0>SZF#V2 9 Q"4=Z ]*Q+#F%90]*:I/1)[O !W/Q2(?JD_1WJ(N#
M,Q-W8/6;J.Y5:8"?UJ :G$=@J=J= >UNK-XVQRAWVEI=-)<;*0"Z$X#W:PWU
M=G_C3F;:D[C5/U!+ P04    " !(KW!2;>2'HU "  !D!@  &    'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;)5578_:,!#\*U;4ASOIBO-)Z2E$*IRJ]J$2
M.M3VV20+L7#LU';@VE]?VPE1.$  #\2[WIF=L6&3[H7<JA) H[>*<37U2JWK
M9XQ57D)%U$C4P,W.6LB*:!/*#5:U!%(X4,5PZ/MC7!'*O2QUN87,4M%H1CDL
M)%)-51'Y=P9,[*=>X!T2KW13:IO 65J3#2Q!_ZP7TD2X9REH!5Q1P9&$]=3[
M$CS/$UOO"GY1V*O!&EDG*R&V-OA>3#W?"@(&N;8,Q#QV, ?&+)&1\:?C]/J6
M%CA<']B_.N_&RXHHF OVFQ:ZG'H3#Q6P)@W3KV+_#3H_3F NF'+?:-_6)J8X
M;Y0650<V"BK*VR=YZ\YA  CB"X"P X2W J(.$#FCK3)GZX5HDJ52[)&TU8;-
M+MS9.+1Q0[F]Q:669I<:G,[F@BO!:$$T%&A&&.$YH*6E4^AA021P78*F.6'J
M$7U$'Q!&JC1IE6)MVEL2G'>M9FVK\$*K%\A'* J>4.B'_AGX_&9X\/D8CHWI
MWGG8.P\=7WS1>569WY$YX7S[A&HBT8ZP!M #Y:@0C!&I4 VRM?MXSF[+/W'\
M]M^RR_R1[P<IW@U=7:LZ$A_UXJ,[Q+<W@DBC2R'I/W.3UD2;/:N\)4\&F@+_
M\'DG_Z;2(P]Q[R&^WP-5JKFN/SX1-8[]((GC]X=_6AA%\<2/QLEY[4FO/;E?
MNQF22A->4+ZY9B"YU<!IX04#># #[/S]0>2&<H48K W4'WTR'+*=:6V@1>W&
MPDIH,V3<LC2O 9"VP.ROA="'P$Z:_L62_0=02P,$%     @ 2*]P4DV"S%1)
M!   Q0T  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6RE5]MNXS80_15"
MZ$,*;")1=P6V@4W2RP+=-DBPW6=:&EO$2J)+TG;Z]QU2LNQ(LK9%7RQ1GCD\
M<^',<'$4\ILJ 31YJZM&+9U2Z]V]ZZJ\A)JI.[&#!O_9"%DSC4NY==5. BNL
M4EVYON?%;LUXXZP6]MNS7"W$7E>\@6=)U+ZNF?S[ 2IQ7#K4.7UXX=M2FP_N
M:K%C6W@%_67W+''E]B@%KZ%17#1$PF;I?*3WCS0Q"E;B3PY'=?%.C"EK(;Z9
MQ:=BZ7B&$520:P/!\'& 1Z@J@X0\_NI G7Y/HWCY?D+_V1J/QJR9@D=1?>6%
M+I=.ZI "-FQ?Z1=Q_!4Z@R*#EXM*V5]R;&43%,[W2HNZ4T8&-6_:)WOK''&A
M0.,K"GZGX \5PBL*0:<06$-;9M:L)Z;9:B'%D4@CC6CFQ?K&:J,UO#%A?-42
M_^6HIU>/HE&BX@734)!7C0^,D59$;,@?.Y#,^%J16_+E]8G<_/#CPM6XJ5%U
M\VZ#AW8#_\H&U">?1:-+17YJ"BC> [C(MJ?LGR@_^+.(3Y#?D8!^(+[G>Q.$
M'O^U.LUFZ 2]!P.+%US!Z]S4; F\X>%2H.YG4,,>-;2HX174%U# 9%X2UA28
ME@<\;SL3F:D M$B)13+']K#*0C^)XV3A'B[],I:+8YI%V5GN'=6HIQK-4OT%
M&O1 99FR G.4*VT\<H ILBU6=$DB#$/J90.R8[DP#4(_#:?)QCW9>);L$V"U
MR[G-ZREZ\6A;Z@4T3@?LQF)9DM%HFEO2<TMFN?TFE"(;*6HB^J,WQ3$9;7Y+
M,8IA%H8#FE.2-(IHDL735-.>:CJ?]+H$27B3BQKFTCWK\;)9TS\U&B0HW4%.
M69V-(T-#/QHF^5@LC0+/GS:7>N<RZ?WGV) U8!^%CC/1[ TFX]5!#P*6QEZ<
M#ME/BM(PCC&X5TRXJ/3T.SX^T43B#6RX)C==R9JNZW3L\3B)@I0.28\%;X/
M3],KYX'Z9\K^+.7?<8ZIT/.3]/P)5X741#L>$IP2Q4.0!4EVA>*Y^M/@.P4%
M.R:6:'[@!9@**+DRS<#FRI%)R1J-G2$O6;.=S.L._SVY+/*"9%ATYIF8@>]>
M[5@.2P=KG )Y &=%9@XG/3<C.M^-3G$@3&O)UWO-UA5FDB"8434.8SBFY-]*
M414@IV,U;CVW-*9!%*?#DC4I.A^K<Z.BT6S5>BV9/:[M](M'>*YTT7-+H?,]
MI?<.5@:B[!XX/EVZYH,9-7G>-G->[<VP=<,;4HBJ8O)"<?H@MMMGER[Q[H*A
MXR:DZ%URI=#3<U.B\UWIJYV$D3 [8.';0DL4)\2]5AH-PF3_G^8EHXACD0EH
MEHQ,'$O&B1='WC SW(N!N :YM?<$A2'9-[H=-/NO_5WDHYW !]\?S!W%#MIG
MF/:"\YG)+<<>4,$&(;V[!%-/MG>&=J'%SH[=:Z%QB+>O)=ZS0!H!_'\CA#XM
MS ;]S6WU#U!+ P04    " !(KW!26?HD:=X$   A%@  &    'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;+U876^C.!3]*U:TTLY(3?$%S$>51)HF6>T\S*IJ
M=W8?5OO@!B=!!9S!3M/Y]VL32A)L:-.M^M)@N!_GGFNN3QGM>/D@UHQ)])1G
MA1@/UE)NKAQ'+-8LI^*2;UBAGBQYF5.IEN7*$9N2T:1RRC/'Q3AP<IH6@\FH
MNG=33D9\*[.T8#<E$ML\I^7/:Y;QW7@ @^<;M^EJ+?4-9S+:T!6[8_+[YJ94
M*Z>)DJ0Y*T3*"U2RY7CP!:[F$&N'RN*OE.W$T372I=QS_J 77Y/Q &M$+&,+
MJ4-0]?/(IBS+="2%XT<==-#DU(['U\_1?ZN*5\7<4\&F//L[3>1Z/(@&*&%+
MNLWD+=_]SNJ"B(ZWX)FH_J)=;8L':+$5DN>ULT*0I\7^ES[51!PYN&Z'@UL[
MN"T'+^AP\&H'KYTA['#P:P>_Y0!>AP.I':K2G7WM%7$S*NED5/(=*K6UBJ8O
M*O8K;\576NB-<B=+]315?G(RY87@69I0R1)T)]6/V@52(+Y$TS4M5DR@M% /
M^.)AS;.$E>)7-/^Q3>5/-$3?[V;HTR^?1XY42'0\9U%GO=YG=3NSYCFOPZ)_
MOK'\GI7_6L),^\-\29)4;S>:H1N:)D.%=$HWJ53KGJ"S_J"W3*KW2[$QIV61
M%BO1%VO>'^M/KK"<NCFJ04V7W*9+;A7'[XAS33-:+!CZI"H4:UHR\1E1B69L
M<8D\N$ NALC6A7U44D75(^-QXGEAX'IXY#Q:X'@-'.]5<%X#81\I/(40-OGW
M;3:-8D(\-XK@U'!F&@[#.';]((Y/+>>F)9  @)#87KO?U.[WUOY5B&U5O'I#
M%OMM+/0VOD!J4 ^7VR)16V='RY+JUX@6A\4%*M3@5V[I<X@%%\KFJ*DV GVC
MA^ &4>2&@;T0TA1"/K80&WAB=D&#;[6?F"5"C(F+6_MDUEN1/E.OQ(8NV'B@
M2A"L?&2#";*]M=:$$$8QL7,:-)P&;^(4;3?JDCVQ<I&*ZFE#[ O=#TRDH0\D
MZMK&88,T?&>D-G2AV5Z%+FBU-S2G4!0"QJU7=M:+^(SNVO)%D>]V-#=J*(MZ
M*:M.JZ%6)8FF3$DU02NQPY[T-;,1U!OQ]25-(Z,D D1-\A:#[Y1N_F*Z$P+C
MAL"XE\ _U-3(N+#NI%[/,XAZISBSV&!@"*".&B]L'S2OL3RA"_!!F^'_>^S'
M5O&%+>>^'V$OZ'@%X$@NPEN.?CL,L)S]?OM,G]9FI],8(M<_'G*U<C--AVIN
MNSX.6V?*W&*J<'J^V[6+X2#&H%^-?;@$ %/' ?AN1,*N6@Y*#OJEW(>H +"(
M,84_;F\$SRP3>QYV<7O.]1=UQJ"SIU1'F <=S!YT(KQ-*+Y="X!%"L:  X+]
M#K '+0AO$X/GR0&PR#T-L-UG4WZ%81!Y(6ZW^;WTGC5C%/I=&AH.@@_Z%=];
M1$%_R#,..S#58>BI?W*,L?E."><O)SRE\:!&H5^.]DF#?M=SZ'JG0#,P%>80
M?(B(U][K\U>9GI)VT*/0+TA?E@<NMA)JRKO QT!\OVOH'10>]$L\NSSH@!$;
MTT+#,*:%:0:*/!(38LP+TW0(F,0X]B*_W1C35BD.W9KVF>H<?5W3'T^_T7*5
M%@)E;*E<\66HB"SWWR/W"\DWU0>W>RXESZO+-:,)*[6!>K[D7#XO]#>\YJOP
MY#]02P,$%     @ 2*]P4J;U_ =M!0  BA,  !@   !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6RM6-MNXS80_17"Z$,+)&N1N@>.@<1IT3YL-]A@VV=:HFUV
M)5%+TD[R]QU2BF1+E+*+]L6Z>&9XSG XA^+J6<BOZL"81B]E4:G;Q4'K^F:Y
M5-F!E51]$#6KX)^=D"75\"CW2U5+1G/K5!9+XGG1LJ2\6JQ7]MVC7*_$41>\
M8H\2J6-94OEZSPKQ?+O B[<7G_G^H,V+Y7I5TSU[8OI+_2CA:=E%R7G)*L5%
MA23;W2[N\,V&!,;!6OS%V;,ZNT>&RE:(K^;AC_QVX1E$K&"9-B$H7$YLPXK"
M1 (<W]J@BVY,XWA^_Q;]-TL>R&RI8AM1_,US?;A=) N4LQT]%OJS>/Z=M81"
M$R\3A;*_Z+FQC:,%RHY*B[)U!@0EKYHK?6D3<>: IQQ(ZT"&#L&$@]\Z^)9H
M@\S2>J":KE=2/"-IK"&:N;&YL=[ AE=F&I^TA'\Y^.GU1E1*%#RGFN7H2<,%
MYD@K)'9H0]4!_0;SK- U^O+T@'[^Z9?54L.@QG69M0/<-P.0B0$P01]%I0\*
M_5KE++\,L 2T'63R!OF>S$9\8-D'Y.,K1#SB.0!MOML=IS-P_"Z#OHWG3\3[
M5#-)-:_V34ERS9FZF8D;='$#&S>8B/LGK.%"*.5*>>,96T^S4$_K:QS@)/2]
M:+4\G>?"98GC-/7CM+.\@!=V\,)9VG?Y/U"=3;%H 2LZ$U7&"X:J%K=Y:^XS
M4T9'!>7%*R1^,%E1AR::3=8#@R:6<6I:@RMAC7=XE@;L^3A*!MD:FZ5QBD-W
MIN(.6SR+[4F+[.NUZ34YRD0)#5A9G(B]F'OFPAN/@,1^A'$ZP#LV"W$81\0-
M..D )[. -P=:[9F9+NB'3$H[=8"<(4U?F+,@DQ&0:QS%H9_@ >*QH>^3))E(
M<=HA3F>+L4&L!A6F%(/BI%6."DZWO'BWVK#7=TUO-D6/DM64YV]3J*X@5;50
MO!U/Z .3+0!GR_0<$Y?@:#B_#KN 1'$<N-.%S[H^GL5_EV7B:)9N35_IMF!7
ML!XS>60]HS,>9]ESDL'C51-ZD4>&9,9V811'9XOPD@SIR9!W.^6[7<:)G#C*
MU@]#$I'13#A,TR1,_'BB='&O'WA>0*S.[JS.UE*<.*@DVKZB':\H=-3O;I6X
M%Q8\KRR/4F2,Y0KMI"@13#%2%!HW2#XL\A(:DS(=RYFPP-%'$Q)CSQOF:Q:"
MV9S>J)IF['8!C5LQ>6*+-9ICU^L2#O\'=E>0:W:].YH]"7JF4M*J7;MO#T[^
MLT-_%ZLV/>$XD<3'21I&$^74*R&>E\(Q?_;"9,;5* >7O!WY<*9@K)&)%T0@
MI\,*&!OZ29($9&K!]'J*YP7UD;Z:?8>A(W8@4&:-9$)-X!UK)"Q< J(SQ.LP
MQ!%)R,1&"?=RBN?UM.M/[RUO)_ZQ8N(X2;WDK/&T!!R6D1<$T,\F&/3RBM-W
M&< 6 +X3E=T76#:F:.P-^W;D)UAC4Q63CD7,]Q,2Q$,"8\,()Q&.8S=^TLLU
MF9?KS11>1#7:LCVO*C,34%"OC$H7"3)68MAQQ[$?#)7"80G[;=AT3\P"Z46;
MS(OV+ MFY'H&_UA\X7L!AV$Z+".7Y9#I)8%>J F95;JG8UT7]@.3%BCG*H/O
MA*.T?:D2U;6EQ:L34XUV Z,?%4'2JR[Q9Y/YZ:)SF**F@SV1!3#<%CES.SO2
M#ZA"&^@\]<0WO6HB\;WBDWG%[[]1"[N$I3G<,&F''5.S3;W8)K\Z6?YW16]9
MCK])?3\@WE 7EF>G&B63>WO8HY"=I.:TH'O;'2C=V6.4P?M[?+-ICH7Z,,TI
MU4<J8>TKR,H.0GH?8DB]; Y^F@<M:GMVLA5:B]+>'AC-F30&\/]."/WV8 ;H
MCM_6_P)02P,$%     @ 2*]P4GRB%E V P  G 8  !@   !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q]54UOXT8,_2N$+GMQ+%M.NA^P#<1Q@P;%;HPD;0]%
M#V.)M@8>#=49*K+WUR]G9*L.NO$AT7R0CX]O2'K:DMOY$I%A7QGK9TG)7'])
M4Y^76"D_I!JMW&S(58IEZ[:IKQVJ(CI5)LU&HU_22FF;S*?Q;.7F4VK8:(LK
M![ZI*N4."S34SI)Q<CIXTMN2PT$ZG]9JB\_(?]0K)[NT1RETA=9KLN!P,TMN
MQU\6U\$^&ORIL?5G:PB9K(EV8?-0S))1((0&<PX(2CZO>(?&!""A\>\1,^E#
M!L?S]0G]/N8NN:R5QSLR?^F"RUGR*8$"-ZHQ_$3M;WC,YR;@Y61\_ ]M9WLS
M2B!O/%-U=!8&E;;=5^V/.IPY?'K/(3LZ9)%W%RBR7"I6\ZFC%ERP%K2PB*E&
M;R&G;7B49W9RJ\6/Y]^($<9P!8]NJZS^KCJM; %+]+G3==S3!A:-%U?OIRE+
MV."<YL<0BRY$]DZ(<09?R7+IX5=;8/$6(!6^/>GL1'J1741<8CZ$R7@ V2@;
M7<";]"),(M[D@@@>F.!>6V5SK0P\LV*4XF-_ ?^ZQ[^.^-?OX2MN' 85'VMT
M46(/?[_@GF%A*-_]\S-1+T..A[#4FTT3FV-5*BG0'!O6N3(>'FP^'("2)S2J
M51(Y)U=3%UC.+6AKZ56%?H"UIOJ-NQA7M;('J>U7Z=E:VRV(-1K@4LC7.DA5
M*@:TI8B%X1C65!P^>%!K;30?@I0%&H%W0/O#%FTX"79"1GEH!0A!,V@/%E&*
M BKR/(07,;GKP@N:D2$#M:.BR1ERJ4E=R*,,X.7Y;A!<UQBX'6D*AL0XYU3T
M^HCP9S2T]XWDT&HN06;2Z<H$'"_R&$^PL]1*&W@H#S7MM0IJ>G2:&A_U,:+4
MJ3.J(%;X8J%S>29A'K(1D=G)T%%K@[&A A^=R[2X8KIB$4*2(DDJEL-0'@U4
MT>T"S9@DO]'C?U+ \O[;%=QDGP>P>IC\GM[N.*U>'I^ 6Y*FEHOP][,"3L\F
M1H5N&^=B2*VQW V/_K0?O;?=Q/G/O)O;7Y7;:AM>:R.NH^''FP1<-PN[#5,=
MY\^:6*997);RLNB"@=QO2-KON D!^A^D^0]02P,$%     @ 2*]P4KCW[0:]
M P  Z@<  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6Q]54UOXS80_2N$
M+KVDD2U[V\7",;!.&K1 =QMLMNVAZ(&61A)KBM0.R=CNK^\C)2M.D?@B\6/F
MS7O#X7"UM[QS+9$7ATX;=Y.UWO<?\MR5+7727=N>#'9JRYWTF'*3NYY)5LFI
MTWDQF_V0=U*9;+U*:P^\7MG@M3+TP,*%KI-\W)"V^YMLGIT6OJBF]7$A7Z]Z
MV= C^=_[!\8LGU JU9%QRAK!5-]D'^<?-LMHGPS^4+1W9V,1E6RMW<7)+]5-
M-HN$2%/I(X+$[XEN2>L(!!K?1LQL"AD=S\<G]/ND'5JVTM&MU7^JRK<WV?M,
M5%3+H/T7N_^91CWO(EYIM4M?L1]L%\M,E,%YVXW.8- I,_SE8<S#F</[V1L.
MQ>A0)-Y#H,3R3GJY7K'="X[60(N#)#5Y@YPR\5 >/6-7P<^O/UM/HA#?BU_5
MMZ JY8^KW ,W[N;EB+$9,(HW,.:%^&2-;YWXR514O03(06AB59Q8;8J+B'=4
M7HO%_$H4LV)V 6\QJ5PDO,4%E4YX*^Z5D:944HM'+SVANKR[@+^<\)<)?_D&
M_I0\<:=<J:T+3.*OKW3P8J-MN?O[M:1>ABRNQ=>6Q*WM>FF.HI5.&.O%9_MB
MF:D)6K(^"CKTVC)42NV)C8S%+CJ2Q@E;BWK0;1JA/!9Z8ADO!:Q-)1S1SHDZ
MF"H:^)9M:%KQ)%G9X(2S@4MR5T*94H=DTH>M5F7R[5D](9' * ,KKRB&JXEA
M!A=4IY9;RP,;R2Q-,R0=9>Y;Q%)<)5V=/(ZS.(HKOSV3A !_)EHBN2YL_\'%
MCF=:$GMT'\'*[09!P8QKB<\S[Y,D;,04Z62,0QHF-3J$991)*SWH:6Q#"6+L
M6T)X3M88FW,RWSFDP%8!9B7V525CI6VIM!T$]]A[HDI4')J!6HO"<JHQJE:P
M]Q%*,33S#@W8M5%:"KVE*V0>&-"^;U79)M7HJDY5]+^$@$.)^\=6#S6CR31(
M;C12D07"EM;YN%#1$_IP'Y,Q+'<=<;P/ZM_A[,G1:X(PRBTC14K'TA[B=P*)
MB@?B//KWB534.BI'4O%#\;A!%)HH*D-JE.N8VI<JZNEV0@^N4VK;H%D'GZ).
M%?'R;J#T@34>7*QO.BCGHYY2NG80&@>$2PI.J?QDJBKT&>JV.-I3K[D2][3E
M@.<I3N=@Q$A<&A;QM[A^K5OD9_T7^6S2*Q,/)1@_M.)I=7K(/@[]^]E\> 4_
M26X42EY3#=?9]8_O,A1V>EF&B;=]ZN9;Z_$VI&&+QY@X&F"_MNAUXR0&F)[W
M]7]02P,$%     @ 2*]P4GZ$WRH_#   ?Q\  !@   !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6RM6=MR&[D1_164DFQVJRC>)-GRM8J2UALG:ULEV9N'5![
M&9"$-;<%,*2X7Y_3W9@+*=+KASR((F> 1E]/GYYYO2G=@U\9$]1CGA7^S<DJ
MA.KE:.23E<FU'Y:5*7!G4;I<!_QTRY&OG-$I;\JST70\?C;*M2U.WK[F:[?N
M[>NR#IDMS*U3OLYS[;97)BLW;TXF)\V%.[M<!;HP>ONZTDMS;\*7ZM;AUZB5
MDMK<%-Z6A7)F\>9D-GEY=4[K><%OUFQ\[[LB2^9E^4 _WJ=O3L:DD,E,$DB"
MQK^UN3991H*@QN]1YDE[)&WL?V^DOV/;8<M<>W-=9O^V:5B].;D\4:E9Z#H+
M=^7F'R;:<T'RDC+S_*DVLO8Y%B>U#V4>-T.#W!;R7S]&/_0V7(Z/;)C&#5/6
M6PYB+6]TT&]?NW*C'*V&-/K"IO)N*&<+"LI]<+AKL2^\_5@&H\[4J;K2WGI5
M+M2M,]X408O3BE3=2[SHWKU=%G9A$UT$-4N2LBZ"+9;JMLQL8HU_/0I0B02/
MDGC\E1P_/7+\9*H^E$58>?5SD9IT5\ (MK0&31N#KJ;?E'ACDJ$ZFPS4=#P=
M?T/>6>N@,Y9W]@T'>15*]<X6NDBLSM0]G&.0F,%_0_YY*_^<Y9\?D?\G+E7_
M^6P>@[K*RN3AOX?\^VWI9\/_2V"/"/F\,BBKI,PK76QI?5(6'EM2^"=5B]9A
MOG48B0C8=2U[U$JOC9H;4RA 2J4=MMF"9;H4FPVJ(:S4+[/9[5#-L!XE:YRA
M&U@&0=ZHH@F0KBIHJ^>94<O:RG8HG1LR"O=Y+WTA<4I[M8"9:134MQKQ+5+M
M4@\U4_9*Z[*#J[Y49'!K6Y<H!U=?E?@W5%^@.C;\[(/->3<Y4YP@Q^'F00]"
M7[B9X-B&;><?F/=[;1VYHN=?6)OK!Z-,>PQ9H3TPN*)3:+4.2B\60$G>"0U*
M1^'3.>G.5F&]";(ULWIN,QML%)5:GV2EKQU; \7(6NAY=(^<0@YK_'702MIW
M3!WSB);D(2RM'?FV6T>_*N-L"0=_HHBILEB6='5."3S8\8U9ZZQFGUC([3Q4
M>]JPLL!>A]AG?)ZSG'6D5@DA3BW03TH'D;9(LCIM]$AJY\A\ U>4N4V4*=;6
ME059-=PI,PM3/9KA_"N[OL379-4/%%S:#U3MJ:9*IZK:5:67?$M-,$B$@HZ'
MOLG#*;6H5%%-PD==XNHN%4D&5;%V.(]C:-9HSE7.8:,NR:$:J@^Z0%_FRW.3
M6:S:=Q6TGI/OM2\++CP4%-48.<*ZI,X14;@-LF9)J.%*G(MVZ:%?G5'R+*@D
M?>>5;*L6KLPA 19V!PW5.VV=^@T!X[3I2NQ]X8.K)6>H@A+M'$-1+U]Z0?^[
M[Z6;[?;VPYAHCSB@F) ?;2Y&_WE5Z2U;"K1QY2.KAUR <FM6+L4?O$)'^A4R
M\I3BHPH=8H6(8;V3AU -+BI"5_;7@$$;U)WU#SU+>WND:"L 'R*J,S@-*4IR
M]TH_Z4MF5R0BVI%H FLD.4 'MMN*Y= 2,A^*I*@HC[6,,#FB9JO,['G/AII%
M2V'-=<;1)BF;E45V+0B4#(?5/":&$M@@0?@H[*\)[S,+(",WT+GD:O[R<\__
MGWM6L=(005%!^P#G@JC,8C4A.3(TQ'AR-0'D\[(P6X"@>P##72 _<8]-(G!P
M=@E[,MQ&? A..4+.&/0Y\%Z'*Z01*2/ET5?%&>I2R(C^4M,N1822$N[-C/>4
M/C5\R'T1CL56VZO-G*#K#[Y Z> E;8$C9J,SR3^;XYBUZ84?M,!$D 0T+.H,
M;EAW7:C!7T<U4=F@,_N'2:FH;8&-ND$SZCC6R<((K-0@J!X(RK#CIJ\O&BK9
MC8*%-$H3#=QQFKCO*9$/ 5H%504&FA).OZ'D(&8+^D;,#:?11 0)IFIRH7X%
MC)_^BIWHP&(77\GX2L]29]:@[0U.-O5!SH.-')7-"H>0<OB0;II2?S?BT_ 4
M04C5F$M\3*ZW1#GX#US3Y',(:_@F/B8OA@ EP-[2$DRPNCMIL](443K8H)C0
M!:(9[V_O?M!Y]>I&3AJHFW<?3]7%],5 _?5R^.S 87M7Z&0L5[?OS_XUFCV$
M4?[YTUU?EVA!:I!&*>$#LZ].D1@;<B19]PD-CJ1/\(L%'S/WKM],;GK-Y(/^
MBCA0+T(1%DU6'^D\">>]P#!I!> LI&,<7O]C4^$>L.,:/N*,%)G)JZS<&B*7
M!<RC)*/2#-L##9+ @KACPXXRD&UAL#HAWK(5W7[BNT1Q'+HD;GOCUI;P[L?O
M:*?$2XBT2=7LMJ2Y6>EL\5-3^TWI_4FG/EJP,TED0H=89_OL:)<(,8$GYHC>
M)@"3ZS2V,>M23ODO%:H1IQY9<JNIUJ+^\0<[K=]8F]AD9HG QMO'S)!0<$T3
MS.("H3;(;T0)N9\2]_'<X=:F(X:1T^^,([M#"$&VM$4J5WC J,_Z$5MG2 )L
M!,5R,3GZKJI])-A<2SOL%DW&H+NSS_?8EI4# AU > K20Q;B]U&:' V/.$M"
M=M%T43.C(!%D);?9A/EU<'9>!^8H"(]0++DW-V%#H]81TGV0.YE'N)>O'9\!
M(,]RHE:&G[&P5E1F<CNZ&C(P*,BE2$/X0-BVH<'H^QV#B4ZH@S!U-#,N1]KE
MF)92'L@EF0J9#.$V.R4&(Z;(%L7%^2(M2.@9_$'AQVC<=U^3J8WDN80(S81J
M&C36A)!Q_2F9++B_ TPVS2A*+=QR*J,+@4KS>%HZ MX'0UJNT!B:YD)_L_MK
M]?Q\K";CMN]<C(?CO\6+ XR5'>>_[G/^?L>)_O([$X)FIQ-+6:+;AM-TC\@*
MF K#V9DF8I%]1^\G-M9A3MOS-SS_?CY455>9AH+WR:H$:U(?RM1DY&G1B$8/
MM@ 9);Z->1-GZ&8$ZQE!O?OICFY4SKL)ITV5KW6Z%( MTKWA>7_86Y< -*G]
M)V,&? ;J*<<+AG2Y0R/!DPU]1?W>CM12WD"?K359V@['NY8>/[_I.#$1V#J*
M]U#03H8R&+=HIEJ5K)B!B0M:'W&<FI((_>ET<'SZ;/)%1CX4#;G2R=C2R2*$
MBYC6A/4=<0<0:Q#6W2ARPNZ[B)VZT7Z'<3:!^N$OE]/I^)4'$<PP:>*>8#5?
MG[SBTUO&$$- S2CL\3:>5;"[]W# %O)DG!0CO)4.W9^)1<4X@^EY68?&4O-H
M7&+AFPJP#;HC<%?1U-#4CF@E&<J3OIQ$C&%MR6?47O8+0QPD-?;$9@(="5/,
M"I! AP@W*=2<C,HNDE4'\2WSH3D>$GF#T<3;Z3C =_<TAE"5^(=)GY+& :$9
MQ594QO29]"OI0+^E?IS/&]-%321^N2GZ@>B+$Z)&K(8C4-7SS"9RI> N0D(%
MK1H'MHG4*VH:H766\-QVH. .>+O1FTL#!X$Y-UC^$7SA5VJ MW#&M53G_8J:
M"CU<352!^]P@*WHDPC>L0&]-:LVW@@+DXG;I?K?O%STPE.?D^995W_#["0+^
M&.ZBYK 01*Z8_?'SNSYHU($>W_")\4D;A[MYP'9C,];LD.+"XJ6 ##]<9'B!
M:P;- Q[3&]#:0N!Q 6.\\S'4WB0TF5O3&^EE1>"9)C5SB.Y?J5Q#(R+V[A@%
M;(GHL8.WG#$U/S\PU/?0UZQP?%[%P^&& 4S LJ$/%G'F[@Y58;1@*R7C09<2
MU8P1;2IESK&7)ZE'W=E[LGTXR(/O##'T YI*6+P&"Z+LGY=AU>8Y.Z/W$(L:
M0C2?.(ONU&-FB)-9;V)]\8QF?*1R6)1$?Y@#]!Y6=3O:X.XD6_=2P#QR'J5=
MSHCW6B1HG/;$]"8 G=A!!/1M#.2<8"+8TT:;ET?FVZ96=_-'O1A,QN/!9#)5
MT^G@[/)B,#F?"!UK<VHZF)Z/!]/QN3H;OQA,GS]3D\G@#)?.)L]HU[,7YX/S
MR7/,SXD\(WN/;((-5^@0'^%!)$NK$FDRP-6AZ#29#I@#W@NZ;YMTFNT.'CN3
M32MK<A'-8UCJ1':*S%+88'9>=]QB_,/W)(Y0T&U6+VMT*FR^Y,</EVI\-@ J
MM"\$WCFD&+V4/577S"=\DU6]17?"Q40JZ=Q[TONAXRM(M,OI>$@?(#?_U$5-
M]+RQXM![N%'OI6ANW))?_?*3YR+(^]'V:OMV>28O5;OE\FKZ@W9+*IO,++!U
M/'Q^<:*<O.Z5'Z&L^!4K2BF4.7]=&0S(CA;@_J)$^L<?=$#[SOWM_P!02P,$
M%     @ 2*]P4N !M$7: @  3 8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL?57?;]LX#/Y7"&,/&^"+?R9MBB3 LJ[8 =TA6+>[AV$/BDW'0F7)
MD^@EW5]_E)UZ*=#DQ:(H\B,_,F06>V,?78U(<&B4=LN@)FIOHL@5-3;"34R+
MFE\J8QM!?+6[R+461=D[-2I*XW@6-4+J8+7H=1N[6IB.E-2XL>"ZIA'V:8W*
M[)=!$CPKOLA=35X1K1:MV.$#TK=V8_D6C2BE;% [:318K);!^^1FG7O[WN!?
MB7MW(H-GLC7FT5_^+I=![!-"A05Y!,''+_R 2GD@3N/G$3,80WK'4_D9_:[G
MSERVPN$'H_Z3)=7+X#J $BO1*?IB]I_PR&?J\0JC7/^%_6 [S0,H.D>F.3IS
M!HW4PRD.QSJ<.%S'9QS2HT/:YST$ZK.\%216"VOV8+TUHWFAI]I[<W)2^Z8\
MD.57R7ZT^L<00@Y_P<9RHRT]@= E?/S9R99+3XN(.(@WC8HCX'H 3,\ )BE\
M-IIJ!Q]UB>5+@(BS&U-,GU-<IQ<1;[&80):$D,9I? $O&REG/5YV@;(#,G G
MM="%% H>2!!ZONX"?C[BYSU^?@;_N9(A;)30]+*@<"M=H8SK+,+WKW@@6"M3
M//YXK="7P^23,SU[J<9171@>)4<.3 54(U1&\4A*O;L!+C$V6[1CF?F3S.%>
M;(T59.S3"<P;2*[3,)M>G4AWG=62/"<?TE25+/#$)9DF89ZGXWF//$>U427(
MIK7FUU!ZR+,XC.-X/+\:XMZTK[.YFF7AU7P^GO?HW T/>=$UG>)NECR;O*:X
MO</TL[-HC"7Y>U"\G25Y.(L3> =OIPGGE64LOEZZ$#3VQ/-YF,RO64JG3'PV
MX\)=BH$'WIT.82\<B):)'"3O$51/\":>)&>J/GGM)QB=3'B#=M?O,<<M[30-
MPSYJQU7Y?M@0?\R'/?M9V)W4#A16[!I/KJ8!V&%W#1<R;;\OMH9X^_1BS>L>
MK3?@]\KP !TO/L#X![+Z'U!+ P04    " !(KW!2-8)7 \X"   F!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6R55=MNVS ,_17"V*,7W^+&"9(
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MA$P??[U6D+/AV&Y?Z)JEN'*HG36J)W36\>0_'\( QS%<MO"TAXL1/)74S]J
MS($PD$M!8X%7^P50.;'<D=FII/0)Y@-_S9X5@5OZDZQ04'U&OM_!11RYR7Q.
M4I"$[LQ/7@B4S%';84*%S9'0Y"CQYS!-W"AZP:64*)X21ILFLR$/[('KQ[$;
MS1.(9VXT2_JL1*2[F,+,=P-R]R -V9)[=S:[<*<SG^0H3MPX"N&U1^2->K=$
MM6\GE,T3/96NC0?M, 0ON]Y_@7<3]#-3>UYI$)B3J3^9Q0ZH;BIU&R/K=A+L
MI*&YTHH%#7)4%D#GN:06Z#?6P?!K6/\!4$L#!!0    ( $BO<%(_R^1SDP0
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MTUU"NH7333CX,<APC0B?%>YMW'@!_-]J'(']PAL8;H+K_P!02P,$%     @
M2*]P4F[9O18C!0  W0P  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
MG5?;;MLX$/V5@1&@+XHMZJXB,9!+B[;8;H-F=_NPV =&HFVB$NF25)S\_<Y0
MLB*G2;;9!]N\S3DSPYGA^&2GS7>[$<+!7=LH>SK;.+=]NUC8:B-:;N=Z*Q3N
MK+1IN<.I62_LU@A>>Z&V641AF"U:+M5L>>+7KLSR1'>ND4I<&;!=VW)S?RX:
MO3N=L=E^X:M<;QPM+)8G6[X6U\+]N;TR.%N,*+5LA;)2*S!B=3H[8V_/$SKO
M#_PEQ<Y.QD"6W&C]G28?Z]-92 J)1E2.$#C^W(H+T30$A&K\&#!G(R4)3L=[
M]/?>=K3EAEMQH9MOLG:;TUDQ@UJL>->XKWKW00SVI(17Z<;Z;]CU9]-L!E5G
MG6X'8=2@E:K_Y7>#'R8"1?B,0#0(1%[OGLAK><D=7YX8O0-#IQ&-!MY4+XW*
M2467<NT,[DJ4<\O?M1.0PS%<.UU]W^BF%L:^@7<_.NGN@:L:+G3;HOO\/GSC
MQG#E[,G"(3E!+*J!Z+PGBIXA8A%\ULIM++Q3M:@/ 1:H]:AZM%?]/'H1\5)4
M<XA9 %$8A2_@Q:,K8H\7O^ *"T[#>ZFXJB1OT&CN!(;@8X,/\),1/_'XR3/X
M3WK8^_]2VJK1MC,"_OY#W#DX;_#H/T\Y^44*RN"W=LLK<3K#%+7"W(K9,I^_
M\G*]0^&C@L_\WH^#<02,!4E4!&D>P1&;ARE^A_/X83_-Z4#YL("G8A:EL,+D
M@[.ZEI2,O&GN ^"-U2"G-&D0AB%]X A14_HFV8/E-,IB=-NM:&^$@<)??SJ'
MHV@> H9$O[P/"[*BTDH--6 GW0;<1L!N;ZJX$Z:25M2'BD3I U\9%[C*2L(:
M"6@A.)Q"%D19%N1%/AD10%J@)?%4/7_\4Z<$L+@W@ XF,9J,)'SP$GK(>6TI
M.*1:@U[YZ2%,C!!Q7!) 5A:L=S2BC"[J53V8HD=9F/B+RH(X2@*6Q*!1G2@*
MBC3':;*_@1AOMQ].KIX5TUGZV._$A_MAR8*<9811_HI=CU0<(LD[)D]'N_I+
M(HK]"%@0LSP(LW R.DKF18GZI_-L EQZ;R>T'(;S7U%J),E2= WZ(ILS5J ^
MZ3/)<]D9$I<47+>\Z;B//$03?=I5#;=6KF35;^"[ZGD0;,O5_1N+\>IAK8<=
M U5:V_51ZN.Z]T#!4DA"BD,C;SF];]:G]0=1KU&) %&5,_CR61+D"FNO(QTL
MZ)W:UX$>!)1V_I,4!"BM0X!.V@T9\YOD-[)!/R'^RNAV+[J708@ SBQ9^5,*
M!O"E<]:A6H3TE:NU\-X8$@^V1E;XC1)VP[$"OKO;2M/[IN94D2_^TQ\LQ_Z@
MP<,UE>]K= :*G5'BWPKCY$U#+&(EC,$3/8Y>X904*L,X*'*,EQ@C/<3K-M6&
M](Y^A;>8\M(M?N*JP]ZFWSNXR)&0!:R@R&98&K%FA?CV'C$*QXEP%+_,_HAU
MC-$O#R1Q$04EB_M()XY]W-)ABI%)%<&$> W=89Z.G$E)A6-?NH_'Q!VJZNLX
M#FO<R#$I=KY:'H]E[] <,M#75U];7^]+S+"1<RQ$])(]!,C_A/V(,8D29E\P
M,-Z'1$B"Z:M#K]SQ^/Y,7([$)5;O,&#84@W%AACN!3<@J+=Z*@>5!D9B69"&
M6/Z*GQ]+7[2#/,L!*VC"J-J5?>E^JO=93%K.5IBU;ZRI=G7*]=WGN#KV[F=]
MR_IPO&_\T:-8K"PT8H6BX3Q/9V#Z9KJ?.+WU#>R-=M@.^^$&_W\(0P=P?Z6Q
MB1HF1##^HUG^"U!+ P04    " !(KW!27+[8A$H%   )#   &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6R=5FUOVS80_BL'+QE:0)5%O3M+ L1-VG5
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M@EA&7V:B7_S&NP4ZC1BE871(H%&T-T+W5 99'@4Y*[=2GE\\6[[J]1\K@/N
M.M4?Q4441%'T5*0_SO(DHY2LZ(A%9&=:"$J\8\Y=WJW0T)72* \R.X57[<8B
M[MU:D.P (&BB&DP0V4TW!Q52-E5:(I=J0M(:Z'=&-;+&@0-^2*D[QAC3'M<
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M2^,PB^CSPJ(N47 @YJDI5V1!G$9!'*4NO! 54H:C".NX' 517@#69\!G^5D
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MKHY^.<-=76@G@/.)PMUG_>$,;&[_I_\ 4$L#!!0    ( $BO<%*^R_LD804
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M3$#W"TVC5+=A ?T?B(M_ 5!+ P04    " !(KW!2#27:*%D"   3!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q]E$MOVS ,@/\*X<LN6_Q(NA5%
M$J!)5ZR'#D&:;8=A!\5F8J&RZ$G,TO[[47+B94"3BR5*Y,>'28WWY)Y]C<CP
MTACK)TG-W-ZDJ2]K;)0?4(M6;C;D&L4BNFWJ6X>JBD:-28LL^Y@V2MMD.HYG
M"S<=TXZ-MKAPX'=-H]SK# WM)TF>' ^6>EMS.$BGXU9M\0GY6[MP(J4]I=(-
M6J_)@L/-)+G-;V:CH!\5OFO<^Y,]A$S61,]!>*@F218"0H,E!X*2Y0_.T9@
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M\UZNF$Q)W^WX\0TJ148RVF5Y5D%.ZB_Y42;W;[C-2@G&"/Z[ BZQ,_OZSC?
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MZ&$5GT2\PN(,DLB'.(S#$WC).)/$X24G9J*A;_ $W&2$FSBXR1MP;P_QM^.
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M^FL!K@W4_(JILE%V] +5?U#X&U!+ P04    " !(KW!23\< K;8#   %#0
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M:--!W3 W;QQ(FV#64V'Z7CNQ&W2OYN0?4$L#!!0    ( $BO<%(8-SA=) (
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M8'T"[:\--50?^/X<7M?B%5!+ P04    " !(KW!2$=?88A@(  #M+@  &0
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M7&O78>E..@.-EI;*R]1%:?_K)DLS\2P0<B+RE20$'_[F+&G7W]P]!4]",C7
M"B*M*MH3+7SAX><9.0"Q4),F-+/F6V)6J5(!;8V/JE9H@H1FAGQ#U)(&&*TA
M[HBM4#,<? '%%01_ BX]SY=5&0M$2B-*/)& L[Q*$Z0'[J3*QQA2*.16#(%=
M+ $UL4$SL]V*FK+TL,S"!%ID^'6+//$@]&I.@CU)Z6N@MTE.9O1J@H)FAGI#
M]+K-F&L-*;)QAPV:^J"9^RHL.[]L\BOX#_PTG(CW?K1-I-[@6Q:N?Q1('IZ
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MX$/Q"%%?=W8-'E8]L%L]3L3C1 :U_([=_-Y"8XV/\4 ?#6IVR*%E]]#-[C\
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M%6]1"90!EPI&%1BAT".=\GG(_J$:8\ CK?&5*^(7-@/67J1W2C8EG&MZ\+E
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MHT(+P/L9YVK[H,\STP/OWG]02P,$%     @ 2*]P4N48&_23 @  %@<  !D
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MH/>3&+Z"4VE_T;:O#3Q4K*7B30_6"IJ:=4_RW.<P .#T "#L >$N(#X B'I
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MA]FMIII9[:,+)PDJ8-9VDO;?K[D$2$),,LIH^]!B.#[G^XZ/_9UZLF7\3:P
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M4Z7-JQND:B!97E["O#(I65H^KH!&P L#]7W!F-P-B@#-/=[L/U!+ P04
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M"SO<4+D$>[Z6]L$W@;N@'9?)'U!+ P04    " !(KW!2BL.!V7(#  #3"@
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MMA(2I&2(ZU1F*4G2*\ OEQ3^\RU5NJ"=YQ4>7SRS* JSLUW8$3N$!..<I-&
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M@!6#)$KS;_I:).( H.Q4 YP"X%P*< N >PKHU  Z!:!S"NC6 +P"X%WJH5L
MNB;W>;),IB=4TM& LRUPO5I9TP]FNPQ:)3A*M;+FDJNWD<+)T1<F$0B!GV&>
M+01^SS"5,'U1GP*N)BAI% OX%5]E1N-/:M73? )7/WT:6%(YUR:LH'!TESMR
M:AP1>&"I7 N8IB&&%?AQ,]YY#S]]QW^3 4MEK4R=LTO=G=-H\1X7;7#\:W!L
MAU0%U Q_H+P-Q*N%3RZ!.[7P:3-\@D$;7&+@=@7\_F(XZ3?DTBUEZ!I[G1I[
MXY@* 6P)WRCG5$F0<3"GW#5,7Y$'D< 0)AF/TA7,D$<LA*LH!;&F'$65&J>Y
M/\_XT\?KRXCTB=WU[,[ >CD,M&)AKT,\W^N7"X]"ZI0A=1I#FG$6((8"EIPE
M95R[:$05Y]Q@[X"*;W>ZQ'9/*)^O<WW?[SA>-6.O9.Q]@/%G(3*:!JAW9<R2
M1)6!N63!<Q5Q[XP0L7VG1VS[A'DC 5U%;\2&!CALJ3(ID+]@:P0-\NJ6D74;
M(SL]V^"/!TP6R/]LL-TK;??^7^F.>V>*[#BN;1\D\XBH7Q+U_V5!COVS?74<
M^XA)?E15K+/M>L;]DG'_OQ'D7;]"D V$B+TOE_:/*0G^@B=56/B61Q+Y+KT"
MU%:/69H6%ZEM)-<@UPBJ>/!,7>7,\7T4#CPNEVC4<H%(R4&=)S\JTR^9=J/?
MS3%00I41"AC3.%;"7;SM0]DAQ#L"OBNH')VI7=_I.[V:]#O[*)Q_^F.#&8]R
MD=00#UD<4RY@HV(V053'D!,AY#"(MN.3NE.6[&L=:2YV)2^:ACMBCYD44HW5
MOE^K^Q9/X.IWI+R:6K-Y#]X44C2I9E_#2',1:Y+[+%O$45#*]1H^IT&<"=4H
MZ.0?_ACF1BH7Z7E?JTASL<I_*_I,.#U>KPM_2MBJL3$KWE>L=Z98U^VJ2X#K
MU^SVOO20=VI/'GS.]+I0YVR7E8\H,O?C'PG2KI7COGZ1Y@)VN%./&W-,2:9V
MEP=KU;+!;1A&>I+&95YS?4[H6S7/9G>N#2%]:Y3GOJ*1CY2TCQ0(<EZR7.)4
ME0CKH+E*D*],&RP@8%DJ\PMN.5NVVK>FP3R9'Y.;":F8G^K6W#1S>_-Y7Z_N
M^*LH%1#C4KFRVSVE3YZWROE LHUI[19,JD;1/*Z1JNW4"]3[)5/M73'0#LH_
M+$9_ U!+ P04    " !(KW!25#B$LV4"  #(#0  #0   'AL+W-T>6QE<RYX
M;6S5EUUOFS 4AO^*Y4Y3*TT%DB5I5D#:*E6:M$Z5FHO=54XP8,D?S)B,]-?/
MQ@1(6C+4B[7<Q.?#?L\#G*"#GZL=Q0\IQ@J4C/(\@*E2V1?'R3<I9BB_%!GF
M.A,+R9#2KDR</),81;DYQ*@S<=VYPQ#A,/1YP6Z9RL%&%%P%<-&$@%V^1P'T
MYI\AL'(W(L(!?#S_^+L0ZOH#L.O9I[,S]])]O+@^SIS7J0OHO"@\&R#<*]LG
M.A]$ZY[B=7O%%\/$3VGW25\-Y#X-WBN_'"K_#_V^ @OWL, ![S&?4S=>Z,>"
MM_TWA3:@]1'#8(MH &\0)6M)S*D8,4)W-CPQ@8V@0@*E&U\7]$PD?[)ISWKF
M/U'K,,*%K&K;"O9W76\_2NP] T@H;0 GT 9"/T-*8<EOM5-MKH+/4J"V5[M,
M$R82[;S)#+8'JD4760L98=F4\> ^%/H4QP9'DB0UJQ*98Y)*"::-B*!$<%0Q
M[$_4AI;=8$H?S OC5WR@7<:=)U<]-]Z8&J@VK8QUC'Y7S6IW9:>OT@49V0KU
MK="7PRO?M!N^ES@F9>67<0/0I^[UJZ,LH[NOE"2<87OQ@PN&/MJ? ZF0Y$E7
M,ZVRT0$L(=ABJ<BF&_DC4;;"I=JW4QGW,T]&R/Q_[W.".9:(=J%U[[_GN_QJ
MXNGBK9"KM\HQ\(N,]13PWB%G8X"<CP%R%#UY-0;(Y0@@%V_VUCP)Z=131F>4
M.1ADFB@P V, ?YH!E+9%P;H@5!%>>RF)(LR?S3-:7J&U_JPZT-?[(QRC@JI5
MDPQ@:]_AB!1LV>RZ-S>BWM7:/\SE>?.J8/OM%OX%4$L#!!0    ( $BO<%*7
MBKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E
M\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!
M2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/
M06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3
MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
M  @ 2*]P4HK-=X/> P  &1X   \   !X;"]W;W)K8F]O:RYX;6S%F<MNVS@4
M0'^%T*:916KK8>>!ND ;9V8"%(T1&]T.:.K:)B*1+DDG:;Z^EQ*,4DAT,1M3
M*YL/44>7(@]%?GK6YG&M]2-[J2ME9\G.N?WU:&3%#FIN/^H]*"S9:%-SATFS
M'=F] 5[:'8"KJU$V'D]'-9<J^?SIV-;"C,*$=B"<U HS?<8/"<_V3[E/LB=I
MY5I6TOV:)<W_"A)62R5K^0KE+!DGS.[T\[_:R%>M'*^6PNBJFB5I6_ #C)/B
M3?;20Z[XVC8YCJ\?.(+,DND8&]Q(8UU3HVF?(^,38.4V=7#Z;UDY,'/NX!^C
M#WNIMKX9?(I1\!A-'(Z_;1"OS?\)H]YLI("Y%H<:E&OC:*#R@,KNY-XF3/$:
M9LFQ"ONB2G:K' :)W:FV*:SKGQ1O?5>V3^T0-XBAN9988.[*!OQTD#>8UI4L
M\>XE^\HKK@2P)K@V ,P(P&PP0':VX %D3D#F$2&7'L)?8)G>L/L]F "R(""+
MP2!O=CQ\'R<$Y&0X2&YW >24@)R>%O([SHPL9>?LWFRYDJ]-#<9QF,_!BK"[
M+PC(BPB0&4)^DS\/LL39)^"Z)+@N(W#ER/656]ET[,* Q6O:* :05P3D503(
M B'1@CB <>;VO7N+@=S[*\.Y>TQ-WN,(F!/$_"*$.>"(N7W!UBS8!O<^Q"0=
M<V+)-)A3Q+S1=2U=.Z(](8YV)SLFI$R3GE@U#>8%8BZ=%H\[795@[(>FU_T+
M$&)2KDE/+)L&\_*(>;[F%GPD:]_S6#O$I&R3GE@W#>858MXIH6M@*_X"X9HB
MI2R3GE@S[0P^1KH'7XP!7' _RE>&8Q!%B$EY)HTB&F^:Y6%MX>?!+R=OG_SX
M"1$IRZ0GULQ2;I7$NMPO=(70!S^BMVR!$A>RV^&4=-(AK?-?%F)2VDF']$X'
M,Z.\DPWIG2XFY9UL2.]T,<DOG"&]T\6DO),-Z9TN)N6=; COL+,51PS[5TA)
M"2B+(:#.ZIR=S<%Q65FV@I<0DQ)0%D- O=-F'F)2$LIB?.OT8A8A)B6A+(:$
M>F?W3C0I"66#2BB,9DY)*!]40F$T<TI"^: 2ZF!2$LIC2*@7L]/IY$9;# GU
MNK(334I">0P)]6)VHDE9*(]AH5ZE=Z))62B/8:%>S$XT*0OE,2S4BSD),2D+
MY3$LU(LY#3$I"^4Q+/1V'7=<)(5[ZI2%BA@6>H-YSN:P 6,@Q*0L5,2PT#N8
M_GBBNVE44!8J8ECH'<P'$%J)#B9EH2*&A=[?E_%O:(A)'O@T%AH=CR)+V$@%
MY7>\A<5\P2NQ,,S_M%NCQ<3O36P.576#>??JF^;E\63S>"K[^3=02P,$%
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MW>X-S\??EX^3G;?WCK.#?U&+7U!+ P04    " !(KW!2+M+XP*X!  #*&@
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $BO<%)EE%A^> 0  )40   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !(KW!2;(V%CV %  "5$P  &               @(&\#   >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 2*]P4FWDAZ-0 @  9 8
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M965T-RYX;6Q02P$"% ,4    " !(KW!2N/?M!KT#  #J!P  &
M    @(%Z)P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M2*]P4GZ$WRH_#   ?Q\  !@              ("!;2L  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $BO<%+@ ;1%V@(  $P&   9
M          " @>(W  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#
M%     @ 2*]P4C6"5P/. @  )@8  !D              ("!\SH  'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !(KW!2/\OD<Y,$   5
M"@  &0              @('X/0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+ 0(4 Q0    ( $BO<%)NV;T6(P4  -T,   9              " @<)"
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 2*]P4ER^
MV(1*!0  "0P  !D              ("!'$@  'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"% ,4    " !(KW!2OLO[)&$%  !,#   &0
M    @(&=30  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M $BO<%(-)=HH60(  !,%   9              " @353  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ 2*]P4G2&)4-B @  , 4  !D
M             ("!Q54  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !(KW!2:P\&#GT-  #C)P  &0              @(%>6   >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $BO<%)3*L1PFP(
M %@%   9              " @1)F  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ 2*]P4N9$_ONI @  M04  !D              ("!
MY&@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !(KW!2
MCK08-9,"  !S!0  &0              @('$:P  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $BO<%++%Z7.9@(  /@$   9
M      " @8YN  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ 2*]P4KT#H:9A P  "P@  !D              ("!*W$  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !(KW!2..+'"U@$  !("@
M&0              @('#=   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( $BO<%(L9ORV1 0  "0*   9              " @5)Y  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 2*]P4@)'+<SH
M @  $PD  !D              ("!S7T  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !(KW!23\< K;8#   %#0  &0
M@('L@   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $BO
M<%)DK8WDO (  $$'   9              " @=F$  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ 2*]P4A@W.%TD @  L 0  !D
M         ("!S(<  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " !(KW!2YV$[D<@"  #("   &0              @($GB@  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $BO<%*=548]B@(  -@&
M   9              " @2:-  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ 2*]P4MLFGF8) P  +@D  !D              ("!YX\
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !(KW!25T"K
M?TD"  !I!0  &0              @($GDP  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( $BO<%(1U]AB& @  .TN   9
M  " @:>5  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M2*]P4J,HU#84!0  CAP  !D              ("!]IT  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !(KW!2*6<\D/\$  #\%@  &0
M            @(%!HP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( $BO<%+E&!OTDP(  !8'   9              " @7>H  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 2*]P4K9+PNUU!
MTQ,  !D              ("!0:L  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !(KW!2:.&3L T#  !8"P  &0              @('M
MKP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $BO<%)W
M&2A>0 (  #H%   9              " @3&S  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ 2*]P4HK#@=ER P  TPH  !D
M     ("!J+4  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M  #(#0  #0              @ '6PP  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( $BO<%*7BKL<P    !,"   +              "  6;&  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( $BO<%**S7>#W@,  !D>   /              "
M 4_'  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !(KW!21QQ@N:0!  ";
M&@  &@              @ %:RP  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !(KW!2+M+XP*X!  #*&@  $P              @ $V
LS0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -  T ",.   5SP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>105</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-changes-in-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-1-organization-and-description-of-business</Role>
      <ShortName>Note 1 - Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity</Role>
      <ShortName>Note 2 - Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment</Role>
      <ShortName>Note 4 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities</Role>
      <ShortName>Note 5 - Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-</Role>
      <ShortName>Note 6 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants</Role>
      <ShortName>Note 7 - Stockholders' Equity and Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation</Role>
      <ShortName>Note 8 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes</Role>
      <ShortName>Note 9 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-10-related-party-transactions</Role>
      <ShortName>Note 10 - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events</Role>
      <ShortName>Note 11 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 4 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-tables</Role>
      <ShortName>Note 4 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 5 - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-tables</Role>
      <ShortName>Note 5 - Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 6 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-tables</Role>
      <ShortName>Note 6 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables</Role>
      <ShortName>Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 8 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-tables</Role>
      <ShortName>Note 8 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 9 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-tables</Role>
      <ShortName>Note 9 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 2 - Liquidity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity-details-textual</Role>
      <ShortName>Note 2 - Liquidity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-2-liquidity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 4 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-details-textual</Role>
      <ShortName>Note 4 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-tables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 4 - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-4-property-and-equipment-property-and-equipment-details</Role>
      <ShortName>Note 4 - Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 5 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-5-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details</Role>
      <ShortName>Note 5 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 6 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 6 - Commitments and Contingencies - Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-6-commitments-and-contingencies-future-minimum-rental-payments-details</Role>
      <ShortName>Note 6 - Commitments and Contingencies - Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual</Role>
      <ShortName>Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 8 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-details-textual</Role>
      <ShortName>Note 8 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-tables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 9 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-details-textual</Role>
      <ShortName>Note 9 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 9 - Income Taxes - Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-operating-loss-carryforwards-details</Role>
      <ShortName>Note 9 - Income Taxes - Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 9 - Income Taxes - Reconciliation of Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-rate-details</Role>
      <ShortName>Note 9 - Income Taxes - Reconciliation of Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dffn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 11 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events-details-textual</Role>
      <ShortName>Note 11 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20201231/role/statement-note-11-subsequent-events</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dffn-20201231.xml</File>
    <File>dffn-20201231.xsd</File>
    <File>dffn-20201231_cal.xml</File>
    <File>dffn-20201231_def.xml</File>
    <File>dffn-20201231_lab.xml</File>
    <File>dffn-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001437749-21-006236-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-21-006236-xbrl.zip
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MA$M/?^M[;V)$,>*YC'ANQRA?:2Q]":)( CF#9CR8^A*3-R=[AG+X5$^NO7W
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M,-!2NQ<?L!$5$WK,_YM!51AW84)^M]?<!9ZUXJ[,[%M&WS!*@,W/OSF &QX
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M:BEBV4>M]\=C\AS1OQ*L)_<"_WJ:3BB/RRY_OQB-?=DMU?I2JE-&E+F,J[6
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ME8!6%@G9"Z!?MVN@:ZPHW&+TP;6J >;7^<:T&P%9"Y?5";ZFIA=;F#8 Y'T
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MUX,OYWIP>OKX87$]V'E,I8S4X5A<#W;WL?V&6N)^\"SQU\GN!\_1)_4E#/Q
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M[RQ%@D7FU1;,'X^;&3;BL0%V5F2UXEW^5HV%R15E,%)G@_$T&^Q>4J^8)C[
M;#QCJ6./"UK7OK[)_$49RN/,/)("O3@T%L9=>ZY!B.G7.JP\U#+#@HS8M.(M
MS48Q,46&1GLC,2S?9ZUC,"Z1UDL?I+IOQ5M$NTFS5FD<#0\DWKP"X0'?Q1:Y
M*,AD?M!XZ*CV% ;$QIL:KO'/FB8UGB)_S:OP%NVTXH-B(23NWP=CLLAZ2;^/
MVNVT1C(6D9N;PH]^0C46ONJD>K[4+P^:HI9)!,WBBAN@U#3DPGK(U)7G"5IQ
MG5_:;PLK<?.JW-VH^MR!G)3DS&MO0-)MWZTS7'N_9:)E"FG=;LSVBY@TX4W]
MWB.IKHZTC2K68J<Y:ZZTI VZL++[@^6&/K;63%5^CIZVK2?@.?H]//J>\T5=
M>F,@RS+^5Z(YW-#+:@\]:%82P4*4R.%/N LW'G9NXIC_9UZ$WO$MD["6Z;'F
M2LKP,PV7^2']EJ'[2R;;B>G0[1H74J11:-<!IE;R>IE5XZ>IIY$2B!8Q2/^%
MWXA9RB,& 4UBTC-IZ !_8+<5;[?-.1$O959K.50*K ><0ZS[F2F(IZXGC;Y8
M__35BI@6_ +S*!MGQ+$ZT7:8A/3$,/NA-M:1HL!C:4:3:<?#C#(J[$=NTK;I
M0,-4,\ :B:$.Y4+<1O.:%S8Q@CAG,Q'%>\STH=V6:"OID)OW2$)C'H:'Q-L8
MI+:?IS;GEV7YO/%DTCPAW=8PE36:](ZE_9KXO/RH TA;W=:R:3^<' 9V%HI;
M4QS4!04)"!*]=OU8KG@7CNU^&X/MKAS%>;.5#[3T-W^&+C!BUN G'U0^Y&Z?
M9_,GWI*DQ@Z?Q#.9E\".#J:\T5;<O/U5K-U('(;<*H!I[4RBCBM; RX&^6-(
MA* :U?)S;;9#R]/3YB..34\AJ()H\31Z'H@3/&-B<N+RMR,5=Y;@_6P=DMDJ
M!\4.29&!?I(,]!V5>)KU'&8&+G,?.DTX#B<#=3(93&?3$CV*&;S9$YI3HMQ;
MFE"V2QCMHUNL]#,3?81#"U;SY$5?>--/V,7FG*"@^\>S4[A!M6(TS8C5'L>6
MG[.2,D&\&$ODC6*]5^-.<?4>>_X1.D12-';FR8+F@(%F*]MACW$$^1-K ]4'
M6X O1EJ9$Z+[EOPD^KTMUWL5-7P2K*L!WVI:7?[W#GC$Y>%D/E-*E*/PB(L^
MB*> ?[%CK+@08[,0,#-XZ0URR@-K6AXZQIJ[4QX/%'FTX]HO#PW9_6EM,%!3
M1P-EE'.1>N1R$5)_6N+G0)]W T#4=<CVPO/J%NR!>T_HE3'U)K3@]E 'L_$4
M*#.J8@T0VJ3!;I976KQ>84K=]UW#HL[3F%#47^MB)^#F\'!A5$#N,H">$"*#
MWH)CJ(!0T?4<)=4>S PX><MB25\61>ZB0<-!)KS\4\WV.EN730*6#I9^G1JF
MU=6,MZ''4'K?YD5!WJ+51T5YK@RFV1+\#'BZ?EZ^$I\T/88GUZ+-R/V\4.X[
M >PZ!Z+:.F-5P3EG$./4B3/62)N*J*/^B6*]EW7M'V6B<3MQBE$&FC(=R)-*
M%X5,*K;B1O![3?J\#YECIWW>H^%LGM4XS</[\7!2:.9WQ_J<Q@>=&+\Y]4./
M3NB''@]EN32[1BCCMG'1'J5Y$D@T&0]F8^U\$-%DJ"BS,D@T:.745PZ&<O$@
M?GB'<;NH"NR-Y%L@ 7!$S(2%@&Y=1<1.HH 9.;L/K<X@)N2@3,'.;TC[ZI4[
M0-"13+#8/ OL!(XFO'B3K?L^K0*>";Y.QV,6M&"/]&-]86];680UNJ$H0,\\
M/ O06<@K1^CP)[-&/@:^KD$3&YYUQSV6L-XZ*]XK&>U55V.$D5Q38P1"03H<
M.)E3\'^)>4\-Y3OX@:<;R 8.6I,/V"UIDQ[SQV/'!,OVZ/!,X?0#F65+[4V/
M=B/+UEYCG8W G/V;QG&[](#EWNEWEDTSKGV?^'Y!=+Y9&XS)SV6!7;3P%HFI
M$]N*YF+02LJ6WL &CF99QC\P?;U( N (#1P?6OX2E>BO?!583Y!B#)[1GCE@
MT.8>FR;W>1T&++J<AH0WMH4>0>5'822>F/S "RFH#): TI<8!8\=T0A9\?P)
MV&N;MF'S637#S3:SK0AA -\D"WH&8Z8($Q\B59,>B?%/O2*>58UW8<".K6!9
ML1!C;/]\PUWC:=8@K+5'>EO1R#XE(<*)J435E7(2N*%MPB$X-K',7F)O-!T+
MF406V%H ,P&FYQEDW4>5[8.8JSJ]&?&M3?'2:QI%4YYMA,M@4CF46>HF/[78
MMON8"1!,YRBB@3!H/YT=H0:O.\P/NYDV?LVT)&M4_.9"OI ,8MN\DV_\M[_6
MC>AOOKJR!92N-S--F;8&MIQ+WFUX*LM1I_>H\>_>3N[\V_2[1_9HE_CPX^D/
MA40K[AI]W!A*I2$,%XGMO+E08TH7!$,=REI[.U,KZR>)9I1E&U/GY]Y@9C1?
MV9;J;? DO?VS+XD"J'Q\KH=)\KVS%120@SBG3>;4+B3/?62OE2XQZNR'OTH[
MU<69,_!7;)U'/1?<>?EL+] 9$(7Y;V,':Q<D.\?5])170?]6T@"-B&$T$>V'
MRI/OE\!]>%I;/*,;/>*["ZUE*/\J\%+;L ^U2'>Z\<>]Y\*Y[1+TJ>N]IE13
MY=% 4C5,A1^/(]K5BVV:C.&^#-PUYQ3^1L0=\;Z\V^,C565E&C=I!/1]"X >
M9G2%#JVH!P"Z&A?$\VC6.S['+:B<MDMV$WDZ</75Q:_%(5 8T]+N(5,_7]CK
MS#.=R]I@-I6WI"FW,,=]]/3UFPOV_Q?/IF79HKJU@:/N[U_Y^7__TIYM=':E
M@=1Q#ZMI0VTO:Y[QEG5)ZII&+5U&(_OW])/N&4N,U%&W]K1A7#(>4TCRHG')
M+(U+T'>8M+N&SS*7OP*0=%P[*@-EA@'62I^48Y-.G>.&*-6UQ0:R5K.MJ$.Y
MJMEN:ED-P)'+?4N*W6\-N]R2)3>NGPN 'DZD9GX9%_%+_9Z>+CIK^@U[$CNK
M:M4W4#ADG@]\<H GC@HN*E4O\$VG\(TV4P=S95M>!+[I";XI-%<"W@AX4\PN
M!=D$ N#T!."@7<4XN%3%)W54?2>%BZ=VI)/-"Q=PI^-P9S3'&C2]NE\28&=7
M!1H!=@38.:B8A, Z/<(ZIX WPI&3@C?9TJ("WG0<WA047!7PIE_P)E]E60 <
M 7 .JD@L $Y/ $[&B4/=.K36.]9Y%RZ=DU]>J;* .UV'.P6U#[L.=]J-%GZV
MLFT6[IQUM#!VSVU_62(R6(".2I'!K6,,X5<IPAC740&TJ GOAX),S+Z"CHK9
MN)W!)@?-MZ8+J4%!0\A65&QAHJEPY-1V+L\W2A:.'.'(.:CG:D..G-I*1PB@
MM6M#4X$AY^C/Z=AA]_G81 -;;[HA9HWW YSLGG ]3#P?*+(\4)3M-,*VT8EV
M=NBD-2QRL)>EGH4T #X.7LGSQ3 ',WJR)872TV)Y*.TDY(IM9_0GUJI+S&S:
MYI8B13K4GZ$;_#6WVN2#9Z#'0\ON=6..K3;\4N5&&GXY;H:^21M&K.,#JZFS
M0QM:S<E@+(^*ARQH*080SO<;:3,R*^NJ?19=W ;3R;2]?9T.1@JVEIA7WM?F
M>D-VMT=<^O7?7H7^Y;VNKU_39@-+UP8$Z[,2SY_=@+RW?.Q+$GKD&ZB>7VSX
MSMO__B])^EO\L_#.)W^&H) ^/, _?OPU+/.$ZNHK60 =?T>]<2DK\#_V4E$O
M->5"LLPW%[XRG8TGH]G%VTK4CY1L0 GD (&\0F-79-^>>S@M:10Q/^AH6DN?
MB$+^5TK[[F0YX8@I)OLLL8W>>6(^ 5<WXU\ZOEIO:YQ0)P>!:&:;I^<O/9[?
MA:1KA9-/CN *%T8G_A$46VT&/TJ]9QA.R5C[8.FYX?VRMK'8':8R9D-ED469
M-;[;2*O0#JRU321NAC(-J'3>[JT^(ST:J-K6S4ZJ./B.EC"T\=W]O4?NL=G2
M-CC4U_#7D[6"3^U-;:!"'69;"A\,*AIFZR(>[JWPG8D"S[22*HJ7.TZ)"T:J
MS$@U-E[]2.Z\J'Z*TG;WU<S@F;$CML+J:H]+"U2_%;#":?Q\1YN%UC0/31M,
MQK/!.'L5MZ.G@\3Z-=&^*H_PF( X@ZV^L*R3::Z!*0\%B;];FR)7AKDKIW2W
M0,LQ[-#'KC P8KRL'#%AIMC=+XCF&-E18,K+16C;:$[Q_7C5\'Q.F[KV(6,V
M+TU]([FL;4S&:B>MV-E26'^<%GD2Q@18P4K_)28[<^[/]K2IU0V@%)OL@:0O
M<$M,8H8&=EM*-@K_0/:U?!][?@TD&-QP0T!, [K]Y&E-' #BM(T/\"GM@YMZ
M$.WTF#"VX?H!$'U'PU&_[HZC^S>EL.UH4:O/'/OB6P&@1U\W**?MZ%2JIW>[
MSJ[/$ZS&HTY+E$]I\U+&]^GUM-B?%+APII1I'-&R?9]GK,S%E?>$K6"4S9?%
M%R"MCK+X*QP+WL$N;\"ZP&Z;QSC'C$M%:<HQ=N)60:4-@^C<JG4+JN,R;"IW
M(SSUR!/'NZC]^N<OOTH9=GM=QMN9J);GD'#'/25_;+?Z'W4Y8JFV]BCIJYUG
MG_3.@![Y+KN-2T5A!-]^41$2>"X<)R0P+X'*=@Y@UR0P"DZIA#X.R:%YMGB?
M&)=\)"#7NEUQHYH(*:UIA)+PQ+_L'TKM?JJM,A[(6%QDMAVBGEW:25,!!:]T
M@5?&@]EH-)A/2Z.&N\(JM>CDHEC[ONODVT /RC,0>R-E!X_0 ^%"12Q/!_/)
MI.O2)5A$Z-_J^C>)UBYSDU;W?V8]I]\=CQCNO0,3-;_I3[\0ARS8+5[B)+5^
MQT-$Y!DUB6&!PO3?7%QJW$\ZE6<S;2I/+J30L?AO?'>D*M/+T#<OWLK)3$O&
M.VY2B;NV=%+*K+9)^>3+XH,?T,@2_P O,IV(IHQ:B+$43Q1//.\G/M<]4Q)%
M?++@4= J>!47ZY5GNZQ>3I@O7NJN/;+6>:MI(./"<G3'L##B 4'ZBM B(PXJ
M:["#*RO82(]6L)3^?G5U(WGDS]#"N^/TA7C@PMA_$(G$BIY>T?I^N*(1%OAM
M/9#TQ8(8["H?9N!Z&.2@KVBH (U!]'T2L)_:EGYGV59@\4>9<50_N[-VT%IC
M:'?9;X+,G2V^+EPE_JYL.G'<@IGDM;#OX5\ &2S7[,0E<,<X[ N-7G*=>Q?I
M=*?[EI\-GR /NAU2+D%XDO!,B,$=TM+"XC5X6J8[X%G$,=B5/PL46>@&?.[S
ML",SVADC]#QD"( DCKNR#(DX#Y;G.KC/0^D6EF$MX*'P#0LVWY?\\.[?E!E=
M>&DLTZR+$08IU@VCU)MUZ*U=GX5-F 3##RP'AZ>Q$Y>P4&+22#;@&B9;5 @,
M&@L3A6R!Y! ::TRYFCP0VUVO*",;@?5 F7<H?=(=_9YRJ'1'; N^E2<5S/H.
MN5'W78?>B=,X#48(RS/"%? XD V>=64$(9"2!14A  MM%">,:Y'\A"KV)HIT
M@!4F Y6G9[3X.@4Y,V@RBS1YX+]_Y9A?T<[X7\( J8 <\@U#10IPL#P&P/G[
M.QNV^\N"/^"+1W]^]63YEZ L/^D;_&H4"!2-\HE>EZ2QZF@ROGA[,_XMF>V^
M&3US_M'A8L?\;VS=H'QTA<J2?Z%@ZC.U_:DKEYJ\8^K1,_\%ED>9?8('+'U\
MUC6-O;IVWKF.0VA0%7X#-BJJCH%/CW:K8*ES7*KRFS*3WW=UN>/?,/*HEL6.
M.K>O55ER/F]]ZONT0<6IC^5INU-7X02M7JJS'5/_GH3Q18\OX*HH#A(?R<+P
M:11^EL%^ST67?=NL"1TC]_XV8:;3X]@1S@)_O%ZX;N"X ?D5_I">Z%N>BVAG
M&03KUZ]>/3X^#I_N/'OH>O>O5%G67N''K_"+%_S[ <STS050CB8F7[QB3\<?
M6:_1VT&G2O^\9/&1%_0;\7=68&X!@;YE?[&O_.U5]C/ZR%?),W>, 7""[!P!
MOW#4\S,>F\(!^#=>?[]]_]P1+@&C7>Z@&AAQRR3\O<R3/H<K]+NY7OSAH?.D
MOWBUZXFIX=X3!(;.[@'W[6U^Q.V'1I^FUEU&3B[(E*(FUT'<&Q9[#K/$!+F"
MXUA^=19"< !R".F,):BHC%3XQ!C>NP^OWEW_W\5;6985>:Q-YDHTJ>3'N05D
MQN(CL5-/?GP062]X#Y#L;;*&Z"G)9[D?@1 F/Z%K308V4S^(WDT-';W%Z7<@
M27^_@H69EAT"X":W! X.%'9_>,+C!#$QAQ%/*F% 03S@3=U#F._?$.\6^>*7
M3?$#J!+\L%K;[H80ICCI"8(KPO8W,MD?<H]F*\_U)DSC:6U;AL65-9P+X'L8
MQ?_F(E+1#1+KXFTT2"G5V-JV)KHEBMD5"@Y^!@=G<8W@VG*NS5!*<&HAI[9Q
MXNDICY:2YN*MN5@XKVLCD&#-0M:\=@QW16XC9_"OKD&U 67.OQ,'(PCA7')E
MHI?/#]!=_D ^,)]POQEOQ\(3Y5:) H*S#N:LK]P!#(1]G[A_7PY?55B_X*H2
MKC+) B01?2 /: ("W;FW[FQR1>_ ?ME\TO_M>M2J4$Z[=FB^L.\7DYS^JN\,
M=Q!%N%VM3A?!B(6,^!6HS%Q^G_0G:Q6N^LE%OA>\CI=R\1;_S*Q'[/Z^W0?1
M.ZO=3Z]'['[A[L?6G55<Q%.TZV H!>6(J[AXQHUNX2%%7V/83C\Y)*DSN6/)
M";#9N7;!34=P4^H*ZD5PT-9Z!=<<P35?2:!C=8'(I_<B6*=XT8)_^+5^Q#_L
MAA\OJBW3TKW-K6Z3+PLJ<1S/;O![-[1^UGEX&4L7RT]#.Y9\*O89'\P^=%\;
M8A\EI7XJ!O$()_:6$[L_;FOE".V%?-$=]JLC9.[,V;$&$@GV? 9[B@N_,[SP
MZSIKEN.^-"E?$OC;MV[!2/QPDCN EC)25$?II3'2OG6?BI'4[IQ$BU*=V^>&
MYY$T6L,!)(W6VA))17#G(6+]\H([7S@'B^#.W@1W]H%3L49*G/]S?MHQO3RA
MS^KADJ_$#SS+"(A)Z??=L0+_Z^UWGEOVS0H07EX[-'LFU&V&JBV/8-+W6;+3
M3H+L8ZDJXV-H0R%=6=1#EKB"APMY6,0*]S)6N.><)6*%.QDKW NN$K'"YQ\K
MW -&O+%UY[.^XB<$&L,"HH_+?2#XF2HKXWXS5GJ%G&MVKE,PRGY&P3(0L%M?
M%M^6!"G'"(I?.3M>V;=4P2Z%[")R$,3NBQR$E[G[(@>A-SD(O><FD8,@N.9P
MKA$Y""?-0>@@_XQC_J&QZKV,_#@P+C]::TLDW56X$9M.G\75][X0TNV5GDK^
M.LXLY2%\VS5_^\TR^T+WRM8K&(<65HT,?_2RND/SP$*I/66ONMV?A[)V 8$3
M2%)(Z9,PMG(X(LG]I$'&U@#[O QN/7N.P:ULAV/&@F/.A6/&37&,FG ,+5 N
M.*9S''-@AD2TE9WDF!VH/IN4<HVM8WS )E\6J<KX-#JX[[Z:1IBOSO/&H3OQ
MP@6#]J:8]2A?R'*P@T/P-IEV_'#^29TD$9=!W;X,ZA0WB,N<E[CKXC*F]<N8
MEO;_>2V;>LH >Z\ RI=\@NW/U69J9/M%/:]NU?/JS/;O+C[U IGC:(*<'>L\
MITUA3YFC;X8C4]*EY>T7E?SZ6,FO<^PC*O&=4R6^3K*7J*1W#I7T6F8M40FO
MJY7PVF.$/EXHS!MU)NWK6"C.!*<_$YQP^_<"X'01Q//0FL\^$Y23Y$S9A]6U
M^*8_787!TO5@DJR"$;SI!Y;QS@V=P-OTFRN*UYC</10N]F7M-[VEN7),K&MB
M_R/T+-^TC/Y71-NW\WN6?;8\((JMG&>QE989Z<9SX0FL^D, B\<K7KKT7S9Q
MX-O'T .ZAAZ*V4?K"5_U_$:[PJH3#5.^_!?,$[_J=ZZG!ZZWB3]] 2Q!=4;I
MTE\R.Q#=)TO7-J]7H% ?Z/GM)>F('>L_4ZX009!]"8(\/3>((,B7N.LB"/*4
M09"M[+]H2M/1IC3M,$*%.AB?R6/68_M)W\SPE_WF@WU>ZCW+;I\-\C4+6F8#
M40[E!6WV=GF/2!;.>^OWK?L%,\+-5984O].+&N*M=3AAQ[5-_O?=OP \/7KT
M 8[YSOWUUW<OA67R%-K'+%5F@=4]BPC-!R\G]YERJJC U)4*3.UM_.12DWL6
M<Q1-NR&2]#$,*U\KL0F2B-YBI^DM=M)=%KW!1&^P]GFP"F2^=AY@*^*SY(<G
MXAE6WWLP5<?#.Y<OV**8+N?2HZ)E=JFJMKK0-J//+-GGQAD]8<E3]/+H($L*
MQ^/)'8^G9(1H^5=!H,,>FM_<6QB*^%?O7!!*+\"XT!N/ *T\CG//FT&.I<>+
M99P74[[C>>DVG2K?T5?6>6F@O3&6$C#^5&S[$H!]Y]CV14-]D1G;[\S8_K*/
M,->UL94PV*=C76&R3\*ZPFCOVH]_Z$ZH>XBD9L)F[Z:(8)[*I!(6NRZF$@;[
M9(PK[/4I&%>8:U&1MK<5:?O+/L)BU\96PF2?CG6%S3X)Z[X HRUJ_G6FYM\I
M]UO4_.M&S;^6>$#4_#OWFG^M,!)6M(IS;EDY$Y XG.X#P<_ 4H_[S1CI%?)=
MW[G.<]UH4=RQ3\4=.\,3HKAC%XH[=H<=1'''[A1W;(4K1'''GA1W[  WB.*.
M+W'717''$Q9W;'3_E4M9O51G.[SCW^'8[3UZ<.SV8N_OMM_W([GSV&6MJJ1D
M)N<MQT(UY,\02?\ _\28(_=^O]EKGP^]1H+6X5-/%Q$JV)N4'ZYHDTX@#IQE
M&Q6'@QAU1Z6I;(; M6/8H6\]P%=23'"[U'M_"F^&>0Z=P:X:6(?NQ/DQM@9F
MI&^%H/BTGT&2Z!W\%_[\_U!+ P04    " !(KW!249CU&0@/   CM@  $0
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M6"!8G#*!]APV'V"_,)E0$>\1I.M@_R##* ED#'4LP:22C2U8M+6P^*!V)ID
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M;6SM75ESX[@1?D]5_H.B?:9EV3M;\=1XMV39,^4JS]CE(]D\;4%D4T*6(A2
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MFQ((U8/M;/!J8(Q**GOV%JS:851959LZK-JNJ$;XVZ"9ZJA5B1:X#Q%JV=1
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MHT5<E*NH+.*<Q@D7$/0I2NETFD>;Q03L7=:2HL70QSGF8\_9G^O1'&0+"-9
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M.$/%,9.#=Z200]HXRA*$9\Q<XHH^7B(FK^/UOI""VC[<$LR7U6V&D\\9B>6
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M[B[0!24[*-E=*@10BM %.]UBSE_G**9H(PY67^.21\96(&6JQTI! 0\*>%#
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MA[2Q6"*0 #]Y1@!;[D]'N7@_18OU]A6Y8FBS=WMFU^DN:SM?KAM\(0/N967
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MMN%\J$MBN/Z>4OWRCB/5XEV.XFCXTL1QYP.W]I<P>LF>=N_L&MR++3E5_NW
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MUO++REHVE#WV>)A=QL5%(81&*JXM*U(]-&8Z10O8S XPPP,T:M42BL+3T1Z
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MWJ2]XU\//:TPIW='OA&N[7D\VCO[.S.NY\>^'E[@I CO! ],(6@+W7NG!$B
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MZ$6"+K:3=RD5P-L&5CW>0")]\(Q(+7Y.=0QU_3W_A].0??/_ 5!+ P04
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ML&1XWIW]:*]!9>70QEVH$D,$N=6AIM$"ER4K!O()2][NC+QD=LLC&-SS;8\
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M/*IK[J.0:_7[_BVZ/D'M[J:]5=F<BY5DO;[I!=A9)#B'*)+0D/,5S4!'AEY
M4\Z^G39I2VPK#),PM52,*>OFDD D+O'SKMU& ?\ CXG%0O(5'=$8&=JU>%#P
M:/^T _SSPXSK4VTIL3XOXWTBIU-=YP5^2,L*0X>&]M3R&J3F59<4K[YICC(=
M8@20'UG&(SI4]WRG&2]QLLZH-2@5F'&2,3FBGZX6^Z$7S'8<.Y XAZ=[P^H*
MK\"'F#;?(F&W<*?1*JVBK!OT/)4&0^XY@WA?;L^)]6U-RNLH!;\'7^Q.)(5
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MQI:#*-+8,^LM%I@5SN?I>7?1RPV5%?!^4BG)4GZ=P2H2;1VL(KXT&$J7:35
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M\C/]1+]LOJ+_@^9B])O_!U!+ P04    " !(KW!2AK/OX+@W  ".\00 %0
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M5EE!>3IGYP?;:/5)NM ^/9#WGZ=_L)FXS_#=(A=GP.7E:3UA\M8]D/0MW*B
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ME/X2<9N@G;.DG>(+',V\*JM$F%=.[2NGP D#J9M*DS^(F/#6T> #D.B]@C=
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M>-I6!0B5<4<$RO&$]@/)\:A#>9/.R8?V]L1E-Z%X7U1X$U2X>M)Q*&R-_?U
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MZ7B?CNL^';FV+'NLSF5T?*67)F2:;P727J-P!B1?T&( !2V&C@IHD0 D,&<
M@1PM/3@>]"6(#FT! 4WBKBP@D$RCUT&B+T-V*&NKOY"?T9:)\"$_]AX1'CU2
M;=P'^FZLP<+3SABK[_@=+E!03X>^<WEPV/01WP&&RYU* LH>6C!&[I0'Z-EQ
M#T;0G73_7B) P+BYD\NOZL6P$4@<D922!,<\ZS*8A0D_00*Z0(BM_!*'!<IQ
M%"9[#N61Q.IC&@TE;DN>CR4^(JN'6.*>(KX>+[RK,)MF8GO&(JU:$G6BT-,J
M6\#7^@ ]!L!&*?I"67C:>@#D'YSB4!XJNOA@)C6BI_.]5_R*4*$,3&8TS\*H
M]M%%A:[.1&F-W/T&F2H?]/!R@AY\(NN@K=J6D&C65E5%.N<6"A2>9A'1.:>K
M&BQ58J=SOD(U2&JE6&L9T!\#RLD3=2:97O]8*BJ8AS@+UJ*P5LAF<EG6Y-HE
M"\-M&;U\QGRF=#\4>XM'_Q:/FOS2Q_GK>28/LTRU?:2S^D2S_$!U8O]UK#;Q
MIRZ^A0]X62PKDRAJ?S=$&DZ;2:OZW0QIU[R28<5ZKOS-($FU6%7\:BE]K4U=
MR'U!Q\GC=N&%"_GS/6?\'1=VHEZSS5>G\9OZKB.0_D[X:XP).Y!-@UK]Y9'#
M>HWIGU\RA"[2'#'9)#<%:M-W+4':IKYYTWKA'K^Z''O]'_3F9F^55<I$TR<K
M>ONM^_;;:N&22 2\L7,M-]DV"-UC-T,V3GF#_C-V.V,SW_4JZ=CGVZ2+9J!3
M[UTTAM\/4A1WG=MB<E3-*63.;5YSX$),""_+UV38[&7-8?4+UYB6.!<OQ@1A
MRC6HE#_GA](((QK,B[S(4+ LQ:6 @QLFP:IDN*W[JM^/FG=FZ:#?N[;LN[;Z
MG5>0HTO'4C)IG[I$E"(T72'^I&IZ=XG8>7B)PYFX1+;G(CTKZBQ7T.[!^^&S
M^)UMX=M[E*S1-S:%BSKK8MOA;%:-@]+,J]'?WI..G&]'&2S#/](8TX@43!*-
MSQ\BUG2RY/_5ANVZL8+THSWN:VBMX:^FM2^3Z4W]?9OZ>[XMO>'??<._#]P>
MA55PL#FS?8EK^A;1Z*&KD??TV?-R_AKTF!$[5H<TV.8^E5"E[&#,MVW'!!98
MK@9#-_Z:)HH"NS6;Y*]E0,>") QX&B#QL/56VN,9 .7/P?VVFL'C/\AC/D"0
MDR",6,^,I]+S9(& S /^=-R3,=K9+^T1:-[6:9M7;Q<U9A>]7:!O(2]5^/8B
M72,V)]E15;'ZYZ(4N_9*[*Z8XJZZ"83*YCX]D+<OM9+G8;1 \2VY81]$=')*
M&$!9CID$?K6[3D1*4SW97<?JD9TR">VXT*4 ]>33TYJJ<GY:#Z:=(;90SE D
MOLEIZ<H2:#@33/U7F);52$\^]L"3=#03+'TGZS[G23Z<3@>4O<L6Y*RR+0OX
M?"Z?S^5*/I=_F]*_37DTUD!8!Y23 G;SCC_O^.O'\6=1\O!.0O>=A"\[.\@_
MY.7?2-'R1DH_ABM7XOK5<>MJ>7%EQ?GTQ6.>??JBL^\F]75,@.WH^CS@XP1.
MP0H,AD[YA8_10@=U=("A4W[X8ZC0J7D?P?@H/^LQ?'P4?,ACO^U,AJ<._.(;
M<GCJ$%-4U:RP8Q>'>\!&S0YO+?RMOIY1:: D(JDXX&]@K[D5M.\2LJ"O#*F"
MK +!/IKLB*Q!%9 %363'^K$*BV4411.GNQ(#XFSC-V?YE%R=&ZGO[UA-\^N/
MF3\0OP-0/%FC++Q#3ZX*_5 V?7W< *]P)OK0B[1\?E4;F,^^9#6%MBL_7T@V
M1YAG,^I&KN)+HT;NZ_8M]I*5KQFAM3$ ^KXT/M@.%(>+-,]P2G$DZMAH J_V
M>V,^[PZ8TGH+/_M.\+,'31VT#TZ 9D%T 7[=D54Y8(!'O()_1Y1SE<;[>HF$
M_^F \\G=72;23XU<2)WI<7$*M![(JI]W$6 +9TL_1 UP,JBZCJ@#?DUDC!#P
M"M72!N MR1@AX$\U4AM8JU,PHM=4GAONGDH"O;^F(OV@=66Y'ZZ.ULDUXEX2
M=A&=DE0\M5R$B9;7:MI3,F;@ZV_Z.G;?:0*^ R4>=J.4C'F]*PN\IL^?_@GT
MF7<^\ZZ?S+NNGG2?/N=^^IS)(,:QA*<-,(AQ)70R]OTL'V)9.NU.,7UK[.4@
MJ^+N<2XV6RO(TF@"Y^*\N\&IRQ*E(1UJ^+543001N9(L96C]=K)::\BN<G\1
M0V((74G+,K2(._FZP%A_= 9KF[94,-R?G*F$;2R($:YZM-3JSE,GCV1IS!X<
MV)9*G?O J@28P>%6?Y1AT(>$76\+''9EW6_8L.O,5(*#ZL[3#Y9REN!0*^M^
MPX;:;E "'';E(ALO 79)K T<W9>A"VJ)]H6#[(X2.)#87CCTR@KA8*$?8! '
MW(LR%N^PY1T 2N.P5OWC4X!3U@@%>?B ^).EY7SR_PQ"2M'VW=-D^VH71L^>
M-046 .G^(?,U0/JBV9<!.2)+7QF0L^T<W88/$S%#I^$*YV&"_\5W.,TIVZK3
M?%']7(MR9QT$-SZ"K=)%!W'3C.V=]"PK[D[9GW%>628%WJM?$B\?]V%9G&K^
M@R)!@83*^HXM2Q.HUJCI?M" RM3T=9Z9C)G<3=.%H/SI9!TQ#^D2I-SD;9N9
M_<[X_FQM-C4]?H?5*NF/SWH2R@[*+-O,2<8E(]FT*(PP #;9/W9_XR)>2M$3
M03&-/Z,4S=F95BU)\FL#BD</G[(9-_^,'R[GEJ0G";D/T]HT,$!/JS5BJJ\*
M.3-#/'<.:/I*2'R/DX2M+*:;,(6'%\@O)^#XOY5X51C7;ND?GT,PT@AP[6*.
M3R/P:00^C6 0:01#M!JV%F7U+9C!>LA,B+DO(_2_E7'E983QJ]O%-,3=CP87
MF%E30P#]\(.ZVZBB&J+?=X<Z8=,T"I@JK%,:8M='M7YZTH@UA*4/%\8.EGD-
M\>1/<;H=^F:$V;MUQ(:/#"@X1':]\62G500,/AI$AWI%/VYXE2]8][^K$^L=
M[T=D67A_H\,DMG%JJB\2HX9X1BC-<71*BC3/-D^?&#LVKC>U-4_Z_G:9%/F"
M9-5K#-9X",17[EQH<_,,*'M;A^A<%;<TDX$OV3>3_RHR3&,L'G-LW ? 7MY_
MY/U'6OQ'2C>*=QR]',>1Y)(CJO>)*[C(O4D0\< 5WQI\E0 $/E<<'7!0E&Y_
M5]:,"9?TP%>(=TFKV;;4/=!V;5L9BD@:X027U3W)_.#G@'&"^C%P*7_&NI6K
M)<7>U&7,U'4^GR->?Q;M;[%K-BW73^;MF5?^"F41F_(JTU:7\>PD*"BOT3:6
MO)8;P:0R73US/,$2IP4[B[>',DGK+ /P 6S&_D,6Z"3_@MAM&B;\NBH899LG
MC97X5QK9:@@QA/[3!<\EO4C;Q\?W_!6;20(05KX3?I$5K!F3_+8A8LK9%?U_
M:.BPB1">2?S/@N:B5EX'8(Z'&CKK3Y3$?;O:%(TN0_J,!6]QUFUQ5I=\O-GY
MY9B=?;[",(U#PXVJTREM:UA2;@ )%B T6&R'BV#_!@]]"0Z#3:G1K _J2XT8
M-:+=M$4-V10N@"K3-%]@;D5[FZ -WPZ;3$H2'/.+YE&MH5QI(<^LGW(?CM)P
M1GTU+2CS/AEC/IDSQ*8C/L-K'#/(O[!M]T?(B_CEYP^1N FK/!'23I:KCK!E
M'.WOGE5&Q.5#ZH)6:]M;M=Z%&:\YR:4W<5=.9E04GZRSS$F:VV> 7?8X E+_
MI*U]TL]P4K##"TC\46OSY']%*==#F0HUB9<XQ7PE\&MQ*WK5L 'L92L$G4=G
M\(.FZCK_C.8D0P>JXOD#(Y[)-S@-F1K.Y06VKR->OI4D2?D("&(W7=UFTOA%
MF][(DMR]+"4Y422M+:8B;%?DMMI!(_G/6EN]F':+H*1M2QA;)_M Z?JJ=BI=
MS3/&/OZX9VHX>-+&YC9X0LAD'>*$VT)O"5-$E]SZ1*(_%R1ANA%MNK(41['*
M\,$R>;)^)"< N)_%K)XM153"BK2]11:D.Z>BI<WE=,U41*8P+YBD<(;6*"$K
M?C\T"Q>@/MXM[-W"[>+AZZ44[]_U_EWOW_7!_[+@_V:YP!50Y.R25G>V*]M'
M"1\E@XF^["(+7BPEF,#658W^:/,>*R6(  *^*SL,=BPK:IZN',]PMDD7RY"^
MM61AH[7$S)B!U[$@I0YPRVVQ3MT K9!J-))J""\:S5)JZ7;6&#PTQA6E;J=V
M+BN^4>Z >=%=$3>DW#8@4^&A=T5$[0)+I>]_8-%E44@7P3PA]_U$EST?;BC1
M9764^>BR([+T19=-YVR;BZ=S*:_8/(DB7J*'7H6;"M^%0H\>2+O*2(10+#2
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MQ.^WB-^6"S+.@=+(<K5+XT546(/BHF!@<<6[H8P11*UT)719&1R :<.YS37
M3)I5*9+G898/L7Z?U,*A;XT,'1DMPK-S9W4EACUZ=9P[O[L !G <N1*3J+!)
M>[* N!*JV FY-O825_)6@&FH1GU]K@1!PK!M\&V!@?C83@XY3^-!2B$R9PX8
MET]NX:+%=@>);MK^PO^'[W#VE_\/4$L! A0#%     @ 2*]P4K9J :!FIP
M1/X( !$              ( !     &1F9FXM,C R,#$R,S$N>&UL4$L! A0#
M%     @ 2*]P4E&8]1D(#P  ([8  !$              ( !E:<  &1F9FXM
M,C R,#$R,S$N>'-D4$L! A0#%     @ 2*]P4@"I(@M]"@  F(D  !4
M         ( !S+8  &1F9FXM,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M $BO<%([3&ARZ#0  ,:.!  5              "  7S!  !D9F9N+3(P,C Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " !(KW!27CR1<\=*   (( 0 %0
M        @ &7]@  9&9F;BTR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @
M2*]P4H:S[^"X-P  CO$$ !4              ( !D4$! &1F9FXM,C R,#$R
@,S%?<')E+GAM;%!+!08     !@ & (H!  !\>0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
